!ID 000001
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v036!20121
!v042!1
!v043!^a2012^cS&#0xe3;o Paulo^menero/mar.^les^nno.1^tArq. Gastroenterol.^vvol.49
!v043!^a2012^cS&#0xe3;o Paulo^mjan./mar.^lpt^nno.1^tArq. Gastroenterol.^vvol.49
!v043!^a2012^cS&#0xe3;o Paulo^mJan./Mar.^len^nno.1^tArq. Gastroenterol.^vvol.49
!v048!^hSumario^les
!v048!^hSum&#0xe1;rio^lpt
!v048!^hTable of Contents^len
!v049!^cORIGINAL_ARTICLE^len^tOriginal Article
!v049!^cPEDIATRIC_GASTROENTEROLOGY^len^tPediatric Gastroenterology
!v049!^cEDITORIAL^len^tEditorial
!v049!^cREVIEW^len^tReview
!v049!^cEXPERIMENTAL_GASTROENTEROLOGY^len^tExperimental Gastroenterology
!v065!20120300
!v085!decs
!v091!20120502
!v117!vancouv
!v122!15
!v130!Arquivos de Gastroenterologia
!v151!Arq. gastroenterol
!v200!0
!v230!Archives of Gastroenterology
!v421!Arq Gastroenterol
!v480!Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia - IBEPEGE 
!v480!Col&#0xe9;gio Brasileiro de Cirurgia Digestiva - CBCD 
!v480!Sociedade Brasileira de Motilidade Digestiva - SBMD 
!v480!Federa&#0xe7;&#0xe3;o Brasileira de Gastroenterologia - FBG
!v480!Sociedade Brasileira de Hepatologia - SBH
!v480!Sociedade Brasileira de Endoscopia Digestiva - SOBED
!v540!^t<a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80x15.png" /></a> Todo el contenido de esta revista, excepto d&#0xf3;nde est&#0xe1; identificado, est&#225; bajo una <a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/">Licencia Creative Commons</a>^les
!v540!^t<a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80x15.png" /></a> Todo o conte&#0xfa;do deste peri&#0xf3;dico, exceto onde est&#225 identificado, est&#225; licenciado sob uma <a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/">Licen&#231;a Creative Commons</a>^lpt
!v540!^t<a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80x15.png" /></a> All the contents of this journal, except where otherwise noted, is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution License</a>^len
!v541!BY-NC
!v700!0
!v701!1
!v706!i
!v930!AG
!v935!0004-2803
!v991!1
!ID 000002
!v002!0004-2803-ag-49-01-01.xml
!v004!v49n1
!v091!20120814
!v092!164244
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-01.xml
!v703!62
!v705!S
!v706!o
!v708!1
!ID 000003
!v001!br1.1
!v002!0004-2803-ag-49-01-01.xml
!v004!v49n1
!v010!^1fn01^sFaintuch^rauthor^nJoel
!v010!^sViebig^rauthor^nRicardo Guilherme
!v012!^tAnother link in the chain
!v012!^tMais um elo na corrente^lpt
!v014!^l02^f01
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!ND
!v040!en
!v042!1
!v049!EDITORIAL
!v064!Jan-Mar
!v065!20120300
!v071!oa
!v072!2
!v085!^kScientific and technical publications^len
!v085!^kManuscripts, medical^len
!v085!^kEditorial policies^len
!v085!^kNutrition, public health^len
!v085!^kPublicacoes cientificas tecnicas^lpt
!v085!^kManuscritos medicos^lpt
!v085!^kPoliticas editoriais^lpt
!v085!^kNutricao em saude publica^lpt
!v100!Arquivos de Gastroenterologia
!v120!XML_3.0
!v121!01
!v237!10.1590/S0004-28032012000100001
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-01.xml
!v705!S
!v706!h
!v708!1
!ID 000004
!v001!br1.1
!v002!0004-2803-ag-49-01-01.xml
!v004!v49n1
!v010!^1fn01^sFaintuch^rauthor^nJoel
!v010!^sViebig^rauthor^nRicardo Guilherme
!v012!^tAnother link in the chain
!v012!^tMais um elo na corrente^lpt
!v014!^l02^f01
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!ND
!v040!en
!v042!1
!v049!EDITORIAL
!v064!Jan-Mar
!v065!20120300
!v071!oa
!v072!2
!v085!^kScientific and technical publications^len
!v085!^kManuscripts, medical^len
!v085!^kEditorial policies^len
!v085!^kNutrition, public health^len
!v085!^kPublicações científicas técnicas^lpt
!v085!^kManuscritos médicos^lpt
!v085!^kPolíticas editoriais^lpt
!v085!^kNutrição em saúde pública^lpt
!v100!Arquivos de Gastroenterologia
!v120!XML_3.0
!v121!01
!v237!10.1590/S0004-28032012000100001
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-01.xml
!v705!S
!v706!f
!v708!1
!ID 000005
!v001!br1.1
!v002!0004-2803-ag-49-01-01.xml
!v004!v49n1
!v010!^1fn01^sFaintuch^rauthor^nJoel
!v010!^sViebig^rauthor^nRicardo Guilherme
!v012!^tAnother link in the chain
!v012!^tMais um elo na corrente^lpt
!v014!^l02^f01
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!ND
!v040!en
!v042!1
!v049!EDITORIAL
!v064!Jan-Mar
!v065!20120300
!v071!oa
!v072!2
!v085!^kScientific and technical publications^len
!v085!^kManuscripts, medical^len
!v085!^kEditorial policies^len
!v085!^kNutrition, public health^len
!v085!^kPublicacoes cientificas tecnicas^lpt
!v085!^kManuscritos medicos^lpt
!v085!^kPoliticas editoriais^lpt
!v085!^kNutricao em saude publica^lpt
!v100!Arquivos de Gastroenterologia
!v120!XML_3.0
!v121!01
!v237!10.1590/S0004-28032012000100001
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-01.xml
!v705!S
!v706!l
!v708!1
!ID 000006
!v001!br1.1
!v002!0004-2803-ag-49-01-01.xml
!v004!v49n1
!v010!^sAnonymous^rND
!v012!Necessity of publishing a condensed analysis of parliamentary evidence^len
!v014!271-72
!v030!Prov Med Surg J
!v031!1
!v064!1840
!v064!1841
!v065!1840
!v065!1841
!v071!journal
!v118!1
!v514!^l272^f271
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-01.xml
!v705!S
!v706!c
!v708!2
!v865!20120300
!ID 000007
!v001!br1.1
!v002!0004-2803-ag-49-01-01.xml
!v004!v49n1
!v010!^sScobba^rND^nV
!v012!PS1-36. The collaborative research library: creative strategies for the advancement of scholarship^len
!v014!167-68
!v030!Clin Med Res
!v031!9
!v064!2011
!v065!20110000
!v118!2
!v514!^l168^f167
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-01.xml
!v705!S
!v706!c
!v708!2
!v865!20120300
!ID 000008
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v091!20120814
!v092!164246
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v703!107
!v705!S
!v706!o
!v708!1
!ID 000009
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sMendoza Torres^rauthor^nEvelyn
!v010!^sVarela Prieto^rauthor^nLourdes Luz
!v010!^sVillarreal Camacho^rauthor^nJose Luis
!v010!^sVillanueva Torregroza^rauthor^nDaniel Antonio
!v012!^sgenotyping of single nucleotide polymorphism (SNP C/T-13910) is not consistent with breath test in Colombian Caribbean population^tDiagnosis of adult-type hypolactasia/lactase persistence
!v012!^sa genotipagem do polimorfismo de um unico nucleotideo (SNP) C/T-13910 nao e consistente com o teste de hidrogenio na populacao do Caribe Colombiano^tDiagnostico de hipolactasia tipo adulto/persistencia da lactase^lpt
!v014!^l8^f5
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidad Libre Seccional Barranquilla^cBarranquilla^iaff1^1^pColombia^9Universidad Libre Seccional Barranquilla, Barranquilla, Colombia
!v071!oa
!v072!29
!v083!^a<sec>					<title>CONTEXT:</title>					 Genotyping of single nucleotide polymorphism (SNP C/T-13910) located upstream of the lactase gene is used to determine adult-type hypolactasia/lactase persistence in North-European Caucasian subjects. The applicability of this polymorphism has been studied by comparing it with the standard diagnostic methods in different populations. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To compare the lactose hydrogen breath test with the genetic test in a sample of the Colombian Caribbean population. 				</sec>				<sec>					<title>METHODS:</title>					 Lactose hydrogen breath test and genotyping of SNP C/T-13910 were applied to 128 healthy individuals (mean age 35 &#177; 1). A positive lactose hydrogen breath test was indicative of hypolactasia. Genotyping was done using polymerase chain reaction/restriction fragment length polymorphism. The kappa index was used to establish agreement between the two methods. 				</sec>				<sec>					<title>RESULTS:</title>					 Seventy-six subjects (59%) were lactose-maldigesters (hypolactasia) and 52 subjects (41%) were lactose-digesters (lactase persistence). The frequencies of the CC, CT and TT genotypes were 80%, 20% and 0%, respectively. Genotyping had 97% sensitivity and 46% specificity. The kappa index = 0.473 indicates moderate agreement between the genotyping of SNP C/T-13910 and the lactose hydrogen breath test. 				</sec>				<sec>					<title>CONCLUSION:</title>					 The moderate agreement indicates that the genotyping of the SNP C/T-13910 is not applicable to determine adult-type hypolactasia/lactase persistence in the population participating in this study.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 A genotipagem do SNP C/T-13910 localizado corrente acima do gene da lactase e usada para determinar hipolactasia e persistencia da lactase tipo adulto em individuos caucasianos do Norte da Europa. A aplicabilidade deste polimorfismo tem sido estudada em comparacao com metodos padronizados de diagnostico em diferentes populacoes. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Comparar o teste de hidrogenio expirado apos a ingestao de lactose com o teste genetico em uma mostra da populacao do Caribe Colombiano. 				</sec>				<sec>					<title>MeTODOS:</title>					 O teste de hidrogenio expirado apos a ingestao de lactose  e a genotipagem do SNP C/T-13910 foram aplicados em 128 sujeitos sadios (idade media 35 &#177; 1). O teste de hidrogenio positivo foi indicativo de hipolactasia. A genotipagem foi feita pelo metodo "polymerase chain reaction/restriction fragment length polymorphism". O indice Kappa foi utilizado para estabelecer a concordancia entre os dois metodos. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Setenta e seis individuos (59%) foram mau digestores da lactose (hipolactasia) e 52 outros (41%) foram digestores da lactose (persistencia da lactase). As frequencias dos genotipos CC, CT e TT foram 80%, 20% e 0%, respectivamente. A genotipagem mostrou 97% da sensibilidade e 46% da especificidade. O indice kappa: 0,473 indicou moderada concordancia entre os dois metodos. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 A moderada concordancia indica que a genotipagem do SNP C/T-13910 nao e aplicavel para determinar hipolactasia tipo adulto/persistencia da lactase na populacao estudada.				</sec>^lpt
!v085!^kLactose intolerance^len
!v085!^kLactase^len
!v085!^kPolymorphism, single nucleotide^len
!v085!^kBreath tests^len
!v085!^kColombia^len
!v085!^kCaribbean region^len
!v085!^kIntolerancia a lactose^lpt
!v085!^kLactase^lpt
!v085!^kPolimorfismo de um unico nucleotideo^lpt
!v085!^kTestes respiratorios^lpt
!v085!^kColombia^lpt
!v085!^kRegiao do Caribe^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d11
!v112!2011
!v113!^y2011^m08^d05
!v114!2011
!v120!XML_3.0
!v121!5
!v237!10.1590/S0004-28032012000100002
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!h
!v708!1
!ID 000010
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sMendoza Torres^rauthor^nEvelyn
!v010!^sVarela Prieto^rauthor^nLourdes Luz
!v010!^sVillarreal Camacho^rauthor^nJosé Luis
!v010!^sVillanueva Torregroza^rauthor^nDaniel Antonio
!v012!^sgenotyping of single nucleotide polymorphism (SNP C/T-13910) is not consistent with breath test in Colombian Caribbean population^tDiagnosis of adult-type hypolactasia/lactase persistence
!v012!^sa genotipagem do polimorfismo de um único nucleotídeo (SNP) C/T-13910 não é consistente com o teste de hidrogênio na população do Caribe Colombiano^tDiagnóstico de hipolactasia tipo adulto/persistência da lactase^lpt
!v014!^l8^f5
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidad Libre Seccional Barranquilla^cBarranquilla^iaff1^1^pColombia^9Universidad Libre Seccional Barranquilla, Barranquilla, Colombia
!v071!oa
!v072!29
!v083!^a<sec>					<title>CONTEXT:</title>					<p> Genotyping of single nucleotide polymorphism (SNP C/T-<sub>13910</sub>) located upstream of the lactase gene is used to determine adult-type hypolactasia/lactase persistence in North-European Caucasian subjects. The applicability of this polymorphism has been studied by comparing it with the standard diagnostic methods in different populations. </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To compare the lactose hydrogen breath test with the genetic test in a sample of the Colombian Caribbean population. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> Lactose hydrogen breath test and genotyping of SNP C/T-<sub>13910</sub> were applied to 128 healthy individuals (mean age 35 &#177; 1). A positive lactose hydrogen breath test was indicative of hypolactasia. Genotyping was done using polymerase chain reaction/restriction fragment length polymorphism. The kappa index was used to establish agreement between the two methods. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> Seventy-six subjects (59%) were lactose-maldigesters (hypolactasia) and 52 subjects (41%) were lactose-digesters (lactase persistence). The frequencies of the CC, CT and TT genotypes were 80%, 20% and 0%, respectively. Genotyping had 97% sensitivity and 46% specificity. The kappa index = 0.473 indicates moderate agreement between the genotyping of SNP C/T-<sub>13910</sub> and the lactose hydrogen breath test. </p>				</sec>				<sec>					<title>CONCLUSION:</title>					<p> The moderate agreement indicates that the genotyping of the SNP C/T-<sub>13910</sub> is not applicable to determine adult-type hypolactasia/lactase persistence in the population participating in this study.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> A genotipagem do SNP C/T-<sub>13910</sub> localizado corrente acima do gene da lactase &#233; usada para determinar hipolactasia e persist&#234;ncia da lactase tipo adulto em indiv&#237;duos caucasianos do Norte da Europa. A aplicabilidade deste polimorfismo tem sido estudada em compara&#231;&#227;o com m&#233;todos padronizados de diagn&#243;stico em diferentes popula&#231;&#245;es. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Comparar o teste de hidrog&#234;nio expirado ap&#243;s a ingest&#227;o de lactose com o teste gen&#233;tico em uma mostra da popula&#231;&#227;o do Caribe Colombiano. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> O teste de hidrog&#234;nio expirado ap&#243;s a ingest&#227;o de lactose  e a genotipagem do SNP C/T-<sub>13910</sub> foram aplicados em 128 sujeitos sadios (idade media 35 &#177; 1). O teste de hidrog&#234;nio positivo foi indicativo de hipolactasia. A genotipagem foi feita pelo m&#233;todo "polymerase chain reaction/restriction fragment length polymorphism". O &#237;ndice Kappa foi utilizado para estabelecer a concord&#226;ncia entre os dois m&#233;todos. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Setenta e seis indiv&#237;duos (59%) foram mau digestores da lactose (hipolactasia) e 52 outros (41%) foram digestores da lactose (persist&#234;ncia da lactase). As frequ&#234;ncias dos genotipos CC, CT e TT foram 80%, 20% e 0%, respectivamente. A genotipagem mostrou 97% da sensibilidade e 46% da especificidade. O &#237;ndice kappa: 0,473 indicou moderada concord&#226;ncia entre os dois m&#233;todos. </p>				</sec>				<sec>					<title>CONCLUS&#195;O:</title>					<p> A moderada concord&#226;ncia indica que a genotipagem do SNP C/T-<sub>13910</sub> nao &#233; aplic&#225;vel para determinar hipolactasia tipo adulto/persist&#234;ncia da lactase na popula&#231;&#227;o estudada.</p>				</sec>^lpt
!v085!^kLactose intolerance^len
!v085!^kLactase^len
!v085!^kPolymorphism, single nucleotide^len
!v085!^kBreath tests^len
!v085!^kColombia^len
!v085!^kCaribbean region^len
!v085!^kIntolerância à lactose^lpt
!v085!^kLactase^lpt
!v085!^kPolimorfismo de um único nucleotídeo^lpt
!v085!^kTestes respiratórios^lpt
!v085!^kColômbia^lpt
!v085!^kRegião do Caribe^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d11
!v112!2011
!v113!^y2011^m08^d05
!v114!2011
!v120!XML_3.0
!v121!5
!v237!10.1590/S0004-28032012000100002
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!f
!v708!1
!ID 000011
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sMendoza Torres^rauthor^nEvelyn
!v010!^sVarela Prieto^rauthor^nLourdes Luz
!v010!^sVillarreal Camacho^rauthor^nJose Luis
!v010!^sVillanueva Torregroza^rauthor^nDaniel Antonio
!v012!^sgenotyping of single nucleotide polymorphism (SNP C/T-13910) is not consistent with breath test in Colombian Caribbean population^tDiagnosis of adult-type hypolactasia/lactase persistence
!v012!^sa genotipagem do polimorfismo de um unico nucleotideo (SNP) C/T-13910 nao e consistente com o teste de hidrogenio na populacao do Caribe Colombiano^tDiagnostico de hipolactasia tipo adulto/persistencia da lactase^lpt
!v014!^l8^f5
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidad Libre Seccional Barranquilla^cBarranquilla^iaff1^1^pColombia^9Universidad Libre Seccional Barranquilla, Barranquilla, Colombia
!v071!oa
!v072!29
!v083!^a<sec>					<title>CONTEXT:</title>					 Genotyping of single nucleotide polymorphism (SNP C/T-13910) located upstream of the lactase gene is used to determine adult-type hypolactasia/lactase persistence in North-European Caucasian subjects. The applicability of this polymorphism has been studied by comparing it with the standard diagnostic methods in different populations. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To compare the lactose hydrogen breath test with the genetic test in a sample of the Colombian Caribbean population. 				</sec>				<sec>					<title>METHODS:</title>					 Lactose hydrogen breath test and genotyping of SNP C/T-13910 were applied to 128 healthy individuals (mean age 35 &#177; 1). A positive lactose hydrogen breath test was indicative of hypolactasia. Genotyping was done using polymerase chain reaction/restriction fragment length polymorphism. The kappa index was used to establish agreement between the two methods. 				</sec>				<sec>					<title>RESULTS:</title>					 Seventy-six subjects (59%) were lactose-maldigesters (hypolactasia) and 52 subjects (41%) were lactose-digesters (lactase persistence). The frequencies of the CC, CT and TT genotypes were 80%, 20% and 0%, respectively. Genotyping had 97% sensitivity and 46% specificity. The kappa index = 0.473 indicates moderate agreement between the genotyping of SNP C/T-13910 and the lactose hydrogen breath test. 				</sec>				<sec>					<title>CONCLUSION:</title>					 The moderate agreement indicates that the genotyping of the SNP C/T-13910 is not applicable to determine adult-type hypolactasia/lactase persistence in the population participating in this study.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 A genotipagem do SNP C/T-13910 localizado corrente acima do gene da lactase e usada para determinar hipolactasia e persistencia da lactase tipo adulto em individuos caucasianos do Norte da Europa. A aplicabilidade deste polimorfismo tem sido estudada em comparacao com metodos padronizados de diagnostico em diferentes populacoes. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Comparar o teste de hidrogenio expirado apos a ingestao de lactose com o teste genetico em uma mostra da populacao do Caribe Colombiano. 				</sec>				<sec>					<title>MeTODOS:</title>					 O teste de hidrogenio expirado apos a ingestao de lactose  e a genotipagem do SNP C/T-13910 foram aplicados em 128 sujeitos sadios (idade media 35 &#177; 1). O teste de hidrogenio positivo foi indicativo de hipolactasia. A genotipagem foi feita pelo metodo "polymerase chain reaction/restriction fragment length polymorphism". O indice Kappa foi utilizado para estabelecer a concordancia entre os dois metodos. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Setenta e seis individuos (59%) foram mau digestores da lactose (hipolactasia) e 52 outros (41%) foram digestores da lactose (persistencia da lactase). As frequencias dos genotipos CC, CT e TT foram 80%, 20% e 0%, respectivamente. A genotipagem mostrou 97% da sensibilidade e 46% da especificidade. O indice kappa: 0,473 indicou moderada concordancia entre os dois metodos. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 A moderada concordancia indica que a genotipagem do SNP C/T-13910 nao e aplicavel para determinar hipolactasia tipo adulto/persistencia da lactase na populacao estudada.				</sec>^lpt
!v085!^kLactose intolerance^len
!v085!^kLactase^len
!v085!^kPolymorphism, single nucleotide^len
!v085!^kBreath tests^len
!v085!^kColombia^len
!v085!^kCaribbean region^len
!v085!^kIntolerancia a lactose^lpt
!v085!^kLactase^lpt
!v085!^kPolimorfismo de um unico nucleotideo^lpt
!v085!^kTestes respiratorios^lpt
!v085!^kColombia^lpt
!v085!^kRegiao do Caribe^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d11
!v112!2011
!v113!^y2011^m08^d05
!v114!2011
!v120!XML_3.0
!v121!5
!v237!10.1590/S0004-28032012000100002
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!l
!v708!1
!ID 000012
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sArola^rND^nH
!v010!^sKoivula^rND^nT
!v010!^sJokela^rND^nH
!v010!^sJauhiainen^rND^nM
!v010!^sKeyrilainen^rND^nO
!v010!^sAhola^rND^nT
!v010!^sUusitalo^rND^nA
!v010!^sIsokoski^rND^nM
!v012!Comparison of indirect diagnostic methods for hypolactasia^len
!v014!351-57
!v030!Scand J Gastroenterol
!v031!23
!v064!1988
!v065!19880000
!v071!journal
!v118!1
!v514!^l357^f351
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000013
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sBersaglieri^rND^nT
!v010!^sSabeti^rND^nPC
!v010!^sPatterson^rND^nN
!v010!^sVanderploeg^rND^nT
!v010!^sSchaffner^rND^nSF
!v010!^sDrake^rND^nJA
!v010!^sRhodes^rND^nM
!v010!^sReich^rND^nDE
!v010!^sHirschhorn^rND^nJN
!v012!Genetic signatures of strong recent positive selection at the lactase gene^len
!v014!1111-120
!v030!Am J Hum Genet
!v031!74
!v064!2004
!v065!20040000
!v118!2
!v514!^l1120^f1111
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000014
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sBulhoes^rND^nAC
!v010!^sGoldani^rND^nHA
!v010!^sOliveira^rND^nFS
!v010!^sMatte^rND^nUS
!v010!^sMazzuca^rND^nRB
!v010!^sSilveira^rND^nTR
!v012!Correlation between lactose absorption and the C/T-13910 and G/A-22018 mutations of the lactase-phlorizin hydrolase (LCT) gene in adult-type hypolactasia^len
!v014!1441-446
!v030!Braz J Med Biol Res
!v031!40
!v064!2007
!v065!20070000
!v118!3
!v514!^l1446^f1441
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000015
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sDahlqvist^rND^nA
!v012!Assay of intestinal disaccharidases^len
!v014!169-72
!v030!Scand J Clin Lab Invest
!v031!44
!v064!1984
!v065!19840000
!v118!4
!v514!^l172^f169
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000016
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sDi Stefano^rND^nM
!v010!^sTerulla^rND^nV
!v010!^sTana^rND^nP
!v010!^sMazzocchi^rND^nS
!v010!^sRomero^rND^nE
!v010!^sCorazza^rND^nGR
!v012!Genetic test for lactase non-persistence and hydrogen breath test: is genotype better than phenotype to diagnose lactose malabsorption?^len
!v014!474-79
!v030!Dig Liver Dis
!v031!41
!v064!2009
!v065!20090000
!v118!5
!v514!^l479^f474
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000017
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sEnattah^rND^nNS
!v010!^sSahi^rND^nT
!v010!^sSavilahti^rND^nE
!v010!^sTerwilliger^rND^nJD
!v010!^sPeltonen^rND^nL
!v010!^sJarvela^rND^nI
!v012!Identification of a variant associated with adult-type hypolactasia^len
!v014!233-37
!v030!Nat Genet
!v031!30
!v064!2002
!v065!20020000
!v118!6
!v514!^l237^f233
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000018
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sEnattah^rND^nNS
!v010!^sJensen^rND^nTG
!v010!^sNielsen^rND^nM
!v010!^sLewinski^rND^nR
!v010!^sKuokkanen^rND^nM
!v010!^sRasinpera^rND^nH
!v010!^sEl-Shanti^rND^nH
!v010!^sSeo^rND^nJK
!v010!^sAlifrangis^rND^nM
!v010!^sKhalil^rND^nIF
!v010!^sNatah^rND^nA
!v010!^sAli^rND^nA
!v010!^sNatah^rND^nS
!v010!^sComas^rND^nD
!v010!^sMehdi^rND^nSQ
!v010!^sGroop^rND^nL
!v010!^sVestergaard^rND^nEM
!v010!^sImtiaz^rND^nF
!v010!^sRashed^rND^nMS
!v010!^sMeyer^rND^nB
!v010!^sTroelsen^rND^nJ
!v010!^sPeltonen^rND^nL
!v012!Independent introduction of two lactase-persistence alleles into human populations reflects different history of adaptation to milk culture^len
!v014!57-72
!v030!Am J Hum Genet
!v031!82
!v064!2008
!v065!20080000
!v118!7
!v514!^l72^f57
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000019
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sExcoffier^rND^nL
!v010!^sLaval^rND^nG
!v010!^sSchneider^rND^nS
!v012!Arlequin (version 3.0): an integrated software package for population genetics data analysis^len
!v014!47-50
!v030!Evol Bioinform Online
!v031!1
!v064!2007
!v065!20070000
!v118!8
!v514!^l50^f47
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000020
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sGoncalves^rND^nVF
!v010!^sCarvalho^rND^nCM
!v010!^sBortolini^rND^nMC
!v010!^sBydlowski^rND^nSP
!v010!^sPena^rND^nSD
!v012!The phylogeography of African Brazilians^len
!v014!23-32
!v030!Hum Hered
!v031!65
!v064!2008
!v065!20080000
!v118!9
!v514!^l32^f23
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000021
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sHogenauer^rND^nC
!v010!^sHammer^rND^nHF
!v010!^sMellitzer^rND^nK
!v010!^sRenner^rND^nW
!v010!^sKrejs^rND^nGJ
!v010!^sToplak^rND^nH
!v012!Evaluation of a new DNA test compared with the lactose hydrogen breath test for the diagnosis of lactase non-persistence^len
!v014!371-76
!v030!Eur J Gastroenterol Hepatol
!v031!17
!v064!2005
!v065!20050000
!v118!10
!v514!^l376^f371
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000022
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sIngram^rND^nCJ
!v010!^sElamin^rND^nMF
!v010!^sMulcare^rND^nCA
!v010!^sWeale^rND^nME
!v010!^sTarekegn^rND^nA
!v010!^sRaga^rND^nTO
!v010!^sBekele^rND^nE
!v010!^sElamin^rND^nFM
!v010!^sThomas^rND^nMG
!v010!^sBradman^rND^nN
!v010!^sSwallow^rND^nDM
!v012!A novel polymorphism associated with lactose tolerance in Africa: multiple causes for lactase persistence?^len
!v014!779-88
!v030!Hum Genet
!v031!120
!v064!2007
!v065!20070000
!v118!11
!v514!^l788^f779
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000023
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sIngram^rND^nCJ
!v010!^sMulcare^rND^nCA
!v010!^sItan^rND^nY
!v010!^sThomas^rND^nMG
!v010!^sSwallow^rND^nDM
!v012!Lactose digestion and the evolutionary genetics of lactase persistence^len
!v014!579-91
!v030!Hum Genet
!v031!124
!v064!2009
!v065!20090000
!v118!12
!v514!^l591^f579
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000024
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sKrawczyk^rND^nM
!v010!^sWolska^rND^nM
!v010!^sSchwartz^rND^nS
!v010!^sGruenhage^rND^nF
!v010!^sTerjung^rND^nB
!v010!^sPortincasa^rND^nP
!v010!^sSauerbruch^rND^nT
!v010!^sLammert^rND^nF
!v012!Concordance of genetic and breath tests for lactose intolerance in a tertiary referral centre^len
!v014!135-39
!v030!J Gastrointestin Liver Dis
!v031!17
!v064!2008
!v065!20080000
!v118!13
!v514!^l139^f135
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000025
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sKuokkanen^rND^nM
!v010!^sEnattah^rND^nNS
!v010!^sOksanen^rND^nA
!v010!^sSavilahti^rND^nE
!v010!^sOrpana^rND^nA
!v010!^sJarvela^rND^nI
!v012!Transcriptional regulation of the lactase-phlorizin hydrolase gene by polymorphisms associated with adult-type hypolactasia^len
!v014!647-52
!v030!Gut
!v031!52
!v064!2003
!v065!20030000
!v118!14
!v514!^l652^f647
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000026
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sMattar^rND^nR
!v010!^sMonteiro^rND^nMdoS
!v010!^sVillares^rND^nCA
!v010!^sdos Santos^rND^nAF
!v010!^sCarrilho^rND^nFJ
!v012!Single nucleotide polymorphism C/T(-13910), located upstream of the lactase gene, associated with adult-type hypolactasia: validation for clinical practice^len
!v014!628-30
!v030!Clin Biochem
!v031!41
!v064!2008
!v065!20080000
!v118!15
!v514!^l630^f628
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000027
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sMattar^rND^nR
!v010!^sMonteiro^rND^nMS
!v010!^sVillares^rND^nCA
!v010!^sSantos^rND^nAF
!v010!^sSilva^rND^nJM
!v010!^sCarrilho^rND^nFJ
!v012!Frequency of LCT-13910C>T single nucleotide polymorphism associated with adult-type hypolactasia/lactase persistence among Brazilians of different ethnic groups^len
!v014!46-8
!v030!Nutr J
!v031!8
!v064!2009
!v065!20090000
!v118!16
!v514!^l48^f46
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000028
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sMendoza^rND^nE
!v010!^sHernandez^rND^nAC
!v010!^sWilches^rND^nR
!v010!^sVarela^rND^nLL
!v010!^sVillarreal^rND^nJL
!v010!^sBarrera^rND^nLA
!v010!^sVillanueva^rND^nDA
!v012!Genotype frequencies of C/T-13910 and G/A-22018 polymorphisms in a Colombian Caribbean population do not correspond with lactase persistence prevalence reported in the region^len
!v014!290-94
!v030!Colomb Med
!v031!41
!v064!2010
!v065!20100000
!v118!17
!v514!^l294^f290
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000029
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sMulcare^rND^nCA
!v010!^sWeale^rND^nME
!v010!^sJones^rND^nAL
!v010!^sConnell^rND^nB
!v010!^sZeitlyn^rND^nD
!v010!^sTarekegn^rND^nA
!v010!^sSwallow^rND^nDM
!v010!^sBradman^rND^nN
!v010!^sThomas^rND^nMG
!v012!The T allele of a single-nucleotide polymorphism 13.9 kb upstream of the lactase gene (LCT) (C-13.9kbT) does not predict or cause the lactase-persistence phenotype in Africans^len
!v014!1102-110
!v030!Am J Hum Genet
!v031!74
!v064!2004
!v065!20040000
!v118!18
!v514!^l1110^f1102
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000030
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sNagy^rND^nD
!v010!^sBojacsi-Szabo^rND^nE
!v010!^sVarkonyi^rND^na
!v010!^sCsanyi^rND^nB
!v010!^sCzibula^rND^na
!v010!^sBede^rND^nO
!v010!^sTari^rND^nB
!v010!^sRasko^rND^nI
!v012!Prevalence of adult-type hypolactasia as diagnosed with genetic and lactose hydrogen breath tests in Hungarians^len
!v014!909-12
!v030!Eur J Clin Nutr
!v031!63
!v064!2009
!v065!20090000
!v118!19
!v514!^l912^f909
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000031
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sOjetti^rND^nV
!v010!^sLa Mura^rND^nR
!v010!^sZocco^rND^nMA
!v010!^sCesaro^rND^nP
!v010!^sDe Masi^rND^nE
!v010!^sLa Mazza^rND^nA
!v010!^sCammarota^rND^nG
!v010!^sGasbarrini^rND^nG
!v010!^sGasbarrini^rND^nA
!v012!Quick test: a new test for the diagnosis of duodenal hypolactasia^len
!v014!1589-592
!v030!Dig Dis Sci
!v031!53
!v064!2008
!v065!20080000
!v118!20
!v514!^l1592^f1589
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000032
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sOlds^rND^nLC
!v010!^sAhn^rND^nJK
!v010!^sSibley^rND^nE
!v012!13915*G DNA polymorphism associated with lactase persistence in Africa interacts with Oct-1^len
!v014!111-13
!v030!Hum Genet
!v031!129
!v064!2011
!v065!20110000
!v118!21
!v514!^l113^f111
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000033
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sPohl^rND^nD
!v010!^sSavarino^rND^nE
!v010!^sHersberger^rND^nM
!v010!^sBehlis^rND^nZ
!v010!^sStutz^rND^nB
!v010!^sGoetze^rND^nO
!v010!^sEckardstein^rND^nAV
!v010!^sFried^rND^nM
!v010!^sTutuian^rND^nR
!v012!Excellent agreement between genetic and hydrogen breath tests for lactase deficiency and the role of extended symptom assessment^len
!v014!900-07
!v030!Br J Nutr
!v031!104
!v064!2010
!v065!20100000
!v118!22
!v514!^l907^f900
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000034
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sRidefelt^rND^nP
!v010!^sHakansson^rND^nLD
!v012!Lactose intolerance: lactose tolerance test versus genotyping^len
!v014!822-26
!v030!Scand J Gastroenterol
!v031!40
!v064!2005
!v065!20050000
!v118!23
!v514!^l826^f822
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000035
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sRomagnuolo^rND^nJ
!v010!^sSchiller^rND^nD
!v010!^sBailey^rND^nRJ
!v012!Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation^len
!v014!1113-126
!v030!Am J Gastroenterol
!v031!97
!v064!2002
!v065!20020000
!v118!24
!v514!^l1126^f1113
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000036
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sSahi^rND^nT
!v012!Genetics and epidemiology of adult-type hypolactasia^len
!v014!7-20
!v030!Scand J Gastroenterol Suppl
!v031!202
!v064!1994
!v065!19940000
!v118!25
!v514!^l20^f7
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000037
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sSalzano^rND^nFM
!v010!^sBortolini^rND^nMC
!v018!The evolution and genetics of Latin American populations
!v062!Cambridge University Press
!v064!2002
!v065!20020000
!v066!Cambridge, UK
!v118!26
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000038
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sSwallow^rND^nDM
!v012!Genetics of lactase persistence and lactose intolerance^len
!v014!197-219
!v030!Ann Rev Genet
!v031!37
!v064!2003
!v065!20030000
!v118!27
!v514!^l219^f197
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000039
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sTishkoff^rND^nSA
!v010!^sReed^rND^nFA
!v010!^sRanciaro^rND^nA
!v010!^sVoight^rND^nBF
!v010!^sBabbitt^rND^nCC
!v010!^sSilverman^rND^nJS
!v010!^sPowell^rND^nK
!v010!^sMortensen^rND^nHM
!v010!^sHirbo^rND^nJB
!v010!^sOsman^rND^nM
!v010!^sIbrahim^rND^nM
!v010!^sOmar^rND^nSA
!v010!^sLema^rND^nG
!v010!^sNyambo^rND^nTB
!v010!^sGhori^rND^nJ
!v010!^sBumpstead^rND^nS
!v010!^sPritchard^rND^nJK
!v010!^sWray^rND^nGA
!v010!^sDeloukas^rND^nP
!v012!Convergent adaptation of human lactase persistence in Africa and Europe^len
!v014!31-40
!v030!Nat Genet
!v031!39
!v064!2007
!v065!20070000
!v118!28
!v514!^l40^f31
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000040
!v001!br1.1
!v002!0004-2803-ag-49-01-05.xml
!v004!v49n1
!v010!^sTorniainen^rND^nS
!v010!^sParker^rND^nMI
!v010!^sHolmberg^rND^nV
!v010!^sLahtela^rND^nE
!v010!^sDandara^rND^nC
!v010!^sJarvela^rND^nI
!v012!Screening of variants for lactase persistence/non-persistence in populations from South Africa and Ghana^len
!v014!31
!v030!BMC Genet
!v031!10
!v064!2009
!v065!20090000
!v118!29
!v514!^f31
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-05.xml
!v705!S
!v706!c
!v708!29
!v865!20120300
!ID 000041
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v091!20120814
!v092!164249
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v703!115
!v705!S
!v706!o
!v708!1
!ID 000042
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^1aff1
!v010!^1aff2
!v010!^sCoelho-Borges^rauthor^nSilvia
!v010!^sCheinquer^rauthor^nHugo
!v010!^sWolff^rauthor^nFernando Herz
!v010!^sCheinquer^rauthor^nNelson
!v010!^sKrug^rauthor^nLuciano
!v010!^sAshton-Prolla^rauthor^nPatricia
!v012!^tEffect of HFE gene polymorphism on sustained virological response in patients with chronic hepatitis C and elevated serum ferritin
!v012!^tEfeito do polimorfismo do gene HFE sobre a resposta viral sustentada em portadores de hepatite cronica C com ferritina serica elevada^lpt
!v014!^l13^f9
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal do Rio Grande do Sul (UFRGS)^iaff1^9Graduate Program in Medicine: Gastroenterology - Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS)^1Graduate Program in Medicine: Gastroenterology - Faculdade de Medicina^l1
!v070!Gastroenterology Department, Hospital de Clinicas de Porto Alegre^iaff2^9Gastroenterology Department, Hospital de Clinicas de Porto Alegre^5?^l2
!v070!UFRGS^iaff3^9Graduate Program in Epidemiology - Faculdade de Medicina, UFRGS^1Graduate Program in Epidemiology - Faculdade de Medicina^l3
!v070!<label>4</label>National Institute of Science and Technology for Health Technology Assessment (IATS) CNPq/Brazil^iaff4^l4
!v070!<label>5</label>Amplicon - Molecular Biology Laboratory^iaff5^l5
!v070!Medical Genetics Service, Hospital de Clinicas de Porto Alegre^iaff6^9Medical Genetics Service, Hospital de Clinicas de Porto Alegre^5?^l6
!v070!UFRGS^cPorto Alegre^iaff7^l7^1Genetics Department^pBrasil^sRS^9Genetics Department, UFRGS, Porto Alegre, RS, Brasil
!v071!oa
!v072!37
!v083!^a<sec>					<title>CONTEXT:</title>					 Abnormal serum ferritin levels are found in approximately 20%-30% of the patients with chronic hepatitis C and are associated with a lower response rate to interferon therapy. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To determine if the presence of HFE gene mutations had any effect on the sustained virological response rate to interferon based therapy in chronic hepatitis C patients with elevated serum ferritin. 				</sec>				<sec>					<title>METHODS:</title>					 A total of 44 treatment naive patients with histologically demonstrated chronic hepatitis C, all infected with hepatitis C virus genotype non-1 (38 genotype 3; 6 genotype 2) and serum ferritin above 500 ng/mL were treated with interferon (3 MU, 3 times a week) and ribavirin (1.000 mg, daily) for 24 weeks. 				</sec>				<sec>					<title>RESULTS:</title>					 Sustained virological response was defined as negative qualitative HCV-RNA more than 24 weeks after the end of treatment. Serum HCV-RNA was measured by qualitative in house polymerase chain reaction with a limit of detection of 200 IU/mL. HFE gene mutation was detected using restriction-enzyme digestion with RsaI (C282Y mutation analysis) and BclI (H63D mutation analysis) in 16 (37%) patients, all heterozygous (11 H63D, 2 C282Y and 3 both). Sustained virological response was achieved in 0 of 16 patients with HFE gene mutations and 11 (41%) of 27 patients without HFE gene mutations (P = 0.002; exact Fisher test). 				</sec>				<sec>					<title>CONCLUSION:</title>					 Heterozigozity for H63D and/or C282Y HFE gene mutation predicts absence of sustained virological response to combination treatment with interferon and ribavirin in patients with chronic hepatitis C, non-1 genotype and serum ferritin levels above 500 ng/mL.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 Niveis sericos anormais de ferritina sao encontrados em aproximadamente 20%-30% dos pacientes com hepatite cronica C e estao associadas a uma baixa taxa de resposta a terapia com interferon. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar a associacao entre a presenca de mutacoes do gene HFE e a taxa de resposta virologica sustentada ao interferon em pacientes portadores de hepatite cronica C com ferritina serica elevada. 				</sec>				<sec>					<title>MeTODOS:</title>					 Um total de 44 pacientes, virgem de tratamento, infectado pelo virus da hepatite C de genotipos nao-1 (38 genotipo 3; 6 genotipo 2) e ferritina serica acima de 500 ng/mL foi tratado com interferon (3 MU, tres vezes por semana) e ribavirina (1000 mg/dia) por 24 semanas. Resposta virologica sustentada foi definida como HCV-RNA indetectavel 24 semanas apos o fim do tratamento. Foi utilizado tecnica de reacao em cadeia da polimerase em tempo-real com limite de deteccao de 200 UI /mL. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Mutacoes do gene HFE foram detectadas por "restriction-enzyme digestion" com RsaI (analise de mutacao C282Y) e BclI (analise de mutacao H63D) em 16 pacientes (37%), todos heterozigotos (11 H63D, 2 C282Y e 3 ambos). Resposta virologica sustentada foi alcancada em 0 de 16 pacientes com mutacoes do gene HFE e 11 (41%) dos 27 pacientes sem mutacoes do gene HFE (P = 0,002; teste exato de Fisher). 				</sec>				<sec>					<title>CONCLUSaO:</title>					 A heterozigose para os genes H63D e/ou C282Y HFE esta associada a reducao significativa da taxa de resposta virologica sustentada ao tratamento com interferon e ribavirina em pacientes com hepatite cronica C, genotipo nao-1 e com niveis sericos de ferritina acima de 500 ng/mL.				</sec>^lpt
!v085!^kPolymorphysm, genetic^len
!v085!^kHepatitis C, chronic^len
!v085!^kFerritins^len
!v085!^kInterferons^len
!v085!^kPolimorfismo genetico^lpt
!v085!^kHepatite C cronica^lpt
!v085!^kFerritinas^lpt
!v085!^kInterferons^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d25
!v112!2011
!v113!^y2011^m08^d10
!v114!2011
!v120!XML_3.0
!v121!9
!v237!10.1590/S0004-28032012000100003
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!h
!v708!1
!ID 000043
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^1aff1
!v010!^1aff2
!v010!^sCoelho-Borges^rauthor^nSilvia
!v010!^sCheinquer^rauthor^nHugo
!v010!^sWolff^rauthor^nFernando Herz
!v010!^sCheinquer^rauthor^nNelson
!v010!^sKrug^rauthor^nLuciano
!v010!^sAshton-Prolla^rauthor^nPatricia
!v012!^tEffect of HFE gene polymorphism on sustained virological response in patients with chronic hepatitis C and elevated serum ferritin
!v012!^tEfeito do polimorfismo do gene HFE sobre a resposta viral sustentada em portadores de hepatite crônica C com ferritina sérica elevada^lpt
!v014!^l13^f9
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal do Rio Grande do Sul (UFRGS)^iaff1^9Graduate Program in Medicine: Gastroenterology - Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS)^1Graduate Program in Medicine: Gastroenterology - Faculdade de Medicina^l1
!v070!Gastroenterology Department, Hospital de Cl&#237;nicas de Porto Alegre^iaff2^9Gastroenterology Department, Hospital de Cl&#237;nicas de Porto Alegre^5?^l2
!v070!UFRGS^iaff3^9Graduate Program in Epidemiology - Faculdade de Medicina, UFRGS^1Graduate Program in Epidemiology - Faculdade de Medicina^l3
!v070!<label>4</label>National Institute of Science and Technology for Health Technology Assessment (IATS) CNPq/Brazil^iaff4^l4
!v070!<label>5</label>Amplicon - Molecular Biology Laboratory^iaff5^l5
!v070!Medical Genetics Service, Hospital de Cl&#237;nicas de Porto Alegre^iaff6^9Medical Genetics Service, Hospital de Cl&#237;nicas de Porto Alegre^5?^l6
!v070!UFRGS^cPorto Alegre^iaff7^l7^1Genetics Department^pBrasil^sRS^9Genetics Department, UFRGS, Porto Alegre, RS, Brasil
!v071!oa
!v072!37
!v083!^a<sec>					<title>CONTEXT:</title>					<p> Abnormal serum ferritin levels are found in approximately 20%-30% of the patients with chronic hepatitis C and are associated with a lower response rate to interferon therapy. </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To determine if the presence of HFE gene mutations had any effect on the sustained virological response rate to interferon based therapy in chronic hepatitis C patients with elevated serum ferritin. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> A total of 44 treatment na&#207;ve patients with histologically demonstrated chronic hepatitis C, all infected with hepatitis C virus genotype non-1 (38 genotype 3; 6 genotype 2) and serum ferritin above 500 ng/mL were treated with interferon (3 MU, 3 times a week) and ribavirin (1.000 mg, daily) for 24 weeks. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> Sustained virological response was defined as negative qualitative HCV-RNA more than 24 weeks after the end of treatment. Serum HCV-RNA was measured by qualitative in house polymerase chain reaction with a limit of detection of 200 IU/mL. HFE gene mutation was detected using restriction-enzyme digestion with RsaI (C282Y mutation analysis) and BclI (H63D mutation analysis) in 16 (37%) patients, all heterozygous (11 H63D, 2 C282Y and 3 both). Sustained virological response was achieved in 0 of 16 patients with HFE gene mutations and 11 (41%) of 27 patients without HFE gene mutations (<italic>P</italic> = 0.002; exact Fisher test). </p>				</sec>				<sec>					<title>CONCLUSION:</title>					<p> Heterozigozity for H63D and/or C282Y HFE gene mutation predicts absence of sustained virological response to combination treatment with interferon and ribavirin in patients with chronic hepatitis C, non-1 genotype and serum ferritin levels above 500 ng/mL.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> N&#237;veis s&#233;ricos anormais de ferritina s&#227;o encontrados em aproximadamente 20%-30% dos pacientes com hepatite cr&#244;nica C e est&#227;o associadas a uma baixa taxa de resposta &#224; terapia com interferon. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Avaliar a associa&#231;&#227;o entre a presen&#231;a de muta&#231;&#245;es do gene HFE e a taxa de resposta virol&#243;gica sustentada ao interferon em pacientes portadores de hepatite cr&#244;nica C com ferritina s&#233;rica elevada. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Um total de 44 pacientes, virgem de tratamento, infectado pelo v&#237;rus da hepatite C de gen&#243;tipos n&#227;o-1 (38 gen&#243;tipo 3; 6 gen&#243;tipo 2) e ferritina s&#233;rica acima de 500 ng/mL foi tratado com interferon (3 MU, tr&#234;s vezes por semana) e ribavirina (1000 mg/dia) por 24 semanas. Resposta virol&#243;gica sustentada foi definida como HCV-RNA indetect&#225;vel 24 semanas ap&#243;s o fim do tratamento. Foi utilizado t&#233;cnica de rea&#231;&#227;o em cadeia da polimerase em tempo-real com limite de detec&#231;&#227;o de 200 UI /mL. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Muta&#231;&#245;es do gene HFE foram detectadas por "restriction-enzyme digestion" com RsaI (an&#225;lise de muta&#231;&#227;o C282Y) e BclI (an&#225;lise de muta&#231;&#227;o H63D) em 16 pacientes (37%), todos heterozigotos (11 H63D, 2 C282Y e 3 ambos). Resposta virol&#243;gica sustentada foi alcan&#231;ada em 0 de 16 pacientes com muta&#231;&#245;es do gene HFE e 11 (41%) dos 27 pacientes sem muta&#231;&#245;es do gene HFE (P = 0,002; teste exato de Fisher). </p>				</sec>				<sec>					<title>CONCLUS&#195;O:</title>					<p> A heterozigose para os genes H63D e/ou C282Y HFE est&#225; associada &#224; redu&#231;&#227;o significativa da taxa de resposta virol&#243;gica sustentada ao tratamento com interferon e ribavirina em pacientes com hepatite cr&#244;nica C, gen&#243;tipo n&#227;o-1 e com n&#237;veis s&#233;ricos de ferritina acima de 500 ng/mL.</p>				</sec>^lpt
!v085!^kPolymorphysm, genetic^len
!v085!^kHepatitis C, chronic^len
!v085!^kFerritins^len
!v085!^kInterferons^len
!v085!^kPolimorfismo genético^lpt
!v085!^kHepatite C crônica^lpt
!v085!^kFerritinas^lpt
!v085!^kInterferons^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d25
!v112!2011
!v113!^y2011^m08^d10
!v114!2011
!v120!XML_3.0
!v121!9
!v237!10.1590/S0004-28032012000100003
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!f
!v708!1
!ID 000044
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^1aff1
!v010!^1aff2
!v010!^sCoelho-Borges^rauthor^nSilvia
!v010!^sCheinquer^rauthor^nHugo
!v010!^sWolff^rauthor^nFernando Herz
!v010!^sCheinquer^rauthor^nNelson
!v010!^sKrug^rauthor^nLuciano
!v010!^sAshton-Prolla^rauthor^nPatricia
!v012!^tEffect of HFE gene polymorphism on sustained virological response in patients with chronic hepatitis C and elevated serum ferritin
!v012!^tEfeito do polimorfismo do gene HFE sobre a resposta viral sustentada em portadores de hepatite cronica C com ferritina serica elevada^lpt
!v014!^l13^f9
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal do Rio Grande do Sul (UFRGS)^iaff1^9Graduate Program in Medicine: Gastroenterology - Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS)^1Graduate Program in Medicine: Gastroenterology - Faculdade de Medicina^l1
!v070!Gastroenterology Department, Hospital de Clinicas de Porto Alegre^iaff2^9Gastroenterology Department, Hospital de Clinicas de Porto Alegre^5?^l2
!v070!UFRGS^iaff3^9Graduate Program in Epidemiology - Faculdade de Medicina, UFRGS^1Graduate Program in Epidemiology - Faculdade de Medicina^l3
!v070!<label>4</label>National Institute of Science and Technology for Health Technology Assessment (IATS) CNPq/Brazil^iaff4^l4
!v070!<label>5</label>Amplicon - Molecular Biology Laboratory^iaff5^l5
!v070!Medical Genetics Service, Hospital de Clinicas de Porto Alegre^iaff6^9Medical Genetics Service, Hospital de Clinicas de Porto Alegre^5?^l6
!v070!UFRGS^cPorto Alegre^iaff7^l7^1Genetics Department^pBrasil^sRS^9Genetics Department, UFRGS, Porto Alegre, RS, Brasil
!v071!oa
!v072!37
!v083!^a<sec>					<title>CONTEXT:</title>					 Abnormal serum ferritin levels are found in approximately 20%-30% of the patients with chronic hepatitis C and are associated with a lower response rate to interferon therapy. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To determine if the presence of HFE gene mutations had any effect on the sustained virological response rate to interferon based therapy in chronic hepatitis C patients with elevated serum ferritin. 				</sec>				<sec>					<title>METHODS:</title>					 A total of 44 treatment naive patients with histologically demonstrated chronic hepatitis C, all infected with hepatitis C virus genotype non-1 (38 genotype 3; 6 genotype 2) and serum ferritin above 500 ng/mL were treated with interferon (3 MU, 3 times a week) and ribavirin (1.000 mg, daily) for 24 weeks. 				</sec>				<sec>					<title>RESULTS:</title>					 Sustained virological response was defined as negative qualitative HCV-RNA more than 24 weeks after the end of treatment. Serum HCV-RNA was measured by qualitative in house polymerase chain reaction with a limit of detection of 200 IU/mL. HFE gene mutation was detected using restriction-enzyme digestion with RsaI (C282Y mutation analysis) and BclI (H63D mutation analysis) in 16 (37%) patients, all heterozygous (11 H63D, 2 C282Y and 3 both). Sustained virological response was achieved in 0 of 16 patients with HFE gene mutations and 11 (41%) of 27 patients without HFE gene mutations (P = 0.002; exact Fisher test). 				</sec>				<sec>					<title>CONCLUSION:</title>					 Heterozigozity for H63D and/or C282Y HFE gene mutation predicts absence of sustained virological response to combination treatment with interferon and ribavirin in patients with chronic hepatitis C, non-1 genotype and serum ferritin levels above 500 ng/mL.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 Niveis sericos anormais de ferritina sao encontrados em aproximadamente 20%-30% dos pacientes com hepatite cronica C e estao associadas a uma baixa taxa de resposta a terapia com interferon. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar a associacao entre a presenca de mutacoes do gene HFE e a taxa de resposta virologica sustentada ao interferon em pacientes portadores de hepatite cronica C com ferritina serica elevada. 				</sec>				<sec>					<title>MeTODOS:</title>					 Um total de 44 pacientes, virgem de tratamento, infectado pelo virus da hepatite C de genotipos nao-1 (38 genotipo 3; 6 genotipo 2) e ferritina serica acima de 500 ng/mL foi tratado com interferon (3 MU, tres vezes por semana) e ribavirina (1000 mg/dia) por 24 semanas. Resposta virologica sustentada foi definida como HCV-RNA indetectavel 24 semanas apos o fim do tratamento. Foi utilizado tecnica de reacao em cadeia da polimerase em tempo-real com limite de deteccao de 200 UI /mL. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Mutacoes do gene HFE foram detectadas por "restriction-enzyme digestion" com RsaI (analise de mutacao C282Y) e BclI (analise de mutacao H63D) em 16 pacientes (37%), todos heterozigotos (11 H63D, 2 C282Y e 3 ambos). Resposta virologica sustentada foi alcancada em 0 de 16 pacientes com mutacoes do gene HFE e 11 (41%) dos 27 pacientes sem mutacoes do gene HFE (P = 0,002; teste exato de Fisher). 				</sec>				<sec>					<title>CONCLUSaO:</title>					 A heterozigose para os genes H63D e/ou C282Y HFE esta associada a reducao significativa da taxa de resposta virologica sustentada ao tratamento com interferon e ribavirina em pacientes com hepatite cronica C, genotipo nao-1 e com niveis sericos de ferritina acima de 500 ng/mL.				</sec>^lpt
!v085!^kPolymorphysm, genetic^len
!v085!^kHepatitis C, chronic^len
!v085!^kFerritins^len
!v085!^kInterferons^len
!v085!^kPolimorfismo genetico^lpt
!v085!^kHepatite C cronica^lpt
!v085!^kFerritinas^lpt
!v085!^kInterferons^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d25
!v112!2011
!v113!^y2011^m08^d10
!v114!2011
!v120!XML_3.0
!v121!9
!v237!10.1590/S0004-28032012000100003
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!l
!v708!1
!ID 000045
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sAlves^rND^nAV
!v010!^sde Azevedo^rND^nAP
!v010!^sPerin^rND^nC
!v010!^sRamos^rND^nGZ
!v010!^sBrandao^rND^nAB
!v010!^sde Mattos^rND^nAA
!v010!^sde Almeida^rND^nPR
!v014!227-32
!v030!Arq Gastroenterol
!v031!40
!v064!2003
!v065!20030000
!v071!journal
!v118!1
!v514!^l232^f227
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000046
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sBeinker^rND^nNK
!v010!^sVoigt^rND^nMD
!v010!^sArendse^rND^nM
!v010!^sSmit^rND^nJ
!v010!^sStander^rND^nIA
!v010!^sKirsch^rND^nRE
!v012!Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C^len
!v014!633-38
!v030!J Hepatol
!v031!25
!v064!1996
!v065!19960000
!v118!2
!v514!^l638^f633
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000047
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sBonkovsky^rND^nHL
!v010!^sBanner^rND^nBF
!v010!^sRothman^rND^nAL
!v012!Iron and chronic viral hepatitis^len
!v014!759-68
!v030!Hepatology
!v031!25
!v064!1997
!v065!19970000
!v118!3
!v514!^l768^f759
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000048
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sBonkovsky^rND^nHL
!v012!Iron as a comorbid factor in chronic viral hepatitis^len
!v014!1-4
!v030!Am J Gastroenterol
!v031!97
!v064!2002
!v065!20020000
!v118!4
!v514!^l4^f1
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000049
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sBonkovsky^rND^nHL
!v010!^sTroy^rND^nN
!v010!^sMcNeal^rND^nK
!v010!^sBanner^rND^nBF
!v010!^sSharma^rND^nA
!v010!^sObando^rND^nJ
!v010!^sMehta^rND^nS
!v010!^sKoff^rND^nRS
!v010!^sLiu^rND^nQ
!v010!^sHsieh^rND^nCC
!v012!Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C^len
!v014!848-54
!v030!J Hepatol
!v031!37
!v064!2002
!v065!20020000
!v118!5
!v514!^l854^f848
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000050
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sBonkovsky^rND^nHL
!v010!^sNaishadham^rND^nD
!v010!^sLambrecht^rND^nRW
!v010!^sChung^rND^nRT
!v010!^sHoefs^rND^nJC
!v010!^sNash^rND^nSR
!v010!^sRogers^rND^nTE
!v010!^sBanner^rND^nBF
!v010!^sSterling^rND^nRK
!v010!^sDonovan^rND^nJA
!v010!^sFontana^rND^nRJ
!v010!^sDi Bisceglie^rND^nAM
!v010!^sGhany^rND^nMG
!v010!^sMorishima^rND^nC
!v012!Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C^len
!v014!1440-451
!v030!Gastroenterology
!v031!131
!v064!2006
!v065!20060000
!v118!6
!v514!^l1451^f1440
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000051
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v018!Portaria 34 de 28 de setembro de 2007. Dispoe sobre protocolo clinico e diretrizes terapeuticas para hepatite viral C
!v062!Ministerio da Saude
!v064!2007
!v065!20070000
!v066!Brasilia
!v118!7
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000052
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sCarneiro^rND^nMV
!v010!^sSouza^rND^nFF
!v010!^sTeixeira^rND^nAC
!v010!^sFigueiredo^rND^nJF
!v010!^sVillanova^rND^nMG
!v010!^sSecaf^rND^nM
!v010!^sPassos^rND^nAD
!v010!^sRamalho^rND^nLN
!v010!^sCarneiro^rND^nFP
!v010!^sZucoloto^rND^nS
!v010!^sCandolo Martinelli^rND^nAL
!v012!The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C^len
!v014!1204-210
!v030!Eur J Gastroenterol Hepatol
!v031!22
!v064!2010
!v065!20100000
!v118!8
!v514!^l1210^f1204
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000053
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sDe Nicola^rND^nS
!v010!^sAghemo^rND^nA
!v010!^sRumi^rND^nMG
!v010!^sColombo^rND^nM
!v012!HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C^len
!v014!964-66
!v030!J Hepatol
!v031!51
!v064!2009
!v065!20090000
!v118!9
!v514!^l966^f964
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000054
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sDi Bisceglie^rND^nAM
!v010!^sAxiotis^rND^nCA
!v010!^sHoofnagle^rND^nJH
!v010!^sBacon^rND^nBR
!v012!Measurements of iron status in patients with chronic hepatitis^len
!v014!2108-113
!v030!Gastroenterology
!v031!102
!v064!1992
!v065!19920000
!v118!10
!v514!^l2113^f2108
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000055
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sDi Bisceglie^rND^nAM
!v010!^sBonkovsky^rND^nHL
!v010!^sChopra^rND^nS
!v010!^sFlamm^rND^nS
!v010!^sReddy^rND^nRK
!v010!^sGrace^rND^nN
!v010!^sKillenberg^rND^nP
!v010!^sHunt^rND^nC
!v010!^sTamburro^rND^nC
!v010!^sTavill^rND^nAS
!v010!^sFerguson^rND^nR
!v010!^sKrawitt^rND^nE
!v010!^sBanner^rND^nB
!v010!^sBacon^rND^nBR
!v012!Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial^len
!v014!135-38
!v030!Hepatology
!v031!32
!v064!2000
!v065!20000000
!v118!11
!v514!^l138^f135
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000056
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sDistante^rND^nS
!v010!^sBjoro^rND^nK
!v010!^sHellum^rND^nKB
!v010!^sMyrvang^rND^nB
!v010!^sBerg^rND^nJP
!v010!^sSkaug^rND^nK
!v010!^sRaknerud^rND^nN
!v010!^sBell^rND^nH
!v012!Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection^len
!v014!269-75
!v030!Liver
!v031!22
!v064!2002
!v065!20020000
!v118!12
!v514!^l275^f269
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000057
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sFeder^rND^nJN
!v010!^sGnirke^rND^nA
!v010!^sThomas^rND^nW
!v010!^sTsuchihashi^rND^nZ
!v010!^sRuddy^rND^nDA
!v010!^sBasava^rND^nA
!v010!^sDormishian^rND^nF
!v010!^sDomingo^rND^nR Jr
!v010!^sEllis^rND^nMC
!v010!^sFullan^rND^nA
!v010!^sHinton^rND^nLM
!v010!^sJones^rND^nNL
!v010!^sKimmel^rND^nBE
!v010!^sKronmal^rND^nGS
!v010!^sLauer^rND^nP
!v010!^sLee^rND^nVK
!v010!^sLoeb^rND^nDB
!v010!^sMapa^rND^nFA
!v010!^sMcClelland^rND^nE
!v010!^sMeyer^rND^nNC
!v010!^sMintier^rND^nGA
!v010!^sMoeller^rND^nN
!v010!^sMoore^rND^nT
!v010!^sMorikang^rND^nE
!v010!^sPrass^rND^nCE
!v010!^sQuintana^rND^nL
!v010!^sStarnes^rND^nSM
!v010!^sSchatzman^rND^nRC
!v010!^sBrunke^rND^nKJ
!v010!^sDrayna^rND^nDT
!v010!^sRisch^rND^nNJ
!v010!^sBacon^rND^nBR
!v010!^sWolff^rND^nRK
!v012!A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis^len
!v014!399-408
!v030!Nat Genet
!v031!13
!v064!1996
!v065!19960000
!v118!13
!v514!^l408^f399
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000058
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sFerenci^rND^nP
!v012!Predictors of response to therapy for chronic hepatitis C^len
!v014!25-31
!v030!Semin Liver Dis
!v031!24
!v064!2004
!v065!20040000
!v118!14
!v514!^l31^f25
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000059
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sFried^rND^nMW
!v010!^sShiffman^rND^nML
!v010!^sReddy^rND^nKR
!v010!^sSmith^rND^nC
!v010!^sMarinos^rND^nG
!v010!^sGoncales^rND^nFL Jr
!v010!^sHaussinger^rND^nD
!v010!^sDiago^rND^nM
!v010!^sCarosi^rND^nG
!v010!^sDhumeaux^rND^nD
!v010!^sCraxi^rND^nA
!v010!^sLin^rND^nA
!v010!^sHoffman^rND^nJ
!v010!^sYu^rND^nJ
!v012!Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection^len
!v014!975-82
!v030!N Engl J Med
!v031!347
!v064!2002
!v065!20020000
!v118!15
!v514!^l982^f975
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000060
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sFujita^rND^nN
!v010!^sSugimoto^rND^nR
!v010!^sUrawa^rND^nN
!v010!^sAraki^rND^nJ
!v010!^sMifuji^rND^nR
!v010!^sYamamoto^rND^nM
!v010!^sHoriike^rND^nS
!v010!^sTanaka^rND^nH
!v010!^sIwasa^rND^nM
!v010!^sKobayashi^rND^nY
!v010!^sAdachi^rND^nY
!v010!^sKaito^rND^nM
!v012!Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C^len
!v014!1886-893
!v030!J Gastroenterol Hepatol
!v031!22
!v064!2007
!v065!20070000
!v118!16
!v514!^l1893^f1886
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000061
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sFuller^rND^nMJ
!v010!^sShoukry^rND^nNH
!v010!^sGushima^rND^nT
!v010!^sBowen^rND^nDG
!v010!^sCallendret^rND^nB
!v010!^sCampbell^rND^nKJ
!v010!^sHasselschwert^rND^nDL
!v010!^sHughes^rND^nAL
!v010!^sWalker^rND^nCM
!v012!Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection^len
!v014!378-87
!v030!Hepatology
!v031!51
!v064!2010
!v065!20100000
!v118!17
!v514!^l387^f378
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000062
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sGerhard^rND^nGS
!v010!^sTen Elshof^rND^nAE
!v010!^sChorney^rND^nMJ
!v012!Hereditary haemochromatosis as an immunological disease^len
!v014!247-55
!v030!Br J Haematol
!v031!100
!v064!1998
!v065!19980000
!v118!18
!v514!^l255^f247
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000063
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sHayes^rND^nCN
!v010!^sKobayashi^rND^nM
!v010!^sAkuta^rND^nN
!v010!^sSuzuki^rND^nF
!v010!^sKumada^rND^nH
!v010!^sAbe^rND^nH
!v010!^sMiki^rND^nD
!v010!^sImamura^rND^nM
!v010!^sOchi^rND^nH
!v010!^sKamatani^rND^nN
!v010!^sNakamura^rND^nY
!v010!^sChayama^rND^nK
!v012!HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy^len
!v014!261-67
!v030!Gut
!v031!60
!v064!2011
!v065!20110000
!v118!19
!v514!^l267^f261
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000064
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sHearnshaw^rND^nS
!v010!^sThompson^rND^nNP
!v010!^sMcGill^rND^nA
!v012!The epidemiology of hyperferritinaemia^len
!v014!5866-869
!v030!World J Gastroenterol
!v031!12
!v064!2006
!v065!20060000
!v118!20
!v514!^l5869^f5866
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000065
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sHerrera^rND^nJL
!v012!Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy^len
!v014!3571-575
!v030!Am J Gastroenterol
!v031!94
!v064!1999
!v065!19990000
!v118!21
!v514!^l3575^f3571
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000066
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sHezode^rND^nC
!v010!^sCazeneuve^rND^nC
!v010!^sCoue^rND^nO
!v010!^sRoudot-Thoraval^rND^nF
!v010!^sLonjon^rND^nI
!v010!^sBastie^rND^nA
!v010!^sDuvoux^rND^nC
!v010!^sPawlotsky^rND^nJM
!v010!^sZafrani^rND^nES
!v010!^sAmselem^rND^nS
!v010!^sDhumeaux^rND^nD
!v012!Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions^len
!v014!979-84
!v030!J Hepatol
!v031!31
!v064!1999
!v065!19990000
!v118!22
!v514!^l984^f979
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000067
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sHofer^rND^nH
!v010!^sOsterreicher^rND^nC
!v010!^sJessner^rND^nW
!v010!^sPenz^rND^nM
!v010!^sSteindl-Munda^rND^nP
!v010!^sWrba^rND^nF
!v010!^sFerenci^rND^nP
!v012!Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C^len
!v014!1018-022
!v030!J Hepatol
!v031!40
!v064!2004
!v065!20040000
!v118!23
!v514!^l1022^f1018
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000068
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sKazemi-Shirazi^rND^nL
!v010!^sDatz^rND^nC
!v010!^sMaier-Dobersberger^rND^nT
!v010!^sKaserer^rND^nK
!v010!^sHackl^rND^nF
!v010!^sPolli^rND^nC
!v010!^sSteindl^rND^nPE
!v010!^sPenner^rND^nE
!v010!^sFerenci^rND^nP
!v012!The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C^len
!v014!127-34
!v030!Gastroenterology
!v031!116
!v064!1999
!v065!19990000
!v118!24
!v514!^l134^f127
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000069
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sLebray^rND^nP
!v010!^sZylberberg^rND^nH
!v010!^sHue^rND^nS
!v010!^sPoulet^rND^nB
!v010!^sCarnot^rND^nF
!v010!^sMartin^rND^nS
!v010!^sChretien^rND^nY
!v010!^sPol^rND^nS
!v010!^sCaillat-Zuckman^rND^nS
!v010!^sBrechot^rND^nC
!v010!^sNalpas^rND^nB
!v012!Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C^len
!v014!175-82
!v030!J Viral Hepat
!v031!11
!v064!2004
!v065!20040000
!v118!25
!v514!^l182^f175
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000070
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sMangia^rND^nA
!v010!^sThompson^rND^nAJ
!v010!^sSantoro^rND^nR
!v010!^sPiazzolla^rND^nV
!v010!^sTillmann^rND^nHL
!v010!^sPatel^rND^nK
!v010!^sShianna^rND^nKV
!v010!^sMottola^rND^nL
!v010!^sPetruzzellis^rND^nD
!v010!^sBacca^rND^nD
!v010!^sCarretta^rND^nV
!v010!^sMinerva^rND^nN
!v010!^sGoldstein^rND^nDB
!v010!^sMcHutchison^rND^nJG
!v012!An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response^len
!v014!821-27
!v030!Gastroenterology
!v031!139
!v064!2010
!v065!20100000
!v118!26
!v514!^l827^f821
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000071
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sManns^rND^nMP
!v010!^sMcHutchison^rND^nJG
!v010!^sGordon^rND^nSC
!v010!^sRustgi^rND^nVK
!v010!^sShiffman^rND^nM
!v010!^sReindollar^rND^nR
!v010!^sGoodman^rND^nZD
!v010!^sKoury^rND^nK
!v010!^sLing^rND^nM
!v010!^sAlbrecht^rND^nJK
!v012!Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial^len
!v014!958-65
!v030!Lancet
!v031!358
!v064!2001
!v065!20010000
!v118!27
!v514!^l965^f958
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000072
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sNeumann-Haefelin^rND^nC
!v010!^sSpangenberg^rND^nHC
!v010!^sBlum^rND^nHE
!v010!^sThimme^rND^nR
!v012!Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection^len
!v014!4839-847
!v030!World J Gastroenterol
!v031!13
!v064!2007
!v065!20070000
!v118!28
!v514!^l4847^f4839
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000073
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sPianko^rND^nS
!v010!^sMcHutchison^rND^nJG
!v010!^sGordon^rND^nSC
!v010!^sHeaton^rND^nS
!v010!^sGoodman^rND^nZD
!v010!^sPatel^rND^nK
!v010!^sCortese^rND^nCM
!v010!^sBrunt^rND^nEM
!v010!^sBacon^rND^nBR
!v010!^sBlatt^rND^nLM
!v012!Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection^len
!v014!483-89
!v030!J Interferon Cytokine Res
!v031!22
!v064!2002
!v065!20020000
!v118!29
!v514!^l489^f483
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000074
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sRauch^rND^nA
!v010!^sKutalik^rND^nZ
!v010!^sDescombes^rND^nP
!v010!^sCai^rND^nT
!v010!^sDi Iulio^rND^nJ
!v010!^sMueller^rND^nT
!v010!^sBochud^rND^nM
!v010!^sBattegay^rND^nM
!v010!^sBernasconi^rND^nE
!v010!^sBorovicka^rND^nJ
!v010!^sColombo^rND^nS
!v010!^sCerny^rND^nA
!v010!^sDufour^rND^nJF
!v010!^sFurrer^rND^nH
!v010!^sGunthard^rND^nHF
!v010!^sHeim^rND^nM
!v010!^sHirschel^rND^nB
!v010!^sMalinverni^rND^nR
!v010!^sMoradpour^rND^nD
!v010!^sMullhaupt^rND^nB
!v010!^sWitteck^rND^nA
!v010!^sBeckmann^rND^nJS
!v010!^sBerg^rND^nT
!v010!^sBergmann^rND^nS
!v010!^sNegro^rND^nF
!v010!^sTelenti^rND^nA
!v010!^sBochud^rND^nPY
!v012!Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study^len
!v014!1338-345
!v030!Gastroenterology
!v031!138
!v064!2010
!v065!20100000
!v118!30
!v514!^l1345^f1338
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000075
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sRhodes^rND^nSL
!v010!^sErlich^rND^nH
!v010!^sIm^rND^nKA
!v010!^sWang^rND^nJ
!v010!^sLi^rND^nJ
!v010!^sBugawan^rND^nT
!v010!^sJeffers^rND^nL
!v010!^sTong^rND^nX
!v010!^sSu^rND^nX
!v010!^sRosen^rND^nHR
!v010!^sYee^rND^nLJ
!v010!^sLiang^rND^nTJ
!v010!^sYang^rND^nH
!v012!Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection^len
!v014!328-33
!v030!Genes Immun
!v031!9
!v064!2008
!v065!20080000
!v118!31
!v514!^l333^f328
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000076
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sSmith^rND^nBC
!v010!^sGorve^rND^nJ
!v010!^sGuzail^rND^nMA
!v010!^sDay^rND^nCP
!v010!^sDaly^rND^nAK
!v010!^sBurt^rND^nAD
!v010!^sBassendine^rND^nMF
!v012!Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C^len
!v014!1695-699
!v030!Hepatology
!v031!27
!v064!1998
!v065!19980000
!v118!32
!v514!^l1699^f1695
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000077
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sSouza^rND^nRM
!v010!^sFreitas^rND^nLA
!v010!^sLyra^rND^nAC
!v010!^sMoraes^rND^nCF
!v010!^sBraga^rND^nEL
!v010!^sLyra^rND^nLG
!v012!Effect of iron overload on the severity of liver histologic alterations and on the response to interferon and ribavirin therapy of patients with hepatitis C infection^len
!v014!79-83
!v030!Braz J Med Biol Res
!v031!39
!v064!2006
!v065!20060000
!v118!33
!v514!^l83^f79
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000078
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sTen Elshof^rND^nAE
!v010!^sBrittenham^rND^nGM
!v010!^sChorney^rND^nKA
!v010!^sPage^rND^nMJ
!v010!^sGerhard^rND^nG
!v010!^sCable^rND^nEE
!v010!^sChorney^rND^nMJ
!v012!Gamma delta intraepithelial lymphocytes drive tumor necrosis factor-alpha responsiveness to intestinal iron challenge: relevance to hemochromatosis^len
!v014!223-32
!v030!Immunol Rev
!v031!167
!v064!1999
!v065!19990000
!v118!34
!v514!^l232^f223
!v700!38
!v701!34
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000079
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sThorburn^rND^nD
!v010!^sCurry^rND^nG
!v010!^sSpooner^rND^nR
!v010!^sSpence^rND^nE
!v010!^sOien^rND^nK
!v010!^sHalls^rND^nD
!v010!^sFox^rND^nR
!v010!^sMcCruden^rND^nEA
!v010!^sMacSween^rND^nRN
!v010!^sMills^rND^nPR
!v012!The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C^len
!v014!248-52
!v030!Gut
!v031!50
!v064!2002
!v065!20020000
!v118!35
!v514!^l252^f248
!v700!39
!v701!35
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000080
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sTseng^rND^nKC
!v010!^sChang^rND^nCK
!v010!^sChou^rND^nAL
!v010!^sHsieh^rND^nYH
!v010!^sTseng^rND^nCA
!v010!^sLai^rND^nNS
!v012!Prognostic effect of human leukocyte antigen class I and II alleles on chronic hepatitis C patients treated by pegylated interferon-alfa plus ribavirin in Taiwan^len
!v014!456-61
!v030!Hepatogastroenterology
!v031!57
!v064!2010
!v065!20100000
!v118!36
!v514!^l461^f456
!v700!40
!v701!36
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000081
!v001!br1.1
!v002!0004-2803-ag-49-01-09.xml
!v004!v49n1
!v010!^sTung^rND^nBY
!v010!^sEmond^rND^nMJ
!v010!^sBronner^rND^nMP
!v010!^sRaaka^rND^nSD
!v010!^sCotler^rND^nSJ
!v010!^sKowdley^rND^nKV
!v012!Hepatitis C, iron status, and disease severity: relationship with HFE mutations^len
!v014!318-26
!v030!Gastroenterology
!v031!124
!v064!2003
!v065!20030000
!v118!37
!v514!^l326^f318
!v700!41
!v701!37
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-09.xml
!v705!S
!v706!c
!v708!37
!v865!20120300
!ID 000082
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v091!20120814
!v092!164252
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v703!104
!v705!S
!v706!o
!v708!1
!ID 000083
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^1aff1^sRocha^rauthor^nHaroldo Luis Oliva Gomes
!v010!^sDiniz^rauthor^nAngelica Lemos Debs
!v010!^sBorges^rauthor^nValeria Ferreira de Almeida e
!v010!^sSalomao^rauthor^nFrederico Chaves
!v012!^tAssessment of portal venous index as a non-invasive method for diagnosing liver fibrosis in patients with chronic hepatitis C
!v012!^tEmprego do indice venoso portal como metodo nao-invasivo no diagnostico de fibrose hepatica em pacientes portadores de hepatite C cronica^lpt
!v014!^l18^f14
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal de Uberlandia (HC-UFU)^iaff1^9Servico de Gastroenterologia, Hospital de Clinicas, Universidade Federal de Uberlandia (HC-UFU)^1Servico de Gastroenterologia, Hospital de Clinicas^l1
!v070!UFU^iaff2^9Pos-graduacao - Ciencias da Saude, UFU^1Pos-graduacao - Ciencias da Saude^l2
!v070!Uberlandia^cMG^iaff3^l3^1Departamento de Anatomia Patologica - UFU^pBrasil^9Departamento de Anatomia Patologica - UFU, Uberlandia, MG, Brasil
!v071!oa
!v072!26
!v083!^a<sec>					<title>CONTEXT:</title>					 Hepatitis C is an important cause of chronic liver disease worldwide. The grading of hepatic fibrosis in chronic hepatitis C is important for better clinical management. However, until now, liver biopsy is the only test accepted for this purpose, despite their contraindications and complications. New methods for non-invasive assessment of hepatic fibrosis are under investigation. One proposal is the Doppler ultrasound, as a non-invasive, widely available and inexpensive. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To compare Doppler parameters of portal vein in patients with chronic hepatitis C with a healthy control group and to correlate these parameters with fibrosis degree obtained by liver biopsy. 				</sec>				<sec>					<title>METHODS:</title>					 Fifty patients with chronic hepatitis C submitted to liver biopsy and 44 healthy controls had Doppler of the portal vein performed, with the calculation of the portal venous index. We conducted a comparison between the averages of the two groups of portal venous index. For the correlation between portal venous index and fibrosis was employed the Spearman test. 				</sec>				<sec>					<title>RESULTS:</title>					 There was a difference between the average portal venous index between controls (0.33 &#177; 0.07) and patients (0.23 &#177; 0.09) with P&lt;0.001. No difference was observed between the portal venous index in patients with chronic hepatitis C who have significant fibrosis or not. The correlation between the portal venous index and fibrosis degree was reverse and moderate (r =-0.448 P&lt;0.001). The area under the ROC curve was 78.4% (95% CI: 68.8% to 88%). The cutoff for the portal venous index was 0.28 with sensitivity of 73.5% and specificity of 71.1%.				</sec>				<sec>					<title> CONCLUSION:</title>					 The portal venous index was useful in distinguishing healthy patients from patients with CHC. However, there was no significant difference in the quantification of degree of fibrosis.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 A hepatite C e uma importante causa de hepatopatia cronica no mundo. A avaliacao do grau de fibrose hepatica na hepatite C cronica e importante para o melhor manejo clinico. Entretanto, ate o momento, a biopsia hepatica e o unico teste aceito para esta finalidade, apesar de suas contra-indicacoes e complicacoes. Novos metodos para avaliacao nao invasiva de fibrose hepatica estao sendo pesquisados. Uma proposta e o ultrassom com Doppler, por ser um metodo nao-invasivo, amplamente disponivel e de baixo custo. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Comparar os parametros Doppler da veia porta de portadores de hepatite C cronica com um grupo controle sadio e correlacionar estes parametros com os graus de fibrose obtidos por biopsia hepatica. 				</sec>				<sec>					<title>MeTODOS:</title>					 Cinquenta pacientes portadores de hepatite C cronica com biopsia hepatica e 44 controles sadios foram submetidos ao Doppler da veia porta, com calculo do indice venoso portal. Realizou-se a comparacao entre as medias do indice venoso portal dos dois grupos. Para a correlacao entre o indice venoso portal e os graus de fibrose empregou-se o teste de Spearman. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Houve diferenca entre a media do indice venoso portal entre os controles (0,33 &#177; 0,07) e os doentes (0,23 &#177; 0,09) com P&lt;0,001. Nao foi observada diferenca do indice venoso portal entre os pacientes com hepatite C cronica que tem ou nao fibrose significante. A correlacao entre o indice venoso portal e o grau de fibrose foi inversa e moderada (r = -0,448 P&lt;0,001). A area sob a curva ROC foi de 78,4% (IC 95%: 68,8%-88%). O ponto de corte para o indice venoso portal foi de 0,28 com sensibilidade de 73,5% e especificidade de 71,1%. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 O indice venoso portal foi util em diferenciar pacientes sadios de pacientes portadores de hepatite C cronica. No entanto, nao se encontrou diferenca significante na quantificacao dos graus de fibrose.				</sec>^lpt
!v085!^kHepatitis C, chronic^len
!v085!^kLiver cirrhosis^len
!v085!^kPortal vein, ultrasonography^len
!v085!^kUltrasonography^len
!v085!^kHepatite C cronica^lpt
!v085!^kCirrose hepatica^lpt
!v085!^kVeia porta, ultrassonografia^lpt
!v085!^kUltrassonografia Doppler^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m07^d24
!v112!2011
!v113!^y2011^m10^d19
!v114!2011
!v120!XML_3.0
!v121!14
!v237!10.1590/S0004-28032012000100004
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!h
!v708!1
!ID 000084
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^1aff1^sRocha^rauthor^nHaroldo Luis Oliva Gomes
!v010!^sDiniz^rauthor^nAngélica Lemos Debs
!v010!^sBorges^rauthor^nValéria Ferreira de Almeida e
!v010!^sSalomão^rauthor^nFrederico Chaves
!v012!^tAssessment of portal venous index as a non-invasive method for diagnosing liver fibrosis in patients with chronic hepatitis C
!v012!^tEmprego do índice venoso portal como método não-invasivo no diagnóstico de fibrose hepática em pacientes portadores de hepatite C crônica^lpt
!v014!^l18^f14
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal de Uberl&#226;ndia (HC-UFU)^iaff1^9Servi&#231;o de Gastroenterologia, Hospital de Cl&#237;nicas, Universidade Federal de Uberl&#226;ndia (HC-UFU)^1Servi&#231;o de Gastroenterologia, Hospital de Cl&#237;nicas^l1
!v070!UFU^iaff2^9P&#243;s-gradua&#231;&#227;o - Ci&#234;ncias da Sa&#250;de, UFU^1P&#243;s-gradua&#231;&#227;o - Ci&#234;ncias da Sa&#250;de^l2
!v070!Uberl&#226;ndia^cMG^iaff3^l3^1Departamento de Anatomia Patol&#243;gica - UFU^pBrasil^9Departamento de Anatomia Patol&#243;gica - UFU, Uberl&#226;ndia, MG, Brasil
!v071!oa
!v072!26
!v083!^a<sec>					<title>CONTEXT:</title>					<p> Hepatitis C is an important cause of chronic liver disease worldwide. The grading of hepatic fibrosis in chronic hepatitis C is important for better clinical management. However, until now, liver biopsy is the only test accepted for this purpose, despite their contraindications and complications. New methods for non-invasive assessment of hepatic fibrosis are under investigation. One proposal is the Doppler ultrasound, as a non-invasive, widely available and inexpensive. </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To compare Doppler parameters of portal vein in patients with chronic hepatitis C with a healthy control group and to correlate these parameters with fibrosis degree obtained by liver biopsy. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> Fifty patients with chronic hepatitis C submitted to liver biopsy and 44 healthy controls had Doppler of the portal vein performed, with the calculation of the portal venous index. We conducted a comparison between the averages of the two groups of portal venous index. For the correlation between portal venous index and fibrosis was employed the Spearman test. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> There was a difference between the average portal venous index between controls (0.33 &#177; 0.07) and patients (0.23 &#177; 0.09) with <italic>P</italic>&lt;0.001. No difference was observed between the portal venous index in patients with chronic hepatitis C who have significant fibrosis or not. The correlation between the portal venous index and fibrosis degree was reverse and moderate (r =-0.448 <italic>P</italic>&lt;0.001). The area under the ROC curve was 78.4% (95% CI: 68.8% to 88%). The cutoff for the portal venous index was 0.28 with sensitivity of 73.5% and specificity of 71.1%.</p>				</sec>				<sec>					<title> CONCLUSION:</title>					<p> The portal venous index was useful in distinguishing healthy patients from patients with CHC. However, there was no significant difference in the quantification of degree of fibrosis.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> A hepatite C &#233; uma importante causa de hepatopatia cr&#244;nica no mundo. A avalia&#231;&#227;o do grau de fibrose hep&#225;tica na hepatite C cr&#244;nica &#233; importante para o melhor manejo cl&#237;nico. Entretanto, at&#233; o momento, a biopsia hep&#225;tica &#233; o &#250;nico teste aceito para esta finalidade, apesar de suas contra-indica&#231;&#245;es e complica&#231;&#245;es. Novos m&#233;todos para avalia&#231;&#227;o n&#227;o invasiva de fibrose hep&#225;tica est&#227;o sendo pesquisados. Uma proposta &#233; o ultrassom com Doppler, por ser um m&#233;todo n&#227;o-invasivo, amplamente dispon&#237;vel e de baixo custo. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Comparar os par&#226;metros Doppler da veia porta de portadores de hepatite C cr&#244;nica com um grupo controle sadio e correlacionar estes par&#226;metros com os graus de fibrose obtidos por biopsia hep&#225;tica. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Cinquenta pacientes portadores de hepatite C cr&#244;nica com biopsia hep&#225;tica e 44 controles sadios foram submetidos ao Doppler da veia porta, com c&#225;lculo do &#237;ndice venoso portal. Realizou-se a compara&#231;&#227;o entre as m&#233;dias do &#237;ndice venoso portal dos dois grupos. Para a correla&#231;&#227;o entre o &#237;ndice venoso portal e os graus de fibrose empregou-se o teste de Spearman. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Houve diferen&#231;a entre a m&#233;dia do &#237;ndice venoso portal entre os controles (0,33 &#177; 0,07) e os doentes (0,23 &#177; 0,09) com <italic>P</italic>&lt;0,001. N&#227;o foi observada diferen&#231;a do &#237;ndice venoso portal entre os pacientes com hepatite C cr&#244;nica que tem ou n&#227;o fibrose significante. A correla&#231;&#227;o entre o &#237;ndice venoso portal e o grau de fibrose foi inversa e moderada (r = -0,448 <italic>P</italic>&lt;0,001). A &#225;rea sob a curva ROC foi de 78,4% (IC 95%: 68,8%-88%). O ponto de corte para o &#237;ndice venoso portal foi de 0,28 com sensibilidade de 73,5% e especificidade de 71,1%. </p>				</sec>				<sec>					<title>CONCLUS&#195;O:</title>					<p> O &#237;ndice venoso portal foi &#250;til em diferenciar pacientes sadios de pacientes portadores de hepatite C cr&#244;nica. No entanto, n&#227;o se encontrou diferen&#231;a significante na quantifica&#231;&#227;o dos graus de fibrose.</p>				</sec>^lpt
!v085!^kHepatitis C, chronic^len
!v085!^kLiver cirrhosis^len
!v085!^kPortal vein, ultrasonography^len
!v085!^kUltrasonography^len
!v085!^kHepatite C crônica^lpt
!v085!^kCirrose hepática^lpt
!v085!^kVeia porta, ultrassonografia^lpt
!v085!^kUltrassonografia Doppler^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m07^d24
!v112!2011
!v113!^y2011^m10^d19
!v114!2011
!v120!XML_3.0
!v121!14
!v237!10.1590/S0004-28032012000100004
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!f
!v708!1
!ID 000085
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^1aff1^sRocha^rauthor^nHaroldo Luis Oliva Gomes
!v010!^sDiniz^rauthor^nAngelica Lemos Debs
!v010!^sBorges^rauthor^nValeria Ferreira de Almeida e
!v010!^sSalomao^rauthor^nFrederico Chaves
!v012!^tAssessment of portal venous index as a non-invasive method for diagnosing liver fibrosis in patients with chronic hepatitis C
!v012!^tEmprego do indice venoso portal como metodo nao-invasivo no diagnostico de fibrose hepatica em pacientes portadores de hepatite C cronica^lpt
!v014!^l18^f14
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal de Uberlandia (HC-UFU)^iaff1^9Servico de Gastroenterologia, Hospital de Clinicas, Universidade Federal de Uberlandia (HC-UFU)^1Servico de Gastroenterologia, Hospital de Clinicas^l1
!v070!UFU^iaff2^9Pos-graduacao - Ciencias da Saude, UFU^1Pos-graduacao - Ciencias da Saude^l2
!v070!Uberlandia^cMG^iaff3^l3^1Departamento de Anatomia Patologica - UFU^pBrasil^9Departamento de Anatomia Patologica - UFU, Uberlandia, MG, Brasil
!v071!oa
!v072!26
!v083!^a<sec>					<title>CONTEXT:</title>					 Hepatitis C is an important cause of chronic liver disease worldwide. The grading of hepatic fibrosis in chronic hepatitis C is important for better clinical management. However, until now, liver biopsy is the only test accepted for this purpose, despite their contraindications and complications. New methods for non-invasive assessment of hepatic fibrosis are under investigation. One proposal is the Doppler ultrasound, as a non-invasive, widely available and inexpensive. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To compare Doppler parameters of portal vein in patients with chronic hepatitis C with a healthy control group and to correlate these parameters with fibrosis degree obtained by liver biopsy. 				</sec>				<sec>					<title>METHODS:</title>					 Fifty patients with chronic hepatitis C submitted to liver biopsy and 44 healthy controls had Doppler of the portal vein performed, with the calculation of the portal venous index. We conducted a comparison between the averages of the two groups of portal venous index. For the correlation between portal venous index and fibrosis was employed the Spearman test. 				</sec>				<sec>					<title>RESULTS:</title>					 There was a difference between the average portal venous index between controls (0.33 &#177; 0.07) and patients (0.23 &#177; 0.09) with P&lt;0.001. No difference was observed between the portal venous index in patients with chronic hepatitis C who have significant fibrosis or not. The correlation between the portal venous index and fibrosis degree was reverse and moderate (r =-0.448 P&lt;0.001). The area under the ROC curve was 78.4% (95% CI: 68.8% to 88%). The cutoff for the portal venous index was 0.28 with sensitivity of 73.5% and specificity of 71.1%.				</sec>				<sec>					<title> CONCLUSION:</title>					 The portal venous index was useful in distinguishing healthy patients from patients with CHC. However, there was no significant difference in the quantification of degree of fibrosis.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 A hepatite C e uma importante causa de hepatopatia cronica no mundo. A avaliacao do grau de fibrose hepatica na hepatite C cronica e importante para o melhor manejo clinico. Entretanto, ate o momento, a biopsia hepatica e o unico teste aceito para esta finalidade, apesar de suas contra-indicacoes e complicacoes. Novos metodos para avaliacao nao invasiva de fibrose hepatica estao sendo pesquisados. Uma proposta e o ultrassom com Doppler, por ser um metodo nao-invasivo, amplamente disponivel e de baixo custo. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Comparar os parametros Doppler da veia porta de portadores de hepatite C cronica com um grupo controle sadio e correlacionar estes parametros com os graus de fibrose obtidos por biopsia hepatica. 				</sec>				<sec>					<title>MeTODOS:</title>					 Cinquenta pacientes portadores de hepatite C cronica com biopsia hepatica e 44 controles sadios foram submetidos ao Doppler da veia porta, com calculo do indice venoso portal. Realizou-se a comparacao entre as medias do indice venoso portal dos dois grupos. Para a correlacao entre o indice venoso portal e os graus de fibrose empregou-se o teste de Spearman. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Houve diferenca entre a media do indice venoso portal entre os controles (0,33 &#177; 0,07) e os doentes (0,23 &#177; 0,09) com P&lt;0,001. Nao foi observada diferenca do indice venoso portal entre os pacientes com hepatite C cronica que tem ou nao fibrose significante. A correlacao entre o indice venoso portal e o grau de fibrose foi inversa e moderada (r = -0,448 P&lt;0,001). A area sob a curva ROC foi de 78,4% (IC 95%: 68,8%-88%). O ponto de corte para o indice venoso portal foi de 0,28 com sensibilidade de 73,5% e especificidade de 71,1%. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 O indice venoso portal foi util em diferenciar pacientes sadios de pacientes portadores de hepatite C cronica. No entanto, nao se encontrou diferenca significante na quantificacao dos graus de fibrose.				</sec>^lpt
!v085!^kHepatitis C, chronic^len
!v085!^kLiver cirrhosis^len
!v085!^kPortal vein, ultrasonography^len
!v085!^kUltrasonography^len
!v085!^kHepatite C cronica^lpt
!v085!^kCirrose hepatica^lpt
!v085!^kVeia porta, ultrassonografia^lpt
!v085!^kUltrassonografia Doppler^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m07^d24
!v112!2011
!v113!^y2011^m10^d19
!v114!2011
!v120!XML_3.0
!v121!14
!v237!10.1590/S0004-28032012000100004
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!l
!v708!1
!ID 000086
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sBalci^rND^nA
!v010!^sKarazincir^rND^nS
!v010!^sSumbas^rND^nH
!v010!^sOter^rND^nY
!v010!^sEgilmez^rND^nE
!v010!^sInandi^rND^nT
!v012!Effects of diffuse fatty infiltration of the liver on portal vein flow hemodynamics^len
!v014!134-40
!v030!J Clin Ultrasound
!v031!36
!v064!2008
!v065!20080000
!v071!journal
!v118!1
!v514!^l140^f134
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000087
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sBarakat^rND^nM
!v012!Portal vein pulsatility and spectral width changes in patients with portal hypertension: relation to the severity of liver disease^len
!v014!417-21
!v030!Br J Radiol
!v031!75
!v064!2002
!v065!20020000
!v118!2
!v514!^l421^f417
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000088
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sBedossa^rND^nP
!v010!^sPoynard^rND^nT
!v012!An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group^len
!v014!289-93
!v030!Hepatology
!v031!24
!v064!1996
!v065!19960000
!v118!3
!v514!^l293^f289
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000089
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sBedossa^rND^nP
!v010!^sDargere^rND^nD
!v010!^sParadis^rND^nV
!v012!Sampling variability of liver fibrosis in chronic hepatitis C^len
!v014!1449-457
!v030!Hepatology
!v031!38
!v064!2003
!v065!20030000
!v118!4
!v514!^l1457^f1449
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000090
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sBernatik^rND^nT
!v010!^sStrobel^rND^nD
!v010!^sHahn^rND^nEG
!v010!^sBecker^rND^nD
!v012!Doppler measurements: a surrogate marker of liver fibrosis?^len
!v014!383-87
!v030!Eur J Gastroenterol Hepatol
!v031!14
!v064!2002
!v065!20020000
!v118!5
!v514!^l387^f383
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000091
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sBorges^rND^nVFA
!v010!^sDiniz^rND^nALD
!v010!^sCotrim^rND^nHP
!v010!^sRocha^rND^nHLOG
!v010!^sSalomao^rND^nFC
!v012!Dopplerfluxometria da veia hepatica em pacientes com esteatose hepatica nao alcoolica^lpt
!v014!1-6
!v030!Radiol Bras
!v031!44
!v064!2011
!v065!20110000
!v118!6
!v514!^l6^f1
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000092
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sCoco^rND^nB
!v010!^sOliveri^rND^nF
!v010!^sMaina^rND^nAM
!v010!^sCiccorossi^rND^nP
!v010!^sSacco^rND^nR
!v010!^sColombatto^rND^nP
!v010!^sBonino^rND^nF
!v010!^sBrunetto^rND^nMR
!v012!Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases^len
!v014!360-69
!v030!J Viral Hepat
!v031!14
!v064!2007
!v065!20070000
!v118!7
!v514!^l369^f360
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000093
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sColli^rND^nA
!v010!^sCocciolo^rND^nM
!v010!^sRiva^rND^nC
!v010!^sMartinez^rND^nE
!v010!^sPrisco^rND^nA
!v010!^sPirola^rND^nM
!v010!^sBratina^rND^nG
!v012!Abnormalities of Doppler waveform of the hepatic veins in patients with chronic liver disease: correlation with histologic findings^len
!v014!833-37
!v030!AJR Am J Roentgenol
!v031!162
!v064!1994
!v065!19940000
!v118!8
!v514!^l837^f833
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000094
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sde Araujo^rND^nES
!v010!^sMendonca^rND^nJS
!v010!^sBarone^rND^nAA
!v010!^sGoncales^rND^nFL Jr
!v010!^sFerreira^rND^nMS
!v010!^sFocaccia^rND^nR
!v010!^sPawlotsky^rND^nJM
!v012!Consensus of the Brazilian Society of Infectious Diseases on the management and treatment of hepatitis C^len
!v014!446-50
!v030!Braz J Infect Dis
!v031!11
!v064!2007
!v065!20070000
!v118!9
!v514!^l450^f446
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000095
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sFarrell^rND^nGC
!v010!^sGeorge^rND^nJ
!v010!^sPauline de la^rND^nM
!v010!^sHall^rND^nP
!v010!^sMcCullough^rND^nAJ
!v014!1-319
!v018!Fatty liver disease: NASH and related disorders
!v062!Blackwell
!v064!2005
!v065!20050000
!v066!Malden, MA
!v118!10
!v514!^l319^f1
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000096
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sGallix^rND^nBP
!v010!^sTaourel^rND^nP
!v010!^sDauzat^rND^nM
!v010!^sBruel^rND^nJM
!v010!^sLafortune^rND^nM
!v012!Flow pulsatility in the portal venous system: a study of Doppler sonography in healthy adults^len
!v014!141-44
!v030!AJR Am J Roentgenol
!v031!169
!v064!1997
!v065!19970000
!v118!11
!v514!^l144^f141
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000097
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sGayotto^rND^nLCC
!v010!^sComite^rND^nSBP/SBH
!v012!Visao historica e consenso nacional sobre a classificacao das hepatites cronicas - projeto do Clube de Patologia Hepatica da Sociedade Brasileira de Patologia aprovado pela Sociedade Brasileira de Hepatologia^lpt
!v014!137-40
!v030!GED Gastroenterol Endosc Dig
!v031!19
!v064!2000
!v065!20000000
!v118!12
!v514!^l140^f137
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000098
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v012!Global burden of disease (GBD) for hepatitis C^len
!v014!20-9
!v030!J Clin Pharmacol
!v031!44
!v064!2004
!v065!20040000
!v118!13
!v514!^l29^f20
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000099
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v012!Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium^len
!v014!35-47
!v030!J Viral Hepat
!v031!6
!v064!1999
!v065!19990000
!v118!14
!v514!^l47^f35
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000100
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sIliopoulos^rND^nP
!v010!^sVlychou^rND^nM
!v010!^sMargaritis^rND^nV
!v010!^sTsamis^rND^nI
!v010!^sTepetes^rND^nK
!v010!^sPetsas^rND^nT
!v010!^sKaratza^rND^nC
!v012!Gray and color Doppler ultrasonography in differentiation between chronic viral hepatitis and compensated early stage cirrhosis^len
!v014!279-86
!v030!J Gastrointestin Liver Dis
!v031!16
!v064!2007
!v065!20070000
!v118!15
!v514!^l286^f279
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000101
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sKarabulut^rND^nN
!v010!^sKazil^rND^nS
!v010!^sYagci^rND^nB
!v010!^sSabir^rND^nN
!v012!Doppler waveform of the hepatic veins in an obese population^len
!v014!2268-272
!v030!Eur Radiol
!v031!14
!v064!2004
!v065!20040000
!v118!16
!v514!^l2272^f2268
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000102
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sLim^rND^nAK
!v010!^sPatel^rND^nN
!v010!^sEckersley^rND^nRJ
!v010!^sKuo^rND^nYT
!v010!^sGoldin^rND^nRD
!v010!^sThomas^rND^nHC
!v010!^sCosgrove^rND^nDO
!v010!^sTaylor-Robinson^rND^nSD
!v010!^sBlomley^rND^nMJ
!v012!Can Doppler sonography grade the severity of hepatitis C-related liver disease?^len
!v014!1848-853
!v030!AJR Am J Roentgenol
!v031!184
!v064!2005
!v065!20050000
!v118!17
!v514!^l1853^f1848
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000103
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sMartinez-Noguera^rND^nA
!v010!^sMontserrat^rND^nE
!v010!^sTorrubia^rND^nS
!v010!^sVillalba^rND^nJ
!v012!Doppler in hepatic cirrhosis and chronic hepatitis^len
!v014!19-36
!v030!Semin Ultrasound CT MR
!v031!23
!v064!2002
!v065!20020000
!v118!18
!v514!^l36^f19
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000104
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sMyers^rND^nRP
!v012!Noninvasive markers of liver fibrosis: playing the probabilities^len
!v014!1328-331
!v030!Liver Int
!v031!28
!v064!2008
!v065!20080000
!v118!19
!v514!^l1331^f1328
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000105
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sRidolfi^rND^nF
!v010!^sAbbattista^rND^nT
!v010!^sMarini^rND^nF
!v010!^sVedovelli^rND^nA
!v010!^sQuagliarini^rND^nP
!v010!^sBusilacchi^rND^nP
!v010!^sBrunelli^rND^nE
!v012!Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C^len
!v014!929-35
!v030!Dig Liver Dis
!v031!39
!v064!2007
!v065!20070000
!v118!20
!v514!^l935^f929
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000106
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sRonot^rND^nM
!v010!^sAsselah^rND^nT
!v010!^sParadis^rND^nV
!v010!^sMichoux^rND^nN
!v010!^sDorvillius^rND^nM
!v010!^sBaron^rND^nG
!v010!^sMarcellin^rND^nP
!v010!^sVan Beers^rND^nBE
!v010!^sVilgrain^rND^nV
!v012!Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT^len
!v014!135-42
!v030!Radiology
!v031!256
!v064!2010
!v065!20100000
!v118!21
!v514!^l142^f135
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000107
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sSearle^rND^nJ
!v010!^sMendelson^rND^nR
!v010!^sZelesco^rND^nM
!v010!^sSanford^rND^nJ
!v010!^sCheng^rND^nW
!v010!^sMcKinstry^rND^nC
!v010!^sRamsay^rND^nD
!v012!Non-invasive prediction of the degree of liver fibrosis in patients with hepatitis C using an ultrasound contrast agent. A pilot study^len
!v014!130-33
!v030!J Med Imaging Radiat Oncol
!v031!52
!v064!2008
!v065!20080000
!v118!22
!v514!^l133^f130
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000108
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sStrader^rND^nDB
!v010!^sWright^rND^nT
!v010!^sThomas^rND^nDL
!v010!^sSeeff^rND^nLB
!v012!Diagnosis, management, and treatment of hepatitis C^len
!v014!1147-171
!v030!Hepatology
!v031!39
!v064!2004
!v065!20040000
!v118!23
!v514!^l1171^f1147
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000109
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sTchelepi^rND^nH
!v010!^sRalls^rND^nPW
!v010!^sRadin^rND^nR
!v010!^sGrant^rND^nE
!v012!Sonography of diffuse liver disease^len
!v014!1023-032
!v030!J Ultrasound Med
!v031!21
!v064!2002
!v065!20020000
!v118!24
!v514!^l1032^f1023
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000110
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sVerna^rND^nEC
!v010!^sRS^rND^nBrown
!v012!Hepatitis C virus and liver transplantation^len
!v014!919-40
!v030!Clin Liver Dis.
!v031!10
!v064!2006
!v065!20060000
!v118!25
!v514!^l940^f919
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000111
!v001!br1.1
!v002!0004-2803-ag-49-01-14.xml
!v004!v49n1
!v010!^sWalsh^rND^nKM
!v010!^sLeen^rND^nE
!v010!^sMacSween^rND^nRN
!v010!^sMorris^rND^nAJ
!v012!Hepatic blood flow changes in chronic hepatitis C measured by duplex Doppler color sonography: relationship to histological features^len
!v014!2584-590
!v030!Dig Dis Sci
!v031!43
!v064!1998
!v065!19980000
!v118!26
!v514!^l2590^f2584
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-14.xml
!v705!S
!v706!c
!v708!26
!v865!20120300
!ID 000112
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v091!20120814
!v092!164255
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v703!120
!v705!S
!v706!o
!v708!1
!ID 000113
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sFernandes^rauthor^nSabrina Alves
!v010!^sBassani^rauthor^nLilian
!v010!^sNunes^rauthor^nFlavia Feijo
!v010!^sAydos^rauthor^nMaria Eugenia Deutrich
!v010!^sAlves^rauthor^nAlexandro Vaesken
!v010!^sMarroni^rauthor^nClaudio Augusto
!v012!^tNutritional assessment in patients with cirrhosis
!v012!^tAvaliacao nutricional de pacientes cirroticos^lpt
!v014!^l27^f19
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal de Ciencias da Saude de Porto Alegre^cPorto Alegre^iaff1^1Postgraduate Program of Hepatology^pBrasil^sRS^9Postgraduate Program of Hepatology, Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, RS, Brasil
!v071!oa
!v072!42
!v083!^a<sec>					<title>CONTEXT:</title>					 Malnutrition in cirrhotic patients with end-stage disease is common, and the degree of nutritional debilitation can play an important role in the pathogenesis of complications and cause a negative impact on prognosis. However, it involves difficulties and controversies regarding the identification of the best nutritional assessment method. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To identify a method that provides a safe and effective nutritional diagnosis. 				</sec>				<sec>					<title>METHODS:</title>					 Cross-sectional study with 129 cirrhotic patients. Anthropometric measurements, subjective global assessment, hand grip strength and bioelectrical impedance. 				</sec>				<sec>					<title>RESULTS:</title>					 Through phase angle of bioelectrical impedance analysis (BIA) method, significant associations with Child-Pugh (P = 0.008), age group and gender were observed. The ROC (receiver operator characteristic) curve was generated to determine the best cutoff point of the phase angle of cirrhotic patients, serving as one of the reference parameters for the nutritional assessment with bioimpedance in this study, considering the classification through Child-Pugh score as the reference standard for the clinical conditions of patients with cirrhosis. 				</sec>				<sec>					<title>CONCLUSIONS:</title>					 The assessment through bioelectrical impedance presented a statistically significant correlation with Child-Pugh score. The identification of phase angle of 5.44&#186; is the new parameter suggested for the classification of the nutritional conditions of cirrhotic patients.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 A desnutricao em pacientes cirroticos com doenca em estagio final e comum, e o grau de debilitacao nutricional pode desempenhar papel importante na patogenese de complicacoes e causar impacto negativo no prognostico. No entanto, envolve dificuldades e controversias sobre a identificacao do melhor metodo de avaliacao nutricional. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Identificar um metodo que ofereca diagnostico nutricional seguro e eficiente. 				</sec>				<sec>					<title>MeTODOS:</title>					 Estudo transversal avaliou 129 pacientes com cirrose hepatica. Foram realizadas medidas antropometricas, avaliacao subjetiva global, dinamometria e bioimpedancia eletrica. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Atraves do angulo de fase do metodo BIA, associacoes significativas com Child-Pugh (P = 0,008), faixa etaria e sexo foram observadas. A curva ROC (receiver operator characteristic) foi realizada para determinar o melhor ponto de corte do angulo de fase de pacientes cirroticos, servindo como um dos parametros de referencia para a avaliacao nutricional com bioimpedancia neste estudo, considerando a classificacao por pontuacao Child-Pugh como o padrao de referencia para as condicoes clinicas dos pacientes com cirrose. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 A avaliacao por meio de bioimpedancia eletrica apresentou correlacao estatisticamente significativa com o escore de Child-Pugh. A identificacao do angulo de fase de 5,44&#186; e o novo parametro sugerido para a classificacao do estado nutricional de pacientes cirroticos.				</sec>^lpt
!v085!^kLiver cirrhosis^len
!v085!^kElectrical impedance^len
!v085!^kMalnutrition^len
!v085!^kNutrition assessment^len
!v085!^kCirrose hepatica^lpt
!v085!^kImpedancia eletrica^lpt
!v085!^kDesnutricao^lpt
!v085!^kAvaliacao nutricional^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2009^m10^d08
!v112!2009
!v113!^y2011^m08^d10
!v114!2011
!v120!XML_3.0
!v121!19
!v237!10.1590/S0004-28032012000100005
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!h
!v708!1
!ID 000114
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sFernandes^rauthor^nSabrina Alves
!v010!^sBassani^rauthor^nLilian
!v010!^sNunes^rauthor^nFlávia Feijó
!v010!^sAydos^rauthor^nMaria Eugênia Deutrich
!v010!^sAlves^rauthor^nAlexandro Vaesken
!v010!^sMarroni^rauthor^nCláudio Augusto
!v012!^tNutritional assessment in patients with cirrhosis
!v012!^tAvaliação nutricional de pacientes cirróticos^lpt
!v014!^l27^f19
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal de Ciências da Saúde de Porto Alegre^cPorto Alegre^iaff1^1Postgraduate Program of Hepatology^pBrasil^sRS^9Postgraduate Program of Hepatology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brasil
!v071!oa
!v072!42
!v083!^a<sec>					<title>CONTEXT:</title>					<p> Malnutrition in cirrhotic patients with end-stage disease is common, and the degree of nutritional debilitation can play an important role in the pathogenesis of complications and cause a negative impact on prognosis. However, it involves difficulties and controversies regarding the identification of the best nutritional assessment method. </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To identify a method that provides a safe and effective nutritional diagnosis. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> Cross-sectional study with 129 cirrhotic patients. Anthropometric measurements, subjective global assessment, hand grip strength and bioelectrical impedance. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> Through phase angle of bioelectrical impedance analysis (BIA) method, significant associations with Child-Pugh (<italic>P</italic> = 0.008), age group and gender were observed. The ROC (receiver operator characteristic) curve was generated to determine the best cutoff point of the phase angle of cirrhotic patients, serving as one of the reference parameters for the nutritional assessment with bioimpedance in this study, considering the classification through Child-Pugh score as the reference standard for the clinical conditions of patients with cirrhosis. </p>				</sec>				<sec>					<title>CONCLUSIONS:</title>					<p> The assessment through bioelectrical impedance presented a statistically significant correlation with Child-Pugh score. The identification of phase angle of 5.44&#186; is the new parameter suggested for the classification of the nutritional conditions of cirrhotic patients.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> A desnutri&#231;&#227;o em pacientes cirr&#243;ticos com doen&#231;a em est&#225;gio final &#233; comum, e o grau de debilita&#231;&#227;o nutricional pode desempenhar papel importante na patog&#234;nese de complica&#231;&#245;es e causar impacto negativo no progn&#243;stico. No entanto, envolve dificuldades e controv&#233;rsias sobre a identifica&#231;&#227;o do melhor m&#233;todo de avalia&#231;&#227;o nutricional. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Identificar um m&#233;todo que ofere&#231;a diagn&#243;stico nutricional seguro e eficiente. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Estudo transversal avaliou 129 pacientes com cirrose hep&#225;tica. Foram realizadas medidas antropom&#233;tricas, avalia&#231;&#227;o subjetiva global, dinamometria e bioimped&#226;ncia el&#233;trica. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Atrav&#233;s do &#226;ngulo de fase do m&#233;todo BIA, associa&#231;&#245;es significativas com Child-Pugh (<italic>P</italic> = 0,008), faixa et&#225;ria e sexo foram observadas. A curva ROC (receiver operator characteristic) foi realizada para determinar o melhor ponto de corte do &#226;ngulo de fase de pacientes cirr&#243;ticos, servindo como um dos par&#226;metros de refer&#234;ncia para a avalia&#231;&#227;o nutricional com bioimped&#226;ncia neste estudo, considerando a classifica&#231;&#227;o por pontua&#231;&#227;o Child-Pugh como o padr&#227;o de refer&#234;ncia para as condi&#231;&#245;es cl&#237;nicas dos pacientes com cirrose. </p>				</sec>				<sec>					<title>CONCLUS&#213;ES:</title>					<p> A avalia&#231;&#227;o por meio de bioimped&#226;ncia el&#233;trica apresentou correla&#231;&#227;o estatisticamente significativa com o escore de Child-Pugh. A identifica&#231;&#227;o do &#226;ngulo de fase de 5,44&#186; &#233; o novo par&#226;metro sugerido para a classifica&#231;&#227;o do estado nutricional de pacientes cirr&#243;ticos.</p>				</sec>^lpt
!v085!^kLiver cirrhosis^len
!v085!^kElectrical impedance^len
!v085!^kMalnutrition^len
!v085!^kNutrition assessment^len
!v085!^kCirrose hepática^lpt
!v085!^kImpedância elétrica^lpt
!v085!^kDesnutrição^lpt
!v085!^kAvaliação nutricional^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2009^m10^d08
!v112!2009
!v113!^y2011^m08^d10
!v114!2011
!v120!XML_3.0
!v121!19
!v237!10.1590/S0004-28032012000100005
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!f
!v708!1
!ID 000115
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sFernandes^rauthor^nSabrina Alves
!v010!^sBassani^rauthor^nLilian
!v010!^sNunes^rauthor^nFlavia Feijo
!v010!^sAydos^rauthor^nMaria Eugenia Deutrich
!v010!^sAlves^rauthor^nAlexandro Vaesken
!v010!^sMarroni^rauthor^nClaudio Augusto
!v012!^tNutritional assessment in patients with cirrhosis
!v012!^tAvaliacao nutricional de pacientes cirroticos^lpt
!v014!^l27^f19
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal de Ciencias da Saude de Porto Alegre^cPorto Alegre^iaff1^1Postgraduate Program of Hepatology^pBrasil^sRS^9Postgraduate Program of Hepatology, Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, RS, Brasil
!v071!oa
!v072!42
!v083!^a<sec>					<title>CONTEXT:</title>					 Malnutrition in cirrhotic patients with end-stage disease is common, and the degree of nutritional debilitation can play an important role in the pathogenesis of complications and cause a negative impact on prognosis. However, it involves difficulties and controversies regarding the identification of the best nutritional assessment method. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To identify a method that provides a safe and effective nutritional diagnosis. 				</sec>				<sec>					<title>METHODS:</title>					 Cross-sectional study with 129 cirrhotic patients. Anthropometric measurements, subjective global assessment, hand grip strength and bioelectrical impedance. 				</sec>				<sec>					<title>RESULTS:</title>					 Through phase angle of bioelectrical impedance analysis (BIA) method, significant associations with Child-Pugh (P = 0.008), age group and gender were observed. The ROC (receiver operator characteristic) curve was generated to determine the best cutoff point of the phase angle of cirrhotic patients, serving as one of the reference parameters for the nutritional assessment with bioimpedance in this study, considering the classification through Child-Pugh score as the reference standard for the clinical conditions of patients with cirrhosis. 				</sec>				<sec>					<title>CONCLUSIONS:</title>					 The assessment through bioelectrical impedance presented a statistically significant correlation with Child-Pugh score. The identification of phase angle of 5.44&#186; is the new parameter suggested for the classification of the nutritional conditions of cirrhotic patients.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 A desnutricao em pacientes cirroticos com doenca em estagio final e comum, e o grau de debilitacao nutricional pode desempenhar papel importante na patogenese de complicacoes e causar impacto negativo no prognostico. No entanto, envolve dificuldades e controversias sobre a identificacao do melhor metodo de avaliacao nutricional. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Identificar um metodo que ofereca diagnostico nutricional seguro e eficiente. 				</sec>				<sec>					<title>MeTODOS:</title>					 Estudo transversal avaliou 129 pacientes com cirrose hepatica. Foram realizadas medidas antropometricas, avaliacao subjetiva global, dinamometria e bioimpedancia eletrica. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Atraves do angulo de fase do metodo BIA, associacoes significativas com Child-Pugh (P = 0,008), faixa etaria e sexo foram observadas. A curva ROC (receiver operator characteristic) foi realizada para determinar o melhor ponto de corte do angulo de fase de pacientes cirroticos, servindo como um dos parametros de referencia para a avaliacao nutricional com bioimpedancia neste estudo, considerando a classificacao por pontuacao Child-Pugh como o padrao de referencia para as condicoes clinicas dos pacientes com cirrose. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 A avaliacao por meio de bioimpedancia eletrica apresentou correlacao estatisticamente significativa com o escore de Child-Pugh. A identificacao do angulo de fase de 5,44&#186; e o novo parametro sugerido para a classificacao do estado nutricional de pacientes cirroticos.				</sec>^lpt
!v085!^kLiver cirrhosis^len
!v085!^kElectrical impedance^len
!v085!^kMalnutrition^len
!v085!^kNutrition assessment^len
!v085!^kCirrose hepatica^lpt
!v085!^kImpedancia eletrica^lpt
!v085!^kDesnutricao^lpt
!v085!^kAvaliacao nutricional^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2009^m10^d08
!v112!2009
!v113!^y2011^m08^d10
!v114!2011
!v120!XML_3.0
!v121!19
!v237!10.1590/S0004-28032012000100005
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!l
!v708!1
!ID 000116
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sAbbott^rND^nWJ
!v010!^sThomson^rND^nA
!v010!^sSteadman^rND^nC
!v010!^sGatton^rND^nML
!v010!^sBothwell^rND^nC
!v010!^sKerlin^rND^nP
!v010!^sWall^rND^nDR
!v010!^sLynch^rND^nSV
!v012!Child-Pugh class, nutritional indicators and early liver transplant outcomes^len
!v014!823-27
!v030!Hepatogastroenterology
!v031!48
!v064!2001
!v065!20010000
!v071!journal
!v118!1
!v514!^l827^f823
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000117
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sAlberino^rND^nF
!v010!^sGatta^rND^nA
!v010!^sAmodio^rND^nP
!v010!^sMerkel^rND^nC
!v010!^sDi Pascoli^rND^nL
!v010!^sBoffo^rND^nG
!v010!^sCaregaro^rND^nL
!v012!Nutrition and survival in patients with liver cirrhosis^len
!v014!445-50
!v030!Nutrition
!v031!17
!v064!2001
!v065!20010000
!v118!2
!v514!^l450^f445
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000118
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^salvares-da-Silva^rND^nMR
!v010!^sGottschall^rND^nCA
!v010!^sPruineli^rND^nRD
!v010!^sWaetchter^rND^nFL
!v010!^sCardoso^rND^nF
!v010!^sSampaio^rND^nJA
!v010!^sSmith^rND^nMM
!v010!^sFrancisconi^rND^nCFM
!v010!^sPereira-Lima^rND^nLM
!v012!Nutritional evaluation in liver transplantation^len
!v014!746(A)
!v030!Hepatology
!v031!28
!v064!1998
!v065!19980000
!v118!3
!v514!^f746(A)
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000119
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^salvares-da-Silva^rND^nMR
!v010!^sSilveira^rND^nTR
!v012!O estudo da forca do aperto de mao nao-dominante em individuos sadios: determinacao dos valores de referencia para o uso da dinamometria^lpt
!v014!203-06
!v030!GED Gastroenterol Endosc Dig
!v031!17
!v064!1998
!v065!19980000
!v118!4
!v514!^l206^f203
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000120
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^salvares-da-Siva^rND^nMR
!v010!^sSilveira^rND^nTR
!v012!Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients^len
!v014!113-17
!v030!Nutrition
!v031!21
!v064!2005
!v065!20050000
!v118!5
!v514!^l117^f113
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000121
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^salvares-da-Siva^rND^nMR
!v010!^sSilveira^rND^nTR
!v012!Hand-grip strength or muscle mass in cirrhotic patients: who is the best?^len
!v014!218-19
!v030!Nutrition
!v031!22
!v064!2006
!v065!20060000
!v118!6
!v514!^l219^f218
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000122
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sBarbosa-Silva^rND^nMC
!v010!^sBarros^rND^nAJ
!v010!^sPost^rND^nCL
!v010!^sWaitzberg^rND^nDL
!v010!^sHeymsfield^rND^nSB
!v012!Can bioelectrical impedance analysis identify malnutrition in preoperative nutrition assessment?^len
!v014!422-26
!v030!Nutrition
!v031!19
!v064!2003
!v065!20030000
!v118!7
!v514!^l426^f422
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000123
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sBarbosa-Silva^rND^nMC
!v010!^sBarros^rND^nAJ
!v010!^sWang^rND^nJ
!v010!^sHeymsfield^rND^nSB
!v010!^sPierson^rND^nRN
!v012!Bioelectrical impedance analysis: population reference values for phase angle bay age and sex^len
!v014!49-52
!v030!Am J Clin Nutr
!v031!82
!v064!2005
!v065!20050000
!v118!8
!v514!^l52^f49
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000124
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sDetsky^rND^nAS
!v010!^sMcLaughlin^rND^nJR
!v010!^sBaker^rND^nJP
!v010!^sJohnston^rND^nN
!v010!^sWhittaker^rND^nS
!v010!^sMendelson^rND^nRA
!v010!^sJeejeebhoy^rND^nKN
!v012!What is subjective global assessment of nutritional status?^len
!v014!8-13
!v030!JPEN J Parenter Enteral Nutr
!v031!11
!v064!1987
!v065!19870000
!v118!9
!v514!^l13^f8
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000125
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sDuarte^rND^nAC
!v018!Semiologia imunologica nutricional
!v062!Axcel Books do Brasil
!v064!2003
!v065!20030000
!v066!Rio de Janeiro
!v118!10
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000126
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sDuarte^rND^nACG
!v018!Avaliacao nutricional: aspectos clinicos e laboratoriais
!v062!Atheneu
!v064!2007
!v065!20070000
!v066!Sao Paulo
!v118!11
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000127
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sFigueiredo^rND^nF
!v010!^sDickson^rND^nER
!v010!^sPasha^rND^nT
!v010!^sKasparova^rND^nP
!v010!^sTherneau^rND^nT
!v010!^sMalinchoc^rND^nM
!v010!^sDiCecco^rND^nS
!v010!^sFrancisco-Ziller^rND^nN
!v010!^sCharlton^rND^nM
!v012!Impact of nutritional status on outcome after liver transplantation^len
!v014!1347-352
!v030!Transplantation
!v031!70
!v064!2000
!v065!20000000
!v118!12
!v514!^l1352^f1347
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000128
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sFigueiredo^rND^nFA
!v010!^sPerez^rND^nRM
!v010!^sFreitas^rND^nMM
!v010!^sKondo^rND^nM
!v012!Comparison of three methods of nutritional assessment in liver cirrhosis: subjective global assessment, traditional nutritional parameters, and body composition analysis^len
!v014!476-82
!v030!J Gastroenterol
!v031!41
!v064!2006
!v065!20060000
!v118!13
!v514!^l482^f476
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000129
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sGottschall^rND^nCB
!v010!^sAlvares-da-Silva^rND^nMR
!v010!^sCamargo^rND^nAC
!v010!^sBurtett^rND^nRM
!v010!^sda Silveira^rND^nTR
!v014!220-24
!v030!Arq Gastroenterol
!v031!41
!v064!2004
!v065!20040000
!v118!14
!v514!^l224^f220
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000130
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sGupta^rND^nD
!v010!^sLis^rND^nCG
!v010!^sDahlk^rND^nSL
!v010!^sVashi^rND^nPG
!v010!^sGrutsch^rND^nJF
!v010!^sLammersfeld^rND^nCA
!v012!Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer^len
!v014!957-62
!v030!Br J Nutr
!v031!92
!v064!2004
!v065!20040000
!v118!15
!v514!^l962^f957
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000131
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sHasse^rND^nJ
!v010!^sStrong^rND^nS
!v010!^sGorman^rND^nMA
!v010!^sLiepa^rND^nG
!v012!Subjective global assessment: alternative nutrition-assessment technique for live transplant candidates^len
!v014!339-43
!v030!Nutrition
!v031!9
!v064!1993
!v065!19930000
!v118!16
!v514!^l343^f339
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000132
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sKyle^rND^nUG
!v010!^sBosaeus^rND^nI
!v010!^sDe Lorenzo^rND^nAD
!v010!^sDeurenberg^rND^nP
!v010!^sElia^rND^nM
!v010!^sGomez^rND^nJM
!v010!^sHeitmann^rND^nBL
!v010!^sKent-Smith^rND^nL
!v010!^sMelchior^rND^nJC
!v010!^sPirlich^rND^nM
!v010!^sSharfetter^rND^nH
!v010!^sSchols^rND^nAM
!v010!^sPichard^rND^nC
!v012!Bioelectrical impedance analysis-part I: review of principles and methods^len
!v014!1226-243
!v030!Clin Nutr
!v031!23
!v064!2004
!v065!20040000
!v118!17
!v514!^l1243^f1226
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000133
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sKyle^rND^nUG
!v010!^sBosaeus^rND^nI
!v010!^sDe Lorenzo^rND^nAD
!v010!^sDeurenberg^rND^nP
!v010!^sElia^rND^nM
!v010!^sManuel Gomez^rND^nJ
!v010!^sLilienthal Heitmann^rND^nB
!v010!^sKent-Smith^rND^nL
!v010!^sMelchior^rND^nJC
!v010!^sPirlich^rND^nM
!v010!^sScharfetter^rND^nH
!v010!^sM W J Schols^rND^nA
!v010!^sPichard^rND^nC
!v012!Bioelectrical impedance analysis-part II: utilization in clinical practice^len
!v014!1430-453
!v030!Clin Nutr
!v031!23
!v064!2004
!v065!20040000
!v118!18
!v514!^l1453^f1430
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000134
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sLee^rND^nSY
!v010!^sGallagher^rND^nD
!v012!Assessment methods in human body composition^len
!v014!566-72
!v030!Curr Opin Clin Nutr Metab Care
!v031!11
!v064!2008
!v065!20080000
!v118!19
!v514!^l572^f566
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000135
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sLehnert^rND^nME
!v010!^sClarke^rND^nDD
!v010!^sGibbons^rND^nJG
!v010!^sWard^rND^nLC
!v010!^sGolding^rND^nSM
!v010!^sShepherd^rND^nRW
!v010!^sCornish^rND^nBH
!v010!^sCrawford^rND^nDH
!v012!Estimation of body water compartments in cirrhosis by multiple-frequency bioelectrical-impedance analysis^len
!v014!31-4
!v030!Nutrition
!v031!17
!v064!2001
!v065!20010000
!v118!20
!v514!^l34^f31
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000136
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sLochs^rND^nH
!v010!^sPlauth^rND^nM
!v012!Liver cirrhosis: rationale and modalities for nutritional support - the European Society of Parenteral and Enteral Nutrition consensus and beyond^len
!v014!345-49
!v030!Curr Opin Clin Nutr Metab Care
!v031!2
!v064!1999
!v065!19990000
!v118!21
!v514!^l349^f345
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000137
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sMa^rND^nZ
!v010!^sZhang^rND^nY
!v010!^sHuet^rND^nPM
!v010!^sLee^rND^nSS
!v012!Differential effects of jaundice and cirrhosis on alfa-adrenoceptor signalling in three rat models of cirrhotic cardiomyopathy^len
!v014!485-91
!v030!J Hepatol
!v031!30
!v064!1999
!v065!19990000
!v118!22
!v514!^l491^f485
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000138
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sMaio^rND^nR
!v010!^sDichi^rND^nJB
!v010!^sBurini^rND^nRC
!v014!52-7
!v030!Arq Gastroenterol
!v031!37
!v064!2000
!v065!20000000
!v118!23
!v514!^l57^f52
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000139
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sMccullough^rND^nAJ
!v010!^sBugianesi^rND^nE
!v012!Protein-calorie malnutrition and the etiology of cirrhosis^len
!v014!734-38
!v030!Am J Gastroenterol
!v031!92
!v064!1997
!v065!19970000
!v118!24
!v514!^l738^f734
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000140
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sMccullough^rND^nAJ
!v012!^tNutritional state and abnormal metabolism of nutrients
!v014!204-44
!v018!Postgraduate course: newer aspects on alcohol, nutrition and hepatic encephalopathy
!v064!1992
!v065!19920000
!v118!25
!v514!^l244^f204
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000141
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sMccullough^rND^nAJ
!v012!Malnutrition and liver disease^len
!v014!S85-S96
!v030!Liver Transpl
!v031!4
!v064!2000
!v065!20000000
!v118!26
!v514!^lS96^fS85
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000142
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sMerli^rND^nM
!v010!^sRiggio^rND^nO
!v010!^sDally^rND^nL
!v012!Does malnutrition affect survival cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi)^len
!v014!1041-046
!v030!Hepatology
!v031!23
!v064!1996
!v065!19960000
!v118!27
!v514!^l1046^f1041
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000143
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sMiwa^rND^nY
!v010!^sShiraki^rND^nM
!v010!^sKato^rND^nM
!v010!^sTajika^rND^nM
!v010!^sMohri^rND^nH
!v010!^sMurakami^rND^nN
!v010!^sKato^rND^nT
!v010!^sOhnishi^rND^nH
!v010!^sMorioku^rND^nT
!v010!^sMuto^rND^nY
!v010!^sMoriwaki^rND^nH
!v012!Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis^len
!v014!184-89
!v030!Hepatol Res
!v031!18
!v064!2000
!v065!20000000
!v118!28
!v514!^l189^f184
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000144
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sMuller^rND^nMJ
!v010!^sBoker^rND^nKH
!v010!^sSelberg^rND^nO
!v012!Are patients with liver cirrhosis hypermetabolic?^len
!v014!131-44
!v030!Clin Nutr
!v031!13
!v064!1994
!v065!19940000
!v118!29
!v514!^l144^f131
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000145
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sNaveau^rND^nS
!v010!^sBelda^rND^nE
!v010!^sBorotto^rND^nE
!v010!^sGenuist^rND^nF
!v010!^sChaput^rND^nJC
!v012!Comparision of clinical judgment and antropometric parameters for evaluating nutritional status in patients with alcoholic liver disease^len
!v014!234-35
!v030!J Hepatol
!v031!23
!v064!1995
!v065!19950000
!v118!30
!v514!^l235^f234
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000146
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sNorman^rND^nK
!v010!^sSmoliner^rND^nC
!v010!^sValentini^rND^nL
!v010!^sLochs^rND^nH
!v010!^sPirlich^rND^nM
!v012!Is bioelectrical impedance vector analysis of value in the elderly with malnutrition and impaired functionality?^len
!v014!564-69
!v030!Nutrition
!v031!23
!v064!2007
!v065!20070000
!v118!31
!v514!^l569^f564
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000147
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v012!Italian Multicentre Cooperative Project On Nutrition In Liver Cirrhosis^len
!v014!317-25
!v030!J Hepatol
!v031!21
!v064!1994
!v065!19940000
!v118!32
!v514!^l325^f317
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000148
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sOtt^rND^nM
!v010!^sFischer^rND^nH
!v010!^sPolat^rND^nH
!v010!^sHelm^rND^nEB
!v010!^sFranz^rND^nM
!v010!^sCaspary^rND^nWF
!v010!^sLembcke^rND^nB
!v012!Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection^len
!v014!20-5
!v030!J Acquir Immune Defic Syndr Hum Retrovirol
!v031!9
!v064!1995
!v065!19950000
!v118!33
!v514!^l25^f20
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000149
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sPiquet^rND^nMA
!v010!^sOllivier^rND^nI
!v010!^sGloro^rND^nR
!v010!^sCastel^rND^nH
!v010!^sTiengou^rND^nLE
!v010!^sDao^rND^nT
!v012!Nutritional indices in cirrhotic patients^len
!v014!216-17
!v030!Nutrition
!v031!22
!v064!2006
!v065!20060000
!v118!34
!v514!^l217^f216
!v700!38
!v701!34
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000150
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sPirlich^rND^nM
!v010!^sSchutz^rND^nT
!v010!^sSpachos^rND^nT
!v010!^sErtl^rND^nS
!v010!^sWeiss^rND^nML
!v010!^sLochs^rND^nH
!v010!^sPlauth^rND^nM
!v012!Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites^len
!v014!1208-215
!v030!Hepatology
!v031!32
!v064!2000
!v065!20000000
!v118!35
!v514!^l1215^f1208
!v700!39
!v701!35
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000151
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sPupim^rND^nLB
!v010!^sKent^rND^nP
!v010!^sIkizler^rND^nTA
!v012!Bioelectrical impedance analysis in dialysis patients^len
!v014!400-06
!v030!Miner Electrolyte Metab
!v031!25
!v064!1999
!v065!19990000
!v118!36
!v514!^l406^f400
!v700!40
!v701!36
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000152
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sScheunemann^rND^nL
!v010!^sWazlawik^rND^nE
!v010!^sBastos^rND^nJL
!v010!^sRistow^rND^nTC
!v010!^sMayumi^rND^nNL
!v012!Agreement and association between the phase angle and parameters of nutritional status assessment in surgical patients^len
!v014!480-87
!v030!Nutr Hosp
!v031!26
!v064!2011
!v065!20110000
!v118!37
!v514!^l487^f480
!v700!41
!v701!37
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000153
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sSchwenk^rND^nA
!v010!^sBeisenherz^rND^nA
!v010!^sRomer^rND^nK
!v010!^sKremer^rND^nG
!v010!^sSalzberger^rND^nB
!v010!^sElia^rND^nM
!v012!Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment^len
!v014!496-501
!v030!Am J Clin Nutr
!v031!72
!v064!2000
!v065!20000000
!v118!38
!v514!^l501^f496
!v700!42
!v701!38
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000154
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sSelberg^rND^nO
!v010!^sSelberg^rND^nD
!v012!Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized, and patients with liver cirrhosis^len
!v014!509-16
!v030!Eur J Appl Physiol
!v031!86
!v064!2002
!v065!20020000
!v118!39
!v514!^l516^f509
!v700!43
!v701!39
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000155
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v018!Adolphe Quetelet
!v037!http://www.morris.umn.edu/~sungurea/introstat/history/w98/Quetelet.html
!v118!40
!v700!44
!v701!40
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000156
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v010!^sWagner^rND^nD
!v010!^sAdunka^rND^nC
!v010!^sKniepeiss^rND^nD
!v010!^sJakoby^rND^nE
!v010!^sSchaffellner^rND^nS
!v010!^sKandlbauer^rND^nM
!v010!^sFahrleitner-Pammer^rND^nA
!v010!^sRoller^rND^nRE
!v010!^sKornprat^rND^nP
!v010!^sMuller^rND^nH
!v010!^sIberer^rND^nF
!v010!^sTscheliessnigg^rND^nKH
!v012!Serum albumin, subjective global assessment, body mass index and the bioimpedance analysis in the assessment of malnutrition in patients up to 15 years after liver transplantation^len
!v014!1-5
!v030!Clin Transplant
!v031!3
!v064!2011
!v065!20110000
!v118!41
!v514!^l5^f1
!v700!45
!v701!41
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000157
!v001!br1.1
!v002!0004-2803-ag-49-01-19.xml
!v004!v49n1
!v018!Physical status: the use and interpretation of anthropometry
!v062!WHO
!v064!1995
!v065!19950000
!v066!Geneva
!v118!42
!v700!46
!v701!42
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-19.xml
!v705!S
!v706!c
!v708!42
!v865!20120300
!ID 000158
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v091!20120814
!v092!164259
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v703!118
!v705!S
!v706!o
!v708!1
!ID 000159
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^1aff1^sLeandro-Merhi^rauthor^nVania Aparecida
!v010!^sAquino^rauthor^nJose Luiz Braga de
!v012!^tInvestigation of nutritional risk factors using anthropometric indicators in hospitalized surgery patients
!v012!^tInvestigacao de fatores de risco nutricional por meio de indicadores antropometricos em pacientes cirurgicos hospitalizados^lpt
!v014!^l34^f28
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Escola de Nutricao, PUC-Campinas^iaff1^9Escola de Nutricao, PUC-Campinas^5?^l1
!v070!Escola de Medicina, PUC-Campinas^cCampinas^iaff2^l2^pBrasil^sSP^5?^9Escola de Medicina, PUC-Campinas, Campinas, SP, Brasil
!v071!oa
!v072!40
!v083!^a<sec>					<title>CONTEXT:</title>					 The investigation of risk factors associated with nutritional status could contribute for better knowledge of the malnutrition. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To investigate the incidence of malnutrition and its possible association with many parameters that assess nutritional status and to identify the associated risk factors. 				</sec>				<sec>					<title>METHODS:</title>					 The nutritional status was assessed in 235 hospitalized patients. Malnutrition was defined as present when the patient presented at least two anthropometric criteria below the normal range and habitual energy intake below 75% of the energy requirement (HEI/ER&lt;75%). Gender, age, type of disease, recent weight change and dental problems were investigated as possible associated risk factors. The chi-square and Mann-Whitney tests were used to compare the data and univariate and multiple logistic regressions were used to identify the factors associated with malnutrition. The odds ratio (OR) and confidence interval (CI) of 95% were calculated with the significance level set at 5% (P&lt;0.05). 				</sec>				<sec>					<title>RESULTS:</title>					 One-fifth (20%) of the patients were malnourished on admission to the hospital and 27.5% reported recent weight loss. Malnutrition (P&lt;0.0001) was greater in patients with malignant diseases. The only variables significantly associated with malnutrition according to univariate logistic regression were recent weight loss (P = 0.0058; OR = 2.909; IC95% = 1.362; 6.212) and malignant disease (P = 0.0001; OR = 3.847; IC95% = 1.948; 7.597). When multiple regression was used in the model which included type of disease, malignant disease was shown to increase the chance of malnutrition fourfold (P = 0.0002; OR = 3.855; IC95% = 1.914; 7.766). When disease was excluded, recent weight loss also increased malnutrition fourfold (P = 0.0012; OR = 3.716; IC95% = 1.677; 8.236). 				</sec>				<sec>					<title>CONCLUSION:</title>					 Patients with a history of recent weight loss and those with malignant diseases are more susceptible to malnutrition.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO</title>					: A investigacao de fatores de risco associados ao estado nutricional pode contribuir para o melhor conhecimento da desnutricao. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Investigar a incidencia de risco nutricional com a associacao de varios parametros de avaliacao nutricional e identificar os fatores de risco relacionados. 				</sec>				<sec>					<title>MeTODO:</title>					 Foi avaliado o risco nutricional em 235 pacientes hospitalizados com doencas benignas e malignas, sendo o sexo, a faixa etaria, o tipo de doenca, a alteracao de peso recente e os problemas dentarios, investigados como possiveis fatores de risco associados. Para a comparacao dos dados, foi utilizado o teste Qui ao quadrado e Mann-Whitney e para identificar os fatores associados ao risco nutricional foi utilizada a analise de regressao logistica univariada e multipla, sendo calculado o odds ratio (OR) e o intervalo de confianca (IC) de 95%, com P&lt;0,05. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Verificou-se 20% dos pacientes com risco nutricional na admissao hospitalar e 27,5% referiram perda de peso recente, com diferenca significativa entre os grupos nos parametros avaliados e para o risco nutricional de desnutricao (P&lt;0,0001), maior naqueles com doencas malignas. Na regressao logistica univariada, as unicas variaveis significativas para o risco nutricional foram a perda de peso recente (P = 0,0058; OR = 2,909; IC95% = 1,362; 6,212) e a doenca maligna (P = 0,0001; OR = 3,847; IC95% =1 ,948; 7,597). Posteriormente, na regressao multipla, no modelo com o tipo de doenca, foi comprovado que a doenca maligna elevou a chance de risco nutricional em 4 vezes (P = 0,0002; OR = 3,855; IC95% = 1,914; 7,766). Excluindo-se a doenca, comprovou-se que a perda de peso recente elevou o risco nutricional tambem em quase 4 vezes (P = 0,0012; OR = 3,716; IC95% = 1,677; 8,236). 				</sec>				<sec>					<title>CONCLUSaO:</title>					 Pacientes que perderam peso recentemente e aqueles com doenca maligna apresentaram mais chances de desenvolver risco nutricional.				</sec>^lpt
!v085!^kNutritional status^len
!v085!^kMalnutrition^len
!v085!^kPostoperative period^len
!v085!^kAnthropometry^len
!v085!^kRisk factors^len
!v085!^kInpatients^len
!v085!^kEstado nutricional^lpt
!v085!^kDesnutricao^lpt
!v085!^kPeriodo pos-operatorio^lpt
!v085!^kAntropometria^lpt
!v085!^kFatores de risco^lpt
!v085!^kPacientes internados^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d14
!v112!2011
!v113!^y2011^m08^d11
!v114!2011
!v120!XML_3.0
!v121!28
!v237!10.1590/S0004-28032012000100006
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!h
!v708!1
!ID 000160
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^1aff1^sLeandro-Merhi^rauthor^nVânia Aparecida
!v010!^sAquino^rauthor^nJosé Luiz Braga de
!v012!^tInvestigation of nutritional risk factors using anthropometric indicators in hospitalized surgery patients
!v012!^tInvestigação de fatores de risco nutricional por meio de indicadores antropométricos em pacientes cirúrgicos hospitalizados^lpt
!v014!^l34^f28
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Escola de Nutri&#231;&#227;o, PUC-Campinas^iaff1^9Escola de Nutri&#231;&#227;o, PUC-Campinas^5?^l1
!v070!Escola de Medicina, PUC-Campinas^cCampinas^iaff2^l2^pBrasil^sSP^5?^9Escola de Medicina, PUC-Campinas, Campinas, SP, Brasil
!v071!oa
!v072!40
!v083!^a<sec>					<title>CONTEXT:</title>					<p> The investigation of risk factors associated with nutritional status could contribute for better knowledge of the malnutrition. </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To investigate the incidence of malnutrition and its possible association with many parameters that assess nutritional status and to identify the associated risk factors. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> The nutritional status was assessed in 235 hospitalized patients. Malnutrition was defined as present when the patient presented at least two anthropometric criteria below the normal range and habitual energy intake below 75% of the energy requirement (HEI/ER&lt;75%). Gender, age, type of disease, recent weight change and dental problems were investigated as possible associated risk factors. The chi-square and Mann-Whitney tests were used to compare the data and univariate and multiple logistic regressions were used to identify the factors associated with malnutrition. The odds ratio (OR) and confidence interval (CI) of 95% were calculated with the significance level set at 5% (<italic>P</italic>&lt;0.05). </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> One-fifth (20%) of the patients were malnourished on admission to the hospital and 27.5% reported recent weight loss. Malnutrition (<italic>P</italic>&lt;0.0001) was greater in patients with malignant diseases. The only variables significantly associated with malnutrition according to univariate logistic regression were recent weight loss (<italic>P</italic> = 0.0058; OR = 2.909; IC95% = 1.362; 6.212) and malignant disease (<italic>P</italic> = 0.0001; OR = 3.847; IC95% = 1.948; 7.597). When multiple regression was used in the model which included type of disease, malignant disease was shown to increase the chance of malnutrition fourfold (<italic>P</italic> = 0.0002; OR = 3.855; IC95% = 1.914; 7.766). When disease was excluded, recent weight loss also increased malnutrition fourfold (<italic>P</italic> = 0.0012; OR = 3.716; IC95% = 1.677; 8.236). </p>				</sec>				<sec>					<title>CONCLUSION:</title>					<p> Patients with a history of recent weight loss and those with malignant diseases are more susceptible to malnutrition.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO</title>					<p>: A investiga&#231;&#227;o de fatores de risco associados ao estado nutricional pode contribuir para o melhor conhecimento da desnutri&#231;&#227;o. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Investigar a incid&#234;ncia de risco nutricional com a associa&#231;&#227;o de v&#225;rios par&#226;metros de avalia&#231;&#227;o nutricional e identificar os fatores de risco relacionados. </p>				</sec>				<sec>					<title>M&#201;TODO:</title>					<p> Foi avaliado o risco nutricional em 235 pacientes hospitalizados com doen&#231;as benignas e malignas, sendo o sexo, a faixa et&#225;ria, o tipo de doen&#231;a, a altera&#231;&#227;o de peso recente e os problemas dent&#225;rios, investigados como poss&#237;veis fatores de risco associados. Para a compara&#231;&#227;o dos dados, foi utilizado o teste Qui ao quadrado e Mann-Whitney e para identificar os fatores associados ao risco nutricional foi utilizada a an&#225;lise de regress&#227;o log&#237;stica univariada e m&#250;ltipla, sendo calculado o odds ratio (OR) e o intervalo de confian&#231;a (IC) de 95%, com <italic>P</italic>&lt;0,05. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Verificou-se 20% dos pacientes com risco nutricional na admiss&#227;o hospitalar e 27,5% referiram perda de peso recente, com diferen&#231;a significativa entre os grupos nos par&#226;metros avaliados e para o risco nutricional de desnutri&#231;&#227;o (<italic>P</italic>&lt;0,0001), maior naqueles com doen&#231;as malignas. Na regress&#227;o log&#237;stica univariada, as &#250;nicas vari&#225;veis significativas para o risco nutricional foram a perda de peso recente (<italic>P</italic> = 0,0058; OR = 2,909; IC95% = 1,362; 6,212) e a doen&#231;a maligna (<italic>P</italic> = 0,0001; OR = 3,847; IC95% =1 ,948; 7,597). Posteriormente, na regress&#227;o m&#250;ltipla, no modelo com o tipo de doen&#231;a, foi comprovado que a doen&#231;a maligna elevou a chance de risco nutricional em 4 vezes (<italic>P</italic> = 0,0002; OR = 3,855; IC95% = 1,914; 7,766). Excluindo-se a doen&#231;a, comprovou-se que a perda de peso recente elevou o risco nutricional tamb&#233;m em quase 4 vezes (<italic>P</italic> = 0,0012; OR = 3,716; IC95% = 1,677; 8,236). </p>				</sec>				<sec>					<title>CONCLUS&#195;O:</title>					<p> Pacientes que perderam peso recentemente e aqueles com doen&#231;a maligna apresentaram mais chances de desenvolver risco nutricional.</p>				</sec>^lpt
!v085!^kNutritional status^len
!v085!^kMalnutrition^len
!v085!^kPostoperative period^len
!v085!^kAnthropometry^len
!v085!^kRisk factors^len
!v085!^kInpatients^len
!v085!^kEstado nutricional^lpt
!v085!^kDesnutrição^lpt
!v085!^kPeríodo pós-operatório^lpt
!v085!^kAntropometria^lpt
!v085!^kFatores de risco^lpt
!v085!^kPacientes internados^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d14
!v112!2011
!v113!^y2011^m08^d11
!v114!2011
!v120!XML_3.0
!v121!28
!v237!10.1590/S0004-28032012000100006
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!f
!v708!1
!ID 000161
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^1aff1^sLeandro-Merhi^rauthor^nVania Aparecida
!v010!^sAquino^rauthor^nJose Luiz Braga de
!v012!^tInvestigation of nutritional risk factors using anthropometric indicators in hospitalized surgery patients
!v012!^tInvestigacao de fatores de risco nutricional por meio de indicadores antropometricos em pacientes cirurgicos hospitalizados^lpt
!v014!^l34^f28
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Escola de Nutricao, PUC-Campinas^iaff1^9Escola de Nutricao, PUC-Campinas^5?^l1
!v070!Escola de Medicina, PUC-Campinas^cCampinas^iaff2^l2^pBrasil^sSP^5?^9Escola de Medicina, PUC-Campinas, Campinas, SP, Brasil
!v071!oa
!v072!40
!v083!^a<sec>					<title>CONTEXT:</title>					 The investigation of risk factors associated with nutritional status could contribute for better knowledge of the malnutrition. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To investigate the incidence of malnutrition and its possible association with many parameters that assess nutritional status and to identify the associated risk factors. 				</sec>				<sec>					<title>METHODS:</title>					 The nutritional status was assessed in 235 hospitalized patients. Malnutrition was defined as present when the patient presented at least two anthropometric criteria below the normal range and habitual energy intake below 75% of the energy requirement (HEI/ER&lt;75%). Gender, age, type of disease, recent weight change and dental problems were investigated as possible associated risk factors. The chi-square and Mann-Whitney tests were used to compare the data and univariate and multiple logistic regressions were used to identify the factors associated with malnutrition. The odds ratio (OR) and confidence interval (CI) of 95% were calculated with the significance level set at 5% (P&lt;0.05). 				</sec>				<sec>					<title>RESULTS:</title>					 One-fifth (20%) of the patients were malnourished on admission to the hospital and 27.5% reported recent weight loss. Malnutrition (P&lt;0.0001) was greater in patients with malignant diseases. The only variables significantly associated with malnutrition according to univariate logistic regression were recent weight loss (P = 0.0058; OR = 2.909; IC95% = 1.362; 6.212) and malignant disease (P = 0.0001; OR = 3.847; IC95% = 1.948; 7.597). When multiple regression was used in the model which included type of disease, malignant disease was shown to increase the chance of malnutrition fourfold (P = 0.0002; OR = 3.855; IC95% = 1.914; 7.766). When disease was excluded, recent weight loss also increased malnutrition fourfold (P = 0.0012; OR = 3.716; IC95% = 1.677; 8.236). 				</sec>				<sec>					<title>CONCLUSION:</title>					 Patients with a history of recent weight loss and those with malignant diseases are more susceptible to malnutrition.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO</title>					: A investigacao de fatores de risco associados ao estado nutricional pode contribuir para o melhor conhecimento da desnutricao. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Investigar a incidencia de risco nutricional com a associacao de varios parametros de avaliacao nutricional e identificar os fatores de risco relacionados. 				</sec>				<sec>					<title>MeTODO:</title>					 Foi avaliado o risco nutricional em 235 pacientes hospitalizados com doencas benignas e malignas, sendo o sexo, a faixa etaria, o tipo de doenca, a alteracao de peso recente e os problemas dentarios, investigados como possiveis fatores de risco associados. Para a comparacao dos dados, foi utilizado o teste Qui ao quadrado e Mann-Whitney e para identificar os fatores associados ao risco nutricional foi utilizada a analise de regressao logistica univariada e multipla, sendo calculado o odds ratio (OR) e o intervalo de confianca (IC) de 95%, com P&lt;0,05. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Verificou-se 20% dos pacientes com risco nutricional na admissao hospitalar e 27,5% referiram perda de peso recente, com diferenca significativa entre os grupos nos parametros avaliados e para o risco nutricional de desnutricao (P&lt;0,0001), maior naqueles com doencas malignas. Na regressao logistica univariada, as unicas variaveis significativas para o risco nutricional foram a perda de peso recente (P = 0,0058; OR = 2,909; IC95% = 1,362; 6,212) e a doenca maligna (P = 0,0001; OR = 3,847; IC95% =1 ,948; 7,597). Posteriormente, na regressao multipla, no modelo com o tipo de doenca, foi comprovado que a doenca maligna elevou a chance de risco nutricional em 4 vezes (P = 0,0002; OR = 3,855; IC95% = 1,914; 7,766). Excluindo-se a doenca, comprovou-se que a perda de peso recente elevou o risco nutricional tambem em quase 4 vezes (P = 0,0012; OR = 3,716; IC95% = 1,677; 8,236). 				</sec>				<sec>					<title>CONCLUSaO:</title>					 Pacientes que perderam peso recentemente e aqueles com doenca maligna apresentaram mais chances de desenvolver risco nutricional.				</sec>^lpt
!v085!^kNutritional status^len
!v085!^kMalnutrition^len
!v085!^kPostoperative period^len
!v085!^kAnthropometry^len
!v085!^kRisk factors^len
!v085!^kInpatients^len
!v085!^kEstado nutricional^lpt
!v085!^kDesnutricao^lpt
!v085!^kPeriodo pos-operatorio^lpt
!v085!^kAntropometria^lpt
!v085!^kFatores de risco^lpt
!v085!^kPacientes internados^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d14
!v112!2011
!v113!^y2011^m08^d11
!v114!2011
!v120!XML_3.0
!v121!28
!v237!10.1590/S0004-28032012000100006
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!l
!v708!1
!ID 000162
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sAmaral^rND^nTF
!v010!^sMatos^rND^nLC
!v010!^sTeixeira^rND^nMA
!v010!^sTavares^rND^nMM
!v010!^salvares^rND^nL
!v010!^sAntunes^rND^nA
!v012!Undernutrition and associated factors among hospitalized patients^len
!v014!580-85
!v030!Clin Nutr
!v031!29
!v064!2010
!v065!20100000
!v071!journal
!v118!1
!v514!^l585^f580
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000163
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sBeghetto^rND^nMG
!v010!^sManna^rND^nB
!v010!^sCandal^rND^nA
!v010!^sMello^rND^nED
!v010!^sPolanczyk^rND^nCA
!v012!Triagem nutricional em adultos hospitalizados^lpt
!v014!589-601
!v030!Rev Nutr
!v031!21
!v064!2008
!v065!20080000
!v118!2
!v514!^l601^f589
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000164
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sBeghetto^rND^nMG
!v010!^sLuft^rND^nVC
!v010!^sMello^rND^nED
!v010!^sPolanczyk^rND^nCA
!v012!Accuracy of nutritional assessment tools for predicting adverse hospital outcomes^len
!v014!56-62
!v030!Nutr Hosp
!v031!24
!v064!2009
!v065!20090000
!v118!3
!v514!^l62^f56
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000165
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sBozzetti^rND^nF
!v010!^sGianotti^rND^nL
!v010!^sBraga^rND^nM
!v010!^sDi Carloc^rND^nV
!v010!^sMariani^rND^nL
!v012!Postoperative complications in gastrointestinal cancer patients: the joint role of the nutritional status and the nutritional support^len
!v014!698-709
!v030!Clin Nutr
!v031!26
!v064!2007
!v065!20070000
!v118!4
!v514!^l709^f698
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000166
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sBurr^rND^nML
!v010!^sPhillips^rND^nKM
!v012!Anthropometric norms in the elderly^len
!v014!165-69
!v030!Br J Nutr
!v031!51
!v064!1984
!v065!19840000
!v118!5
!v514!^l169^f165
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000167
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sConover^rND^nWJ
!v018!Practical nonparametric statistics
!v062!John Wiley
!v064!1971
!v065!19710000
!v066!New York
!v118!6
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000168
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sCorreia^rND^nMI
!v010!^sWaitzberg^rND^nDL
!v012!The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis^len
!v014!235-39
!v030!Clin Nutr
!v031!22
!v064!2003
!v065!20030000
!v118!7
!v514!^l239^f235
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000169
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sDe Oliveira^rND^nMRM
!v010!^sLeandro-Merhi^rND^nVA
!v012!Food intake and nutritional status of hospitalized older people^len
!v030!Int J Older People Nurs
!v064!2010
!v065!20100000
!v118!8
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000170
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sDetsky^rND^nAS
!v010!^sMcLaughlin^rND^nJR
!v010!^sBaker^rND^nJP
!v010!^sJohnston^rND^nN
!v010!^sWhittaker^rND^nS
!v010!^sMendelson^rND^nRA
!v010!^sJeejeebhoy^rND^nKN
!v012!What is subjective global assessment of nutritional status?^len
!v014!8-13
!v030!JPEN J Parenter Enteral Nutr
!v031!11
!v064!1987
!v065!19870000
!v118!9
!v514!^l13^f8
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000171
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sFettes^rND^nSB
!v010!^sDavidson^rND^nHIM
!v010!^sRichardson^rND^nRA
!v010!^sPennington^rND^nCR
!v012!Nutritional status of elective gastrointestinal surgery patients pre-and post-operatively^len
!v014!249-54
!v030!Clin Nutr
!v031!21
!v064!2002
!v065!20020000
!v118!10
!v514!^l254^f249
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000172
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sFilipovi&#0x106;^rND^nBF
!v010!^sGaji&#0x106;^rND^nM
!v010!^sMilini&#0x106;^rND^nN
!v010!^sMilovanovi&#0x106;^rND^nB
!v010!^sFilipovi&#0x106;^rND^nBR
!v010!^sCvetkovi&#0x106;^rND^nM
!v010!^sSibali&#0x106;^rND^nN
!v012!Comparison of two nutritional assessment methods in gastroenterology patients^len
!v014!1999-2004
!v030!World J Gastroenterol
!v031!16
!v064!2010
!v065!20100000
!v118!11
!v514!^l2004^f1999
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000173
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sFrisancho^rND^nAR
!v012!New norms of upper limb fat muscle areas for assessment of nutritional status^len
!v014!2540-545
!v030!Am J Clin Nutr
!v031!34
!v064!1981
!v065!19810000
!v118!12
!v514!^l2545^f2540
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000174
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sFrisancho^rND^nAR
!v018!Anthropometric standards for the assessment of growth and nutritional status
!v062!University of Michigan Press
!v064!1990
!v065!19900000
!v066!Ann Arbor
!v118!13
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000175
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sHarris^rND^nJ
!v010!^sBenedict^rND^nF
!v018!A biometric study of basal metabolism in man
!v062!Carnegie Institute of Washington
!v064!1919
!v065!19190000
!v066!Washington, DC
!v118!14
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000176
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sHeymsfield^rND^nSB
!v010!^sThighe^rND^nA
!v010!^sWang^rND^nZM
!v010!^sShills^rND^nME
!v010!^sOlson^rND^nJA
!v010!^sShije^rND^nM
!v012!^tNutritional assessment by anthropometric and biochemical methods
!v014!812-41
!v018!Modern nutrition in health and disease
!v062!Williams & Wilkins
!v063!9 th ed.
!v064!1999
!v065!19990000
!v066!Baltimore
!v118!15
!v514!^l841^f812
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000177
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sHosmer^rND^nDW
!v010!^sLemeshow^rND^nS
!v018!Applied logistic regression
!v062!John Wiley
!v064!1989
!v065!19890000
!v066!New York
!v118!16
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000178
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sKondrup^rND^nJ
!v010!^sAllison^rND^nSP
!v010!^sElia^rND^nM
!v010!^sVellas^rND^nB
!v010!^sPlauth^rND^nM
!v012!ESPEN guidelines for nutrition screening 2002^len
!v014!415-21
!v030!Clin Nutr
!v031!22
!v064!2003
!v065!20030000
!v118!17
!v514!^l421^f415
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000179
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sKorfali^rND^nG
!v010!^sGundo&#0x11e;du^rND^nH
!v010!^sAydmtug^rND^nS
!v010!^sBahar^rND^nM
!v010!^sBesler^rND^nT
!v010!^sMoral^rND^nAR
!v010!^sO&#0x11e;uz^rND^nM
!v010!^sSakarya^rND^nM
!v010!^sUyar^rND^nM
!v010!^sKihctur&#0x11e;ay^rND^nS
!v012!Nutritional risk of hospitalized patients in Turkey^len
!v014!533-37
!v030!Clin Nutr.
!v031!28
!v064!2009
!v065!20090000
!v118!18
!v514!^l537^f533
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000180
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sKyle^rND^nUG
!v010!^sKossovsky^rND^nMP
!v010!^sKarsegard^rND^nVL
!v010!^sPichard^rND^nC
!v012!Comparison of tools for nutritional assessment and screening at hospital admission: a population study^len
!v014!409-17
!v030!Clin Nutr
!v031!25
!v064!2006
!v065!20060000
!v118!19
!v514!^l417^f409
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000181
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sLeandro-Merhi^rND^nVA
!v010!^sPortero-Mclellan^rND^nKC
!v010!^sBernardi^rND^nJLD
!v010!^sFrenhani^rND^nPB
!v010!^sde Camargo^rND^nJG
!v010!^sde Aquino^rND^nJL
!v012!Dental and gastrointestinal changes as indicators of nutritional depletion in elderly inpatients^len
!v014!873-77
!v030!J Eval Clin Pract
!v031!16
!v064!2010
!v065!20100000
!v118!20
!v514!^l877^f873
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000182
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sLeandro-Merhi^rND^nVA
!v010!^sde Aquino^rND^nJL
!v010!^sde Camargo^rND^nJG
!v010!^sFrenhani^rND^nPB
!v010!^sBernardi^rND^nJLD
!v010!^sPortero-Mclellan^rND^nKC
!v012!Clinical and nutritional status of surgical patients with and without malignant diseases: cross-sectional study^len
!v014!58-61
!v030!Arq Gastroenterol
!v031!48
!v064!2011
!v065!20110000
!v118!21
!v514!^l61^f58
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000183
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sLeandro-Merhi^rND^nVA
!v010!^sde Aquino^rND^nJL
!v010!^sSales Chagas^rND^nJF
!v012!Nutrition status and risk factors associated with length of hospital stay for surgical patients^len
!v014!241-48
!v030!JPEN J Parenter Enteral Nutr
!v031!35
!v064!2011
!v065!20110000
!v118!22
!v514!^l248^f241
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000184
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sLiang^rND^nX
!v010!^sJiang^rND^nZM
!v010!^sNolan^rND^nMT
!v010!^sEfron^rND^nDT
!v010!^sKondrup^rND^nJ
!v012!Comparative survey on nutritional risk and nutritional support between Beijing and Baltimore teaching hospitals^len
!v014!9696-676
!v030!Nutrition
!v031!24
!v064!2008
!v065!20080000
!v118!23
!v514!^l9676^f9696
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000185
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sLipschitz^rND^nDA
!v012!Screening for nutritional status in the elderly^len
!v014!55-67
!v030!Prim Care
!v031!22
!v064!1994
!v065!19940000
!v118!24
!v514!^l67^f55
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000186
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sMcLellan^rND^nKCP
!v010!^sBernardi^rND^nJLD
!v010!^sJacob^rND^nP
!v010!^sSoares^rND^nCSR
!v010!^sFrenhani^rND^nPB
!v010!^sLeandro-Merhi^rND^nVA
!v012!Estado nutricional e composicao corporal de pacientes hospitalizados: reflexos da transicao nutricional^lpt
!v014!25-33
!v030!Rev Bras Promoc Saude
!v031!23
!v064!2010
!v065!20100000
!v118!25
!v514!^l33^f25
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000187
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sMimiran^rND^nP
!v010!^sHosseinpour-Niazi^rND^nS
!v010!^sMehrabani^rND^nHH
!v010!^sKavian^rND^nF
!v010!^sAzizi^rND^nF
!v012!Validity and reliability of a nutrition screening tool in hospitalized patients^len
!v014!647-52
!v030!Nutrition
!v031!27
!v064!2010
!v065!20100000
!v118!26
!v514!^l652^f647
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000188
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sNaber^rND^nTH
!v010!^sSchermer^rND^nT
!v010!^sde Bree^rND^nA
!v010!^sNusteling^rND^nK
!v010!^sEggink^rND^nL
!v010!^sKruimel^rND^nJW
!v010!^sBakkeren^rND^nJ
!v010!^svan Heereveld^rND^nH
!v010!^sKatan^rND^nMB
!v012!Prevalence of malnutrition in nonsurgical hospitalized patients and its association with disease complications^len
!v014!1232-239
!v030!Am J Clin Nutr
!v031!66
!v064!1997
!v065!19970000
!v118!27
!v514!^l1239^f1232
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000189
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sPereira Borges^rND^nN
!v010!^sD'Alegria Silva^rND^nB
!v010!^sCohen^rND^nC
!v010!^sPortari^rND^nPE
!v010!^sMedeiros^rND^nFJ
!v012!Comparison of the nutritional diagnosis, obtained through different methods and indicators, in patients with cancer^len
!v014!51-5
!v030!Nutr Hosp
!v031!24
!v064!2009
!v065!20090000
!v118!28
!v514!^l55^f51
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000190
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sPirlich^rND^nM
!v010!^sSchutz^rND^nT
!v010!^sNorman^rND^nK
!v010!^sGastell^rND^nS
!v010!^sLubke^rND^nHJ
!v010!^sBischoff^rND^nSC
!v010!^sBolder^rND^nU
!v010!^sFrieling^rND^nT
!v010!^sGuldenzoph^rND^nH
!v010!^sHahn^rND^nK
!v010!^sJauch^rND^nKW
!v010!^sSchindler^rND^nK
!v010!^sStein^rND^nJ
!v010!^sVolkert^rND^nD
!v010!^sWeimann^rND^nA
!v010!^sWerner^rND^nH
!v010!^sWolf^rND^nC
!v010!^sZurcher^rND^nG
!v010!^sBauer^rND^nP
!v010!^sLochs^rND^nH
!v012!The German hospital malnutrition study^len
!v014!563-72
!v030!Clin Nutr
!v031!25
!v064!2006
!v065!20060000
!v118!29
!v514!^l572^f563
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000191
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sPortero-McLellan^rND^nKC
!v010!^sStaudt^rND^nC
!v010!^sSilva^rND^nFR
!v010!^sDelbue Bernardi^rND^nJL
!v010!^sBaston Frenhani^rND^nP
!v010!^sLeandro-Merhi^rND^nVA
!v012!The use of calf circumference measurement as an anthropometric tool to monitor nutritional status in elderly inpatients^len
!v014!266-70
!v030!J Nutr Health Aging
!v031!14
!v064!2010
!v065!20100000
!v118!30
!v514!^l270^f266
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000192
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sPutwatana^rND^nP
!v010!^sReodecha^rND^nP
!v010!^sSirapo-ngam^rND^nY
!v010!^sLertsithichai^rND^nP
!v010!^sSumboonnanonda^rND
!v012!Nutrition screening tools and the prediction of postoperative infectious and wound complications: comparison of methods in presence of risk adjustment^len
!v014!691-97
!v030!Nutrition
!v031!21
!v064!2005
!v065!20050000
!v118!31
!v514!^l697^f691
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000193
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sRaslan^rND^nM
!v010!^sGonzalez^rND^nMC
!v010!^sDias^rND^nMCG
!v010!^sPaes-Barbosa^rND^nFL
!v010!^sCecconello^rND^nI
!v010!^sWaitzberg^rND^nDL
!v012!Aplicabilidade dos metodos de triagem nutricional no paciente hospitalizado^lpt
!v014!553-61
!v030!Rev Nutr
!v031!21
!v064!2008
!v065!20080000
!v118!32
!v514!^l561^f553
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000194
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sRasmussen^rND^nHH
!v010!^sKondrup^rND^nJ
!v010!^sStaun^rND^nM
!v010!^sLadefoged^rND^nK
!v010!^sKristensen^rND^nH
!v010!^sWengler^rND^nA
!v012!Prevalence of patients at nutritional risk in Danish hospitals^len
!v014!1009-015
!v030!Clin Nutr
!v031!23
!v064!2004
!v065!20040000
!v118!33
!v514!^l1015^f1009
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000195
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v062!SAS Institute Inc
!v064!2008
!v065!20080000
!v066!Cary, NC
!v118!34
!v700!38
!v701!34
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000196
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sSorensen^rND^nJ
!v010!^sKondrup^rND^nJ
!v010!^sProkopowicz^rND^nJ
!v010!^sSchiesser^rND^nM
!v010!^sKrahenbbuhl^rND^nL
!v010!^sMeier^rND^nR
!v010!^sLiberda^rND^nM
!v012!EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome^len
!v014!340-49
!v030!Clin Nutr
!v031!27
!v064!2008
!v065!20080000
!v118!35
!v514!^l349^f340
!v700!39
!v701!35
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000197
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sStratton^rND^nRJ
!v010!^sHackston^rND^nA
!v010!^sLongmore^rND^nD
!v010!^sDixon^rND^nR
!v010!^sPrice^rND^nS
!v010!^sStroud^rND^nM
!v010!^sKing^rND^nC
!v010!^sElia^rND^nM
!v012!Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the 'malnutrition screening tool universal tool' ('MUST') for adults^len
!v014!799-808
!v030!Br J Nutr
!v031!92
!v064!2004
!v065!20040000
!v118!36
!v514!^l808^f799
!v700!40
!v701!36
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000198
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sSungurtekin^rND^nH
!v010!^sSungurtekin^rND^nU
!v010!^sHanci^rND^nV
!v010!^sErdem^rND^nE
!v012!Comparison of two nutrition assessment techniques in hospitalized patients^len
!v014!428-32
!v030!Nutrition
!v031!20
!v064!2004
!v065!20040000
!v118!37
!v514!^l432^f428
!v700!41
!v701!37
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000199
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v018!Programa de Apoio a Nutricao (NUTWIN) - programa de computador, versao 1.5
!v062!UNIFESP/ EPM
!v064!2002
!v065!20020000
!v066!Sao Paulo
!v118!38
!v700!42
!v701!38
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000200
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v010!^sWestergren^rND^nA
!v010!^sWann-Hansson^rND^nC
!v010!^sBorgdal^rND^nEB
!v010!^sSjolander^rND^nJ
!v010!^sStromblad^rND^nR
!v010!^sKlevsgard^rND^nR
!v010!^sAxelsson^rND^nC
!v010!^sLindholm^rND^nC
!v010!^sUlander^rND^nK
!v012!Malnutrition prevalence and precision in nutritional care differed in relation to hospital volume-a cross-sectional survey^len
!v014!20
!v030!Nutr J
!v031!8
!v064!2009
!v065!20090000
!v118!39
!v514!^f20
!v700!43
!v701!39
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000201
!v001!br1.1
!v002!0004-2803-ag-49-01-28.xml
!v004!v49n1
!v018!Obesity: preventing and managing the global epidemic - Report of a WHO consultation on obesity
!v062!WHO
!v064!1998
!v065!19980000
!v066!Geneva
!v118!40
!v700!44
!v701!40
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-28.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000202
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v091!20120814
!v092!164302
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v703!111
!v705!S
!v706!o
!v708!1
!ID 000203
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sSousa^rauthor^nWalysson Alves Tocantins de
!v010!^sRodrigues^rauthor^nLusmar Veras
!v010!^sSilva^rauthor^nRaimundo Geronimo da
!v010!^sVieira^rauthor^nFernando Lopes
!v012!^tImmunohistochemical evaluation of p53 and Ki-67 proteins in colorectal adenomas
!v012!^tAvaliacao imunoistoquimica das proteinas p53 e Ki-67 em adenomas colorretais^lpt
!v014!^l40^f35
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Department of Surgery, Federal University of Ceara^cFortaleza^iaff1^pBrazil^5?^9Department of Surgery, Federal University of Ceara, Fortaleza, Brazil
!v071!oa
!v072!33
!v083!^a<sec>					<title>CONTEXT:</title>					 The appearance of adenomas and their progression to adenocarcinomas is the result of an accumulation of genetic changes in cells of the intestinal mucosa inherited or acquired during life. Several proteins have been studied in relation to the development and progression of colorectal cancer, including tumor protein p53 (p53) and antigen identified by monoclonal antibody Ki-67 (Ki-67). 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To evaluate the expression of p53 and Ki-67 in colorectal adenomas and correlate the observed levels with clinical and pathologic findings. 				</sec>				<sec>					<title>METHOD:</title>					 The sample consisted of 50 adenomatous polyps from patients undergoing colonoscopy. After performing polypectomy, polyps were preserved in a formalin solution with 10% (vol./vol.) phosphate buffer, submitted for routine preparation of sections and slides and stained with hematoxylin and eosin. For each adenoma we then performed immunohistochemistry to detect specific p53 and Ki-67 proteins using a streptavidin-biotin-peroxidase enzyme immunoassay. 				</sec>				<sec>					<title>RESULTS:</title>					 p53 was detected in 18% of the adenomas. The average Ki-67 protein index (i.Ki-67) was 0.49. A statistically significant difference was observed in p53 (P = 0.0003) and Ki-67 (P = 0.02) expression between adenomas with low- and high-grade dysplasia, particularly for p53. The expression of Ki-67 was greater in rectal adenomas than in colic adenomas (P = 0.02). No relationship was found between the expression of the two proteins in the sample. 				</sec>				<sec>					<title>CONCLUSION:</title>					 The p53 protein is expressed in a proportion of adenomas, while the Ki-67 protein was expressed in all adenomas. The expression of p53 was higher in adenomas with high-grade dysplasia. The expression of Ki-67 was higher in rectal adenomas and in adenomas with high-grade dysplasia.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 O aparecimento de adenomas intestinais e sua progressao para adenocarcinoma e o resultado do acumulo de mutacoes geneticas da mucosa intestinal, herdadas ou adquiridas durante a vida. Dessa forma, varias proteinas tem sido estudadas em relacao ao desenvolvimento e progressao do cancer colorretal, incluindo as proteinas p53 e Ki-67. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar a expressao das proteinas p53 e Ki-67 em adenomas colorretais, suas relacoes com caracteristicas clinicopatologicas e avaliar a relacao entre as duas proteinas.  				</sec>				<sec>					<title>MeTODO:</title>					 A amostra consistiu de 50 polipos adenomatosos encontrados em pacientes submetidos a exames colonoscopicos. Apos a realizacao de polipectomia, os polipos eram conservados em solucao tamponada de formalina a 10% e submetidos a rotina de preparo de cortes e laminas e coloracao pela hematoxilina-eosina para confirmacao da natureza adenomatosa. Realizou-se imunoistoquimica especifica para as proteinas p53 e Ki-67 pelo metodo imunoenzimatico da streptoavidina-biotina-peroxidase para cada adenoma. 				</sec>				<sec>					<title>RESULTADOS:</title>					 A proteina p53 foi positiva em 18% dos adenomas e a proteina Ki-67, expresso como indice (i.Ki-67), obteve media de 0,49. Houve diferenca estatisticamente significante na expressao de p53 (P = 0,0003) e Ki-67(P = 0,02) entre os adenomas com alto e baixo grau de displasia, sendo maior no primeiro grupo. Encontrou-se, ainda maior expressao da proteina Ki-67 nos adenomas retais em relacao aos de localizacao colica (P = 0,02). Nao houve relacao entre a expressao das duas proteinas, na amostra. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 A proteina p53 e expressa em parte dos adenomas enquanto Ki-67 e expressa na sua totalidade. A expressao de p53 foi maior nos adenomas com alto grau de displasia. A expressao de Ki-67 foi maior nos adenomas retais e com alto grau de displasia.				</sec>^lpt
!v085!^kColorectal neoplasm^len
!v085!^kTumor suppressor protein p53^len
!v085!^kKi67-antigen^len
!v085!^kImmunohistochemistry^len
!v085!^kNeoplasias colorretais^lpt
!v085!^kProteina supressora de tumor p53^lpt
!v085!^kAntigeno Ki67^lpt
!v085!^kImunoistoquimica^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m06^d01
!v112!2011
!v113!^y2011^m08^d23
!v114!2011
!v120!XML_3.0
!v121!35
!v237!10.1590/S0004-28032012000100007
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!h
!v708!1
!ID 000204
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sSousa^rauthor^nWalysson Alves Tocantins de
!v010!^sRodrigues^rauthor^nLusmar Veras
!v010!^sSilva^rauthor^nRaimundo Gerônimo da
!v010!^sVieira^rauthor^nFernando Lopes
!v012!^tImmunohistochemical evaluation of p53 and Ki-67 proteins in colorectal adenomas
!v012!^tAvaliação imunoistoquímica das proteínas p53 e Ki-67 em adenomas colorretais^lpt
!v014!^l40^f35
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Department of Surgery, Federal University of Ceará^cFortaleza^iaff1^pBrazil^5?^9Department of Surgery, Federal University of Ceará, Fortaleza, Brazil
!v071!oa
!v072!33
!v083!^a<sec>					<title>CONTEXT:</title>					<p> The appearance of adenomas and their progression to adenocarcinomas is the result of an accumulation of genetic changes in cells of the intestinal mucosa inherited or acquired during life. Several proteins have been studied in relation to the development and progression of colorectal cancer, including tumor protein p53 (p53) and antigen identified by monoclonal antibody Ki-67 (Ki-67). </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To evaluate the expression of p53 and Ki-67 in colorectal adenomas and correlate the observed levels with clinical and pathologic findings. </p>				</sec>				<sec>					<title>METHOD:</title>					<p> The sample consisted of 50 adenomatous polyps from patients undergoing colonoscopy. After performing polypectomy, polyps were preserved in a formalin solution with 10% (vol./vol.) phosphate buffer, submitted for routine preparation of sections and slides and stained with hematoxylin and eosin. For each adenoma we then performed immunohistochemistry to detect specific p53 and Ki-67 proteins using a streptavidin-biotin-peroxidase enzyme immunoassay. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> p53 was detected in 18% of the adenomas. The average Ki-67 protein index (i.Ki-67) was 0.49. A statistically significant difference was observed in p53 (<italic>P</italic> = 0.0003) and Ki-67 (<italic>P</italic> = 0.02) expression between adenomas with low- and high-grade dysplasia, particularly for p53. The expression of Ki-67 was greater in rectal adenomas than in colic adenomas (<italic>P</italic> = 0.02). No relationship was found between the expression of the two proteins in the sample. </p>				</sec>				<sec>					<title>CONCLUSION:</title>					<p> The p53 protein is expressed in a proportion of adenomas, while the Ki-67 protein was expressed in all adenomas. The expression of p53 was higher in adenomas with high-grade dysplasia. The expression of Ki-67 was higher in rectal adenomas and in adenomas with high-grade dysplasia.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> O aparecimento de adenomas intestinais e sua progress&#227;o para adenocarcinoma &#233; o resultado do ac&#250;mulo de muta&#231;&#245;es gen&#233;ticas da mucosa intestinal, herdadas ou adquiridas durante a vida. Dessa forma, v&#225;rias prote&#237;nas t&#234;m sido estudadas em rela&#231;&#227;o ao desenvolvimento e progress&#227;o do c&#226;ncer colorretal, incluindo as prote&#237;nas p53 e Ki-67. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Avaliar a express&#227;o das prote&#237;nas p53 e Ki-67 em adenomas colorretais, suas rela&#231;&#245;es com caracter&#237;sticas clinicopatol&#243;gicas e avaliar a rela&#231;&#227;o entre as duas prote&#237;nas.  </p>				</sec>				<sec>					<title>M&#201;TODO:</title>					<p> A amostra consistiu de 50 p&#243;lipos adenomatosos encontrados em pacientes submetidos a exames colonosc&#243;picos. Ap&#243;s a realiza&#231;&#227;o de polipectomia, os p&#243;lipos eram conservados em solu&#231;&#227;o tamponada de formalina a 10% e submetidos a rotina de preparo de cortes e l&#226;minas e colora&#231;&#227;o pela hematoxilina-eosina para confirma&#231;&#227;o da natureza adenomatosa. Realizou-se imunoistoqu&#237;mica espec&#237;fica para as prote&#237;nas p53 e Ki-67 pelo m&#233;todo imunoenzim&#225;tico da streptoavidina-biotina-peroxidase para cada adenoma. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> A prote&#237;na p53 foi positiva em 18% dos adenomas e a prote&#237;na Ki-67, expresso como &#237;ndice (i.Ki-67), obteve m&#233;dia de 0,49. Houve diferen&#231;a estatisticamente significante na express&#227;o de p53 (<italic>P</italic> = 0,0003) e Ki-67(<italic>P</italic> = 0,02) entre os adenomas com alto e baixo grau de displasia, sendo maior no primeiro grupo. Encontrou-se, ainda maior express&#227;o da prote&#237;na Ki-67 nos adenomas retais em rela&#231;&#227;o aos de localiza&#231;&#227;o c&#243;lica (<italic>P</italic> = 0,02). N&#227;o houve rela&#231;&#227;o entre a express&#227;o das duas prote&#237;nas, na amostra. </p>				</sec>				<sec>					<title>CONCLUS&#195;O:</title>					<p> A prote&#237;na p53 &#233; expressa em parte dos adenomas enquanto Ki-67 &#233; expressa na sua totalidade. A express&#227;o de p53 foi maior nos adenomas com alto grau de displasia. A express&#227;o de Ki-67 foi maior nos adenomas retais e com alto grau de displasia.</p>				</sec>^lpt
!v085!^kColorectal neoplasm^len
!v085!^kTumor suppressor protein p53^len
!v085!^kKi67-antigen^len
!v085!^kImmunohistochemistry^len
!v085!^kNeoplasias colorretais^lpt
!v085!^kProteína supressora de tumor p53^lpt
!v085!^kAntígeno Ki67^lpt
!v085!^kImunoistoquímica^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m06^d01
!v112!2011
!v113!^y2011^m08^d23
!v114!2011
!v120!XML_3.0
!v121!35
!v237!10.1590/S0004-28032012000100007
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!f
!v708!1
!ID 000205
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sSousa^rauthor^nWalysson Alves Tocantins de
!v010!^sRodrigues^rauthor^nLusmar Veras
!v010!^sSilva^rauthor^nRaimundo Geronimo da
!v010!^sVieira^rauthor^nFernando Lopes
!v012!^tImmunohistochemical evaluation of p53 and Ki-67 proteins in colorectal adenomas
!v012!^tAvaliacao imunoistoquimica das proteinas p53 e Ki-67 em adenomas colorretais^lpt
!v014!^l40^f35
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Department of Surgery, Federal University of Ceara^cFortaleza^iaff1^pBrazil^5?^9Department of Surgery, Federal University of Ceara, Fortaleza, Brazil
!v071!oa
!v072!33
!v083!^a<sec>					<title>CONTEXT:</title>					 The appearance of adenomas and their progression to adenocarcinomas is the result of an accumulation of genetic changes in cells of the intestinal mucosa inherited or acquired during life. Several proteins have been studied in relation to the development and progression of colorectal cancer, including tumor protein p53 (p53) and antigen identified by monoclonal antibody Ki-67 (Ki-67). 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To evaluate the expression of p53 and Ki-67 in colorectal adenomas and correlate the observed levels with clinical and pathologic findings. 				</sec>				<sec>					<title>METHOD:</title>					 The sample consisted of 50 adenomatous polyps from patients undergoing colonoscopy. After performing polypectomy, polyps were preserved in a formalin solution with 10% (vol./vol.) phosphate buffer, submitted for routine preparation of sections and slides and stained with hematoxylin and eosin. For each adenoma we then performed immunohistochemistry to detect specific p53 and Ki-67 proteins using a streptavidin-biotin-peroxidase enzyme immunoassay. 				</sec>				<sec>					<title>RESULTS:</title>					 p53 was detected in 18% of the adenomas. The average Ki-67 protein index (i.Ki-67) was 0.49. A statistically significant difference was observed in p53 (P = 0.0003) and Ki-67 (P = 0.02) expression between adenomas with low- and high-grade dysplasia, particularly for p53. The expression of Ki-67 was greater in rectal adenomas than in colic adenomas (P = 0.02). No relationship was found between the expression of the two proteins in the sample. 				</sec>				<sec>					<title>CONCLUSION:</title>					 The p53 protein is expressed in a proportion of adenomas, while the Ki-67 protein was expressed in all adenomas. The expression of p53 was higher in adenomas with high-grade dysplasia. The expression of Ki-67 was higher in rectal adenomas and in adenomas with high-grade dysplasia.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 O aparecimento de adenomas intestinais e sua progressao para adenocarcinoma e o resultado do acumulo de mutacoes geneticas da mucosa intestinal, herdadas ou adquiridas durante a vida. Dessa forma, varias proteinas tem sido estudadas em relacao ao desenvolvimento e progressao do cancer colorretal, incluindo as proteinas p53 e Ki-67. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar a expressao das proteinas p53 e Ki-67 em adenomas colorretais, suas relacoes com caracteristicas clinicopatologicas e avaliar a relacao entre as duas proteinas.  				</sec>				<sec>					<title>MeTODO:</title>					 A amostra consistiu de 50 polipos adenomatosos encontrados em pacientes submetidos a exames colonoscopicos. Apos a realizacao de polipectomia, os polipos eram conservados em solucao tamponada de formalina a 10% e submetidos a rotina de preparo de cortes e laminas e coloracao pela hematoxilina-eosina para confirmacao da natureza adenomatosa. Realizou-se imunoistoquimica especifica para as proteinas p53 e Ki-67 pelo metodo imunoenzimatico da streptoavidina-biotina-peroxidase para cada adenoma. 				</sec>				<sec>					<title>RESULTADOS:</title>					 A proteina p53 foi positiva em 18% dos adenomas e a proteina Ki-67, expresso como indice (i.Ki-67), obteve media de 0,49. Houve diferenca estatisticamente significante na expressao de p53 (P = 0,0003) e Ki-67(P = 0,02) entre os adenomas com alto e baixo grau de displasia, sendo maior no primeiro grupo. Encontrou-se, ainda maior expressao da proteina Ki-67 nos adenomas retais em relacao aos de localizacao colica (P = 0,02). Nao houve relacao entre a expressao das duas proteinas, na amostra. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 A proteina p53 e expressa em parte dos adenomas enquanto Ki-67 e expressa na sua totalidade. A expressao de p53 foi maior nos adenomas com alto grau de displasia. A expressao de Ki-67 foi maior nos adenomas retais e com alto grau de displasia.				</sec>^lpt
!v085!^kColorectal neoplasm^len
!v085!^kTumor suppressor protein p53^len
!v085!^kKi67-antigen^len
!v085!^kImmunohistochemistry^len
!v085!^kNeoplasias colorretais^lpt
!v085!^kProteina supressora de tumor p53^lpt
!v085!^kAntigeno Ki67^lpt
!v085!^kImunoistoquimica^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m06^d01
!v112!2011
!v113!^y2011^m08^d23
!v114!2011
!v120!XML_3.0
!v121!35
!v237!10.1590/S0004-28032012000100007
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!l
!v708!1
!ID 000206
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sBrenner^rND^nH
!v010!^sHoffmeister^rND^nM
!v010!^sHaug^rND^nU
!v012!Should colorectal cancer screening start at same age in European countries? Contributions from descriptive epidemiology^len
!v014!532-35
!v030!Br J Cancer
!v031!99
!v064!2008
!v065!20080000
!v071!journal
!v118!1
!v514!^l535^f532
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000207
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sCitarda^rND^nF
!v010!^sTomaselli^rND^nG
!v010!^sCapocaccia^rND^nR
!v010!^sBarcherini^rND^nS
!v010!^sCrespi^rND^nM
!v012!Efficacy in standard clinical pratice of colonoscopic polipectomy in reducing colorectal cancer incidence^len
!v014!812-15
!v030!Gut
!v031!48
!v064!2001
!v065!20010000
!v118!2
!v514!^l815^f812
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000208
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sEnomoto^rND^nT
!v010!^sKuranami^rND^nM
!v010!^sKakita^rND^nA
!v012!Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps^len
!v014!711-17
!v030!Surg Today
!v031!30
!v064!2000
!v065!20000000
!v118!3
!v514!^l717^f711
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000209
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sFearon^rND^nER
!v010!^sVolgelstein^rND^nB
!v012!A genetic model for colorectal tumorigenesis^len
!v014!759-67
!v030!Cell
!v031!61
!v064!1990
!v065!19900000
!v118!4
!v514!^l767^f759
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000210
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sGrizzle^rND^nWE
!v010!^sMyers^rND^nRB
!v010!^sManne^rND^nU
!v010!^sSrivastava^rND^nS
!v010!^sHanausek^rND^nM
!v010!^sWalaszek^rND^nZ
!v012!^tImmunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia
!v014!143-60
!v018!Methods in molecular medicine-tumor marker protocols
!v062!Humana Press
!v064!1998
!v065!19980000
!v066!Totowa
!v118!5
!v514!^l160^f143
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000211
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sHoriuchi^rND^nH
!v010!^sKawamata^rND^nH
!v010!^sOmotehara^rND^nF
!v010!^sFujii^rND^nS
!v010!^sFujimori^rND^nT
!v010!^sKuroda^rND^nY
!v012!Negative immunohistochemical staining of p53 protein does not always reflect wild-type p53 gene in cancer cells^len
!v014!801-03
!v030!J Gastroenterol
!v031!39
!v064!2004
!v065!20040000
!v118!6
!v514!^l803^f801
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000212
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v018!Estimativa 2010 - Incidencia de cancer no Brasil
!v037!http://www.inca.gov.br
!v062!INCA
!v064!2010
!v065!20100000
!v066!Rio de Janeiro
!v118!7
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000213
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sIsobe^rND^nM
!v010!^sEmmanuel^rND^nBS
!v010!^sGivol^rND^nD
!v010!^sOren^rND^nM
!v010!^sCrocen^rND^nCM
!v012!Localization of gene for human p53 tumor antigen to band 17p13^len
!v014!84-5
!v030!Nature
!v031!320
!v064!1986
!v065!19860000
!v118!8
!v514!^l85^f84
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000214
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sLoeve^rND^nF
!v010!^sBoer^rND^nR
!v010!^sZauber^rND^nAG
!v010!^sVan Ballegooijen^rND^nM
!v010!^sVan Oortmarssen^rND^nGJ
!v010!^sWinamer^rND^nSJ
!v010!^sHabbema^rND^nJD
!v012!National polyp study data: evidence for regression of adenomas^len
!v014!633-39
!v030!Int J cancer
!v031!111
!v064!2004
!v065!20040000
!v118!9
!v514!^l639^f633
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000215
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sLustosa^rND^nSA
!v010!^sLogullo^rND^nA
!v010!^sArtigiani^rND^nR
!v010!^sSaad^rND^nSS
!v010!^sGoldenberg^rND^nA
!v010!^sMatos^rND^nD
!v012!Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma^len
!v014!353-57
!v030!Acta Cir Bras
!v031!20
!v064!2005
!v065!20050000
!v118!10
!v514!^l357^f353
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000216
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sMansmann^rND^nU
!v010!^sCrispin^rND^nA
!v010!^sHenschel^rND^nV
!v010!^sAdrion^rND^nC
!v010!^sAugustin^rND^nV
!v010!^sBirkner^rND^nB
!v010!^sMunte^rND^nA
!v012!Epidemiology and quality of control of 245 000 outpatient colonoscopies^len
!v014!434-40
!v030!Dtsch Arztebl Int
!v031!105
!v064!2008
!v065!20080000
!v118!11
!v514!^l440^f434
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000217
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sMatos^rND^nLL
!v010!^sMachado^rND^nLN
!v010!^sSugiyama^rND^nMM
!v010!^sBozzetti^rND^nRM
!v010!^sPinhal^rND^nAS
!v012!Technology applied to the detection of tumor markers^len
!v014!19-25
!v030!Arq Med ABC
!v031!30
!v064!2005
!v065!20050000
!v118!12
!v514!^l25^f19
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000218
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sMay^rND^nP
!v010!^sMay^rND^nE
!v012!Twenty years of p53 research: structural and functions aspects of the protein^len
!v014!7621-738
!v030!Oncogene
!v031!18
!v064!1999
!v065!19990000
!v118!13
!v514!^l7738^f7621
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000219
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sMiller^rND^nC
!v010!^sMohandas^rND^nT
!v010!^sWolf^rND^nD
!v010!^sProkocimer^rND^nM
!v010!^sRotter^rND^nV
!v010!^sKoeffler^rND^nHP
!v012!Human p53 gene localized to short arm of chromosome 17^len
!v014!783-84
!v030!Nature
!v031!319
!v064!1986
!v065!19860000
!v118!14
!v514!^l784^f783
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000220
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sMuneyuki^rND^nT
!v010!^sWatanabe^rND^nM
!v010!^sYamanaka^rND^nM
!v010!^sIsaji^rND^nS
!v010!^sKawarada^rND^nY
!v010!^sYatani^rND^nR
!v012!Combination analysis of genetic alterations and cell proliferation in small intestinal carcinomas^len
!v014!2022-028
!v030!Dig Dis Sci
!v031!45
!v064!2000
!v065!20000000
!v118!15
!v514!^l2028^f2022
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000221
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sNeves^rND^nLR
!v010!^sOshima^rND^nCT
!v010!^sArtingiani-Neto^rND^nR
!v010!^sYanaguibashi^rND^nG
!v010!^sLourenco^rND^nLG
!v010!^sForones^rND^nNM
!v012!Ki67 and p53 in gastrointestinal stromal tumors - GIST^len
!v014!116-20
!v030!Arq Gastroenterol
!v031!46
!v064!2009
!v065!20090000
!v118!16
!v514!^l120^f116
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000222
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sNomura^rND^nM
!v010!^sWatari^rND^nJ
!v010!^sYokota^rND^nK
!v010!^sSaitoh^rND^nY
!v010!^sObara^rND^nT
!v010!^sKohgo^rND^nY
!v012!Morphogenesis of nonpolypoid colorectal adenomas and early carcinomas assessed by cell proliferation and apoptosis^len
!v014!17-24
!v030!Virchows Arch
!v031!437
!v064!2000
!v065!20000000
!v118!17
!v514!^l24^f17
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000223
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sPetroianu^rND^nA
!v010!^sAlberti^rND^nLR
!v010!^sde Lima^rND^nDC
!v010!^sHauter^rND^nHL
!v010!^sRodrigues^rND^nKC
!v010!^sMendes^rND^nJC
!v014!173-78
!v030!Arq Gastroenterol
!v031!46
!v064!2009
!v065!20090000
!v118!18
!v514!^l178^f173
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000224
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sPorcelli^rND^nB
!v010!^sFrosi^rND^nB
!v010!^sArezzini^rND^nL
!v010!^sMarinello^rND^nE
!v010!^sVernillo^rND^nR
!v010!^sDe Martino^rND^nA
!v010!^sVatti^rND^nR
!v010!^sMinacci^rND^nC
!v012!Expression of p185 and p53 in benign and malignant colorectal lesions^len
!v014!51-7
!v030!Histochem J
!v031!33
!v064!2001
!v065!20010000
!v118!19
!v514!^l57^f51
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000225
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sRadovanovic-Dinic^rND^nB
!v010!^sNagorni^rND^nA
!v010!^sKatic^rND^nV
!v010!^sSatmenkovic^rND^nI
!v010!^sZlatic^rND^nA
!v012!An immunohistochemical study of Ki-67 in colorectal adenoma^len
!v014!16-8
!v030!Med Arh
!v031!63
!v064!2009
!v065!20090000
!v118!20
!v514!^l18^f16
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000226
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sSantos^rND^nJCM
!v012!Ano-rectal-colic cancer. Current Issues II - Colorectal cancer - Risk factors and prevention^len
!v014!459-73
!v030!Rev Bras Coloproctol
!v031!27
!v064!2007
!v065!20070000
!v118!21
!v514!^l473^f459
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000227
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sScholzen^rND^nT
!v010!^sGerdes^rND^nJ
!v012!The Ki-67 protein: from the known and the unknown^len
!v014!311-22
!v030!J Cell Physiol
!v031!182
!v064!2000
!v065!20000000
!v118!22
!v514!^l322^f311
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000228
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sShanmugam^rND^nC
!v010!^sKatkoori^rND^nVR
!v010!^sJhala^rND^nNC
!v010!^sGrizzle^rND^nWE
!v010!^sSiegal^rND^nGP
!v010!^sManne^rND^nU
!v012!p53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior^len
!v014!305-12
!v030!J Histochem cytochem
!v031!56
!v064!2008
!v065!20080000
!v118!23
!v514!^l312^f305
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000229
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sSheikh^rND^nRA
!v010!^sMin^rND^nBH
!v010!^sYasmeen^rND^nS
!v010!^sTeplitz^rND^nR
!v010!^sTesluk^rND^nH
!v010!^sRuebner^rND^nBH
!v010!^sTobi^rND^nM
!v010!^sHatfield^rND^nJ
!v010!^sFligiel^rND^nS
!v010!^sLawson^rND^nMJ
!v012!Correlation of Ki-67, p53, and Adnab-9 immunohistochemical staining and ploidy with clinical and histopathologic features of severely dysplastic colorectal adenomas^len
!v014!223-29
!v030!Dig Dis Sci
!v031!48
!v064!2003
!v065!20030000
!v118!24
!v514!^l229^f223
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000230
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sShinozaki^rND^nM
!v010!^sWatanabe^rND^nT
!v010!^sKubota^rND^nY
!v010!^sSawada^rND^nT
!v010!^sNagawa^rND^nH
!v010!^sMuto^rND^nT
!v012!High proliferative activity is associated with diysplasia in ulcerative colitis^len
!v014!34-9
!v030!Dis Colon Rectum
!v031!43
!v064!2000
!v065!20000000
!v118!25
!v514!^l39^f34
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000231
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sSoussi^rND^nT
!v010!^sCaron de Fromentel^rND^nC
!v010!^sMay^rND^nP
!v012!Structural aspects of p53 protein in relation to gene evolution^len
!v014!5945-952
!v030!Oncogene
!v031!5
!v064!1990
!v065!19900000
!v118!26
!v514!^l5952^f5945
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000232
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sSugai^rND^nT
!v010!^sHabano^rND^nW
!v010!^sUesugi^rND^nN
!v010!^sJiao^rND^nY
!v010!^sNakamura^rND^nS
!v010!^sSato^rND^nK
!v010!^sChiba^rND^nT
!v010!^sIshii^rND^nM
!v012!Molecular validation of the modified Vienna classification of colorectal tumors^len
!v014!191-200
!v030!J Mol Diagn
!v031!4
!v064!2002
!v065!20020000
!v118!27
!v514!^l200^f191
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000233
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sVermeulen^rND^nK
!v010!^sVan Bockstaele^rND^nDR
!v010!^sBerneman^rND^nZN
!v012!The cell cycle: a review of regulation, desregulation and therapeutic targets in cancer^len
!v014!131-49
!v030!Cell Prolif
!v031!36
!v064!2003
!v065!20030000
!v118!28
!v514!^l149^f131
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000234
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sVernillo^rND^nR
!v010!^sLorenzi^rND^nB
!v010!^sBanduccci^rND^nT
!v010!^sMinacci^rND^nC
!v010!^sVindigni^rND^nC
!v010!^sLucenti Fei^rND^nA
!v010!^sLorenzi^rND^nM
!v012!Immunohistochemical expression of p53 and ki67 in colorectal adenomas and prediction of malignancy and development of new polyps^len
!v014!89-95
!v030!Int J Biol Markers
!v031!23
!v064!2008
!v065!20080000
!v118!29
!v514!^l95^f89
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000235
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sVoskuil^rND^nDW
!v010!^sKampman^rND^nE
!v010!^svan Geloof^rND^nW
!v010!^sGrubben^rND^nM
!v010!^sKok^rND^nF
!v010!^sVan Muijen^rND^nG
!v010!^sNagengast^rND^nF
!v010!^sVasen^rND^nH
!v010!^sVan't Veer^rND^nP
!v012!No major difference in K-ras and p53 abnormalities in sporadic and hereditary nonpolyposis colorectal adenomas^len
!v014!2187-194
!v030!Dig Dis Sci
!v031!45
!v064!2000
!v065!20000000
!v118!30
!v514!^l2194^f2187
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000236
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sWatatani^rND^nM
!v010!^sIeda^rND^nS
!v010!^sKuroda^rND^nK
!v010!^sInui^rND^nH
!v010!^sNishimura^rND^nK
!v010!^sYasutomi^rND^nM
!v012!Comparison of p53 and bcl-2 expression in initial, synchronous, and metachronous colorectal adenomas^len
!v014!29:707-29:712
!v030!Surg Today
!v064!1999
!v065!19990000
!v118!31
!v514!^l29:712^f29:707
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000237
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sWilliams^rND^nAR
!v010!^sBalasooriya^rND^nBA
!v010!^sDay^rND^nDW
!v012!Polyps and cancer of the large bowel: a necropsy study in Liverpool^len
!v014!835-42
!v030!Gut
!v031!23
!v064!1982
!v065!19820000
!v118!32
!v514!^l842^f835
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000238
!v001!br1.1
!v002!0004-2803-ag-49-01-35.xml
!v004!v49n1
!v010!^sYonish-Rouach^rND^nE
!v012!A question of lie or death: the p53 tumor suppressor gene^len
!v014!815-23
!v030!Pathol Biol
!v031!45
!v064!1997
!v065!19970000
!v118!33
!v514!^l823^f815
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-35.xml
!v705!S
!v706!c
!v708!33
!v865!20120300
!ID 000239
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v091!20120814
!v092!164306
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v703!159
!v705!S
!v706!o
!v708!1
!ID 000240
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^1aff1^sSanto^rauthor^nMarco Aurelio
!v010!^sDomene^rauthor^nCarlos Eduardo
!v010!^sRiccioppo^rauthor^nDaniel
!v010!^sBarreira^rauthor^nLian
!v010!^sTakeda^rauthor^nFlavio Roberto
!v010!^sPinotti^rauthor^nHenrique Walter
!v012!^sanalysis of the videolaparoscopic surgical treatment^tCommon bile duct stones
!v012!^sanalise do tratamento videolaparoscopico^tColedocolitiase^lpt
!v014!^l51^f41
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Departmento de Gastroenterologia^cFaculdade de Medicina da Universidade de Sao Paulo^iaff1^l1^pBrasil^sSP^5?^9Departmento de Gastroenterologia, Faculdade de Medicina da Universidade de Sao Paulo, SP, Brasil
!v071!oa
!v072!81
!v083!^a<sec>					<title>CONTEXT:</title>					 About 9% of the Brazilian population has gallstones and the incidence increases significantly with aging. The choledocholithiasis is found around 15% of these patients, and a third to half of these cases presented as asymptomatic. Once the lithiasis in the common bile duct is characterized through intraoperative cholangiography, the laparoscopic surgical exploration can be done through the transcystic way or directly through choledochotomy. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To evaluate the results and outcomes of the laparoscopic treatment of common bile duct lithiasis. 				</sec>				<sec>					<title>METHODS:</title>					 Seventy consecutive patients were evaluated. They prospectively underwent the treatment of the lithiasis in the common bile duct and the exploration ways were compared according to the following parameters: criteria on their indication, success in the clearance, surgical complications. It was verified that about 1/2 of the choledocholithiasis carriers did not show any expression of predictive factors (clinical antecedents of jaundice and/or acute pancreatitis, compatible sonographic data and the pertaining lab tests). The laparoscopic exploration through the transcystic way is favored when there are no criteria for the practice of primary choledochotomy, which are: lithiasis in the proximal bile duct, large (over 8 mm) or numerous calculi (multiple calculosis). 				</sec>				<sec>					<title>RESULTS:</title>					 The transcystic way was employed in about 50% of the casuistic and the choledochotomy in about 30%. A high success rate (around 80%) was achieved in the clearance of the common bile duct stones through laparoscopic exploration. The transcystic way, performed without fluoroscopy or choledochoscopy, attained a low rate of success (around 45%), being 10% of those by transpapilar pushing of calculi less than 3 mm. The exploration through choledochotomy, either primary or secondary, if the latter was performed after the transcystic route failure, showed high success rate (around 95%). When the indication to choledochotomy was primary, the necessity for choledochoscopy through choledochotomy to help in the removal of the calculi was 55%. However, when choledochotomy was performed secondarily, in situations where the common bile duct diameter was larger than 6 mm, the use of choledochoscopy with the same purpose involved about 20% of the cases. There was no mortality in this series. 				</sec>				<sec>					<title>CONCLUSION:</title>					 The laparoscopic exploration of the common bile duct was related to a low rate of morbidity. Therefore, the use of laparoscopy for the treatment of the lithiasis in the common bile duct depends on the criteria for the choice of the best access, making it a safe procedure with very good results.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 Aproximadamente 9% da populacao brasileira apresenta colecistolitiase e esta incidencia aumenta significativamente com o envelhecimento. A coledocolitiase e encontrada em torno de 15% destes pacientes, e de um terco a metade destes casos apresenta-se de maneira assintomatica. Uma vez que a litiase do ducto biliar comum e caracterizada atraves de colangiografia intra-operatoria, a exploracao cirurgica laparoscopica pode ser feita atraves da via transcistica, ou diretamente atraves de coledocotomia. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar os resultados do tratamento laparoscopico da coledocolitiase. 				</sec>				<sec>					<title>MeTODOS:</title>					 Setenta pacientes foram avaliados prospectivamente. Todos foram submetidos ao tratamento da coledocolitiase por videolaparoscopia, e as formas de exploracao foram comparadas de acordo com os seguintes parametros: os criterios de sua indicacao, o sucesso no clareamento da via biliar, complicacoes cirurgicas. A exploracao laparoscopica transcistica foi favorecida quando nao ha criterios para a pratica de coledocotomia primaria, sendo estes litiase do ducto biliar proximal, calculos grandes (mais de 8 mm) ou calculose multipla. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Verificou-se que cerca de um terco dos doentes com coledocolitiase nao mostraram qualquer expressao de fatores preditivos (antecedentes clinicos de ictericia e/ou pancreatite aguda, suspeita ultrassonografica ou alteracoes de testes laboratoriais relacionados a coledocolitiase). A exploracao transcistica foi empregada em cerca de 50% dos casos e a coledocotomia em cerca de 30%. A depuracao da via biliar atraves da laparoscopia foi alcancada em 80% dos casos. A exploracao transcistica, realizada sem fluoroscopia ou coledocoscopia, atingiu baixa taxa de sucesso (em torno de 45%), sendo 10% desses casos com passagem transpapilar de calculos com menos de 3 mm. A exploracao por coledocotomia, primaria ou secundaria, quando esta foi realizada apos o insucesso da via transcistica, mostrou alta taxa de sucesso (em torno de 95%). Quando a indicacao para coledocotomia era primaria, a necessidade de visualizacao direta atraves da coledocoscopia para ajudar na remocao dos calculos foi de 55%. No entanto, quando foi realizada coledocotomia secundariamente, nas situacoes em que o diametro do ducto biliar comum foi maior do que 6 mm, o uso de coledocoscopio com o mesmo proposito foi necessario em cerca de 20% dos casos. Nao houve mortalidade nesta serie. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 A exploracao laparoscopica da via biliar principal esta relacionada com baixa taxa de morbidade. Portanto, o uso da laparoscopia para o tratamento da coledocolitiase depende dos criterios para a escolha do melhor acesso, tornando-se procedimento seguro, com resultados bastante satisfatorios.				</sec>^lpt
!v085!^kCholedocholithiasis^len
!v085!^kLaparoscopy^len
!v085!^kCholangiography^len
!v085!^kColedocolitiase^lpt
!v085!^kLaparoscopia^lpt
!v085!^kColangiografia^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m07^d26
!v112!2011
!v113!^y2011^m08^d31
!v114!2011
!v120!XML_3.0
!v121!41
!v237!10.1590/S0004-28032012000100008
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!h
!v708!1
!ID 000241
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^1aff1^sSanto^rauthor^nMarco Aurelio
!v010!^sDomene^rauthor^nCarlos Eduardo
!v010!^sRiccioppo^rauthor^nDaniel
!v010!^sBarreira^rauthor^nLian
!v010!^sTakeda^rauthor^nFlavio Roberto
!v010!^sPinotti^rauthor^nHenrique Walter
!v012!^sanalysis of the videolaparoscopic surgical treatment^tCommon bile duct stones
!v012!^sanálise do tratamento videolaparoscópico^tColedocolitíase^lpt
!v014!^l51^f41
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Departmento de Gastroenterologia^cFaculdade de Medicina da Universidade de S&#227;o Paulo^iaff1^l1^pBrasil^sSP^5?^9Departmento de Gastroenterologia, Faculdade de Medicina da Universidade de S&#227;o Paulo, SP, Brasil
!v071!oa
!v072!81
!v083!^a<sec>					<title>CONTEXT:</title>					<p> About 9% of the Brazilian population has gallstones and the incidence increases significantly with aging. The choledocholithiasis is found around 15% of these patients, and a third to half of these cases presented as asymptomatic. Once the lithiasis in the common bile duct is characterized through intraoperative cholangiography, the laparoscopic surgical exploration can be done through the transcystic way or directly through choledochotomy. </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To evaluate the results and outcomes of the laparoscopic treatment of common bile duct lithiasis. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> Seventy consecutive patients were evaluated. They prospectively underwent the treatment of the lithiasis in the common bile duct and the exploration ways were compared according to the following parameters: criteria on their indication, success in the clearance, surgical complications. It was verified that about 1/2 of the choledocholithiasis carriers did not show any expression of predictive factors (clinical antecedents of jaundice and/or acute pancreatitis, compatible sonographic data and the pertaining lab tests). The laparoscopic exploration through the transcystic way is favored when there are no criteria for the practice of primary choledochotomy, which are: lithiasis in the proximal bile duct, large (over 8 mm) or numerous calculi (multiple calculosis). </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> The transcystic way was employed in about 50% of the casuistic and the choledochotomy in about 30%. A high success rate (around 80%) was achieved in the clearance of the common bile duct stones through laparoscopic exploration. The transcystic way, performed without fluoroscopy or choledochoscopy, attained a low rate of success (around 45%), being 10% of those by transpapilar pushing of calculi less than 3 mm. The exploration through choledochotomy, either primary or secondary, if the latter was performed after the transcystic route failure, showed high success rate (around 95%). When the indication to choledochotomy was primary, the necessity for choledochoscopy through choledochotomy to help in the removal of the calculi was 55%. However, when choledochotomy was performed secondarily, in situations where the common bile duct diameter was larger than 6 mm, the use of choledochoscopy with the same purpose involved about 20% of the cases. There was no mortality in this series. </p>				</sec>				<sec>					<title>CONCLUSION:</title>					<p> The laparoscopic exploration of the common bile duct was related to a low rate of morbidity. Therefore, the use of laparoscopy for the treatment of the lithiasis in the common bile duct depends on the criteria for the choice of the best access, making it a safe procedure with very good results.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> Aproximadamente 9% da popula&#231;&#227;o brasileira apresenta colecistolit&#237;ase e esta incid&#234;ncia aumenta significativamente com o envelhecimento. A coledocolit&#237;ase &#233; encontrada em torno de 15% destes pacientes, e de um ter&#231;o a metade destes casos apresenta-se de maneira assintom&#225;tica. Uma vez que a lit&#237;ase do ducto biliar comum &#233; caracterizada atrav&#233;s de colangiografia intra-operat&#243;ria, a explora&#231;&#227;o cir&#250;rgica laparosc&#243;pica pode ser feita atrav&#233;s da via transc&#237;stica, ou diretamente atrav&#233;s de coledocotomia. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Avaliar os resultados do tratamento laparosc&#243;pico da coledocolit&#237;ase. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Setenta pacientes foram avaliados prospectivamente. Todos foram submetidos ao tratamento da coledocolit&#237;ase por videolaparoscopia, e as formas de explora&#231;&#227;o foram comparadas de acordo com os seguintes par&#226;metros: os crit&#233;rios de sua indica&#231;&#227;o, o sucesso no clareamento da via biliar, complica&#231;&#245;es cir&#250;rgicas. A explora&#231;&#227;o laparosc&#243;pica transc&#237;stica foi favorecida quando n&#227;o h&#225; crit&#233;rios para a pr&#225;tica de coledocotomia prim&#225;ria, sendo estes lit&#237;ase do ducto biliar proximal, c&#225;lculos grandes (mais de 8 mm) ou calculose m&#250;ltipla. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Verificou-se que cerca de um ter&#231;o dos doentes com coledocolit&#237;ase n&#227;o mostraram qualquer express&#227;o de fatores preditivos (antecedentes cl&#237;nicos de icter&#237;cia e/ou pancreatite aguda, suspeita ultrassonogr&#225;fica ou altera&#231;&#245;es de testes laboratoriais relacionados &#224; coledocolit&#237;ase). A explora&#231;&#227;o transc&#237;stica foi empregada em cerca de 50% dos casos e a coledocotomia em cerca de 30%. A depura&#231;&#227;o da via biliar atrav&#233;s da laparoscopia foi alcan&#231;ada em 80% dos casos. A explora&#231;&#227;o transc&#237;stica, realizada sem fluoroscopia ou coledocoscopia, atingiu baixa taxa de sucesso (em torno de 45%), sendo 10% desses casos com passagem transpapilar de c&#225;lculos com menos de 3 mm. A explora&#231;&#227;o por coledocotomia, prim&#225;ria ou secund&#225;ria, quando esta foi realizada ap&#243;s o insucesso da via transc&#237;stica, mostrou alta taxa de sucesso (em torno de 95%). Quando a indica&#231;&#227;o para coledocotomia era prim&#225;ria, a necessidade de visualiza&#231;&#227;o direta atrav&#233;s da coledocoscopia para ajudar na remo&#231;&#227;o dos c&#225;lculos foi de 55%. No entanto, quando foi realizada coledocotomia secundariamente, nas situa&#231;&#245;es em que o di&#226;metro do ducto biliar comum foi maior do que 6 mm, o uso de coledocosc&#243;pio com o mesmo prop&#243;sito foi necess&#225;rio em cerca de 20% dos casos. N&#227;o houve mortalidade nesta s&#233;rie. </p>				</sec>				<sec>					<title>CONCLUS&#195;O:</title>					<p> A explora&#231;&#227;o laparosc&#243;pica da via biliar principal est&#225; relacionada com baixa taxa de morbidade. Portanto, o uso da laparoscopia para o tratamento da coledocolit&#237;ase depende dos crit&#233;rios para a escolha do melhor acesso, tornando-se procedimento seguro, com resultados bastante satisfat&#243;rios.</p>				</sec>^lpt
!v085!^kCholedocholithiasis^len
!v085!^kLaparoscopy^len
!v085!^kCholangiography^len
!v085!^kColedocolitíase^lpt
!v085!^kLaparoscopia^lpt
!v085!^kColangiografia^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m07^d26
!v112!2011
!v113!^y2011^m08^d31
!v114!2011
!v120!XML_3.0
!v121!41
!v237!10.1590/S0004-28032012000100008
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!f
!v708!1
!ID 000242
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^1aff1^sSanto^rauthor^nMarco Aurelio
!v010!^sDomene^rauthor^nCarlos Eduardo
!v010!^sRiccioppo^rauthor^nDaniel
!v010!^sBarreira^rauthor^nLian
!v010!^sTakeda^rauthor^nFlavio Roberto
!v010!^sPinotti^rauthor^nHenrique Walter
!v012!^sanalysis of the videolaparoscopic surgical treatment^tCommon bile duct stones
!v012!^sanalise do tratamento videolaparoscopico^tColedocolitiase^lpt
!v014!^l51^f41
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Departmento de Gastroenterologia^cFaculdade de Medicina da Universidade de Sao Paulo^iaff1^l1^pBrasil^sSP^5?^9Departmento de Gastroenterologia, Faculdade de Medicina da Universidade de Sao Paulo, SP, Brasil
!v071!oa
!v072!81
!v083!^a<sec>					<title>CONTEXT:</title>					 About 9% of the Brazilian population has gallstones and the incidence increases significantly with aging. The choledocholithiasis is found around 15% of these patients, and a third to half of these cases presented as asymptomatic. Once the lithiasis in the common bile duct is characterized through intraoperative cholangiography, the laparoscopic surgical exploration can be done through the transcystic way or directly through choledochotomy. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To evaluate the results and outcomes of the laparoscopic treatment of common bile duct lithiasis. 				</sec>				<sec>					<title>METHODS:</title>					 Seventy consecutive patients were evaluated. They prospectively underwent the treatment of the lithiasis in the common bile duct and the exploration ways were compared according to the following parameters: criteria on their indication, success in the clearance, surgical complications. It was verified that about 1/2 of the choledocholithiasis carriers did not show any expression of predictive factors (clinical antecedents of jaundice and/or acute pancreatitis, compatible sonographic data and the pertaining lab tests). The laparoscopic exploration through the transcystic way is favored when there are no criteria for the practice of primary choledochotomy, which are: lithiasis in the proximal bile duct, large (over 8 mm) or numerous calculi (multiple calculosis). 				</sec>				<sec>					<title>RESULTS:</title>					 The transcystic way was employed in about 50% of the casuistic and the choledochotomy in about 30%. A high success rate (around 80%) was achieved in the clearance of the common bile duct stones through laparoscopic exploration. The transcystic way, performed without fluoroscopy or choledochoscopy, attained a low rate of success (around 45%), being 10% of those by transpapilar pushing of calculi less than 3 mm. The exploration through choledochotomy, either primary or secondary, if the latter was performed after the transcystic route failure, showed high success rate (around 95%). When the indication to choledochotomy was primary, the necessity for choledochoscopy through choledochotomy to help in the removal of the calculi was 55%. However, when choledochotomy was performed secondarily, in situations where the common bile duct diameter was larger than 6 mm, the use of choledochoscopy with the same purpose involved about 20% of the cases. There was no mortality in this series. 				</sec>				<sec>					<title>CONCLUSION:</title>					 The laparoscopic exploration of the common bile duct was related to a low rate of morbidity. Therefore, the use of laparoscopy for the treatment of the lithiasis in the common bile duct depends on the criteria for the choice of the best access, making it a safe procedure with very good results.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 Aproximadamente 9% da populacao brasileira apresenta colecistolitiase e esta incidencia aumenta significativamente com o envelhecimento. A coledocolitiase e encontrada em torno de 15% destes pacientes, e de um terco a metade destes casos apresenta-se de maneira assintomatica. Uma vez que a litiase do ducto biliar comum e caracterizada atraves de colangiografia intra-operatoria, a exploracao cirurgica laparoscopica pode ser feita atraves da via transcistica, ou diretamente atraves de coledocotomia. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar os resultados do tratamento laparoscopico da coledocolitiase. 				</sec>				<sec>					<title>MeTODOS:</title>					 Setenta pacientes foram avaliados prospectivamente. Todos foram submetidos ao tratamento da coledocolitiase por videolaparoscopia, e as formas de exploracao foram comparadas de acordo com os seguintes parametros: os criterios de sua indicacao, o sucesso no clareamento da via biliar, complicacoes cirurgicas. A exploracao laparoscopica transcistica foi favorecida quando nao ha criterios para a pratica de coledocotomia primaria, sendo estes litiase do ducto biliar proximal, calculos grandes (mais de 8 mm) ou calculose multipla. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Verificou-se que cerca de um terco dos doentes com coledocolitiase nao mostraram qualquer expressao de fatores preditivos (antecedentes clinicos de ictericia e/ou pancreatite aguda, suspeita ultrassonografica ou alteracoes de testes laboratoriais relacionados a coledocolitiase). A exploracao transcistica foi empregada em cerca de 50% dos casos e a coledocotomia em cerca de 30%. A depuracao da via biliar atraves da laparoscopia foi alcancada em 80% dos casos. A exploracao transcistica, realizada sem fluoroscopia ou coledocoscopia, atingiu baixa taxa de sucesso (em torno de 45%), sendo 10% desses casos com passagem transpapilar de calculos com menos de 3 mm. A exploracao por coledocotomia, primaria ou secundaria, quando esta foi realizada apos o insucesso da via transcistica, mostrou alta taxa de sucesso (em torno de 95%). Quando a indicacao para coledocotomia era primaria, a necessidade de visualizacao direta atraves da coledocoscopia para ajudar na remocao dos calculos foi de 55%. No entanto, quando foi realizada coledocotomia secundariamente, nas situacoes em que o diametro do ducto biliar comum foi maior do que 6 mm, o uso de coledocoscopio com o mesmo proposito foi necessario em cerca de 20% dos casos. Nao houve mortalidade nesta serie. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 A exploracao laparoscopica da via biliar principal esta relacionada com baixa taxa de morbidade. Portanto, o uso da laparoscopia para o tratamento da coledocolitiase depende dos criterios para a escolha do melhor acesso, tornando-se procedimento seguro, com resultados bastante satisfatorios.				</sec>^lpt
!v085!^kCholedocholithiasis^len
!v085!^kLaparoscopy^len
!v085!^kCholangiography^len
!v085!^kColedocolitiase^lpt
!v085!^kLaparoscopia^lpt
!v085!^kColangiografia^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m07^d26
!v112!2011
!v113!^y2011^m08^d31
!v114!2011
!v120!XML_3.0
!v121!41
!v237!10.1590/S0004-28032012000100008
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!l
!v708!1
!ID 000243
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sAmouyal^rND^nP
!v010!^sAmouyal^rND^nG
!v010!^sLevy^rND^nP
!v010!^sTuzet^rND^nS
!v010!^sPalazzo^rND^nL
!v010!^sVilgrain^rND^nV
!v010!^sGayet^rND^nB
!v010!^sBelghiti^rND^nJ
!v010!^sFekete^rND^nF
!v010!^sBernades^rND^nP
!v012!Diagnosis of choledocholithiasis by endoscopic ultrasonography^len
!v014!1062-067
!v030!Gastroenterology
!v031!106
!v064!1994
!v065!19940000
!v071!journal
!v118!1
!v514!^l1067^f1062
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000244
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sAroori^rND^nS
!v010!^sBell^rND^nJC
!v012!Laparoscopic management of common bile duct stones: our initial experience^len
!v014!22-5
!v030!Ulster Med J
!v031!71
!v064!2002
!v065!20020000
!v118!2
!v514!^l25^f22
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000245
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sArregui^rND^nME
!v010!^sCoelho^rND^nJCU
!v010!^sMarchesini^rND^nJB
!v010!^sMalafaia^rND^nO
!v012!^tExploracao da via biliar principal
!v014!243-66
!v018!Complicacoes da videocirurgia: da profilaxia ao tratamento
!v062!Medsi
!v064!1995
!v065!19950000
!v066!Sao Paulo
!v118!3
!v514!^l266^f243
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000246
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sBagnato^rND^nVJ
!v012!Laparoscopic choledochoscopy and choledocholithotomy^len
!v014!164-66
!v030!Surg Laparosc Endosc
!v031!3
!v064!1993
!v065!19930000
!v118!4
!v514!^l166^f164
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000247
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sBarkun^rND^nAN
!v010!^sBarkun^rND^nJS
!v010!^sFried^rND^nGM
!v010!^sGhitulescu^rND^nG
!v010!^sSteinmetz^rND^nO
!v010!^sPham^rND^nC
!v010!^sMeakins^rND^nJL
!v010!^sGoresky^rND^nCA
!v012!Useful predictors of bile duct stones in patients undergoing laparoscopic cholecystectomy^len
!v014!32-9
!v030!Ann Surg
!v031!220
!v064!1994
!v065!19940000
!v118!5
!v514!^l39^f32
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000248
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sBerci^rND^nG
!v010!^sMorgenstein^rND^nL
!v012!Laparoscopic management of common bile duct stones. A multi-institutional SAGES study. Society of American Gastrointestinal Endoscopic Surgeons^len
!v014!1168-175
!v030!Surg Endosc
!v031!8
!v064!1994
!v065!19940000
!v118!6
!v514!^l1175^f1168
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000249
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sBerthou^rND^nJCh
!v010!^sDron^rND^nB
!v010!^sCharboneau^rND^nP
!v010!^sMoussalier^rND^nK
!v010!^sPellissier^rND^nL
!v012!Evaluation of laparoscopic treatment of common bile duct stones in a prospective series of 505 patients: indications and results^len
!v014!1970-974
!v030!Surg Endosc
!v031!21
!v064!2007
!v065!20070000
!v118!7
!v514!^l1974^f1970
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000250
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sBirth^rND^nM
!v010!^sEhlers^rND^nKU
!v010!^sDelinikolas^rND^nK
!v010!^sWeiser^rND^nHF
!v012!Prospective randomized comparison of laparoscopic ultrasonography using a flexible-tip ultrasound probe and intraoperative dynamic cholangiography during laparoscopic cholecystectomy^len
!v014!30-6
!v030!Surg Endosc
!v031!12
!v064!1998
!v065!19980000
!v118!8
!v514!^l36^f30
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000251
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sBoulay^rND^nJ
!v010!^sSchellenberg^rND^nR
!v010!^sBrady^rND^nPG
!v012!Role of ERCP and therapeutic biliary endoscopy in association with laparoscopic cholecystectomy^len
!v014!837-42
!v030!Am J Gastroenterol
!v031!87
!v064!1992
!v065!19920000
!v118!9
!v514!^l842^f837
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000252
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sCecconello^rND^nI
!v018!Contribuicao ao conhecimento da histopatologia do coledoco [dissertacao]
!v062!Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia-IBEPEGE
!v064!1979
!v065!19790000
!v066!Sao Paulo
!v118!10
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000253
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sChampault^rND^nG
!v014!592-97
!v030!Ann Chir
!v031!47
!v064!1993
!v065!19930000
!v118!11
!v514!^l597^f592
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000254
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sClassen^rND^nM
!v010!^sSafrany^rND^nL
!v012!Endoscopic papillotomy and removal of gall stones^len
!v014!371-74
!v030!Br Med J
!v031!15
!v064!1975
!v065!19750000
!v118!12
!v514!^l374^f371
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000255
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sCoelho^rND^nJC
!v010!^sBonilha^rND^nR
!v010!^sPitaki^rND^nSA
!v010!^sCordeiro^rND^nRM
!v010!^sSalvalaggio^rND^nPR
!v010!^sBonin^rND^nEA
!v010!^sHahn^rND^nCG
!v010!^sSoares^rND^nRV
!v010!^sMilcheski^rND^nDA
!v012!Prevalence of gallstones in a Brazilian population^len
!v014!25-8
!v030!Int Surg
!v031!84
!v064!1999
!v065!19990000
!v118!13
!v514!^l28^f25
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000256
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sColcock^rND^nBP
!v010!^sPerey^rND^nB
!v012!Exploration of the common bile duct^len
!v014!20-4
!v030!Surg Gynecol Obstet
!v031!118
!v064!1964
!v065!19640000
!v118!14
!v514!^l24^f20
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000257
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sCollins^rND^nC
!v010!^sMaguire^rND^nD
!v010!^sIreland^rND^nA
!v010!^sFitzgerald^rND^nE
!v010!^sO'Sullivan^rND^nGC
!v012!A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited^len
!v014!28-33
!v030!Ann Surg
!v031!239
!v064!2004
!v065!20040000
!v118!15
!v514!^l33^f28
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000258
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sCotton^rND^nPB
!v012!Endoscopic management of bile duct stones (apples and oranges)^len
!v014!587-97
!v030!Gut
!v031!25
!v064!1984
!v065!19840000
!v118!16
!v514!^l597^f587
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000259
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sCotton^rND^nPB
!v010!^sLehman^rND^nG
!v010!^sVennes^rND^nJ
!v010!^sGeenen^rND^nJE
!v010!^sRussell^rND^nRC
!v010!^sMeyers^rND^nWC
!v010!^sLiguory^rND^nC
!v010!^sNickl^rND^nN
!v012!Endoscopic sphincterotomy complications and their management: an attempt at consensus^len
!v014!383-93
!v030!Gastrointest Endosc
!v031!37
!v064!1991
!v065!19910000
!v118!17
!v514!^l393^f383
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000260
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sCotton^rND^nPB
!v012!Endoscopic retrograde cholangiopancreatography and laparoscopic cholecystectomy^len
!v014!474-78
!v030!Am J Surg
!v031!165
!v064!1993
!v065!19930000
!v118!18
!v514!^l478^f474
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000261
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sCrema^rND^nE
!v010!^sSilva^rND^nAA
!v010!^sMartins^rND^nA Jr
!v012!Anastomose coledoco-duodenal por laparoscopia no tratamento da coledocolitiase^lpt
!v030!Boletim da FBG Gastren
!v032!edicao especial
!v064!1996
!v065!19960000
!v118!19
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000262
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sCrema^rND^nE
!v010!^sCamara^rND^nCA
!v010!^sPastore^rND^nR
!v010!^sTeles^rND^nCJ
!v010!^sTerra^rND^nJA
!v010!^sSilva^rND^nAG
!v012!Assessment of positive perioperative cholangiography in patients undergoing elective laparoscopic cholecystectomy^len
!v014!403-06
!v030!Rev Col Bras Cir
!v031!37
!v064!2010
!v065!20100000
!v118!20
!v514!^l406^f403
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000263
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sCsendes^rND^nA
!v012!Common bile duct stones: introduction^len
!v014!1113
!v030!World J Surg
!v031!22
!v064!1998
!v065!19980000
!v118!21
!v514!^f1113
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000264
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sD'Ippolito^rND^nG
!v010!^sGalvao-Filho^rND^nM
!v010!^sJesus^rND^nPEM
!v010!^sWoloske^rND^nA
!v010!^sBorri^rND^nML
!v012!Colangiopancreatografia por ressonancia magnetica: aplicacoes clinicas^lpt
!v014!149-56
!v030!Radiol Bras
!v031!31
!v064!1998
!v065!19980000
!v118!22
!v514!^l156^f149
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000265
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sDanilewitz^rND^nMD
!v012!Early postoperative endoscopic sphincterotomy for retained common bile duct stones^len
!v014!298-99
!v030!Gastrointest Endosc
!v031!35
!v064!1989
!v065!19890000
!v118!23
!v514!^l299^f298
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000266
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sDePaula^rND^nAL
!v010!^sHashiba^rND^nK
!v010!^sBafutto^rND^nM
!v012!Laparoscopic management of choledocholithiasis^len
!v014!1399-403
!v030!Surg Endosc
!v031!8
!v064!1994
!v065!19940000
!v118!24
!v514!^l1403^f1399
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000267
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sDomene^rND^nCE
!v010!^sIshigawa^rND^nPS
!v010!^sSanto^rND^nMA
!v012!Tratamento videolaparoscopico da coledocolitiase^lpt
!v014!76
!v030!ABCD Arq Bras Cir Dig
!v031!11
!v064!1996
!v065!19960000
!v118!25
!v514!^f76
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000268
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sDomene^rND^nCE
!v010!^sSanto^rND^nMA
!v010!^sVolpe^rND^nP
!v012!Laparoscopy choledochoduodenostomy [abstract]^len
!v014!122
!v030!Hepatogastroenterology
!v031!45
!v064!1998
!v065!19980000
!v118!26
!v514!^f122
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000269
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sDomene^rND^nCE
!v010!^sSanto^rND^nMA
!v010!^sVolpe^rND^nP
!v012!Laparoscopy treatment of choledocholithiasis [abstract]^len
!v014!126
!v030!Hepatogastroenterology
!v031!45
!v064!1998
!v065!19980000
!v118!27
!v514!^f126
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000270
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sEdmundowicz^rND^nSA
!v012!Common bile duct stones^len
!v014!817-24
!v030!Gastrointest Endosc Clin N Am
!v031!5
!v064!1995
!v065!19950000
!v118!28
!v514!^l824^f817
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000271
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sEscudero-Fabre^rND^nA
!v010!^sEscallon^rND
!v010!^sSack^rND^nJ
!v010!^sHalpern^rND^nNB
!v010!^sAldrete^rND^nJS
!v012!Choledochoduodenostomy. Analysis of 71 cases followed for 5 to 15 years^len
!v014!635-44
!v030!Ann Surg
!v031!213
!v064!1991
!v065!19910000
!v118!29
!v514!^l644^f635
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000272
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sFink^rND^nAS
!v012!ERCP or not ERCP? That is the question^len
!v014!375-76
!v030!Surg Endosc
!v031!7
!v064!1993
!v065!19930000
!v118!30
!v514!^l376^f375
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000273
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sFitzgibbons^rND^nRJ Jr
!v010!^sRyberg^rND^nAA
!v010!^sUlualp^rND^nKM
!v010!^sNguyen^rND^nNX
!v010!^sLitke^rND^nBS
!v010!^sCamps^rND^nJ
!v010!^sMcGinn^rND^nTR
!v010!^sJenkins^rND^nJX
!v010!^sFilipi^rND^nCJ
!v012!An alternative technique for treatment of choledocholithiasis found at laparoscopic cholecystectomy^len
!v014!638-42
!v030!Arch Surg
!v031!130
!v064!1995
!v065!19950000
!v118!31
!v514!^l642^f638
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000274
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sFranceschi^rND^nD
!v010!^sBrandt^rND^nC
!v010!^sMargolin^rND^nD
!v010!^sSzopa^rND^nB
!v010!^sPonsky^rND^nJ
!v010!^sPriebe^rND^nP
!v010!^sStellato^rND^nT
!v010!^sEckhauser^rND^nML
!v012!The management of common bile duct stones in patients undergoing laparoscopic cholecystectomy^len
!v014!525-32
!v030!Am Surg
!v031!59
!v064!1993
!v065!19930000
!v118!32
!v514!^l532^f525
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000275
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sFranklin^rND^nME Jr
!v010!^sPharand^rND^nD
!v010!^sRosenthal^rND^nD
!v012!Laparoscopic common bile duct exploration^len
!v014!119-24
!v030!Surg Laparosc Endosc
!v031!4
!v064!1994
!v065!19940000
!v118!33
!v514!^l124^f119
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000276
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sFrazee^rND^nRC
!v010!^sRoberts^rND^nJ
!v010!^sSymmonds^rND^nR
!v010!^sHendricks^rND^nJC
!v010!^sSnyder^rND^nS
!v010!^sSmith^rND^nR
!v010!^sCuster^rND^nMD
!v010!^sStoltenberg^rND^nP
!v010!^sAvots^rND^nA
!v012!Combined laparoscopic and endoscopic management of cholelithiasis and choledocholithiasis^len
!v014!702-06
!v030!Am J Surg
!v031!166
!v064!1993
!v065!19930000
!v118!34
!v514!^l706^f702
!v700!38
!v701!34
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000277
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sGama-Rodrigues^rND^nJJ
!v010!^sBresciani^rND^nC
!v010!^sMincis^rND^nM
!v012!^tColecistectomia por videolaparoscopia
!v014!815-26
!v018!Gastroenterologia e hepatologia: diagnostico e tratamento
!v062!Lemos
!v064!1997
!v065!19970000
!v066!Sao Paulo
!v118!35
!v514!^l826^f815
!v700!39
!v701!35
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000278
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sGigot^rND^nJF
!v010!^sNavez^rND^nB
!v010!^sEtienne^rND^nJ
!v010!^sCambier^rND^nE
!v010!^sJadoul^rND^nP
!v010!^sGuiot^rND^nP
!v010!^sKestens^rND^nPJ
!v012!A stratified intraoperative surgical strategy is mandatory during laparoscopic common bile duct exploration for common bile duct stones. Lessons and limits from an initial experience of 92 patients^len
!v014!722-28
!v030!Surg Endosc
!v031!11
!v064!1997
!v065!19970000
!v118!36
!v514!^l728^f722
!v700!40
!v701!36
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000279
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sHardy^rND^nKJ
!v012!Gallstones and laparoscopic cholecystectomy: a consensus?^len
!v014!583-87
!v030!Aust N Z J Surg
!v031!64
!v064!1994
!v065!19940000
!v118!37
!v514!^l587^f583
!v700!41
!v701!37
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000280
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sHauer-Jensen^rND^nM
!v010!^sKaresen^rND^nR
!v010!^sNygaard^rND^nK
!v010!^sSolheim^rND^nK
!v010!^sAmlie^rND^nEJ
!v010!^sHavig^rND^nO
!v010!^sRosseland^rND^nAR
!v012!Prospective randomized study of routine intraoperative cholangiography during open cholecystectomy: long-term follow-up and multivariate analysis of predictors of choledocholithiasis^len
!v014!318-23
!v030!Surgery
!v031!113
!v064!1993
!v065!19930000
!v118!38
!v514!^l323^f318
!v700!42
!v701!38
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000281
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sHess^rND^nW
!v010!^sHess^rND^nW
!v012!^tColecistectomias dificiles
!v014!379-84
!v018!Enfermedades de las vias biliares y del pancreas
!v062!Editorial Cientifica Medica
!v064!1963
!v065!19630000
!v066!Barcelona
!v118!39
!v514!^l384^f379
!v700!43
!v701!39
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000282
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sHorwood^rND^nJ
!v010!^sAkbar^rND^nF
!v010!^sDavis^rND^nK
!v010!^sMorgan^rND^nR
!v012!Prospective evaluation of a selective approach to cholangiography for suspected common bile duct stones^len
!v014!206-10
!v030!Ann R Coll Surg Engl
!v031!92
!v064!2010
!v065!20100000
!v118!40
!v514!^l210^f206
!v700!44
!v701!40
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000283
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sHoudart^rND^nR
!v010!^sPerniceni^rND^nT
!v010!^sDarne^rND^nB
!v010!^sSalmeron^rND^nM
!v010!^sSimon^rND^nJF
!v012!Predicting common bile duct lithiasis: determination and prospective validation of a model predicting low risk^len
!v014!38-43
!v030!Am J Surg
!v031!170
!v064!1995
!v065!19950000
!v118!41
!v514!^l43^f38
!v700!45
!v701!41
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000284
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sHuguier^rND^nM
!v010!^sBornet^rND^nP
!v010!^sCharpak^rND^nY
!v010!^sHoury^rND^nS
!v010!^sChastang^rND^nC
!v012!Selective contraindications based on multivariate analysis for operative cholangiography in biliary lithiasis^len
!v014!470-74
!v030!Surg Gynecol Obstet
!v031!172
!v064!1991
!v065!19910000
!v118!42
!v514!^l474^f470
!v700!46
!v701!42
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000285
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sHunter^rND^nJG
!v010!^sSoper^rND^nNJ
!v012!Laparoscopic management of bile duct stones^len
!v014!1077-097
!v030!Surg Clin North Am
!v031!72
!v064!1992
!v065!19920000
!v118!43
!v514!^l1097^f1077
!v700!47
!v701!43
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000286
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sKawai^rND^nK
!v010!^sAkasaka^rND^nY
!v010!^sMurakami^rND^nK
!v010!^sTada^rND^nM
!v010!^sKoli^rND^nY
!v012!Endoscopic sphincterotomy of the ampulla of Vater^len
!v014!148-51
!v030!Gastrointest Endosc
!v031!20
!v064!1974
!v065!19740000
!v118!44
!v514!^l151^f148
!v700!48
!v701!44
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000287
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sKazuhisa^rND^nU
!v010!^sHironobu^rND^nO
!v010!^sMasaji^rND^nT
!v010!^sHiroyuki^rND^nK
!v010!^sManabu^rND^nK
!v010!^sMasaki^rND^nU
!v010!^sHiroki^rND^nY
!v012!Long-term prognosis after treatment of patients with choledocholithiasis^len
!v014!97-102
!v030!Ann Surg
!v031!238
!v064!2003
!v065!20030000
!v118!45
!v514!^l102^f97
!v700!49
!v701!45
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000288
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sKhoo^rND^nDE
!v010!^sWalsh^rND^nCJ
!v010!^sCox^rND^nMR
!v010!^sMurphy^rND^nCA
!v010!^sMotson^rND^nRW
!v012!Laparoscopic common bile duct exploration: evolution of a new technique^len
!v014!341-46
!v030!Br J Surg
!v031!83
!v064!1996
!v065!19960000
!v118!46
!v514!^l346^f341
!v700!50
!v701!46
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000289
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sKullman^rND^nE
!v010!^sBorch^rND^nK
!v010!^sLindstrom^rND^nE
!v010!^sSvanvik^rND^nJ
!v010!^sAnderberg^rND^nB
!v012!Management of bile duct stones in the era of laparoscopic cholecystectomy: appraisal of routine operative cholangiography and endoscopic treatment^len
!v014!873-80
!v030!Eur J Surg
!v031!162
!v064!1996
!v065!19960000
!v118!47
!v514!^l880^f873
!v700!51
!v701!47
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000290
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sKum^rND^nCK
!v010!^sGoh^rND^nPM
!v012!Preoperative ERCP in the management of common bile duct stones before laparoscopic cholecystectomy^len
!v014!205-10
!v030!Eur J Surg
!v031!162
!v064!1996
!v065!19960000
!v118!48
!v514!^l210^f205
!v700!52
!v701!48
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000291
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sLacitignola^rND^nS
!v010!^sMinardi^rND^nM
!v010!^sPalmieri^rND^nR
!v010!^sNigri^rND^nA
!v010!^sCaliandro^rND^nL
!v010!^sRosellini^rND^nA
!v012!A "one-stage" laparoscopic procedure for treating choledocholithiasis^len
!v014!419-21
!v030!JSLS
!v031!9
!v064!2005
!v065!20050000
!v118!49
!v514!^l421^f419
!v700!53
!v701!49
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000292
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sLacitignola^rND^nS
!v010!^sMinardi^rND^nM
!v012!Management of common bile duct stones: a ten-year experience at a tertiary care center^len
!v014!62-5
!v030!JSLS
!v031!12
!v064!2008
!v065!20080000
!v118!50
!v514!^l65^f62
!v700!54
!v701!50
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000293
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sLibanori^rND^nHT
!v010!^sDomene^rND^nCE
!v010!^sNasi^rND^nA
!v010!^sPinotti^rND^nHW
!v012!Routine laparoscopic cholangiography by a simple and successful technique^len
!v014!47-50
!v030!ABCD Arq Bras Cir Dig
!v031!10
!v064!1995
!v065!19950000
!v118!51
!v514!^l50^f47
!v700!55
!v701!51
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000294
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sLiberman^rND^nMA
!v010!^sPhillips^rND^nEH
!v010!^sCarrol^rND^nBJ
!v010!^sFallas^rND^nMJ
!v010!^sRosenthal^rND^nR
!v010!^sHiatt^rND^nJ
!v012!Cost-effective management of complicated choledocholithiasis: laparoscopic transcystic duct exploration or endoscopic sphincterotomy^len
!v014!488-94
!v030!J Am Coll Surg
!v031!182
!v064!1996
!v065!19960000
!v118!52
!v514!^l494^f488
!v700!56
!v701!52
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000295
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sLudwig^rND^nK
!v010!^sBernhardt^rND^nJ
!v010!^sLorenz^rND^nD
!v012!Value and consequences of routine intraoperative cholangiography during cholecystectomy^len
!v014!154-59
!v030!Surg Laparosc Endosc Percutan Tech
!v031!12
!v064!2002
!v065!20020000
!v118!53
!v514!^l159^f154
!v700!57
!v701!53
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000296
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sMcSherry^rND^nCK
!v010!^sFerstenberg^rND^nH
!v010!^sCalhoun^rND^nWF
!v010!^sLahman^rND^nE
!v010!^sVirshup^rND^nM
!v012!The natural history of diagnosed gallstone disease in symptomatic and asymptomatic patients^len
!v014!59-63
!v030!Ann Surg
!v031!202
!v064!1985
!v065!19850000
!v118!54
!v514!^l63^f59
!v700!58
!v701!54
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000297
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sMonteiro-da-Cunha^rND^nJE
!v010!^sPenteado^rND^nS
!v010!^sMachado^rND^nMCC
!v010!^sPinotti^rND^nHW
!v010!^sPinotti^rND^nHW
!v010!^sCecconello^rND^nI
!v010!^sGama-Rodrigues^rND^nJJ
!v010!^sHabr-Gama^rND^nA
!v010!^sMachado^rND^nMCC
!v010!^sSaad^rND^nWA
!v010!^sFaintuch^rND^nJ
!v010!^sDomene^rND^nCE
!v012!^tColedocolitiase
!v014!933-40
!v018!Tratado de clinica cirurgica do aparelho digestivo
!v062!Atheneu
!v064!1994
!v065!19940000
!v066!Sao Paulo
!v118!55
!v514!^l940^f933
!v700!59
!v701!55
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000298
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sMorgenstern^rND^nL
!v010!^sBerci^rND^nG
!v010!^sPasternak^rND^nEH
!v012!Bile leakage after biliary tract surgery. A laparoscopic perspective^len
!v014!432-38
!v030!Surg Endosc
!v031!7
!v064!1993
!v065!19930000
!v118!56
!v514!^l438^f432
!v700!60
!v701!56
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000299
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sNeuhaus^rND^nH
!v010!^sFeussner^rND^nH
!v010!^sUngeheuer^rND^nA
!v010!^sHoffmann^rND^nW
!v010!^sSiewert^rND^nJR
!v010!^sClassen^rND^nM
!v012!Prospective evaluation of the use of endoscopic retrograde cholangiography prior to laparoscopic cholecystectomy^len
!v014!745-49
!v030!Endoscopy
!v031!24
!v064!1992
!v065!19920000
!v118!57
!v514!^l749^f745
!v700!61
!v701!57
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000300
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v012!NIH Consensus conference. Gallstones and laparoscopic cholecystectomy^len
!v014!1018-024
!v030!JAMA
!v031!269
!v064!1993
!v065!19930000
!v118!58
!v514!^l1024^f1018
!v700!62
!v701!58
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000301
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sPaganini^rND^nAM
!v010!^sLezoche^rND^nE
!v012!Follow-up of 161 unselected consecutive patients treated laparoscopically for common bile duct stones^len
!v014!23-9
!v030!Surg Endosc
!v031!12
!v064!1998
!v065!19980000
!v118!59
!v514!^l29^f23
!v700!63
!v701!59
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000302
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sPerissat^rND^nJ
!v010!^sHuibregtse^rND^nK
!v010!^sKeane^rND^nFB
!v010!^sRussell^rND^nRC
!v010!^sNeoptolemos^rND^nJP
!v012!Management of bile duct stones in the era of laparoscopic cholecystectomy^len
!v014!799-810
!v030!Br J Surg
!v031!81
!v064!1994
!v065!19940000
!v118!60
!v514!^l810^f799
!v700!64
!v701!60
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000303
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sPetelin^rND^nJB
!v012!Laparoscopic approach to common duct pathology^len
!v014!33-41
!v030!Surg Laparosc Endosc
!v031!1
!v064!1991
!v065!19910000
!v118!61
!v514!^l41^f33
!v700!65
!v701!61
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000304
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sPetelin^rND^nJB
!v012!Laparoscopic approach to common duct pathology^len
!v014!487-91
!v030!Am J Surg
!v031!165
!v064!1993
!v065!19930000
!v118!62
!v514!^l491^f487
!v700!66
!v701!62
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000305
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sPhillips^rND^nEH
!v010!^sRosenthal^rND^nRJ
!v010!^sCarrol^rND^nBJ
!v010!^sFallas^rND^nMJ
!v012!Laparoscopic trans-cystic duct common bile duct exploration^len
!v014!1389-394
!v030!Surg Endosc
!v031!8
!v064!1994
!v065!19940000
!v118!63
!v514!^l1394^f1389
!v700!67
!v701!63
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000306
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sPhillips^rND^nEH
!v010!^sLiberman^rND^nM
!v010!^sCarrol^rND^nBJ
!v010!^sFallas^rND^nMJ
!v010!^sRosenthal^rND^nRJ
!v010!^sHiatt^rND^nJR
!v012!Bile duct stones in the laparoscopic era. Is the preoperative sphincterotomy necessary?^len
!v014!880-86
!v030!Arch Surg
!v031!130
!v064!1995
!v065!19950000
!v118!64
!v514!^l886^f880
!v700!68
!v701!64
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000307
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sPinotti^rND^nHW
!v010!^sDomene^rND^nCE
!v010!^sVolpe^rND^nP
!v010!^sSanto^rND^nMA
!v010!^sOnari^rND^nP
!v012!Formacao do cirurgiao em cirurgia laparoscopica do aparelho digestivo. Experiencia de 1.818 intervencoes sem acidentes e sem mortalidade^lpt
!v014!337-41
!v030!Rev Assoc Med Bras
!v031!45
!v064!1999
!v065!19990000
!v118!65
!v514!^l341^f337
!v700!69
!v701!65
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000308
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sQuattlebaum^rND^nJK Jr
!v010!^sFlanders^rND^nHD
!v012!Laparoscopic treatment of common bile duct stones^len
!v014!26-32
!v030!Surg Laparosc Endosc
!v031!1
!v064!1991
!v065!19910000
!v118!66
!v514!^l32^f26
!v700!70
!v701!66
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000309
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sRhodes^rND^nM
!v010!^sSussman^rND^nL
!v010!^sCohen^rND^nL
!v010!^sLewis^rND^nMP
!v012!Randomised trial of laparoscopic exploration of common bile duct versus postoperative endoscopic retrograde cholangiography for common bile duct stones^len
!v014!159-61
!v030!Lancet
!v031!351
!v064!1998
!v065!19980000
!v118!67
!v514!^l161^f159
!v700!71
!v701!67
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000310
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sRobinson^rND^nG
!v010!^sHollinshead^rND^nJ
!v010!^sFalk^rND^nG
!v010!^sMoulton^rND^nJ
!v012!Technique and results of laparoscopic choledochotomy for the management of bile duct calculi^len
!v014!347-49
!v030!Aust N Z J Surg
!v031!65
!v064!1995
!v065!19950000
!v118!68
!v514!^l349^f347
!v700!72
!v701!68
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000311
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sRosenthal^rND^nRJ
!v010!^sRossi^rND^nRL
!v010!^sMartin^rND^nRF
!v012!Options and strategies for the management of choledocholithiasis^len
!v014!1125-132
!v030!World J Surg
!v031!22
!v064!1998
!v065!19980000
!v118!69
!v514!^l1132^f1125
!v700!73
!v701!69
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000312
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sSakai^rND^nP
!v010!^sArtifon^rND^nELA
!v010!^sIshioka^rND^nS
!v012!Uso de endoprotese biliar plastica na coledocolitiase^lpt
!v014!233-36
!v030!GED Gastroenterol Endosc Dig
!v031!18
!v064!1999
!v065!19990000
!v118!70
!v514!^l236^f233
!v700!74
!v701!70
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000313
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sSantucci^rND^nL
!v010!^sNatalini^rND^nG
!v010!^sSarpi^rND^nL
!v010!^sFiorucci^rND^nS
!v010!^sSolinas^rND^nA
!v010!^sMorelli^rND^nA
!v012!Selective endoscopic retrograde cholangiography and preoperative bile duct stone removal in patients scheduled for laparoscopic cholecystectomy: a prospective study^len
!v014!1326-330
!v030!Am J Gastroenterol
!v031!91
!v064!1996
!v065!19960000
!v118!71
!v514!^l1330^f1326
!v700!75
!v701!71
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000314
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sSavassi-Rocha^rND^nPR
!v010!^sFerreira^rND^nJT
!v010!^sDiniz^rND^nMT
!v010!^sSanches^rND^nSR
!v012!Laparoscopic cholecystectomy in Brazil: analysis of 33,563 cases^len
!v014!208-13
!v030!Int Surg
!v031!82
!v064!1997
!v065!19970000
!v118!72
!v514!^l213^f208
!v700!76
!v701!72
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000315
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sSchwab^rND^nG
!v010!^sPointner^rND^nR
!v010!^sWetscher^rND^nG
!v010!^sGlaser^rND^nK
!v010!^sFoltin^rND^nE
!v010!^sBodner^rND^nE
!v012!Treatment of calculi of the common bile duct^len
!v014!115-20
!v030!Surg Gynecol Obstet
!v031!175
!v064!1992
!v065!19920000
!v118!73
!v514!^l120^f115
!v700!77
!v701!73
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000316
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sShojaiefard^rND^nA
!v010!^sEsmaeilzadeh^rND^nM
!v010!^sGhafouri^rND^nA
!v010!^sMehrabi^rND^nA
!v012!Various techniques for the surgical treatment of common bile duct stones: a meta review^len
!v030!Gastroenterol Res Pract
!v064!2009
!v065!20090000
!v118!74
!v700!78
!v701!74
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000317
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sSjer^rND^nAE
!v010!^sBoland^rND^nDM
!v010!^svan Rijn^rND^nPJ
!v010!^sMohamad^rND^nS
!v012!A decade of washing out common bile duct stones with papillary balloon dilatation as a one-stage procedure during laparoscopic cholecystectomy^len
!v014!2226-230
!v030!Surg Endosc
!v031!24
!v064!2010
!v065!20100000
!v118!75
!v514!^l2230^f2226
!v700!79
!v701!75
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000318
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sSmith^rND^nPC
!v010!^sClayman^rND^nRV
!v010!^sSoper^rND^nNJ
!v012!Laparoscopic cholecystectomy and choledochoscopy for the treatment of cholelithiasis and choledocholithiasis^len
!v014!230-33
!v030!Surgery
!v031!111
!v064!1992
!v065!19920000
!v118!76
!v514!^l233^f230
!v700!80
!v701!76
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000319
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sSperanzini^rND^nMB
!v010!^sCastillo-Netto^rND^nJM
!v010!^sLima^rND^nSE
!v012!Defeitos na drenagem cirurgica do coledoco^lpt
!v014!283-88
!v030!Rev Col Bras Cir
!v031!20
!v064!1993
!v065!19930000
!v118!77
!v514!^l288^f283
!v700!81
!v701!77
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000320
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sStrasberg^rND^nSM
!v010!^sCallery^rND^nMP
!v010!^sSoper^rND^nNJ
!v012!Laparoscopic surgery of the bile ducts^len
!v014!81-105
!v030!Gastrointest Endosc Clin N Am
!v031!6
!v064!1996
!v065!19960000
!v118!78
!v514!^l105^f81
!v700!82
!v701!78
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000321
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sTargarona^rND^nEM
!v010!^sBendahan^rND^nGE
!v012!Management of common bile duct stones: controversies and future perspectives^len
!v014!140-43
!v030!HPB (Oxford)
!v031!6
!v064!2006
!v065!20060000
!v118!79
!v514!^l143^f140
!v700!83
!v701!79
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000322
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sWay^rND^nLW
!v010!^sAdmirand^rND^nWH
!v010!^sDunphy^rND^nJE
!v012!Management of choledocholithiasis^len
!v014!347-59
!v030!Ann Surg
!v031!176
!v064!1972
!v065!19720000
!v118!80
!v514!^l359^f347
!v700!84
!v701!80
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000323
!v001!br1.1
!v002!0004-2803-ag-49-01-41.xml
!v004!v49n1
!v010!^sYeom^rND^nDH
!v010!^sOh^rND^nHJ
!v010!^sSon^rND^nYW
!v010!^sKim^rND^nTH
!v012!What are the risk factors for acute suppurative cholangitis caused by common bile duct stones?^len
!v014!363-67
!v030!Gut Liver
!v031!4
!v064!2010
!v065!20100000
!v118!81
!v514!^l367^f363
!v700!85
!v701!81
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-41.xml
!v705!S
!v706!c
!v708!81
!v865!20120300
!ID 000324
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v091!20120814
!v092!164311
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v703!118
!v705!S
!v706!o
!v708!1
!ID 000325
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^1aff1^sDietz^rauthor^nJudite
!v010!^sUlbrich-Kulcynski^rauthor^nJane Maria
!v010!^sSouto^rauthor^nKatia Elisabete Pires
!v010!^sMeinhardt^rauthor^nNelson Guardiola
!v012!^tPrevalence of upper digestive endoscopy and gastric histopathology findings in morbidly obese patients
!v012!^tPrevalencia de achados gastricos endoscopicos e histopatologicos em pacientes obesos^lpt
!v014!^l55^f52
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Division of Endoscopy, HNSC^iaff1^9Division of Endoscopy, HNSC^5?^l1
!v070!Universidade Federal do Rio Grande do Sul (UFRGS)^iaff2^9Department of Pathology, Universidade Federal do Rio Grande do Sul (UFRGS)^1Department of Pathology^l2
!v070!Division of Endocrinology, HNSC^iaff3^9Division of Endocrinology, HNSC^5?^l3
!v070!Division of Bariatric Surgery, HNSC^cPorto Alegre^iaff4^l4^pBrazil^sRS^5?^9Division of Bariatric Surgery, HNSC, Porto Alegre, RS, Brazil
!v071!oa
!v072!40
!v083!^a<sec>					<title>CONTEXT:</title>					 The prevalence of obesity has been increasing in modern society. Roux-en-y gastric bypass is a bariatric surgery that involves the exclusion of significant part of the stomach. Atrophy, intestinal metaplasia and gastric cancer have been associated with infection by 							Helicobacter							pylori						.  				</sec>				<sec>					<title> OBJECTIVES:</title>					 To evaluate the presence of endoscopy findings and histological changes in morbid obese patients for the presence of inflammatory cells, inflammatory activity, lymphoid hyperplasia, 							H. pylori						 infection, atrophy and intestinal metaplasia in the gastric mucosa. 				</sec>				<sec>					<title>METHODS:</title>					 Upper digestive endoscopy and gastric histopathological were studied in 126 obese patients in the preoperative evaluation for bariatric surgery. 				</sec>				<sec>					<title>RESULTS:</title>					 Upper digestive endoscopy abnormalities were diagnosed in 73/126 (57.9%) patients. In three patients (2.4%) the upper gastrointestinal endoscopy diagnosed gastric ulcer and one patient (0.8%) had duodenal ulcer. The histopathological from gastric biopsies of these obese patients showed 65.1% of mucosa inflammation, inflammatory activity in 50.0%, infection by 							H. pylori						 in 53.2%, lymphoid hyperplasia in 50.0% and atrophy and/or intestinal metaplasia in 16.7%. 				</sec>				<sec>					<title>CONCLUSIONS:</title>					 In present study, with routine preoperative upper gastrointestinal endoscopy and histopathological examination, were detected 57.9% patients with endoscopy abnormalities, high prevalence of infection by H. pylori (53%) and 16.7% of gastric atrophy and/or intestinal metaplasia.				</sec>^len
!v083!^a<sec>					<title>CONTEXT:</title>					 A prevalencia de obesidade tem aumentado significativamente nos ultimos anos. Bypass gastrico em Y-de-Roux, uma das tecnicas cirurgicas realizadas no tratamento da obesidade, envolve exclusao de parte do estomago. Atrofia, metaplasia intestinal e cancer gastrico tem sido associados com infeccao pelo 							Helicobacter							pylori.									</sec>				<sec>					<title> OBJETIVOS:</title>					 Avaliar a prevalencia de achados endoscopicos e alteracoes histopatologicas em pacientes obesos morbidos em relacao a presenca de celulas inflamatorias, atividade inflamatoria, hiperplasia linfoide, infeccao pelo 							H. pylori						, atrofia e metaplasia intestinal na mucosa gastrica.  				</sec>				<sec>					<title>MeTODOS:</title>					 Achados na endoscopia digestiva alta e histopatologia gastrica foram analisados em 126 pacientes obesos na avaliacao pre-operatoria de cirurgia bariatrica. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Anormalidades endoscopicas do trato digestivo superior foram diagnosticadas em 73/126 pacientes, com tres pacientes (2,4%) apresentando ulcera gastrica e um paciente (0,8%) com ulcera duodenal. A histopatologia das biopsias gastricas dos obesos estudados revelou 65,1% de processo inflamatorio na mucosa, atividade inflamatoria em 50,0%; infeccao pelo 							H. pylori						 em 53,2%, hiperplasia linfoide em 50,0%, atrofia e/ou metaplasia intestinal em 16,7%. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 No presente estudo, atraves de endoscopia digestiva alta e histopatologia de biopsias gastricas, foram detectados 57,9% de pacientes com anormalidades endoscopicas, prevalencia de infeccao pelo 							H. pylori						 em 53% e atrofia e/ou metaplasia intestinal em 16,7%.				</sec>^lpt
!v085!^kObesity, morbid^len
!v085!^kGastric bypass^len
!v085!^kEndoscopy gastrointestinal^len
!v085!^kHelicobacter infections^len
!v085!^kObesidade morbida^lpt
!v085!^kDerivacao gastrica^lpt
!v085!^kEndoscopia gastrointestinal^lpt
!v085!^kInfeccoes por helicobacter^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m01^d31
!v112!2011
!v113!^y2011^m09^d01
!v114!2011
!v120!XML_3.0
!v121!52
!v237!10.1590/S0004-28032012000100009
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!h
!v708!1
!ID 000326
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^1aff1^sDietz^rauthor^nJudite
!v010!^sUlbrich-Kulcynski^rauthor^nJane Maria
!v010!^sSouto^rauthor^nKatia Elisabete Pires
!v010!^sMeinhardt^rauthor^nNelson Guardiola
!v012!^tPrevalence of upper digestive endoscopy and gastric histopathology findings in morbidly obese patients
!v012!^tPrevalência de achados gástricos endoscópicos e histopatológicos em pacientes obesos^lpt
!v014!^l55^f52
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Division of Endoscopy, HNSC^iaff1^9Division of Endoscopy, HNSC^5?^l1
!v070!Universidade Federal do Rio Grande do Sul (UFRGS)^iaff2^9Department of Pathology, Universidade Federal do Rio Grande do Sul (UFRGS)^1Department of Pathology^l2
!v070!Division of Endocrinology, HNSC^iaff3^9Division of Endocrinology, HNSC^5?^l3
!v070!Division of Bariatric Surgery, HNSC^cPorto Alegre^iaff4^l4^pBrazil^sRS^5?^9Division of Bariatric Surgery, HNSC, Porto Alegre, RS, Brazil
!v071!oa
!v072!40
!v083!^a<sec>					<title>CONTEXT:</title>					<p> The prevalence of obesity has been increasing in modern society. Roux-en-y gastric bypass is a bariatric surgery that involves the exclusion of significant part of the stomach. Atrophy, intestinal metaplasia and gastric cancer have been associated with infection by <named-content content-type="scientific-name">							<italic>Helicobacter</italic>							<italic>pylori</italic>						</named-content>.  </p>				</sec>				<sec>					<title> OBJECTIVES:</title>					<p> To evaluate the presence of endoscopy findings and histological changes in morbid obese patients for the presence of inflammatory cells, inflammatory activity, lymphoid hyperplasia, <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> infection, atrophy and intestinal metaplasia in the gastric mucosa. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> Upper digestive endoscopy and gastric histopathological were studied in 126 obese patients in the preoperative evaluation for bariatric surgery. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> Upper digestive endoscopy abnormalities were diagnosed in 73/126 (57.9%) patients. In three patients (2.4%) the upper gastrointestinal endoscopy diagnosed gastric ulcer and one patient (0.8%) had duodenal ulcer. The histopathological from gastric biopsies of these obese patients showed 65.1% of mucosa inflammation, inflammatory activity in 50.0%, infection by <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> in 53.2%, lymphoid hyperplasia in 50.0% and atrophy and/or intestinal metaplasia in 16.7%. </p>				</sec>				<sec>					<title>CONCLUSIONS:</title>					<p> In present study, with routine preoperative upper gastrointestinal endoscopy and histopathological examination, were detected 57.9% patients with endoscopy abnormalities, high prevalence of infection by <italic>H</italic>. <italic>pylori</italic> (53%) and 16.7% of gastric atrophy and/or intestinal metaplasia.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXT:</title>					<p> A preval&#234;ncia de obesidade tem aumentado significativamente nos &#250;ltimos anos. Bypass g&#225;strico em Y-de-Roux, uma das t&#233;cnicas cir&#250;rgicas realizadas no tratamento da obesidade, envolve exclus&#227;o de parte do est&#244;mago. Atrofia, metaplasia intestinal e c&#226;ncer g&#225;strico t&#234;m sido associados com infec&#231;&#227;o pelo <named-content content-type="scientific-name">							<italic>Helicobacter</italic>							<italic>pylori</italic>.</named-content>					</p>				</sec>				<sec>					<title> OBJETIVOS:</title>					<p> Avaliar a preval&#234;ncia de achados endosc&#243;picos e altera&#231;&#245;es histopatol&#243;gicas em pacientes obesos m&#243;rbidos em rela&#231;&#227;o &#224; presen&#231;a de c&#233;lulas inflamat&#243;rias, atividade inflamat&#243;ria, hiperplasia linf&#243;ide, infec&#231;&#227;o pelo <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content>, atrofia e metaplasia intestinal na mucosa g&#225;strica.  </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Achados na endoscopia digestiva alta e histopatologia g&#225;strica foram analisados em 126 pacientes obesos na avalia&#231;&#227;o pr&#233;-operat&#243;ria de cirurgia bari&#225;trica. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Anormalidades endosc&#243;picas do trato digestivo superior foram diagnosticadas em 73/126 pacientes, com tr&#234;s pacientes (2,4%) apresentando &#250;lcera g&#225;strica e um paciente (0,8%) com &#250;lcera duodenal. A histopatologia das biopsias g&#225;stricas dos obesos estudados revelou 65,1% de processo inflamat&#243;rio na mucosa, atividade inflamat&#243;ria em 50,0%; infec&#231;&#227;o pelo <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> em 53,2%, hiperplasia linf&#243;ide em 50,0%, atrofia e/ou metaplasia intestinal em 16,7%. </p>				</sec>				<sec>					<title>CONCLUS&#213;ES:</title>					<p> No presente estudo, atrav&#233;s de endoscopia digestiva alta e histopatologia de biopsias g&#225;stricas, foram detectados 57,9% de pacientes com anormalidades endosc&#243;picas, preval&#234;ncia de infec&#231;&#227;o pelo <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> em 53% e atrofia e/ou metaplasia intestinal em 16,7%.</p>				</sec>^lpt
!v085!^kObesity, morbid^len
!v085!^kGastric bypass^len
!v085!^kEndoscopy gastrointestinal^len
!v085!^kHelicobacter infections^len
!v085!^kObesidade mórbida^lpt
!v085!^kDerivação gástrica^lpt
!v085!^kEndoscopia gastrointestinal^lpt
!v085!^kInfecções por helicobacter^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m01^d31
!v112!2011
!v113!^y2011^m09^d01
!v114!2011
!v120!XML_3.0
!v121!52
!v237!10.1590/S0004-28032012000100009
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!f
!v708!1
!ID 000327
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^1aff1^sDietz^rauthor^nJudite
!v010!^sUlbrich-Kulcynski^rauthor^nJane Maria
!v010!^sSouto^rauthor^nKatia Elisabete Pires
!v010!^sMeinhardt^rauthor^nNelson Guardiola
!v012!^tPrevalence of upper digestive endoscopy and gastric histopathology findings in morbidly obese patients
!v012!^tPrevalencia de achados gastricos endoscopicos e histopatologicos em pacientes obesos^lpt
!v014!^l55^f52
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Division of Endoscopy, HNSC^iaff1^9Division of Endoscopy, HNSC^5?^l1
!v070!Universidade Federal do Rio Grande do Sul (UFRGS)^iaff2^9Department of Pathology, Universidade Federal do Rio Grande do Sul (UFRGS)^1Department of Pathology^l2
!v070!Division of Endocrinology, HNSC^iaff3^9Division of Endocrinology, HNSC^5?^l3
!v070!Division of Bariatric Surgery, HNSC^cPorto Alegre^iaff4^l4^pBrazil^sRS^5?^9Division of Bariatric Surgery, HNSC, Porto Alegre, RS, Brazil
!v071!oa
!v072!40
!v083!^a<sec>					<title>CONTEXT:</title>					 The prevalence of obesity has been increasing in modern society. Roux-en-y gastric bypass is a bariatric surgery that involves the exclusion of significant part of the stomach. Atrophy, intestinal metaplasia and gastric cancer have been associated with infection by 							Helicobacter							pylori						.  				</sec>				<sec>					<title> OBJECTIVES:</title>					 To evaluate the presence of endoscopy findings and histological changes in morbid obese patients for the presence of inflammatory cells, inflammatory activity, lymphoid hyperplasia, 							H. pylori						 infection, atrophy and intestinal metaplasia in the gastric mucosa. 				</sec>				<sec>					<title>METHODS:</title>					 Upper digestive endoscopy and gastric histopathological were studied in 126 obese patients in the preoperative evaluation for bariatric surgery. 				</sec>				<sec>					<title>RESULTS:</title>					 Upper digestive endoscopy abnormalities were diagnosed in 73/126 (57.9%) patients. In three patients (2.4%) the upper gastrointestinal endoscopy diagnosed gastric ulcer and one patient (0.8%) had duodenal ulcer. The histopathological from gastric biopsies of these obese patients showed 65.1% of mucosa inflammation, inflammatory activity in 50.0%, infection by 							H. pylori						 in 53.2%, lymphoid hyperplasia in 50.0% and atrophy and/or intestinal metaplasia in 16.7%. 				</sec>				<sec>					<title>CONCLUSIONS:</title>					 In present study, with routine preoperative upper gastrointestinal endoscopy and histopathological examination, were detected 57.9% patients with endoscopy abnormalities, high prevalence of infection by H. pylori (53%) and 16.7% of gastric atrophy and/or intestinal metaplasia.				</sec>^len
!v083!^a<sec>					<title>CONTEXT:</title>					 A prevalencia de obesidade tem aumentado significativamente nos ultimos anos. Bypass gastrico em Y-de-Roux, uma das tecnicas cirurgicas realizadas no tratamento da obesidade, envolve exclusao de parte do estomago. Atrofia, metaplasia intestinal e cancer gastrico tem sido associados com infeccao pelo 							Helicobacter							pylori.									</sec>				<sec>					<title> OBJETIVOS:</title>					 Avaliar a prevalencia de achados endoscopicos e alteracoes histopatologicas em pacientes obesos morbidos em relacao a presenca de celulas inflamatorias, atividade inflamatoria, hiperplasia linfoide, infeccao pelo 							H. pylori						, atrofia e metaplasia intestinal na mucosa gastrica.  				</sec>				<sec>					<title>MeTODOS:</title>					 Achados na endoscopia digestiva alta e histopatologia gastrica foram analisados em 126 pacientes obesos na avaliacao pre-operatoria de cirurgia bariatrica. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Anormalidades endoscopicas do trato digestivo superior foram diagnosticadas em 73/126 pacientes, com tres pacientes (2,4%) apresentando ulcera gastrica e um paciente (0,8%) com ulcera duodenal. A histopatologia das biopsias gastricas dos obesos estudados revelou 65,1% de processo inflamatorio na mucosa, atividade inflamatoria em 50,0%; infeccao pelo 							H. pylori						 em 53,2%, hiperplasia linfoide em 50,0%, atrofia e/ou metaplasia intestinal em 16,7%. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 No presente estudo, atraves de endoscopia digestiva alta e histopatologia de biopsias gastricas, foram detectados 57,9% de pacientes com anormalidades endoscopicas, prevalencia de infeccao pelo 							H. pylori						 em 53% e atrofia e/ou metaplasia intestinal em 16,7%.				</sec>^lpt
!v085!^kObesity, morbid^len
!v085!^kGastric bypass^len
!v085!^kEndoscopy gastrointestinal^len
!v085!^kHelicobacter infections^len
!v085!^kObesidade morbida^lpt
!v085!^kDerivacao gastrica^lpt
!v085!^kEndoscopia gastrointestinal^lpt
!v085!^kInfeccoes por helicobacter^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m01^d31
!v112!2011
!v113!^y2011^m09^d01
!v114!2011
!v120!XML_3.0
!v121!52
!v237!10.1590/S0004-28032012000100009
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!l
!v708!1
!ID 000328
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sArmstrong^rND^nD
!v010!^sBennett^rND^nJR
!v010!^sBlum^rND^nAL
!v010!^sDent^rND^nJ
!v010!^sDe Dombal^rND^nFT
!v010!^sGalmiche^rND^nJP
!v010!^sLundell^rND^nL
!v010!^sMarguilies^rND^nM
!v010!^sRichter^rND^nJE
!v010!^sSpechler^rND^nSJ
!v010!^sTytgat^rND^nGN
!v010!^sWallin^rND^nL
!v012!The endoscopic assessment of esophagitis: a progress report on observer agreement^len
!v014!85-92
!v030!Gastroenterology
!v031!111
!v064!1996
!v065!19960000
!v071!journal
!v118!1
!v514!^l92^f85
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000329
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sAzagury^rND^nD
!v010!^sDomonceau^rND^nJM
!v010!^sMorel^rND^nP
!v010!^sChassot^rND^nG
!v010!^sHuber^rND^nO
!v012!Preoperative work-up in asymptomatic patients undergoing Roux-en-Y gastric bypass: is endoscopy mandatory?^len
!v014!1304-311
!v030!Obes Surg
!v031!16
!v064!2006
!v065!20060000
!v118!2
!v514!^l1311^f1304
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000330
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sBenotti^rND^nPN
!v010!^sForse^rND^nRA
!v012!The role of gastric surgery in the multidisciplinary management of severe obesity^len
!v014!361-67
!v030!Am J Surg
!v031!169
!v064!1995
!v065!19950000
!v118!3
!v514!^l367^f361
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000331
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v012!State-specific prevalence of obesity among adults-United States, 2005^len
!v014!985-88
!v030!MMWR Morb Mortal Wkly Rep
!v031!55
!v064!2006
!v065!20060000
!v118!4
!v514!^l988^f985
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000332
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sCoelho^rND^nLG
!v010!^sLeon-Barua^rND^nR
!v010!^sQuigley^rND^nEM
!v012!Latin-American Consensus Conference on 							Helicobacter							pylori						 infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE)^len
!v014!2688-691
!v030!Am J Gastroenterol
!v031!95
!v064!2000
!v065!20000000
!v118!5
!v514!^l2691^f2688
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000333
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sCorrea^rND^nP
!v012!Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention^len
!v014!6735-740
!v030!Cancer Res
!v031!52
!v064!1992
!v065!19920000
!v118!6
!v514!^l6740^f6735
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000334
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sde Moura Almeida^rND^nA
!v010!^sCotrim^rND^nHP
!v010!^sSantos^rND^nAS
!v010!^sBitencourt^rND^nAG
!v010!^sBarbosa^rND^nDB
!v010!^sLobo^rND^nAP
!v010!^sRios^rND^nA
!v010!^sAlves^rND^nE
!v012!Preoperative upper gastrointestinal endoscopy in obese patients undergoing bariatric surgery: is it necessary?^len
!v014!144-9;discussion 150-1
!v030!Surg Obes Relat Dis
!v031!4
!v064!2008
!v065!20080000
!v118!7
!v514!^r144-9;discussion 150-1
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000335
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sDixon^rND^nMF
!v010!^sGenta^rND^nRM
!v010!^sYardley^rND^nJH
!v010!^sCorrea^rND^nP
!v012!Classification and grading of gastritis. The updated Sydney System. International Workshop on Histopathology of Gastritis, Houston 1994^len
!v014!1161-181
!v030!Am J Surg Pathol
!v031!20
!v064!1996
!v065!19960000
!v118!8
!v514!^l1181^f1161
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000336
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sDixon^rND^nMF
!v012!Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia^len
!v014!2-4
!v030!Gut
!v031!49
!v064!2001
!v065!20010000
!v118!9
!v514!^l4^f2
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000337
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sDooley^rND^nCP
!v010!^sCohen^rND^nH
!v010!^sFitzgibbons^rND^nPL
!v010!^sBauer^rND^nM
!v010!^sAppleman^rND^nMD
!v010!^sPerez-Perez^rND^nGI
!v010!^sBlaser^rND^nMJ
!v012!Prevalence of 							Helicobacter							pylori						 infection and histologic gastritis in asymptomatic persons^len
!v014!1562-566
!v030!N Engl J Med
!v031!321
!v064!1989
!v065!19890000
!v118!10
!v514!^l1566^f1562
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000338
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sDutta^rND^nSK
!v010!^sArora^rND^nM
!v010!^sKireet^rND^nA
!v010!^sBashandy^rND^nH
!v010!^sGandsas^rND^nA
!v012!Upper gastrointestinal symptoms and associated disorders in morbidly obese patients: a prospective study^len
!v014!1243-246
!v030!Dig Dis Sci
!v031!54
!v064!2009
!v065!20090000
!v118!11
!v514!^l1246^f1243
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000339
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sErim^rND^nT
!v010!^sCruz-Correa^rND^nMR
!v010!^sSzomstein^rND^nS
!v010!^sVelis^rND^nE
!v010!^sRosenthal^rND^nR
!v012!Prevalence of 							Helicobacter							pylori						seropositivity among patients undergoing bariatric surgery: a preliminary study^len
!v014!2021-025
!v030!World J Surg
!v031!32
!v064!2008
!v065!20080000
!v118!12
!v514!^l2025^f2021
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000340
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sFennerty^rND^nMB
!v012!Gastric intestinal metaplasia on routine endoscopic biopsy^len
!v014!586-90
!v030!Gastroenteroly
!v031!125
!v064!2003
!v065!20030000
!v118!13
!v514!^l590^f586
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000341
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sGisbert^rND^nJP
!v010!^sBlanco^rND^nM
!v010!^sPajares^rND^nJM
!v014!480-84
!v030!Rev Clin Esp
!v031!200
!v064!2000
!v065!20000000
!v118!14
!v514!^l484^f480
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000342
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sGoodwin^rND^nCS
!v010!^sArmstrong^rND^nJA
!v010!^sMarshall^rND^nBJ
!v012!Campylobacter pyloridis, gastritis and peptic ulceration^len
!v014!353-65
!v030!J Clin Pathol
!v031!39
!v064!1986
!v065!19860000
!v118!15
!v514!^l365^f353
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000343
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v018!Schistosomoses, liver flukes and Helicobacter pylori
!v037!http://monographs.iarc.fr/ENG/Monographs/vol61/index.php
!v061!Avaliable at					<ext-link ext-link-type="uri" ns0:href="http://monographs.iarc.fr/ENG/Monographs/vol61/index.php">http://monographs.iarc.fr/ENG/Monographs/vol61/index.php</ext-link>
!v064!1994
!v065!19940000
!v066!Lyon, France
!v118!16
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000344
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v037!http://www.iarc.fr
!v061![Internet]
!v061!Avaliable at					<ext-link ext-link-type="uri" ns0:href="http://www.iarc.fr">http://www.iarc.fr</ext-link>
!v062!International Agency for Research on Cancer
!v066!Lyon
!v118!17
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000345
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sKhitin^rND^nL
!v010!^sRoses^rND^nRE
!v010!^sBirkett^rND^nDH
!v012!Cancer in the gastric remnant after gastric bypass: a case report^len
!v014!521-23
!v030!Curr Surg
!v031!60
!v064!2003
!v065!20030000
!v118!18
!v514!^l523^f521
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000346
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sLee^rND^nWJ
!v010!^sWang^rND^nW
!v010!^sLin^rND^nCM
!v010!^sChen^rND^nTC
!v010!^sWei^rND^nPL
!v012!Seroprevalence of 							Helicobacter							pylori						in morbidly obese patients^len
!v014!258
!v030!Surg Obes Relat Dis
!v031!1
!v032!3
!v064!2005
!v065!20050000
!v118!19
!v514!^f258
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000347
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sLeung^rND^nWK
!v010!^sLin^rND^nSR
!v010!^sChing^rND^nJY
!v010!^sTo^rND^nKF
!v010!^sNg^rND^nEK
!v010!^sChan^rND^nFK
!v010!^sLau^rND^nJY
!v010!^sSung^rND^nJJ
!v012!Factors predicting progression of gastric intestinal metaplasia: results of a randomized trial on 							Helicobacter							pylori						eradication^len
!v014!1244-249
!v030!Gut
!v031!53
!v064!2004
!v065!20040000
!v118!20
!v514!^l1249^f1244
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000348
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sLord^rND^nRV
!v010!^sEdwards^rND^nPD
!v010!^sColeman^rND^nMJ
!v012!Gastric cancer in the bypassed segment after operation for morbid obesity^len
!v014!580-82
!v030!Aust N Z J Surg
!v031!67
!v064!1997
!v065!19970000
!v118!21
!v514!^l582^f580
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000349
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sLu^rND^nB
!v010!^sChen^rND^nMT
!v010!^sFan^rND^nYH
!v010!^sLiu^rND^nY
!v010!^sMeng^rND^nLN
!v012!Effects of 							Helicobacter							pylori						 eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study^len
!v014!6518-520
!v030!World J Gastroenterol
!v031!11
!v064!2005
!v065!20050000
!v118!22
!v514!^l6520^f6518
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000350
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sMadan^rND^nAK
!v010!^sSpeck^rND^nKE
!v010!^sHiler^rND^nML
!v012!Routine preoperative upper endoscopy for laparoscopic gastric bypass: is it necessary?^len
!v014!684-86
!v030!Am Surg
!v031!70
!v064!2004
!v065!20040000
!v118!23
!v514!^l686^f684
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000351
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sMalfertheiner^rND^nP
!v010!^sSipponen^rND^nP
!v010!^sNaumann^rND^nM
!v010!^sMoayyedi^rND^nP
!v010!^sMegraud^rND^nF
!v010!^sXiao^rND^nSD
!v010!^sSugano^rND^nK
!v010!^sNyren^rND^nO
!v010!^sLejondal^rND^nH
!v012!pylori-Gastric Cancer Task Force. 							Helicobacter							pylori						eradication has the potential to prevent gastric cancer: a state-of-the-art critique^len
!v014!2100-115
!v030!Am J Gastroenterol
!v031!100
!v064!2005
!v065!20050000
!v118!24
!v514!^l2115^f2100
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000352
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sMong^rND^nC
!v010!^sVan Dam^rND^nJ
!v010!^sMorton^rND^nJ
!v010!^sGerson^rND^nL
!v010!^sCuret^rND^nM
!v010!^sBanerjee^rND^nS
!v012!Preoperative endoscopic screening for laparoscopic Roux-en-Y gastric bypass has a low yield for anatomic findings^len
!v014!1067-073
!v030!Obes Surg
!v031!18
!v064!2008
!v065!20080000
!v118!25
!v514!^l1073^f1067
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000353
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sMunoz^rND^nR
!v010!^sIbanez^rND^nL
!v010!^sSalinas^rND^nJ
!v010!^sEscalona^rND^nA
!v010!^sPerez^rND^nG
!v010!^sPimentel^rND^nF
!v010!^sGuzman^rND^nS
!v010!^sBoza^rND^nC
!v012!Importance of routine preoperative upper GI endoscopy: why all patients should be evaluated?^len
!v014!427-31
!v030!Obes Surg
!v031!19
!v064!2009
!v065!20090000
!v118!26
!v514!^l431^f427
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000354
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sNomura^rND^nA
!v010!^sStemmermann^rND^nGN
!v010!^sChyou^rND^nPH
!v010!^sKato^rND^nI
!v010!^sPerez-Perez^rND^nGI
!v010!^sBlaser^rND^nMJ
!v012!Helicobacter							pylori						 infection and gastric carcinoma among Japanese Americans in Hawaii^len
!v014!1132-136
!v030!N Engl J Med
!v031!325
!v064!1991
!v065!19910000
!v118!27
!v514!^l1136^f1132
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000355
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sOhata^rND^nH
!v010!^sKitauchi^rND^nS
!v010!^sYoshimura^rND^nN
!v010!^sMugitani^rND^nK
!v010!^sIwane^rND^nM
!v010!^sNakamura^rND^nH
!v010!^sYoshikawa^rND^nA
!v010!^sYanaoka^rND^nK
!v010!^sArii^rND^nK
!v010!^sTamai^rND^nH
!v010!^sShimizu^rND^nY
!v010!^sTakeshita^rND^nT
!v010!^sMohara^rND^nO
!v010!^sIchinose^rND^nM
!v012!Progression of chronic atrophic gastritis associated with 							Helicobacter							pylori						 infection increases risk of gastric cancer^len
!v014!138-43
!v030!Int J Cancer
!v031!109
!v064!2004
!v065!20040000
!v118!28
!v514!^l143^f138
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000356
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sO'Mahony^rND^nR
!v010!^sErim^rND^nT
!v010!^sSzomstein^rND^nS
!v010!^sRosenthal^rND^nR
!v012!Prevalence of 							Helicobacter							pylori						 infection among patients undergoing bariatric surgery^len
!v014!303
!v030!Surg Obes Relat Dis
!v031!2
!v032!3
!v064!2006
!v065!20060000
!v118!29
!v514!^f303
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000357
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sPapasavas^rND^nPK
!v010!^sGagne^rND^nDJ
!v010!^sDonnelly^rND^nPE
!v010!^sSalgado^rND^nJ
!v010!^sUrbandt^rND^nJE
!v010!^sBurton^rND^nKK
!v010!^sCaushaj^rND^nPF
!v012!Prevalence of 							Helicobacter							pylori						 infection and value of preoperative testing and treatment in patients undergoing laparoscopic Roux-en-Y gastric bypass^len
!v014!383-88
!v030!Surg Obes Relat Dis
!v031!4
!v064!2008
!v065!20080000
!v118!30
!v514!^l388^f383
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000358
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sParsonnet^rND^nJ
!v010!^sFriedman^rND^nGD
!v010!^sVandersteen^rND^nDP
!v010!^sChang^rND^nY
!v010!^sVolgeman^rND^nJH
!v010!^sOrentreich^rND^nN
!v010!^sSibley^rND^nRK
!v012!Helicobacter							pylori						 infection and the risk of gastric carcinoma^len
!v014!1127-131
!v030!N Engl J Med
!v031!325
!v064!1991
!v065!19910000
!v118!31
!v514!^l1131^f1127
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000359
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sRenshaw^rND^nAA
!v010!^sRabaza^rND^nJR
!v010!^sGonzalez^rND^nAM
!v010!^sVerdeja^rND^nJC
!v012!Helicobacter							pylori						 infection in patients undergoing gastric bypass surgery for morbid obesity^len
!v014!281-83
!v030!Obes Surg
!v031!11
!v064!2001
!v065!20010000
!v118!32
!v514!^l283^f281
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000360
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sSafatle-Ribeiro^rND^nAV
!v010!^sKuga^rND^nR
!v010!^sIriya^rND^nK
!v010!^sRibeiro U^rND^nJr
!v010!^sFaintuch^rND^nJ
!v010!^sIshida^rND^nRK
!v010!^sCorbett^rND^nCE
!v010!^sGarrido AB^rND^nJr
!v010!^sIshioka^rND^nS
!v010!^sSakai^rND^nP
!v012!What to expect in the excluded stomach mucosa after vertical banded Roux-en-Y gastric bypass for morbid obesity^len
!v014!133-37
!v030!J Gastrointest Surg
!v031!11
!v064!2007
!v065!20070000
!v118!33
!v514!^l137^f133
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000361
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sSauerland^rND^nS
!v010!^sAngrisani^rND^nL
!v010!^sBelachew^rND^nM
!v010!^sChevallier^rND^nJM
!v010!^sFavretti^rND^nF
!v010!^sFiner^rND^nN
!v010!^sFingerhut^rND^nA
!v010!^sGarcia Caballero^rND^nM
!v010!^sGuisado Macias^rND^nJA
!v010!^sMittermair^rND^nR
!v010!^sMorino^rND^nM
!v010!^sMsika^rND^nS
!v010!^sRubino^rND^nF
!v010!^sTacchino^rND^nR
!v010!^sWeiner^rND^nR
!v010!^sNeugebauer^rND^nEA
!v012!Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES)^len
!v014!200-21
!v030!Surg Endosc
!v031!19
!v064!2005
!v065!20050000
!v118!34
!v514!^l221^f200
!v700!38
!v701!34
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000362
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sSharaf^rND^nRN
!v010!^sWeinshel^rND^nEH
!v010!^sBini^rND^nEJ
!v010!^sRosenberg^rND^nJ
!v010!^sSherman^rND^nA
!v010!^sRen^rND^nCJ
!v012!Endoscopy plays an important preoperative role in bariatric surgery^len
!v014!1367-372
!v030!Obes Surg
!v031!14
!v064!2004
!v065!20040000
!v118!35
!v514!^l1372^f1367
!v700!39
!v701!35
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000363
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sTrincado^rND^nMT
!v010!^sdel Olmo^rND^nJC
!v010!^sGarcia Castano^rND^nJ
!v010!^sCuesta^rND^nC
!v010!^sBlanco^rND^nJI
!v010!^sAwad^rND^nS
!v010!^sCarbajo^rND^nMA
!v012!Gastric pouch carcinoma after gastric bypass for morbid obesity^len
!v014!1215-217
!v030!Obes Surg
!v031!15
!v064!2005
!v065!20050000
!v118!36
!v514!^l1217^f1215
!v700!40
!v701!36
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000364
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sUemura^rND^nN
!v010!^sOkamoto^rND^nS
!v010!^sYamamoto^rND^nS
!v010!^sMatsumura^rND^nN
!v010!^sYamaguchi^rND^nS
!v010!^sYamakido^rND^nM
!v010!^sTaniyama^rND^nK
!v010!^sSasaki^rND^nN
!v010!^sSchlemper^rND^nRJ
!v012!Helicobacter							pylori						infection and the development of gastric cancer^len
!v014!784-89
!v030!N Engl J Med
!v031!345
!v064!2001
!v065!20010000
!v118!37
!v514!^l789^f784
!v700!41
!v701!37
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000365
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sVanek^rND^nVW
!v010!^sCatania^rND^nM
!v010!^sTriveri^rND^nK
!v010!^sWoodruff RW^rND^nJr.
!v012!Retrospective review of the preoperative biliary and gastrointestinal evaluation for gastric bypass surgery^len
!v014!17-22;discussion 22-3
!v030!Surg Obes Relat Dis
!v031!2
!v064!2006
!v065!20060000
!v118!38
!v514!^r17-22;discussion 22-3
!v700!42
!v701!38
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000366
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sVoellinger^rND^nDC
!v010!^sInabnet^rND^nWB
!v012!Laparoscopic Roux-en-Y gastric bypass with remnant gastrectomy for focal intestinal metaplasia of the gastric antrum^len
!v014!695-98
!v030!Obes Surg
!v031!12
!v064!2002
!v065!20020000
!v118!39
!v514!^l698^f695
!v700!43
!v701!39
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000367
!v001!br1.1
!v002!0004-2803-ag-49-01-52.xml
!v004!v49n1
!v010!^sWong^rND^nBC
!v010!^sLam^rND^nSK
!v010!^sWong^rND^nWM
!v010!^sChen^rND^nJS
!v010!^sZheng^rND^nTT
!v010!^sFeng^rND^nRE
!v010!^sLai^rND^nKC
!v010!^sHu^rND^nWH
!v010!^sYuen^rND^nST
!v010!^sLeung^rND^nSY
!v010!^sFong^rND^nDY
!v010!^sHo^rND^nJ
!v010!^sChing^rND^nCK
!v010!^sChen^rND^nJS
!v012!Helicobacter							pylori						eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial^len
!v014!187-94
!v030!JAMA
!v031!291
!v064!2004
!v065!20040000
!v118!40
!v514!^l194^f187
!v700!44
!v701!40
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-52.xml
!v705!S
!v706!c
!v708!40
!v865!20120300
!ID 000368
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v091!20120814
!v092!164314
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v703!116
!v705!S
!v706!o
!v708!1
!ID 000369
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sRodrigues^rauthor^nLino
!v010!^sFaria^rauthor^nCintya Miler de
!v010!^sGeocze^rauthor^nStephan
!v010!^sChehter^rauthor^nLuiz
!v012!^sa prospective, parallel, randomized, open-label, controlled trial^tHelicobacter					pylori eradication does not influence gastroesophageal reflux disease
!v012!^sestudo prospectivo, paralelo, randomizado, aberto e controlado^tErradicacao do Helicobacter						pylori nao influencia a doenca do refluxo gastroesofagico^lpt
!v014!^l63^f56
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Disciplina de Gastroenterologia da Universidade Federal de Sao Paulo (UNIFESP)^cSao Paulo^iaff1^pBrasil^sSP^5?^9Disciplina de Gastroenterologia da Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, SP, Brasil
!v071!oa
!v072!38
!v083!^a<sec>					<title>CONTEXT:</title>																		Helicobacter pylori						has been associated with worsening of gastroesophageal reflux disease (GERD).				</sec>				<sec>					<title>OBJECTIVE:</title>					 To evaluate the effect of 							H. pylori						 eradication in GERD patients. 				</sec>				<sec>					<title>METHODS:</title>					 We conducted a prospective, randomized, controlled trial performing symptom evaluation, endoscopy, histology, manometry and esophageal pH testing on GERD patients. Patients infected with 							H. pylori						 were randomized to: 1) eradication treatment plus proton pump inhibitors treatment, or 2) proton pump inhibitors alone. Patients not infected constituted a negative control group. After 3 months, patients were re-evaluated by symptom assessment, endoscopy, histology and manometry. 				</sec>				<sec>					<title>RESULTS:</title>					 GERD treatment resulted in significantly higher lower esophageal sphincter pressure, as measured by mean expiratory pressure, in 							H. pylori						 negative patients. There was significantly lower proportion of hypotensive waves and significantly higher proportion of normotensive waves in non-eradicated patients. All symptom scores were significantly reduced in the post-treatment period compared to baseline, to values that were similar among the three groups, in the post-treatment period. In the post-treatment period, erosive esophagitis was significantly less frequent on those not eradicated. 				</sec>				<sec>					<title>CONCLUSION:</title>					 Manometric, clinical and endoscopic data showed no benefit in eradicating 							H. pylori						 in GERD. Our data supports the hypothesis that 							H. pylori						 eradication does not influence GERD.				</sec>^len
!v083!^a<sec>                  			<title>CONTEXTO:</title>                			 Existem trabalhos associando a erradicacao do <named-content content-type="scientific-name" ns0:type="simple">                        		Helicobacter pylori                     		 a piora da doenca do refluxo gastroesofagico (DRGE).                  		</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar o efeito da erradicacao do 							H. pylori						 em pacientes com DRGE. 				</sec>				<sec>					<title>MeTODOS:</title>					 Estudo prospectivo, randomizado, controlado em que se avaliaram clinica, endoscopia digestiva alta, histologia, manometria e pHmetria de pacientes com DRGE. Pacientes infectados pelo 							H. pylori						 foram randomizados para: 1) erradicacao da infeccao seguida de tratamento com inibidor de bomba protonica, ou 2) tratamento com inibidor de bomba protonica apenas. Os nao-infectados constituiram grupo-controle negativo. Apos 3 meses, os pacientes foram reavaliados. 				</sec>				<sec>					<title>RESULTADOS:</title>					 A pressao do esfincter inferior do esofago, medida pela pressao expiratoria maxima, foi significativamente maior em pacientes 							H. pylori						 negativos. Houve reducao significativa na proporcao de ondas hipotensivas e aumento significativo na proporcao de ondas normotensivas nos pacientes que permaneceram 							Helicobacter							pylori						 positivos. Todos os escores de sintomas foram reduzidos significativamente em comparacao ao periodo inicial, para valores semelhantes, entre os tres grupos, no pos-tratamento. Esofagite erosiva foi significativamente menos frequente no periodo pos-tratamento no grupo nao-erradicado. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 Os achados manometricos, clinicos e endoscopicos nao mostram beneficio em se erradicar a infeccao em pacientes com DRGE. Este estudo apoia a hipotese de que a erradicacao do 							H. pylori						 nao influencia a DRGE.				</sec>^lpt
!v085!^kHelicobacter infections^len
!v085!^kGastroesophageal reflux^len
!v085!^kInfeccoes por helicobacter^lpt
!v085!^kRefluxo gastroesofagico^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d08
!v112!2011
!v113!^y2011^m09^d01
!v114!2011
!v120!XML_3.0
!v121!56
!v237!10.1590/S0004-28032012000100010
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!h
!v708!1
!ID 000370
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sRodrigues^rauthor^nLino
!v010!^sFaria^rauthor^nCintya Miler de
!v010!^sGeocze^rauthor^nStephan
!v010!^sChehter^rauthor^nLuiz
!v012!^sa prospective, parallel, randomized, open-label, controlled trial^t<italic>Helicobacter</italic>					<italic>pylori</italic> eradication does not influence gastroesophageal reflux disease
!v012!^sestudo prospectivo, paralelo, randomizado, aberto e controlado^tErradica&#231;&#227;o do <italic>Helicobacter</italic>						<italic>pylori</italic> n&#227;o influencia a doen&#231;a do refluxo gastroesof&#225;gico^lpt
!v014!^l63^f56
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Disciplina de Gastroenterologia da Universidade Federal de São Paulo (UNIFESP)^cSão Paulo^iaff1^pBrasil^sSP^5?^9Disciplina de Gastroenterologia da Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brasil
!v071!oa
!v072!38
!v083!^a<sec>					<title>CONTEXT:</title>					<p>						<named-content content-type="scientific-name">							<italic>Helicobacter pylori</italic>						</named-content>has been associated with worsening of gastroesophageal reflux disease (GERD).</p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To evaluate the effect of <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> eradication in GERD patients. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> We conducted a prospective, randomized, controlled trial performing symptom evaluation, endoscopy, histology, manometry and esophageal pH testing on GERD patients. Patients infected with <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> were randomized to: 1) eradication treatment plus proton pump inhibitors treatment, or 2) proton pump inhibitors alone. Patients not infected constituted a negative control group. After 3 months, patients were re-evaluated by symptom assessment, endoscopy, histology and manometry. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> GERD treatment resulted in significantly higher lower esophageal sphincter pressure, as measured by mean expiratory pressure, in <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> negative patients. There was significantly lower proportion of hypotensive waves and significantly higher proportion of normotensive waves in non-eradicated patients. All symptom scores were significantly reduced in the post-treatment period compared to baseline, to values that were similar among the three groups, in the post-treatment period. In the post-treatment period, erosive esophagitis was significantly less frequent on those not eradicated. </p>				</sec>				<sec>					<title>CONCLUSION:</title>					<p> Manometric, clinical and endoscopic data showed no benefit in eradicating <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> in GERD. Our data supports the hypothesis that <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> eradication does not influence GERD.</p>				</sec>^len
!v083!^a<sec>                  			<title>CONTEXTO:</title>                			<p> Existem trabalhos associando a erradica&#231;&#227;o do <named-content content-type="scientific-name" ns0:type="simple">                        		<italic>Helicobacter pylori</italic>                     		</named-content> &#224; piora da doen&#231;a do refluxo gastroesof&#225;gico (DRGE). </p>                 		</sec>				<sec>					<title>OBJETIVO:</title>					<p> Avaliar o efeito da erradica&#231;&#227;o do <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> em pacientes com DRGE. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Estudo prospectivo, randomizado, controlado em que se avaliaram cl&#237;nica, endoscopia digestiva alta, histologia, manometria e pHmetria de pacientes com DRGE. Pacientes infectados pelo <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> foram randomizados para: 1) erradica&#231;&#227;o da infec&#231;&#227;o seguida de tratamento com inibidor de bomba prot&#244;nica, ou 2) tratamento com inibidor de bomba prot&#244;nica apenas. Os n&#227;o-infectados constitu&#237;ram grupo-controle negativo. Ap&#243;s 3 meses, os pacientes foram reavaliados. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> A press&#227;o do esf&#237;ncter inferior do es&#244;fago, medida pela press&#227;o expirat&#243;ria m&#225;xima, foi significativamente maior em pacientes <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> negativos. Houve redu&#231;&#227;o significativa na propor&#231;&#227;o de ondas hipotensivas e aumento significativo na propor&#231;&#227;o de ondas normotensivas nos pacientes que permaneceram <named-content content-type="scientific-name">							<italic>Helicobacter</italic>							<italic>pylori</italic>						</named-content> positivos. Todos os escores de sintomas foram reduzidos significativamente em compara&#231;&#227;o ao per&#237;odo inicial, para valores semelhantes, entre os tr&#234;s grupos, no p&#243;s-tratamento. Esofagite erosiva foi significativamente menos frequente no per&#237;odo p&#243;s-tratamento no grupo n&#227;o-erradicado. </p>				</sec>				<sec>					<title>CONCLUS&#195;O:</title>					<p> Os achados manom&#233;tricos, cl&#237;nicos e endosc&#243;picos n&#227;o mostram benef&#237;cio em se erradicar a infec&#231;&#227;o em pacientes com DRGE. Este estudo apoia a hip&#243;tese de que a erradica&#231;&#227;o do <named-content content-type="scientific-name">							<italic>H</italic>. <italic>pylori</italic>						</named-content> n&#227;o influencia a DRGE.</p>				</sec>^lpt
!v085!^kHelicobacter infections^len
!v085!^kGastroesophageal reflux^len
!v085!^kInfecções por helicobacter^lpt
!v085!^kRefluxo gastroesofágico^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d08
!v112!2011
!v113!^y2011^m09^d01
!v114!2011
!v120!XML_3.0
!v121!56
!v237!10.1590/S0004-28032012000100010
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!f
!v708!1
!ID 000371
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sRodrigues^rauthor^nLino
!v010!^sFaria^rauthor^nCintya Miler de
!v010!^sGeocze^rauthor^nStephan
!v010!^sChehter^rauthor^nLuiz
!v012!^sa prospective, parallel, randomized, open-label, controlled trial^tHelicobacter					pylori eradication does not influence gastroesophageal reflux disease
!v012!^sestudo prospectivo, paralelo, randomizado, aberto e controlado^tErradicacao do Helicobacter						pylori nao influencia a doenca do refluxo gastroesofagico^lpt
!v014!^l63^f56
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Disciplina de Gastroenterologia da Universidade Federal de Sao Paulo (UNIFESP)^cSao Paulo^iaff1^pBrasil^sSP^5?^9Disciplina de Gastroenterologia da Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, SP, Brasil
!v071!oa
!v072!38
!v083!^a<sec>					<title>CONTEXT:</title>																		Helicobacter pylori						has been associated with worsening of gastroesophageal reflux disease (GERD).				</sec>				<sec>					<title>OBJECTIVE:</title>					 To evaluate the effect of 							H. pylori						 eradication in GERD patients. 				</sec>				<sec>					<title>METHODS:</title>					 We conducted a prospective, randomized, controlled trial performing symptom evaluation, endoscopy, histology, manometry and esophageal pH testing on GERD patients. Patients infected with 							H. pylori						 were randomized to: 1) eradication treatment plus proton pump inhibitors treatment, or 2) proton pump inhibitors alone. Patients not infected constituted a negative control group. After 3 months, patients were re-evaluated by symptom assessment, endoscopy, histology and manometry. 				</sec>				<sec>					<title>RESULTS:</title>					 GERD treatment resulted in significantly higher lower esophageal sphincter pressure, as measured by mean expiratory pressure, in 							H. pylori						 negative patients. There was significantly lower proportion of hypotensive waves and significantly higher proportion of normotensive waves in non-eradicated patients. All symptom scores were significantly reduced in the post-treatment period compared to baseline, to values that were similar among the three groups, in the post-treatment period. In the post-treatment period, erosive esophagitis was significantly less frequent on those not eradicated. 				</sec>				<sec>					<title>CONCLUSION:</title>					 Manometric, clinical and endoscopic data showed no benefit in eradicating 							H. pylori						 in GERD. Our data supports the hypothesis that 							H. pylori						 eradication does not influence GERD.				</sec>^len
!v083!^a<sec>                  			<title>CONTEXTO:</title>                			 Existem trabalhos associando a erradicacao do <named-content content-type="scientific-name" ns0:type="simple">                        		Helicobacter pylori                     		 a piora da doenca do refluxo gastroesofagico (DRGE).                  		</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar o efeito da erradicacao do 							H. pylori						 em pacientes com DRGE. 				</sec>				<sec>					<title>MeTODOS:</title>					 Estudo prospectivo, randomizado, controlado em que se avaliaram clinica, endoscopia digestiva alta, histologia, manometria e pHmetria de pacientes com DRGE. Pacientes infectados pelo 							H. pylori						 foram randomizados para: 1) erradicacao da infeccao seguida de tratamento com inibidor de bomba protonica, ou 2) tratamento com inibidor de bomba protonica apenas. Os nao-infectados constituiram grupo-controle negativo. Apos 3 meses, os pacientes foram reavaliados. 				</sec>				<sec>					<title>RESULTADOS:</title>					 A pressao do esfincter inferior do esofago, medida pela pressao expiratoria maxima, foi significativamente maior em pacientes 							H. pylori						 negativos. Houve reducao significativa na proporcao de ondas hipotensivas e aumento significativo na proporcao de ondas normotensivas nos pacientes que permaneceram 							Helicobacter							pylori						 positivos. Todos os escores de sintomas foram reduzidos significativamente em comparacao ao periodo inicial, para valores semelhantes, entre os tres grupos, no pos-tratamento. Esofagite erosiva foi significativamente menos frequente no periodo pos-tratamento no grupo nao-erradicado. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 Os achados manometricos, clinicos e endoscopicos nao mostram beneficio em se erradicar a infeccao em pacientes com DRGE. Este estudo apoia a hipotese de que a erradicacao do 							H. pylori						 nao influencia a DRGE.				</sec>^lpt
!v085!^kHelicobacter infections^len
!v085!^kGastroesophageal reflux^len
!v085!^kInfeccoes por helicobacter^lpt
!v085!^kRefluxo gastroesofagico^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m04^d08
!v112!2011
!v113!^y2011^m09^d01
!v114!2011
!v120!XML_3.0
!v121!56
!v237!10.1590/S0004-28032012000100010
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!l
!v708!1
!ID 000372
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sAllescher^rND^nHD
!v010!^sStoschus^rND^nB
!v010!^sWunsch^rND^nE
!v010!^sSchusdziarra^rND^nV
!v010!^sClassen^rND^nM
!v012!Effect of human gastrin-17 with and without acid suppression on human esophageal motility^len
!v014!385-91
!v030!Z Gastroenterol
!v031!33
!v064!1995
!v065!19950000
!v071!journal
!v118!1
!v514!^l391^f385
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000373
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sBortolotti^rND^nM
!v010!^sPandolfo^rND^nN
!v010!^sLa Rovere^rND^nG
!v010!^sGiovannini^rND^nM
!v010!^sMiglioli^rND^nM
!v012!Effect of clarithromycin on esophageal motility^len
!v014!231-33
!v030!Dis Esophagus
!v031!13
!v064!2000
!v065!20000000
!v118!2
!v514!^l233^f231
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000374
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sBuckley^rND^nM
!v010!^sCulhane^rND^nA
!v010!^sDrumm^rND^nB
!v010!^sKeane^rND^nC
!v010!^sMoran^rND^nAP
!v010!^sO'Connor^rND^nHJ
!v010!^sCollins^rND^nJ
!v010!^sKelleher^rND^nD
!v010!^sMcAvinchey^rND^nD
!v010!^sSloan^rND^nJ
!v010!^sO'Morain^rND^nC
!v012!Guidelines for the management of 							Helicobacter							pylori						-related upper gastrointestinal diseases. Irish 							Helicobacter							Pylori						 Study Group^len
!v014!1-11
!v030!Ir J Med Sci
!v031!165
!v064!1996
!v065!19960000
!v118!3
!v514!^l11^f1
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000375
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sCargill^rND^nG
!v010!^sGiuli^rND^nR
!v012!^tHow can the contribution of intra-abdominal pressure, crural diaphragm, and smooth muscle sphincter be distinguished in LESP and in LES movements?
!v014!19-23
!v018!The esophagogastric junction
!v062!John Libbey Eurotext
!v064!1998
!v065!19980000
!v066!Paris
!v118!4
!v514!^l23^f19
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000376
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sChow^rND^nWH
!v010!^sBlaser^rND^nMJ
!v010!^sBlot^rND^nWJ
!v010!^sGammon^rND^nMD
!v010!^sVaughan^rND^nTL
!v010!^sRisch^rND^nHA
!v010!^sPerez-Perez^rND^nGI
!v010!^sSchoenberg^rND^nJB
!v010!^sStanford^rND^nJL
!v010!^sRotterdam^rND^nH
!v010!^sWest^rND^nAB
!v010!^sFraumeni^rND^nJF Jr
!v012!An inverse relation between cagA+ strains of 							Helicobacter							pylori						infection and risk of esophageal and gastric cardia adenocarcinoma^len
!v014!588-90
!v030!Cancer Res
!v031!58
!v064!1998
!v065!19980000
!v118!5
!v514!^l590^f588
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000377
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sDalton^rND^nCB
!v010!^sCastell^rND^nDO
!v010!^sCastell^rND^nDO
!v010!^sCastell^rND^nJA
!v012!^tMeasurements and interpretations
!v014!61-80
!v018!Esophageal motility testing
!v062!Appleton & Lange
!v064!1994
!v065!19940000
!v066!Norwalk, Connecticut
!v118!6
!v514!^l80^f61
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000378
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sDemeester^rND^nTR
!v010!^sJohnson^rND^nLF
!v010!^sJoseph^rND^nGJ
!v010!^sToscano^rND^nMS
!v010!^sHall^rND^nAW
!v010!^sSkinner^rND^nDB
!v012!Patterns of gastroesophageal reflux in health and disease^len
!v014!459-70
!v030!Ann Surg
!v031!184
!v064!1976
!v065!19760000
!v118!7
!v514!^l470^f459
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000379
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sDent^rND^nJ
!v012!Gastro-oesophageal reflux disease^len
!v014!433-45
!v030!Digestion
!v031!59
!v064!1998
!v065!19980000
!v118!8
!v514!^l445^f433
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000380
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sDixon^rND^nMF
!v010!^sGenta^rND^nRM
!v010!^sYardley^rND^nJH
!v010!^sCorrea^rND^nP
!v012!Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994^len
!v014!1161-181
!v030!Am J Surg Pathol
!v031!20
!v064!1996
!v065!19960000
!v118!9
!v514!^l1181^f1161
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000381
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sGenta^rND^nRM
!v010!^sHuberman^rND^nRM
!v010!^sGraham^rND^nDY
!v012!The gastric cardia in 							Helicobacter							pylori						infection^len
!v014!915-19
!v030!Hum Pathol
!v031!25
!v064!1994
!v065!19940000
!v118!10
!v514!^l919^f915
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000382
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sGisbert^rND^nJP
!v010!^sPajares^rND^nJM
!v010!^sLosa^rND^nC
!v012!Helicobacter							pylori						and gastroesophageal reflux disease: friends or foes?^len
!v014!1023-029
!v030!Hepatogastroenterology
!v031!46
!v064!1999
!v065!19990000
!v118!11
!v514!^l1029^f1023
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000383
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sHackelsberger^rND^nA
!v010!^sSchultze^rND^nV
!v010!^sGunther^rND^nT
!v012!H							pylori						prevalence in reflux esophagitis - a case-control study [abstract]^len
!v014!A137
!v030!Gastroenterology
!v031!112
!v064!1997
!v065!19970000
!v118!12
!v514!^fA137
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000384
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sIwakiri^rND^nK
!v010!^sKawami^rND^nN
!v010!^sSano^rND^nH
!v010!^sTanaka^rND^nY
!v010!^sUmezawa^rND^nM
!v010!^sKotoyori^rND^nM
!v010!^sHoshihara^rND^nY
!v010!^sSakamoto^rND^nC
!v012!Mechanisms of excessive esophageal acid exposure in patients with reflux esophagitis^len
!v014!1686-692
!v030!Dig Dis Sci
!v031!54
!v064!2009
!v065!20090000
!v118!13
!v514!^l1692^f1686
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000385
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sKuipers^rND^nEJ
!v010!^sUyterlinde^rND^nAM
!v010!^sPena^rND^nAS
!v010!^sHazenberg^rND^nHJ
!v010!^sBloemena^rND^nE
!v010!^sLindeman^rND^nJ
!v010!^sKlinkenberg-Knol^rND^nEC
!v010!^sMeuwissen^rND^nSG
!v012!Increase of 							Helicobacter							pylori						-associated corpus gastritis during acid suppressive therapy: implications for long-term safety^len
!v014!1401-406
!v030!Am J Gastroenterol
!v031!90
!v064!1995
!v065!19950000
!v118!14
!v514!^l1406^f1401
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000386
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sLabenz^rND^nJ
!v010!^sTillenburg^rND^nB
!v010!^sPeitz^rND^nU
!v010!^sIdstrom^rND^nJP
!v010!^sVerdu^rND^nEF
!v010!^sStolte^rND^nM
!v010!^sBorsch^rND^nG
!v010!^sBlum^rND^nAL
!v012!Helicobacter							pylori						 augments the pH-increasing effect of omeprazole in patients with duodenal ulcer^len
!v014!725-32
!v030!Gastroenterology
!v031!110
!v064!1996
!v065!19960000
!v118!15
!v514!^l732^f725
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000387
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sLabenz^rND^nJ
!v010!^sBlum^rND^nAL
!v010!^sBayerdorffer^rND^nE
!v010!^sMeining^rND^nA
!v010!^sStolte^rND^nM
!v010!^sBorsch^rND^nG
!v012!Curing 							Helicobacter							pylori						infection in patients with duodenal ulcer may provoke reflux esophagitis^len
!v014!1442-447
!v030!Gastroenterology
!v031!112
!v064!1997
!v065!19970000
!v118!16
!v514!^l1447^f1442
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000388
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sLabenz^rND^nJ
!v010!^sMalfertheiner^rND^nP
!v012!Helicobacter							pylori						in gastro-oesophageal reflux disease: causal agent, independent or protective factor?^len
!v014!277-80
!v030!Gut
!v031!41
!v064!1997
!v065!19970000
!v118!17
!v514!^l280^f277
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000389
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sLaine^rND^nL
!v010!^sSugg^rND^nJ
!v012!Effect of 							Helicobacter							pylori						 eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies^len
!v014!2992-997
!v030!Am J Gastroenterol
!v031!97
!v064!2002
!v065!20020000
!v118!18
!v514!^l2997^f2992
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000390
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sMalfertheiner^rND^nP
!v010!^sMegraud^rND^nF
!v010!^sO'Morain^rND^nC
!v010!^sBell^rND^nD
!v010!^sBianchi Porro^rND^nG
!v010!^sDeltenre^rND^nM
!v010!^sForman^rND^nD
!v010!^sGasbarrini^rND^nG
!v010!^sJaup^rND^nB
!v010!^sMisiewicz^rND^nJJ
!v010!^sPajares^rND^nJ
!v010!^sQuina^rND^nM
!v010!^sRauws^rND^nE
!v012!Current European concepts in the management of 							Helicobacter							pylori						 infection-the Maastricht Consensus Report. The European 							Helicobacter							Pylori						Study Group (EHPSG)^len
!v014!1-2
!v030!Eur J Gastroenterol Hepatol
!v031!9
!v064!1997
!v065!19970000
!v118!19
!v514!^l2^f1
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000391
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sManes^rND^nG
!v010!^sEsposito^rND^nP
!v010!^sLioniello^rND^nM
!v010!^sBove^rND^nA
!v010!^sMosca^rND^nS
!v010!^sBalzano^rND^nA
!v012!Manometric and pH-metric features in gastro-oesophageal reflux disease patients with and without 							Helicobacter							pylori						 infection^len
!v014!372-77
!v030!Dig Liver Dis
!v031!32
!v064!2000
!v065!20000000
!v118!20
!v514!^l377^f372
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000392
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sMarshall^rND^nBJ
!v010!^sWarren^rND^nJR
!v012!Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration^len
!v014!1311-315
!v030!Lancet
!v031!1
!v064!1984
!v065!19840000
!v118!21
!v514!^l1315^f1311
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000393
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sMcCallum^rND^nRW
!v010!^sWalsh^rND^nJH
!v012!Relationship between lower esophageal sphincter pressure and serum gastrin concentration in Zollinger-Ellison syndrome and other clinical settings^len
!v014!76-81
!v030!Gastroenterology
!v031!76
!v064!1979
!v065!19790000
!v118!22
!v514!^l81^f76
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000394
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sMcNamara^rND^nD
!v010!^sO'Morain^rND^nC
!v012!Gastro-oesophageal reflux disease and 							Helicobacter							pylori						: an intricate relation^len
!v014!I13-I17
!v030!Gut
!v031!45
!v064!1999
!v065!19990000
!v118!23
!v514!^lI17^fI13
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000395
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sMittal^rND^nRK
!v010!^sRochester^rND^nDF
!v010!^sMcCallum^rND^nRW
!v012!Sphincteric action of the diaphragm during a relaxed lower esophageal sphincter in humans^len
!v014!G139-G144
!v030!Am J Physiol
!v031!256
!v032!1
!v064!1989
!v065!19890000
!v118!24
!v514!^lG144^fG139
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000396
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sMoayyedi^rND^nP
!v010!^sBardhan^rND^nC
!v010!^sYoung^rND^nL
!v010!^sDixon^rND^nMF
!v010!^sBrown^rND^nL
!v010!^sAxon^rND^nAT
!v012!Helicobacter							pylori						 eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease^len
!v014!1120-126
!v030!Gastroenterology
!v031!121
!v064!2001
!v065!20010000
!v118!25
!v514!^l1126^f1120
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000397
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sNewton^rND^nM
!v010!^sBryan^rND^nR
!v010!^sBurnham^rND^nWR
!v010!^sKamm^rND^nMA
!v012!Evaluation of 							Helicobacter							pylori						 in reflux oesophagitis and Barrett's oesophagus^len
!v014!9-13
!v030!Gut
!v031!40
!v064!1997
!v065!19970000
!v118!26
!v514!^l13^f9
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000398
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v012!Helicobacter							pylori						 in peptic ulcer disease. NIH Consensus Development Panel on 							Helicobacter							pylori						 in Peptic Ulcer Disease^len
!v014!65-9
!v030!JAMA
!v031!272
!v064!1994
!v065!19940000
!v118!27
!v514!^l69^f65
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000399
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sO'Connor^rND^nHJ
!v010!^sCunnane^rND^nK
!v012!Helicobacter							pylori						 and gastro-oesophageal reflux disease - a prospective study^len
!v014!369-73
!v030!Ir J Med Sci
!v031!163
!v064!1994
!v065!19940000
!v118!28
!v514!^l373^f369
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000400
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sSainz^rND^nR
!v010!^sBorda^rND^nF
!v010!^sDominguez^rND^nE
!v010!^sGisbert^rND^nJP
!v014!777-84
!v030!Rev Esp Enferm Dig
!v031!91
!v064!1999
!v065!19990000
!v118!29
!v514!^l784^f777
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000401
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sSarnelli^rND^nG
!v010!^sIerardi^rND^nE
!v010!^sGrasso^rND^nR
!v010!^sVerde^rND^nC
!v010!^sBottiglieri^rND^nME
!v010!^sNardone^rND^nG
!v010!^sBudillon^rND^nG
!v010!^sCuomo^rND^nR
!v012!Acid exposure and altered acid clearance in GERD patients treated for 							Helicobacter							pylori						 infection^len
!v014!151-56
!v030!Dig Liver Dis
!v031!35
!v064!2003
!v065!20030000
!v118!30
!v514!^l156^f151
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000402
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sSchenk^rND^nBE
!v010!^sKuipers^rND^nEJ
!v010!^sKlinkenberg-Knol^rND^nEC
!v010!^sEskes^rND^nSA
!v010!^sMeuwissen^rND^nSGM
!v012!H							pylori						, GERD and the efficacy of omeprazole therapy [abstract]^len
!v014!A282
!v030!Gastroenterology
!v031!112
!v064!1997
!v065!19970000
!v118!31
!v514!^fA282
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000403
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sSekiguchi^rND^nT
!v010!^sShirota^rND^nT
!v010!^sHorikoshi^rND^nT
!v012!Helicobacter							pylori						infection and severity of reflux [abstract]^len
!v014!A755
!v030!Gastroenterology
!v031!110
!v064!1996
!v065!19960000
!v118!32
!v514!^fA755
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000404
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sSimpson^rND^nRJ
!v010!^sGraham^rND^nSM
!v010!^sFlorida-James^rND^nGD
!v010!^sConnaboy^rND^nC
!v010!^sClement^rND^nR
!v010!^sJackson^rND^nAS
!v012!Perceived exertion and heart rate models for estimating metabolic workload in elite British soldiers performing a backpack load-carriage task^len
!v014!650-56
!v030!Appl Physiol Nutr Metab
!v031!35
!v064!2010
!v065!20100000
!v118!33
!v514!^l656^f650
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000405
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sTee^rND^nW
!v010!^sLambert^rND^nJR
!v010!^sDwyer^rND^nB
!v012!Cytotoxin production by 							Helicobacter							pylori						from patients with upper gastrointestinal tract diseases^len
!v014!1203-205
!v030!J Clin Microbiol
!v031!33
!v064!1995
!v065!19950000
!v118!34
!v514!^l1205^f1203
!v700!38
!v701!34
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000406
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sVakily^rND^nM
!v010!^sWu^rND^nJ
!v010!^sAtkinson^rND^nSN
!v012!Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants^len
!v014!1447-455
!v030!J Clin Pharmacol
!v031!49
!v064!2009
!v065!20090000
!v118!35
!v514!^l1455^f1447
!v700!39
!v701!35
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000407
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sVicari^rND^nJJ
!v010!^sPeek^rND^nRM
!v010!^sFalk^rND^nGW
!v010!^sGoldblum^rND^nJR
!v010!^sEasley^rND^nKA
!v010!^sSchnell^rND^nJ
!v010!^sPerez-Perez^rND^nGI
!v010!^sHalter^rND^nSA
!v010!^sRice^rND^nTW
!v010!^sBlaser^rND^nMJ
!v010!^sRichter^rND^nJE
!v012!The seroprevalence of cagA-positive 							Helicobacter							pylori						 strains in the spectrum of gastroesophageal reflux disease^len
!v014!50-7
!v030!Gastroenterology
!v031!115
!v064!1998
!v065!19980000
!v118!36
!v514!^l57^f50
!v700!40
!v701!36
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000408
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sWu^rND^nJC
!v010!^sSung^rND^nJJ
!v010!^sNg^rND^nEK
!v010!^sGo^rND^nMY
!v010!^sChan^rND^nWB
!v010!^sChan^rND^nFK
!v010!^sLeung^rND^nWK
!v010!^sChoi^rND^nCL
!v010!^sChung^rND^nSC
!v012!Prevalence and distribution of 							Helicobacter							pylori						 in gastroesophageal reflux disease: a study from the East^len
!v014!1790-794
!v030!Am J Gastroenterol
!v031!94
!v064!1999
!v065!19990000
!v118!37
!v514!^l1794^f1790
!v700!41
!v701!37
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000409
!v001!br1.1
!v002!0004-2803-ag-49-01-56.xml
!v004!v49n1
!v010!^sZhang^rND^nW
!v010!^sWu^rND^nJ
!v010!^sAtkinson^rND^nSN
!v012!Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects^len
!v014!444-54
!v030!J Clin Pharmacol
!v031!49
!v064!2009
!v065!20090000
!v118!38
!v514!^l454^f444
!v700!42
!v701!38
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-56.xml
!v705!S
!v706!c
!v708!38
!v865!20120300
!ID 000410
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v091!20120814
!v092!164318
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v703!99
!v705!S
!v706!o
!v708!1
!ID 000411
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sHelman^rauthor^nLaura
!v010!^sBiccas^rauthor^nBeatriz Nunes
!v010!^sLemme^rauthor^nEponina M. O.
!v010!^sNovais^rauthor^nPaula
!v010!^sFittipaldi^rauthor^nViviane
!v012!^tEsophageal manometry findings and degree of acid exposure in short and long Barrett's esophagus
!v012!^tAlteracoes manometricas e intensidade do refluxo no esofago de Barrett curto e longo^lpt
!v014!^l68^f64
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal do Rio de Janeiro^cRJ^iaff1^1Unidade de Esofago, Servico de Gastroenterologia, Hospital Universitario Clementino Fraga Filho^pBrasil^9Unidade de Esofago, Servico de Gastroenterologia, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, RJ, Brasil
!v071!oa
!v072!21
!v083!^a<sec>					<title>CONTEXT:</title>					 Barrett's esophagus (BE) is characterized by intestinal metaplasia in the distal esophagus and is classified as short-segment (&lt;3 cm - SSBE) or long-segment (&gt;3 cm - LSSBE). It is suggested that LSSBE is associated with more severe esophageal motor abnormalities and increased acid exposure time than SSBE. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To evaluate the prevalence of esophageal manometriy abnormalities and acid exposure times in patients with SSBE and LSSBE. 				</sec>				<sec>					<title>METHODS:</title>					 Barrett's esophagus patients identified by upper endoscopy and confirmed by histopathology were, retrospectively, reviewed and divided into two groups: SSBE and LSBE. Demographic data, symptom duration, prevalence of hiatal hernia, lower esophagus sphincter basal pressure, prevalence of esophageal body abnormalities and acid exposure times were evaluated. 				</sec>				<sec>					<title>RESULTS:</title>					 Forty-six patients with SSBE (24 males - 52.2%, mean age of 55.2 years) and 28 patients with LSBE (18 males - 64.3%, mean age of 50.5 years). Mean symptom duration was 9.9 years for SSBE and 12.9 years for LSSBE. Hiatal hernia was present in 84.2% of SSBE, 96.3% of LSBE; average lower esophagus sphincter pressure in SSBE 9.15 mm Hg, in LSBE 6.99 mm Hg; lower esophagus sphincter hypotension in SSBE was 65.9%, in LSSBE 82.1%; aperistalsis in SSBE 6.5%, LSSBE 3.6%; mild/moderate ineffective esophageal motility in SSBE 34.8%, LSBE 46.4%; severe moderate ineffective esophageal motility in SSBE 10.9%, LSBE 7,1%; nutcracker esophagus/segmental nutcracker esophagus in SSBE 8.6%, LSBE 0%; normal body in SSBE 39.1%, in LSBE 42.9%, no statistical difference for any of these values (P&lt;0.05). Average % total time pH&lt;4 in SSBE 9.12, LSBE 17.27 (P&lt;0.000); % time pH&lt;4 upright in SSBE 11.91; LSBE 24.29 (P=0.003); % time pH&lt;4 supine in SSBE 10.86, LSBE 33.26 (P = 0.000). 				</sec>				<sec>					<title>CONCLUSION:</title>					 There was no difference between the prevalence of motor disorders in patients with SSBE and LSSBE. Acid reflux in upright and supine positions was more intense in LSBE.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 O esofago de Barrett (EB) se caracteriza pela presenca de metaplasia intestinal no esofago distal, quando menor que 3 cm e chamado Barrett curto (EBC) e com 3 cm ou mais Barrett longo (EBL). Sugere-se que o EBL cursa com mais alteracoes motoras esofagianas e com refluxo mais intenso que o EBC. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar a prevalencia de alteracoes manometricas e a intensidade do refluxo gastroesofagico a pHmetria em pacientes com EBC e EBL. 				</sec>				<sec>					<title>MeTODOS:</title>					 Estudo retrospectivo de pacientes com endoscopia digestiva alta e comprovacao histopatologica de EB, divididos em dois grupos: EBC e EBL. Foram avaliados os dados demograficos, o tempo de doenca, prevalencia de hernia hiatal, dados obtidos a esofagomanometria e pHmetria. 				</sec>				<sec>					<title>RESULTADOS:</title>					 EBC 46 pacientes (24 masculino 52,2% e media de idade de 55,22 anos), EBL 28 pacientes (18 masculino 64,3% e media de idade 50,5 anos); tempo de sintomas: EBC 9,88 anos e EBL 12,94 anos; hernia de hiato: EBC 84,2%, EBL 96,3%; pressao media do esfincter inferior do esofago: EBC 9,15 mm Hg, EBL 6,99 mm Hg; hipotensao do esfincter inferior do esofago: EBC 65,9%, EBL 82,1%; motilidade esofagiana ineficaz (MEI) leve/moderado: EBC 34,8%, EBL 46,4%; MEI acentuado: EBC 5 10,9%, EBL 7,1%; aperistalse: 6,5%, EBL 3,6%; esofago em quebra-nozes: EBC 8,6%, EBL 0%; corpo normal: EBC 39,1%, EBL 42,9%, sem diferenca estatistica para qualquer desses valores (P&lt;0,05). Medias de pHmetria: % de tempo total com pH &lt;4: EBC (29/46) 9,12% EBL (15/28) 27,27% P&lt;0,000; % de tempo ereto com pH&lt;4: EBC 11,91%, EBL 24,29% P = 0,003; % de tempo supino com pH &lt;4: EBC 10,86% EBL 33,26% P = 0,000. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 Nao houve diferenca entre a prevalencia das alteracoes motoras em pacientes com EBC e EBL. O refluxo acido, tanto em posicao ereta como em posicao supina, foi mais intenso no EBL.				</sec>^lpt
!v085!^kBarrett esophagus^len
!v085!^kGastroesophageal reflux^len
!v085!^kManometry^len
!v085!^kEsophageal motility disorders^len
!v085!^kEsofago de Barrett^lpt
!v085!^kRefluxo gastroesofagico^lpt
!v085!^kManometria^lpt
!v085!^kTranstornos da motilidade esofagica^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m08^d23
!v112!2011
!v113!^y2011^m09^d27
!v114!2011
!v120!XML_3.0
!v121!64
!v237!10.1590/S0004-28032012000100011
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!h
!v708!1
!ID 000412
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sHelman^rauthor^nLaura
!v010!^sBiccas^rauthor^nBeatriz Nunes
!v010!^sLemme^rauthor^nEponina M. O.
!v010!^sNovais^rauthor^nPaula
!v010!^sFittipaldi^rauthor^nViviane
!v012!^tEsophageal manometry findings and degree of acid exposure in short and long Barrett's esophagus
!v012!^tAlterações manométricas e intensidade do refluxo no esôfago de Barrett curto e longo^lpt
!v014!^l68^f64
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal do Rio de Janeiro^cRJ^iaff1^1Unidade de Esôfago, Serviço de Gastroenterologia, Hospital Universitário Clementino Fraga Filho^pBrasil^9Unidade de Esôfago, Serviço de Gastroenterologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, RJ, Brasil
!v071!oa
!v072!21
!v083!^a<sec>					<title>CONTEXT:</title>					<p> Barrett's esophagus (BE) is characterized by intestinal metaplasia in the distal esophagus and is classified as short-segment (&lt;3 cm - SSBE) or long-segment (&gt;3 cm - LSSBE). It is suggested that LSSBE is associated with more severe esophageal motor abnormalities and increased acid exposure time than SSBE. </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To evaluate the prevalence of esophageal manometriy abnormalities and acid exposure times in patients with SSBE and LSSBE. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> Barrett's esophagus patients identified by upper endoscopy and confirmed by histopathology were, retrospectively, reviewed and divided into two groups: SSBE and LSBE. Demographic data, symptom duration, prevalence of hiatal hernia, lower esophagus sphincter basal pressure, prevalence of esophageal body abnormalities and acid exposure times were evaluated. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> Forty-six patients with SSBE (24 males - 52.2%, mean age of 55.2 years) and 28 patients with LSBE (18 males - 64.3%, mean age of 50.5 years). Mean symptom duration was 9.9 years for SSBE and 12.9 years for LSSBE. Hiatal hernia was present in 84.2% of SSBE, 96.3% of LSBE; average lower esophagus sphincter pressure in SSBE 9.15 mm Hg, in LSBE 6.99 mm Hg; lower esophagus sphincter hypotension in SSBE was 65.9%, in LSSBE 82.1%; aperistalsis in SSBE 6.5%, LSSBE 3.6%; mild/moderate ineffective esophageal motility in SSBE 34.8%, LSBE 46.4%; severe moderate ineffective esophageal motility in SSBE 10.9%, LSBE 7,1%; nutcracker esophagus/segmental nutcracker esophagus in SSBE 8.6%, LSBE 0%; normal body in SSBE 39.1%, in LSBE 42.9%, no statistical difference for any of these values (<italic>P</italic>&lt;0.05). Average % total time pH&lt;4 in SSBE 9.12, LSBE 17.27 (<italic>P</italic>&lt;0.000); % time pH&lt;4 upright in SSBE 11.91; LSBE 24.29 (<italic>P</italic>=0.003); % time pH&lt;4 supine in SSBE 10.86, LSBE 33.26 (<italic>P</italic> = 0.000). </p>				</sec>				<sec>					<title>CONCLUSION:</title>					<p> There was no difference between the prevalence of motor disorders in patients with SSBE and LSSBE. Acid reflux in upright and supine positions was more intense in LSBE.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> O es&#244;fago de Barrett (EB) se caracteriza pela presen&#231;a de metaplasia intestinal no es&#244;fago distal, quando menor que 3 cm &#233; chamado Barrett curto (EBC) e com 3 cm ou mais Barrett longo (EBL). Sugere-se que o EBL cursa com mais altera&#231;&#245;es motoras esofagianas e com refluxo mais intenso que o EBC. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Avaliar a preval&#234;ncia de altera&#231;&#245;es manom&#233;tricas e a intensidade do refluxo gastroesof&#225;gico &#224; pHmetria em pacientes com EBC e EBL. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Estudo retrospectivo de pacientes com endoscopia digestiva alta e comprova&#231;&#227;o histopatol&#243;gica de EB, divididos em dois grupos: EBC e EBL. Foram avaliados os dados demogr&#225;ficos, o tempo de doen&#231;a, preval&#234;ncia de h&#233;rnia hiatal, dados obtidos &#224; esofagomanometria e pHmetria. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> EBC 46 pacientes (24 masculino 52,2% e m&#233;dia de idade de 55,22 anos), EBL 28 pacientes (18 masculino 64,3% e m&#233;dia de idade 50,5 anos); tempo de sintomas: EBC 9,88 anos e EBL 12,94 anos; h&#233;rnia de hiato: EBC 84,2%, EBL 96,3%; press&#227;o m&#233;dia do esf&#237;ncter inferior do es&#244;fago: EBC 9,15 mm Hg, EBL 6,99 mm Hg; hipotens&#227;o do esf&#237;ncter inferior do es&#244;fago: EBC 65,9%, EBL 82,1%; motilidade esofagiana ineficaz (MEI) leve/moderado: EBC 34,8%, EBL 46,4%; MEI acentuado: EBC 5 10,9%, EBL 7,1%; aperistalse: 6,5%, EBL 3,6%; es&#244;fago em quebra-nozes: EBC 8,6%, EBL 0%; corpo normal: EBC 39,1%, EBL 42,9%, sem diferen&#231;a estat&#237;stica para qualquer desses valores (<italic>P</italic>&lt;0,05). M&#233;dias de pHmetria: % de tempo total com pH &lt;4: EBC (29/46) 9,12% EBL (15/28) 27,27% <italic>P</italic>&lt;0,000; % de tempo ereto com pH&lt;4: EBC 11,91%, EBL 24,29% <italic>P</italic> = 0,003; % de tempo supino com pH &lt;4: EBC 10,86% EBL 33,26% <italic>P</italic> = 0,000. </p>				</sec>				<sec>					<title>CONCLUS&#213;ES:</title>					<p> N&#227;o houve diferen&#231;a entre a preval&#234;ncia das altera&#231;&#245;es motoras em pacientes com EBC e EBL. O refluxo &#225;cido, tanto em posi&#231;&#227;o ereta como em posi&#231;&#227;o supina, foi mais intenso no EBL.</p>				</sec>^lpt
!v085!^kBarrett esophagus^len
!v085!^kGastroesophageal reflux^len
!v085!^kManometry^len
!v085!^kEsophageal motility disorders^len
!v085!^kEsôfago de Barrett^lpt
!v085!^kRefluxo gastroesofágico^lpt
!v085!^kManometria^lpt
!v085!^kTranstornos da motilidade esofágica^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m08^d23
!v112!2011
!v113!^y2011^m09^d27
!v114!2011
!v120!XML_3.0
!v121!64
!v237!10.1590/S0004-28032012000100011
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!f
!v708!1
!ID 000413
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sHelman^rauthor^nLaura
!v010!^sBiccas^rauthor^nBeatriz Nunes
!v010!^sLemme^rauthor^nEponina M. O.
!v010!^sNovais^rauthor^nPaula
!v010!^sFittipaldi^rauthor^nViviane
!v012!^tEsophageal manometry findings and degree of acid exposure in short and long Barrett's esophagus
!v012!^tAlteracoes manometricas e intensidade do refluxo no esofago de Barrett curto e longo^lpt
!v014!^l68^f64
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!ORIGINAL_ARTICLE
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal do Rio de Janeiro^cRJ^iaff1^1Unidade de Esofago, Servico de Gastroenterologia, Hospital Universitario Clementino Fraga Filho^pBrasil^9Unidade de Esofago, Servico de Gastroenterologia, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, RJ, Brasil
!v071!oa
!v072!21
!v083!^a<sec>					<title>CONTEXT:</title>					 Barrett's esophagus (BE) is characterized by intestinal metaplasia in the distal esophagus and is classified as short-segment (&lt;3 cm - SSBE) or long-segment (&gt;3 cm - LSSBE). It is suggested that LSSBE is associated with more severe esophageal motor abnormalities and increased acid exposure time than SSBE. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To evaluate the prevalence of esophageal manometriy abnormalities and acid exposure times in patients with SSBE and LSSBE. 				</sec>				<sec>					<title>METHODS:</title>					 Barrett's esophagus patients identified by upper endoscopy and confirmed by histopathology were, retrospectively, reviewed and divided into two groups: SSBE and LSBE. Demographic data, symptom duration, prevalence of hiatal hernia, lower esophagus sphincter basal pressure, prevalence of esophageal body abnormalities and acid exposure times were evaluated. 				</sec>				<sec>					<title>RESULTS:</title>					 Forty-six patients with SSBE (24 males - 52.2%, mean age of 55.2 years) and 28 patients with LSBE (18 males - 64.3%, mean age of 50.5 years). Mean symptom duration was 9.9 years for SSBE and 12.9 years for LSSBE. Hiatal hernia was present in 84.2% of SSBE, 96.3% of LSBE; average lower esophagus sphincter pressure in SSBE 9.15 mm Hg, in LSBE 6.99 mm Hg; lower esophagus sphincter hypotension in SSBE was 65.9%, in LSSBE 82.1%; aperistalsis in SSBE 6.5%, LSSBE 3.6%; mild/moderate ineffective esophageal motility in SSBE 34.8%, LSBE 46.4%; severe moderate ineffective esophageal motility in SSBE 10.9%, LSBE 7,1%; nutcracker esophagus/segmental nutcracker esophagus in SSBE 8.6%, LSBE 0%; normal body in SSBE 39.1%, in LSBE 42.9%, no statistical difference for any of these values (P&lt;0.05). Average % total time pH&lt;4 in SSBE 9.12, LSBE 17.27 (P&lt;0.000); % time pH&lt;4 upright in SSBE 11.91; LSBE 24.29 (P=0.003); % time pH&lt;4 supine in SSBE 10.86, LSBE 33.26 (P = 0.000). 				</sec>				<sec>					<title>CONCLUSION:</title>					 There was no difference between the prevalence of motor disorders in patients with SSBE and LSSBE. Acid reflux in upright and supine positions was more intense in LSBE.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 O esofago de Barrett (EB) se caracteriza pela presenca de metaplasia intestinal no esofago distal, quando menor que 3 cm e chamado Barrett curto (EBC) e com 3 cm ou mais Barrett longo (EBL). Sugere-se que o EBL cursa com mais alteracoes motoras esofagianas e com refluxo mais intenso que o EBC. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar a prevalencia de alteracoes manometricas e a intensidade do refluxo gastroesofagico a pHmetria em pacientes com EBC e EBL. 				</sec>				<sec>					<title>MeTODOS:</title>					 Estudo retrospectivo de pacientes com endoscopia digestiva alta e comprovacao histopatologica de EB, divididos em dois grupos: EBC e EBL. Foram avaliados os dados demograficos, o tempo de doenca, prevalencia de hernia hiatal, dados obtidos a esofagomanometria e pHmetria. 				</sec>				<sec>					<title>RESULTADOS:</title>					 EBC 46 pacientes (24 masculino 52,2% e media de idade de 55,22 anos), EBL 28 pacientes (18 masculino 64,3% e media de idade 50,5 anos); tempo de sintomas: EBC 9,88 anos e EBL 12,94 anos; hernia de hiato: EBC 84,2%, EBL 96,3%; pressao media do esfincter inferior do esofago: EBC 9,15 mm Hg, EBL 6,99 mm Hg; hipotensao do esfincter inferior do esofago: EBC 65,9%, EBL 82,1%; motilidade esofagiana ineficaz (MEI) leve/moderado: EBC 34,8%, EBL 46,4%; MEI acentuado: EBC 5 10,9%, EBL 7,1%; aperistalse: 6,5%, EBL 3,6%; esofago em quebra-nozes: EBC 8,6%, EBL 0%; corpo normal: EBC 39,1%, EBL 42,9%, sem diferenca estatistica para qualquer desses valores (P&lt;0,05). Medias de pHmetria: % de tempo total com pH &lt;4: EBC (29/46) 9,12% EBL (15/28) 27,27% P&lt;0,000; % de tempo ereto com pH&lt;4: EBC 11,91%, EBL 24,29% P = 0,003; % de tempo supino com pH &lt;4: EBC 10,86% EBL 33,26% P = 0,000. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 Nao houve diferenca entre a prevalencia das alteracoes motoras em pacientes com EBC e EBL. O refluxo acido, tanto em posicao ereta como em posicao supina, foi mais intenso no EBL.				</sec>^lpt
!v085!^kBarrett esophagus^len
!v085!^kGastroesophageal reflux^len
!v085!^kManometry^len
!v085!^kEsophageal motility disorders^len
!v085!^kEsofago de Barrett^lpt
!v085!^kRefluxo gastroesofagico^lpt
!v085!^kManometria^lpt
!v085!^kTranstornos da motilidade esofagica^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m08^d23
!v112!2011
!v113!^y2011^m09^d27
!v114!2011
!v120!XML_3.0
!v121!64
!v237!10.1590/S0004-28032012000100011
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!l
!v708!1
!ID 000414
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sAchem^rND^nSR
!v010!^sKolts^rND^nBE
!v010!^sBurton^rND^nL
!v012!Segmental versus diffuse nutcracker esophagus: an intermittent motility pattern^len
!v014!847-51
!v030!Am J Gastroenterol
!v031!88
!v064!1993
!v065!19930000
!v071!journal
!v118!1
!v514!^l851^f847
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000415
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sCameron^rND^nAJ
!v010!^sLomboy^rND^nCT
!v012!Barrett's esophagus: age, prevalence, and extent of columnar epithelium^len
!v014!1241-245
!v030!Gastroenterology
!v031!103
!v064!1992
!v065!19920000
!v118!2
!v514!^l1245^f1241
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000416
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sChampion^rND^nG
!v010!^sRichter^rND^nJE
!v010!^sVaezi^rND^nMF
!v010!^sSingh^rND^nS
!v010!^sAlexander^rND^nR
!v012!Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus^len
!v014!747-54
!v030!Gastroenterology
!v031!107
!v064!1994
!v065!19940000
!v118!3
!v514!^l754^f747
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000417
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sCsendes^rND^nA
!v010!^sSmok^rND^nG
!v010!^sQuiroz^rND^nJ
!v010!^sBurdiles^rND^nP
!v010!^sRojas^rND^nJ
!v010!^sCastro^rND^nC
!v010!^sHenriquez^rND^nA
!v012!Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia^len
!v014!554-60
!v030!Am J Gastroenterol
!v031!97
!v064!2002
!v065!20020000
!v118!4
!v514!^l560^f554
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000418
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sFass^rND^nR
!v010!^sHell^rND^nRW
!v010!^sGarewal^rND^nHS
!v010!^sMartinez^rND^nP
!v010!^sPulliam^rND^nG
!v010!^sWendel^rND^nC
!v010!^sSampliner^rND^nRE
!v012!Correlation of esophageal acid exposure with Barrett's oesophagus length^len
!v014!310-13
!v030!Gut
!v031!48
!v064!2001
!v065!20010000
!v118!5
!v514!^l313^f310
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000419
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sFrazzoni^rND^nM
!v010!^sManno^rND^nM
!v010!^sDe Micheli^rND^nE
!v010!^sSavarino^rND^nV
!v012!Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?^len
!v014!643-48
!v030!Dig Liver Dis
!v031!38
!v064!2006
!v065!20060000
!v118!6
!v514!^l648^f643
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000420
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sGutschow^rND^nCA
!v010!^sBludau^rND^nM
!v010!^sVallbohmer^rND^nD
!v010!^sSchroder^rND^nW
!v010!^sBollschweiler^rND^nE
!v010!^sHolscher^rND^nAH
!v012!NERD, GERD, and Barrett's esophagus: role of acid and non-acid reflux revisited with combined pH-impedance monitoring^len
!v014!3076-081
!v030!Dig Dis Sci
!v031!53
!v064!2008
!v065!20080000
!v118!7
!v514!^l3081^f3076
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000421
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sLeite^rND^nLP
!v010!^sJohnston^rND^nBT
!v010!^sBarrett^rND^nJ
!v010!^sCastell^rND^nJA
!v010!^sCastell^rND^nDO
!v012!Ineffective esophageal motility (IEM): the primary finding in patients with nonspecific esophageal motility disorder^len
!v014!1859-865
!v030!Dig Dis Sci
!v031!42
!v064!1997
!v065!19970000
!v118!8
!v514!^l1865^f1859
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000422
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sLemme^rND^nEMO
!v010!^sDomingues^rND^nGR
!v010!^sSilva^rND^nLFD
!v010!^sFirman^rND^nCG
!v010!^sPantoja^rND^nJAS
!v012!Esophageal manometry: preliminary values in health adult volunteers^len
!v014!29-35
!v030!GED Gastroenterol Endosc Dig
!v031!20
!v064!2001
!v065!20010000
!v118!9
!v514!^l35^f29
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000423
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sLoughney^rND^nT
!v010!^sMaydonovitch^rND^nCL
!v010!^sWong^rND^nRK
!v012!Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus^len
!v014!916-19
!v030!Am J Gastroenterol
!v031!93
!v064!1998
!v065!19980000
!v118!10
!v514!^l919^f916
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000424
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sOberg^rND^nS
!v010!^sRitter^rND^nMP
!v010!^sCrookes^rND^nPF
!v010!^sFein^rND^nM
!v010!^sMason^rND^nRJ
!v010!^sGadensytatter^rND^nM
!v010!^sBrenner^rND^nCG
!v010!^sPeters^rND^nJH
!v010!^sDeMeester^rND^nTR
!v012!Gastroesophageal reflux disease and mucosal injury with emphasis on short-segment Barrett's esophagus and duodenogastroesophageal reflux^len
!v014!547-52
!v030!J Gastrointestinal Surg
!v031!2
!v064!1998
!v065!19980000
!v118!11
!v514!^l552^f547
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000425
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sOberg^rND^nS
!v010!^sDeMeester^rND^nTR
!v010!^sPeters^rND^nJH
!v010!^sHagen^rND^nJA
!v010!^sNigro^rND^nJJ
!v010!^sDeMeester^rND^nSR
!v010!^sTheisen^rND^nJ
!v010!^sCampos^rND^nGM
!v010!^sCrookes^rND^nPF
!v012!The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure^len
!v014!572-80
!v030!J Thorac Cardiovasc Surg
!v031!117
!v064!1999
!v065!19990000
!v118!12
!v514!^l580^f572
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000426
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sPace^rND^nF
!v010!^sSangaletti^rND^nO
!v010!^sPallotta^rND^nS
!v010!^sMolteni^rND^nP
!v010!^sPorro^rND^nGB
!v012!Biliary reflux and non-acid reflux are two distinct phenomena: a comparison between 24-hour multichannel intraesophageal impedance and bilirubin monitoring^len
!v014!1031-039
!v030!Scand J Gastroenterol
!v031!42
!v064!2007
!v065!20070000
!v118!13
!v514!^l1039^f1031
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000427
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sSharma^rND^nP
!v010!^sMorales^rND^nTG
!v010!^sSampliner^rND^nRE
!v012!Short segment Barrett's esophagus-the need for standardization of the definition and of endoscopic criteria^len
!v014!1033-036
!v030!Am J Gastroenterol
!v031!93
!v064!1998
!v065!19980000
!v118!14
!v514!^l1036^f1033
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000428
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sSilva^rND^nLF
!v010!^sLemme^rND^nEM
!v014!217-23
!v030!Arq Gastroenterol
!v031!37
!v064!2000
!v065!20000000
!v118!15
!v514!^l223^f217
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000429
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sSilva^rND^nLF
!v010!^sde Oliveira Lemme^rND^nEM
!v012!Are there any differences between nutcracker esophagus with and without reflux^len
!v014!198-205
!v030!Dysphagia
!v031!21
!v064!2007
!v065!20070000
!v118!16
!v514!^l205^f198
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000430
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sSimren^rND^nM
!v010!^sSilny^rND^nJ
!v010!^sHolloway^rND^nR
!v010!^sTack^rND^nJ
!v010!^sJanssens^rND^nJ
!v010!^sSifrim^rND^nD
!v012!Relevance of ineffective oesophageal motility during oesophageal acid clearance^len
!v014!784-90
!v030!Gut
!v031!52
!v064!2003
!v065!20030000
!v118!17
!v514!^l790^f784
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000431
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sSpechler^rND^nSJ
!v010!^sCastell^rND^nDO
!v012!Classification of oesophageal motility abnormalities^len
!v014!145-51
!v030!Gut
!v031!49
!v064!2001
!v065!20010000
!v118!18
!v514!^l151^f145
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000432
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sVaezi^rND^nMF
!v010!^sRichter^rND^nJE
!v012!Complicated Barrett's esophagus: role of acid and bile^len
!v014!1630
!v030!Am J Gastroenterol
!v031!89
!v064!1994
!v065!19940000
!v118!19
!v514!^f1630
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000433
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sWang^rND^nKK
!v010!^sSampliner^rND^nRE
!v012!Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus^len
!v014!788-97
!v030!Am J Gastroenterol
!v031!103
!v064!2008
!v065!20080000
!v118!20
!v514!^l797^f788
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000434
!v001!br1.1
!v002!0004-2803-ag-49-01-64.xml
!v004!v49n1
!v010!^sZentilin^rND^nP
!v010!^sConio^rND^nM
!v010!^sMele^rND^nMR
!v010!^sMansi^rND^nC
!v010!^sPandolfo^rND^nN
!v010!^sDulbEcco^rND^nP
!v010!^sGambaro^rND^nC
!v010!^sTessieri^rND^nL
!v010!^sIiritano^rND^nE
!v010!^sBilardi^rND^nC
!v010!^sBiagini^rND^nR
!v010!^sVigneri^rND^nS
!v010!^sSavarino^rND^nV
!v012!Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus^len
!v014!893-98
!v030!Aliment Pharmacol Ther
!v031!16
!v064!2002
!v065!20020000
!v118!21
!v514!^l898^f893
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-64.xml
!v705!S
!v706!c
!v708!21
!v865!20120300
!ID 000435
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v091!20120814
!v092!164321
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v703!134
!v705!S
!v706!o
!v708!1
!ID 000436
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^1aff1^sFerri^rauthor^nPriscila Menezes
!v010!^sFerreira^rauthor^nAlexandre Rodrigues
!v010!^sFagundes^rauthor^nEleonora Druve Tavares
!v010!^sLiu^rauthor^nShinfay Maximilian
!v010!^sRoquete^rauthor^nMariza Leitao Valadares
!v010!^sPenna^rauthor^nFrancisco Jose
!v012!^s20 years experience of a pediatric hepatology reference center^tPortal vein thrombosis in children and adolescents
!v012!^sexperiencia de 20 anos de um servico de referencia em hepatologia pediatrica^tTrombose de veia porta em criancas e adolescentes^lpt
!v014!^l76^f69
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!TAB
!v040!en
!v042!1
!v049!PEDIATRIC_GASTROENTEROLOGY
!v064!Jan-Mar
!v065!20120300
!v070!Departamento de Gastroenterologia Pediatrica do Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte^cMG^iaff1^pBrasil^5?^9Departamento de Gastroenterologia Pediatrica do Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brasil
!v071!oa
!v072!56
!v083!^a<sec>					<title>CONTEXT:</title>					 Portal vein thrombosis refers to a total or partial obstruction of the blood flow in this vein due to a thrombus formation. It is an important cause of portal hypertension in the pediatric age group with high morbidity rates due to its main complication - the upper gastrointestinal bleeding. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To describe a group of patients with portal vein thrombosis without associated hepatic disease of the Pediatric Hepatology Clinic of the Hospital das Clinicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil with emphasis on diagnosis, presentation form and clinical complications, and the treatment of portal hypertension. 				</sec>				<sec>					<title>METHODS:</title>					 This is a descriptive study of a series of children and adolescents cases assisted from January 1990 to December 2010. The portal vein thrombosis diagnosis was established by ultrasound. 				</sec>				<sec>					<title>RESULTS:</title>					 Of the 55 studied patients, 30 (54.5%) were male. In 29 patients (52.7%), none of the risk factors for portal vein thrombosis was observed. The predominant form of presentation was the upper gastrointestinal bleeding (52.7%). In 20 patients (36.4%), the initial manifestation was splenomegaly. During the whole following period of the study, 39 patients (70.9%) showed at least one episode of upper gastrointestinal bleeding. The mean age of patients in the first episode was 4.6 &#177; 3.4 years old. The endoscopic procedure carried out in the urgency or electively for search of esophageal varices showed its presence in 84.9% of the evaluated patients. The prophylactic endoscopic treatment was performed with endoscopic band ligation of varices in 31.3% of patients. Only one died due to refractory bleeding. 				</sec>				<sec>					<title>CONCLUSIONS:</title>					 The portal vein thrombosis is one of the most important causes of upper gastrointestinal bleeding in children. In all non febrile children with splenomegaly and/or hematemesis and without hepatomegaly and with normal hepatic function tests, it should be suspect of portal vein thrombosis. Thus, an appropriate diagnostic and treatment approach is desirable in an attempt to reduce morbidity and mortality.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 Trombose da veia porta refere-se a uma obstrucao total ou parcial do fluxo de sangue nesta veia devido a formacao de um trombo. e uma causa importante da hipertensao porta na faixa etaria pediatrica, com taxas elevadas de morbidade devido a sua principal complicacao - a hemorragia digestiva alta. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Descrever o grupo de criancas e adolescentes com trombose de veia porta sem doenca hepatica associada do Ambulatorio de Hepatologia Pediatrica do Hospital das Clinicas da UFMG, Belo Horizonte, MG, Brasil, com enfase no diagnostico, forma de apresentacao, complicacoes clinicas e na abordagem da hipertensao porta. 				</sec>				<sec>					<title>MeTODOS:</title>					 Trata-se de estudo descritivo de uma serie de casos de criancas e adolescentes atendidos de janeiro de 1990 a dezembro de 2010. O diagnostico de trombose de veia porta foi estabelecido por ultrassonografia. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Dos 55 pacientes analisados, 30 (54,5%) eram do genero masculino. Em 29 pacientes (52,7%) nao foi identificado nenhum fator de risco para trombose de veia porta. A forma de apresentacao predominante foi hemorragia digestiva alta (52,7%). Em 20 pacientes (36,4%), a manifestacao inicial foi esplenomegalia. Durante todo o periodo de seguimento, 39 pacientes (70,9%) apresentaram, pelo menos, um episodio de hemorragia digestiva alta. A media de idade dos pacientes neste primeiro episodio foi de 4,6 &#177; 3,4 anos. O exame endoscopico, seja realizado na urgencia ou eletivamente para pesquisa de varizes esofagicas, mostrou sua presenca em 84,9% dos pacientes avaliados. O tratamento endoscopico profilatico foi realizado com ligadura elastica de varizes em 31,3% dos pacientes. Apenas um evoluiu para obito devido a sangramento refratario. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 A trombose de veia porta e uma das causas mais importantes de hemorragia digestiva alta em criancas. Deve-se suspeitar de trombose de veia porta em toda crianca com esplenomegalia afebril e/ou hematemese, sem hepatomegalia e com testes de funcao hepatica normais. Desta forma, uma abordagem diagnostica e terapeutica adequada e desejavel na tentativa de reduzir a morbimortalidade.				</sec>^lpt
!v085!^kVenous thrombosis^len
!v085!^kPortal vein^len
!v085!^kHypertension, portal^len
!v085!^kChild^len
!v085!^kAdolescent^len
!v085!^kTrombose venosa^lpt
!v085!^kVeia porta^lpt
!v085!^kHipertensao portal^lpt
!v085!^kCriancas^lpt
!v085!^kAdolescentes^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m05^d25
!v112!2011
!v113!^y2011^m09^d05
!v114!2011
!v120!XML_3.0
!v121!69
!v237!10.1590/S0004-28032012000100012
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!h
!v708!1
!ID 000437
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^1aff1^sFerri^rauthor^nPriscila Menezes
!v010!^sFerreira^rauthor^nAlexandre Rodrigues
!v010!^sFagundes^rauthor^nEleonora Druve Tavares
!v010!^sLiu^rauthor^nShinfay Maximilian
!v010!^sRoquete^rauthor^nMariza Leitão Valadares
!v010!^sPenna^rauthor^nFrancisco José
!v012!^s20 years experience of a pediatric hepatology reference center^tPortal vein thrombosis in children and adolescents
!v012!^sexperiência de 20 anos de um serviço de referência em hepatologia pediátrica^tTrombose de veia porta em crianças e adolescentes^lpt
!v014!^l76^f69
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!TAB
!v040!en
!v042!1
!v049!PEDIATRIC_GASTROENTEROLOGY
!v064!Jan-Mar
!v065!20120300
!v070!Departamento de Gastroenterologia Pediátrica do Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte^cMG^iaff1^pBrasil^5?^9Departamento de Gastroenterologia Pediátrica do Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brasil
!v071!oa
!v072!56
!v083!^a<sec>					<title>CONTEXT:</title>					<p> Portal vein thrombosis refers to a total or partial obstruction of the blood flow in this vein due to a thrombus formation. It is an important cause of portal hypertension in the pediatric age group with high morbidity rates due to its main complication - the upper gastrointestinal bleeding. </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To describe a group of patients with portal vein thrombosis without associated hepatic disease of the Pediatric Hepatology Clinic of the Hospital das Cl&#237;nicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil with emphasis on diagnosis, presentation form and clinical complications, and the treatment of portal hypertension. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> This is a descriptive study of a series of children and adolescents cases assisted from January 1990 to December 2010. The portal vein thrombosis diagnosis was established by ultrasound. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> Of the 55 studied patients, 30 (54.5%) were male. In 29 patients (52.7%), none of the risk factors for portal vein thrombosis was observed. The predominant form of presentation was the upper gastrointestinal bleeding (52.7%). In 20 patients (36.4%), the initial manifestation was splenomegaly. During the whole following period of the study, 39 patients (70.9%) showed at least one episode of upper gastrointestinal bleeding. The mean age of patients in the first episode was 4.6 &#177; 3.4 years old. The endoscopic procedure carried out in the urgency or electively for search of esophageal varices showed its presence in 84.9% of the evaluated patients. The prophylactic endoscopic treatment was performed with endoscopic band ligation of varices in 31.3% of patients. Only one died due to refractory bleeding. </p>				</sec>				<sec>					<title>CONCLUSIONS:</title>					<p> The portal vein thrombosis is one of the most important causes of upper gastrointestinal bleeding in children. In all non febrile children with splenomegaly and/or hematemesis and without hepatomegaly and with normal hepatic function tests, it should be suspect of portal vein thrombosis. Thus, an appropriate diagnostic and treatment approach is desirable in an attempt to reduce morbidity and mortality.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> Trombose da veia porta refere-se a uma obstru&#231;&#227;o total ou parcial do fluxo de sangue nesta veia devido &#224; forma&#231;&#227;o de um trombo. &#201; uma causa importante da hipertens&#227;o porta na faixa et&#225;ria pedi&#225;trica, com taxas elevadas de morbidade devido a sua principal complica&#231;&#227;o - a hemorragia digestiva alta. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Descrever o grupo de crian&#231;as e adolescentes com trombose de veia porta sem doen&#231;a hep&#225;tica associada do Ambulat&#243;rio de Hepatologia Pedi&#225;trica do Hospital das Cl&#237;nicas da UFMG, Belo Horizonte, MG, Brasil, com &#234;nfase no diagn&#243;stico, forma de apresenta&#231;&#227;o, complica&#231;&#245;es cl&#237;nicas e na abordagem da hipertens&#227;o porta. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Trata-se de estudo descritivo de uma s&#233;rie de casos de crian&#231;as e adolescentes atendidos de janeiro de 1990 a dezembro de 2010. O diagn&#243;stico de trombose de veia porta foi estabelecido por ultrassonografia. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Dos 55 pacientes analisados, 30 (54,5%) eram do g&#234;nero masculino. Em 29 pacientes (52,7%) n&#227;o foi identificado nenhum fator de risco para trombose de veia porta. A forma de apresenta&#231;&#227;o predominante foi hemorragia digestiva alta (52,7%). Em 20 pacientes (36,4%), a manifesta&#231;&#227;o inicial foi esplenomegalia. Durante todo o per&#237;odo de seguimento, 39 pacientes (70,9%) apresentaram, pelo menos, um epis&#243;dio de hemorragia digestiva alta. A m&#233;dia de idade dos pacientes neste primeiro epis&#243;dio foi de 4,6 &#177; 3,4 anos. O exame endosc&#243;pico, seja realizado na urg&#234;ncia ou eletivamente para pesquisa de varizes esof&#225;gicas, mostrou sua presen&#231;a em 84,9% dos pacientes avaliados. O tratamento endosc&#243;pico profil&#225;tico foi realizado com ligadura el&#225;stica de varizes em 31,3% dos pacientes. Apenas um evoluiu para &#243;bito devido a sangramento refrat&#225;rio. </p>				</sec>				<sec>					<title>CONCLUS&#213;ES:</title>					<p> A trombose de veia porta &#233; uma das causas mais importantes de hemorragia digestiva alta em crian&#231;as. Deve-se suspeitar de trombose de veia porta em toda crian&#231;a com esplenomegalia afebril e/ou hemat&#234;mese, sem hepatomegalia e com testes de fun&#231;&#227;o hep&#225;tica normais. Desta forma, uma abordagem diagn&#243;stica e terap&#234;utica adequada &#233; desej&#225;vel na tentativa de reduzir a morbimortalidade.</p>				</sec>^lpt
!v085!^kVenous thrombosis^len
!v085!^kPortal vein^len
!v085!^kHypertension, portal^len
!v085!^kChild^len
!v085!^kAdolescent^len
!v085!^kTrombose venosa^lpt
!v085!^kVeia porta^lpt
!v085!^kHipertensão portal^lpt
!v085!^kCrianças^lpt
!v085!^kAdolescentes^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m05^d25
!v112!2011
!v113!^y2011^m09^d05
!v114!2011
!v120!XML_3.0
!v121!69
!v237!10.1590/S0004-28032012000100012
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!f
!v708!1
!ID 000438
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^1aff1^sFerri^rauthor^nPriscila Menezes
!v010!^sFerreira^rauthor^nAlexandre Rodrigues
!v010!^sFagundes^rauthor^nEleonora Druve Tavares
!v010!^sLiu^rauthor^nShinfay Maximilian
!v010!^sRoquete^rauthor^nMariza Leitao Valadares
!v010!^sPenna^rauthor^nFrancisco Jose
!v012!^s20 years experience of a pediatric hepatology reference center^tPortal vein thrombosis in children and adolescents
!v012!^sexperiencia de 20 anos de um servico de referencia em hepatologia pediatrica^tTrombose de veia porta em criancas e adolescentes^lpt
!v014!^l76^f69
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!TAB
!v040!en
!v042!1
!v049!PEDIATRIC_GASTROENTEROLOGY
!v064!Jan-Mar
!v065!20120300
!v070!Departamento de Gastroenterologia Pediatrica do Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte^cMG^iaff1^pBrasil^5?^9Departamento de Gastroenterologia Pediatrica do Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brasil
!v071!oa
!v072!56
!v083!^a<sec>					<title>CONTEXT:</title>					 Portal vein thrombosis refers to a total or partial obstruction of the blood flow in this vein due to a thrombus formation. It is an important cause of portal hypertension in the pediatric age group with high morbidity rates due to its main complication - the upper gastrointestinal bleeding. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To describe a group of patients with portal vein thrombosis without associated hepatic disease of the Pediatric Hepatology Clinic of the Hospital das Clinicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil with emphasis on diagnosis, presentation form and clinical complications, and the treatment of portal hypertension. 				</sec>				<sec>					<title>METHODS:</title>					 This is a descriptive study of a series of children and adolescents cases assisted from January 1990 to December 2010. The portal vein thrombosis diagnosis was established by ultrasound. 				</sec>				<sec>					<title>RESULTS:</title>					 Of the 55 studied patients, 30 (54.5%) were male. In 29 patients (52.7%), none of the risk factors for portal vein thrombosis was observed. The predominant form of presentation was the upper gastrointestinal bleeding (52.7%). In 20 patients (36.4%), the initial manifestation was splenomegaly. During the whole following period of the study, 39 patients (70.9%) showed at least one episode of upper gastrointestinal bleeding. The mean age of patients in the first episode was 4.6 &#177; 3.4 years old. The endoscopic procedure carried out in the urgency or electively for search of esophageal varices showed its presence in 84.9% of the evaluated patients. The prophylactic endoscopic treatment was performed with endoscopic band ligation of varices in 31.3% of patients. Only one died due to refractory bleeding. 				</sec>				<sec>					<title>CONCLUSIONS:</title>					 The portal vein thrombosis is one of the most important causes of upper gastrointestinal bleeding in children. In all non febrile children with splenomegaly and/or hematemesis and without hepatomegaly and with normal hepatic function tests, it should be suspect of portal vein thrombosis. Thus, an appropriate diagnostic and treatment approach is desirable in an attempt to reduce morbidity and mortality.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 Trombose da veia porta refere-se a uma obstrucao total ou parcial do fluxo de sangue nesta veia devido a formacao de um trombo. e uma causa importante da hipertensao porta na faixa etaria pediatrica, com taxas elevadas de morbidade devido a sua principal complicacao - a hemorragia digestiva alta. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Descrever o grupo de criancas e adolescentes com trombose de veia porta sem doenca hepatica associada do Ambulatorio de Hepatologia Pediatrica do Hospital das Clinicas da UFMG, Belo Horizonte, MG, Brasil, com enfase no diagnostico, forma de apresentacao, complicacoes clinicas e na abordagem da hipertensao porta. 				</sec>				<sec>					<title>MeTODOS:</title>					 Trata-se de estudo descritivo de uma serie de casos de criancas e adolescentes atendidos de janeiro de 1990 a dezembro de 2010. O diagnostico de trombose de veia porta foi estabelecido por ultrassonografia. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Dos 55 pacientes analisados, 30 (54,5%) eram do genero masculino. Em 29 pacientes (52,7%) nao foi identificado nenhum fator de risco para trombose de veia porta. A forma de apresentacao predominante foi hemorragia digestiva alta (52,7%). Em 20 pacientes (36,4%), a manifestacao inicial foi esplenomegalia. Durante todo o periodo de seguimento, 39 pacientes (70,9%) apresentaram, pelo menos, um episodio de hemorragia digestiva alta. A media de idade dos pacientes neste primeiro episodio foi de 4,6 &#177; 3,4 anos. O exame endoscopico, seja realizado na urgencia ou eletivamente para pesquisa de varizes esofagicas, mostrou sua presenca em 84,9% dos pacientes avaliados. O tratamento endoscopico profilatico foi realizado com ligadura elastica de varizes em 31,3% dos pacientes. Apenas um evoluiu para obito devido a sangramento refratario. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 A trombose de veia porta e uma das causas mais importantes de hemorragia digestiva alta em criancas. Deve-se suspeitar de trombose de veia porta em toda crianca com esplenomegalia afebril e/ou hematemese, sem hepatomegalia e com testes de funcao hepatica normais. Desta forma, uma abordagem diagnostica e terapeutica adequada e desejavel na tentativa de reduzir a morbimortalidade.				</sec>^lpt
!v085!^kVenous thrombosis^len
!v085!^kPortal vein^len
!v085!^kHypertension, portal^len
!v085!^kChild^len
!v085!^kAdolescent^len
!v085!^kTrombose venosa^lpt
!v085!^kVeia porta^lpt
!v085!^kHipertensao portal^lpt
!v085!^kCriancas^lpt
!v085!^kAdolescentes^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m05^d25
!v112!2011
!v113!^y2011^m09^d05
!v114!2011
!v120!XML_3.0
!v121!69
!v237!10.1590/S0004-28032012000100012
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!l
!v708!1
!ID 000439
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sAbd El-Hamid^rND^nN
!v010!^sTaylor^rND^nRM
!v010!^sMarinello^rND^nD
!v010!^sMufti^rND^nGJ
!v010!^sPatel^rND^nR
!v010!^sMieli-Vergani^rND^nG
!v010!^sDavenport^rND^nM
!v010!^sDhawan^rND^nA
!v012!Aetiology and management of extrahepatic portal vein obstruction in children: King's College Hospital experience^len
!v014!630-34
!v030!J Pediatr Gastroenterol Nutr
!v031!47
!v064!2008
!v065!20080000
!v071!journal
!v118!1
!v514!^l634^f630
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000440
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sAlvarez^rND^nF
!v010!^sBernard^rND^nO
!v010!^sBrunelle^rND^nF
!v010!^sHadchouel^rND^nP
!v010!^sOdievre^rND^nM
!v010!^sAlagille^rND^nD
!v012!Portal obstruction in children. I. Clinical investigation and hemorrhage risk^len
!v014!696-702
!v030!J Pediatr
!v031!103
!v064!1983
!v065!19830000
!v118!2
!v514!^l702^f696
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000441
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sAtes^rND^nO
!v010!^sHakguder^rND^nG
!v010!^sOlguner^rND^nM
!v010!^sAkgur^rND^nFM
!v012!Extrahepatic portal hypertension treated by anastomosing inferior mesenteric vein to left portal vein at Rex recessus^len
!v030!J Pediatr Surg
!v031!38
!v064!2003
!v065!20030000
!v118!3
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000442
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sBajaj^rND^nJS
!v010!^sBhattacharjee^rND^nJ
!v010!^sSarin^rND^nSK
!v012!Coagulation profile and platelet function in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis^len
!v014!641-46
!v030!J Gastroenterol Hepatol
!v031!16
!v064!2001
!v065!20010000
!v118!4
!v514!^l646^f641
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000443
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sBalfour^rND^nGW
!v010!^sStewart^rND^nG
!v012!Case of enlarge spleen complicated with ascites, both depending upon varicose dilatation and thrombosis of the portal vein^len
!v014!589-99
!v030!Edinburgh Med J
!v031!14
!v064!1869
!v065!18690000
!v118!5
!v514!^l599^f589
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000444
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sBayraktar^rND^nY
!v010!^sHarmanci^rND^nO
!v012!Etiology and consequences of thrombosis in abdominal vessels^len
!v014!1165-174
!v030!World J Gastroenterol
!v031!12
!v064!2006
!v065!20060000
!v118!6
!v514!^l1174^f1165
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000445
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sBhattacharyya^rND^nM
!v010!^sMakharia^rND^nG
!v010!^sKannan^rND^nM
!v010!^sAhmed^rND^nRP
!v010!^sGupta^rND^nPK
!v010!^sSaxena^rND^nR
!v012!Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India^len
!v014!844-47
!v030!Am J Clin Pathol
!v031!121
!v064!2004
!v065!20040000
!v118!7
!v514!^l847^f844
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000446
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sBilodeau^rND^nM
!v010!^sAubry^rND^nMC
!v010!^sHoule^rND^nR
!v010!^sBurnes^rND^nPN
!v010!^sEthier^rND^nC
!v012!Evaluation of hepatocyte injury following partial ligation of the left portal vein^len
!v014!29-37
!v030!J Hepatol
!v031!30
!v064!1999
!v065!19990000
!v118!8
!v514!^l37^f29
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000447
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sBittencourt^rND^nPL
!v010!^sCouto^rND^nCA
!v010!^sRibeiro^rND^nDD
!v012!Portal vein thrombosis and budd-Chiari syndrome^len
!v014!127-44
!v030!Clin Liver Dis
!v031!13
!v064!2009
!v065!20090000
!v118!9
!v514!^l144^f127
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000448
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sCelinska-Cedro^rND^nD
!v010!^sTeisseyre^rND^nM
!v010!^sWoynarowski^rND^nM
!v010!^sSocha^rND^nP
!v010!^sSocha^rND^nJ
!v010!^sRyzko^rND^nJ
!v012!Endoscopic ligation of esophageal varices for prophylaxis of first bleeding in children and adolescents with portal hypertension: preliminary results of a prospective study^len
!v014!1008-011
!v030!J Pediatr Surg
!v031!38
!v064!2003
!v065!20030000
!v118!10
!v514!^l1011^f1008
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000449
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sChandra^rND^nR
!v010!^sKapoor^rND^nD
!v010!^sTharakan^rND^nA
!v010!^sChaudhary^rND^nA
!v010!^sSarin^rND^nSK
!v012!Portal biliopathy^lpt
!v014!1086-092
!v030!J Gastroenterol Hepatol
!v031!16
!v064!2001
!v065!20010000
!v118!11
!v514!^l1092^f1086
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000450
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sCondat^rND^nB
!v010!^sValla^rND^nD
!v012!Nonmalignant portal vein thrombosis in adults^len
!v014!505-15
!v030!Nat Clin Pract Gastroenterol Hepatol
!v031!3
!v064!2006
!v065!20060000
!v118!12
!v514!^l515^f505
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000451
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sde Franchis^rND^nR
!v012!Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension^len
!v014!167-76
!v030!J Hepatol
!v031!43
!v064!2005
!v065!20050000
!v118!13
!v514!^l176^f167
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000452
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sde Ville de Goyet^rND^nJ
!v010!^sAlberti^rND^nD
!v010!^sFalchetti^rND^nD
!v010!^sRigamonti^rND^nW
!v010!^sMatricardi^rND^nL
!v010!^sClapuyt^rND^nP
!v010!^sSokal^rND^nEM
!v010!^sOtte^rND^nJB
!v010!^sCaccia^rND^nG
!v012!Treatment of extrahepatic portal hypertension in children by mesenteric-to-left portal vein bypass: a new physiological procedure^len
!v014!777-81
!v030!Eur J Surg
!v031!165
!v064!1999
!v065!19990000
!v118!14
!v514!^l781^f777
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000453
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sDenninger^rND^nMH
!v010!^sChait^rND^nY
!v010!^sCasadevall^rND^nN
!v010!^sHillaire^rND^nS
!v010!^sGuillin^rND^nMC
!v010!^sBezeaud^rND^nA
!v010!^sErlinger^rND^nS
!v010!^sBriere^rND^nJ
!v010!^sValla^rND^nD
!v012!Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors^len
!v014!587-91
!v030!Hepatology
!v031!31
!v064!2000
!v065!20000000
!v118!15
!v514!^l591^f587
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000454
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sDentali^rND^nF
!v010!^sSquizzato^rND^nA
!v010!^sBrivio^rND^nL
!v010!^sAppio^rND^nL
!v010!^sCampiotti^rND^nL
!v010!^sCrowther^rND^nM
!v010!^sGrandi^rND^nAM
!v010!^sAgeno^rND^nW
!v012!JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis^len
!v014!5617-623
!v030!Blood
!v031!113
!v064!2009
!v065!20090000
!v118!16
!v514!^l5623^f5617
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000455
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sEl-Karaksy^rND^nH
!v010!^sEl-Koofy^rND^nN
!v010!^sEl-Hawary^rND^nM
!v010!^sMostafa^rND^nA
!v010!^sAziz^rND^nM
!v010!^sEl-Shabrawi^rND^nM
!v010!^sMohsen^rND^nNA
!v010!^sKotb^rND^nM
!v010!^sEl-Raziky^rND^nM
!v010!^sEl-Sonoon^rND^nMA
!v010!^sA-Kader^rND^nH
!v012!Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study^len
!v014!712-15
!v030!Ann Hematol
!v031!83
!v064!2004
!v065!20040000
!v118!17
!v514!^l715^f712
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000456
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sFisher^rND^nNC
!v010!^sWilde^rND^nJT
!v010!^sRoper^rND^nJ
!v010!^sElias^rND^nE
!v012!Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon?^len
!v014!534-39
!v030!Gut
!v031!46
!v064!2000
!v065!20000000
!v118!18
!v514!^l539^f534
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000457
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sGuimaraes^rND^nH
!v010!^sCastelo^rND^nL
!v010!^sGuimaraes^rND^nJ
!v010!^sCardoso^rND^nA
!v010!^sd'Orey^rND^nC
!v010!^sMateus^rND^nM
!v010!^sAlmeida^rND^nA
!v010!^sAmil Dias^rND^nJ
!v010!^sRamos^rND^nI
!v010!^sTeixeira Santos^rND^nN
!v012!Does umbilical vein catheterization to exchange transfusion lead to portal vein thrombosis?^len
!v014!461-63
!v030!Eur J Pediatr
!v031!157
!v064!1998
!v065!19980000
!v118!19
!v514!^l463^f461
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000458
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sGurakan^rND^nF
!v010!^sEren^rND^nM
!v010!^sKocak^rND^nN
!v010!^sYuce^rND^nA
!v010!^sOzen^rND^nH
!v010!^sTemizel^rND^nIN
!v010!^sDemir^rND^nH
!v012!Extrahepatic portal vein thrombosis in children: etiology and long-term follow-up^len
!v014!368-72
!v030!J Clin Gastroenterol
!v031!38
!v064!2004
!v065!20040000
!v118!20
!v514!^l372^f368
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000459
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sHeller^rND^nC
!v010!^sSchobess^rND^nR
!v010!^sKurnik^rND^nK
!v010!^sJunker^rND^nR
!v010!^sGunther^rND^nG
!v010!^sKreuz^rND^nW
!v010!^sNowak-Gotti^rND^nU
!v012!Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group^len
!v014!534-39
!v030!Br J Haematol
!v031!111
!v064!2000
!v065!20000000
!v118!21
!v514!^l539^f534
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000460
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sHirohata^rND^nY
!v010!^sMurata^rND^nA
!v010!^sAbe^rND^nS
!v010!^sOtsuki^rND^nM
!v012!Portal vein thrombosis associated with antiphospholipid syndrome^len
!v014!574-78
!v030!J Gastroenterol
!v031!36
!v064!2001
!v065!20010000
!v118!22
!v514!^l578^f574
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000461
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sJanssen^rND^nHL
!v010!^sMeinardi^rND^nJR
!v010!^sVleggaar^rND^nFP
!v010!^svan Uum^rND^nSH
!v010!^sHaagsma^rND^nEB
!v010!^svan Der Meer^rND^nFJ
!v010!^svan Hattum^rND^nJ
!v010!^sChamuleau^rND^nRA
!v010!^sAdang^rND^nRP
!v010!^sVandenbrouke^rND^nJP
!v010!^svan Hoek^rND^nB
!v010!^sRosendaal^rND^nFR
!v012!Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study^len
!v014!2364-368
!v030!Blood
!v031!96
!v064!2000
!v065!20000000
!v118!23
!v514!^l2368^f2364
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000462
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sKato^rND^nT
!v010!^sRomero^rND^nR
!v010!^sKoutouby^rND^nR
!v010!^sMittal^rND^nNK
!v010!^sThompson^rND^nJF
!v010!^sSchleien^rND^nCL
!v010!^sTzakis^rND^nAG
!v012!Portosystemic shunting in children during the era of endoscopic therapy: improved postoperative growth parameters^len
!v014!419-25
!v030!J Pediatr Gastroenterol Nutr
!v031!30
!v064!2000
!v065!20000000
!v118!24
!v514!^l425^f419
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000463
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sKim^rND^nJH
!v010!^sLee^rND^nYS
!v010!^sKim^rND^nSH
!v010!^sLee^rND^nSK
!v010!^sLim^rND^nMK
!v010!^sKim^rND^nHS
!v012!Does umbilical vein catheterization lead to portal venous thrombosis? Prospective US evaluation in 100 neonates^len
!v014!645-50
!v030!Radiology
!v031!219
!v064!2001
!v065!20010000
!v118!25
!v514!^l650^f645
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000464
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sMack^rND^nCL
!v010!^sSuperina^rND^nRA
!v010!^sWhitington^rND^nPF
!v012!Surgical restoration of portal flow corrects procoagulant and anticoagulant deficiencies associated with extrahepatic portal vein thrombosis^len
!v014!197-99
!v030!J Pediatr
!v031!142
!v064!2003
!v065!20030000
!v118!26
!v514!^l199^f197
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000465
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sMaksoud-Filho^rND^nJG
!v010!^sGoncalves^rND^nME
!v010!^sCardoso^rND^nSR
!v010!^sGibelli^rND^nNE
!v010!^sTannuri^rND^nU
!v012!Long-term follow-up of children with extrahepatic portal vein obstruction: impact of an endoscopic sclerotherapy program on bleeding episodes, hepatic function, hypersplenism, and mortality^len
!v014!1877-883
!v030!J Pediatr Surg
!v031!44
!v064!2009
!v065!20090000
!v118!27
!v514!^l1883^f1877
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000466
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sMcKiernan^rND^nPJ
!v010!^sBeath^rND^nSV
!v010!^sDavison^rND^nSM
!v012!A prospective study of endoscopic esophageal variceal ligation using a multiband ligator^len
!v014!207-11
!v030!J Pediatr Gastroenterol Nutr
!v031!34
!v064!2002
!v065!20020000
!v118!28
!v514!^l211^f207
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000467
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sNorthup^rND^nPG
!v010!^sSundaram^rND^nV
!v010!^sFallon^rND^nMB
!v010!^sReddy^rND^nKR
!v010!^sBalogun^rND^nRA
!v010!^sSanyal^rND^nAJ
!v010!^sAnstee^rND^nQM
!v010!^sHoffman^rND^nMR
!v010!^sIkura^rND^nI
!v010!^sCaldwell^rND^nSH
!v012!Hypercoagulation and thrombophilia in liver disease^len
!v014!2-9
!v030!J Thromb Haemost
!v031!6
!v064!2008
!v065!20080000
!v118!29
!v514!^l9^f2
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000468
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sOdievre^rND^nM
!v010!^sPige^rND^nG
!v010!^sAlagille^rND^nD
!v012!Congenital abnormalities associated with extrahepatic portal hypertension^len
!v014!383-85
!v030!Arch Dis Child
!v031!52
!v064!1977
!v065!19770000
!v118!30
!v514!^l385^f383
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000469
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sOgren^rND^nM
!v010!^sBergqvist^rND^nD
!v010!^sBjorck^rND^nM
!v010!^sAcosta^rND^nS
!v010!^sEriksson^rND^nH
!v010!^sSternby^rND^nNH
!v012!Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies^len
!v014!2115-119
!v030!World J Gastroenterol
!v031!12
!v064!2006
!v065!20060000
!v118!31
!v514!^l2119^f2115
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000470
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sPinto^rND^nRB
!v010!^sSilveira^rND^nTR
!v010!^sBandinelli^rND^nE
!v010!^sRohsig^rND^nL
!v012!Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders^len
!v014!1356-361
!v030!J Pediatr Surg
!v031!39
!v064!2004
!v065!20040000
!v118!32
!v514!^l1361^f1356
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000471
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sPonziani^rND^nFR
!v010!^sZocco^rND^nMA
!v010!^sCampanale^rND^nC
!v010!^sRinninella^rND^nE
!v010!^sTortora^rND^nA
!v010!^sDi Maurizio^rND^nL
!v010!^sBombardieri^rND^nG
!v010!^sDe Cristofaro^rND^nR
!v010!^sDe Gaetano^rND^nAM
!v010!^sLandolfi^rND^nR
!v010!^sGasbarrini^rND^nA
!v012!Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment^len
!v014!143-55
!v030!World J Gastroenterol
!v031!16
!v064!2010
!v065!20100000
!v118!33
!v514!^l155^f143
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000472
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sPrimignani^rND^nM
!v012!Portal vein thrombosis, revisited^len
!v014!163-70
!v030!Dig Liver Dis
!v031!42
!v064!2010
!v065!20100000
!v118!34
!v514!^l170^f163
!v700!38
!v701!34
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000473
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sPugliese^rND^nRP
!v010!^sD´Amico^rND^nEA
!v010!^sRocha^rND^nTR
!v010!^sBydlowski^rND^nSP
!v010!^sVenturinelli^rND^nML
!v010!^sCardoso^rND^nRA
!v010!^sMiura^rND^nIK
!v010!^sChamone^rND^nDA
!v010!^sPorta^rND^nG
!v012!Risk factors in children and adolescents with portal vein thrombosis (PVT) and portal hypertension^len
!v014!551A
!v030!Hepatology
!v031!28
!v064!1998
!v065!19980000
!v118!35
!v514!^f551A
!v700!39
!v701!35
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000474
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sRangari^rND^nM
!v010!^sGupta^rND^nR
!v010!^sJain^rND^nM
!v010!^sMalhotra^rND^nV
!v010!^sSarin^rND^nSK
!v012!Hepatic dysfunction in patients with extrahepatic portal venous obstruction^len
!v014!434-39
!v030!Liver Int
!v031!23
!v064!2003
!v065!20030000
!v118!36
!v514!^l439^f434
!v700!40
!v701!36
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000475
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sRosendaal^rND^nFR
!v012!Venous thrombosis: a multicausal disease^len
!v014!1167-173
!v030!Lancet
!v031!353
!v064!1999
!v065!19990000
!v118!37
!v514!^l1173^f1167
!v700!41
!v701!37
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000476
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sSakha^rND^nSH
!v010!^sRafeey^rND^nM
!v010!^sTarzamani^rND^nMK
!v012!Portal venous thrombosis after umbilical vein catheterization^len
!v014!283-84
!v030!Indian J Gastroenterol
!v031!26
!v064!2007
!v065!20070000
!v118!38
!v514!^l284^f283
!v700!42
!v701!38
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000477
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sSarin^rND^nSK
!v010!^sAgarwal^rND^nSR
!v012!Extrahepatic portal vein obstruction^len
!v014!43-58
!v030!Semin Liver Dis
!v031!22
!v064!2002
!v065!20020000
!v118!39
!v514!^l58^f43
!v700!43
!v701!39
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000478
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sSarin^rND^nSK
!v010!^sSollano^rND^nJD
!v010!^sChawla^rND^nYK
!v010!^sAmarapurkar^rND^nD
!v010!^sHamid^rND^nS
!v010!^sHashizume^rND^nM
!v010!^sJafri^rND^nW
!v010!^sKumar^rND^nA
!v010!^sKudo^rND^nM
!v010!^sLesmana^rND^nLA
!v010!^sSharma^rND^nBC
!v010!^sShiha^rND^nG
!v010!^sJanaka de Silva^rND^nH
!v012!Consensus on extra-hepatic portal vein obstruction^len
!v014!512-19
!v030!Liver Int
!v031!26
!v064!2006
!v065!20060000
!v118!40
!v514!^l519^f512
!v700!44
!v701!40
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000479
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sSchettino^rND^nGC
!v010!^sFagundes^rND^nED
!v010!^sRoquete^rND^nML
!v010!^sFerreira^rND^nAR
!v010!^sPenna^rND^nFJ
!v012!Portal vein thrombosis in children and adolescents^len
!v014!171-78
!v030!J Pediatr (Rio J)
!v031!82
!v064!2006
!v065!20060000
!v118!41
!v514!^l178^f171
!v700!45
!v701!41
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000480
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sSchwartz^rND^nDS
!v010!^sGettner^rND^nPA
!v010!^sKonstantino^rND^nMM
!v010!^sBartley^rND^nCL
!v010!^sKeller^rND^nMS
!v010!^sEhrenkranz^rND^nRA
!v010!^sJacobs^rND^nHC
!v012!Umbilical venous catheterization and the risk of portal vein thrombosis^len
!v014!760-62
!v030!J Pediatr
!v031!131
!v064!1997
!v065!19970000
!v118!42
!v514!^l762^f760
!v700!46
!v701!42
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000481
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sSeixas^rND^nCA
!v010!^sHessel^rND^nG
!v010!^sSiqueira^rND^nLH
!v010!^sMachado^rND^nTF
!v010!^sGallizoni^rND^nAM
!v010!^sAnnichino-Bizzacchi^rND^nJM
!v012!Study of hemostasis in pediatric patients with portal vein thrombosis^len
!v014!955-56
!v030!Haematologica
!v031!83
!v064!1998
!v065!19980000
!v118!43
!v514!^l956^f955
!v700!47
!v701!43
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000482
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sSenders Aguirre^rND^nB
!v010!^sGarcia Sanz^rND^nMC
!v010!^sCasa Morcillo^rND^nA
!v012!Trombosis de la vena porta^les
!v014!565-68
!v030!Ana Esp Pediatr
!v031!55
!v064!2001
!v065!20010000
!v118!44
!v514!^l568^f565
!v700!48
!v701!44
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000483
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sSharma^rND^nS
!v010!^sKumar^rND^nSI
!v010!^sPoddar^rND^nU
!v010!^sYachha^rND^nSK
!v010!^sAggarwal^rND^nR
!v012!Factor V Leiden and prothrombin gene G20210A mutations are uncommon in portal vein thrombosis in India^len
!v014!236-39
!v030!Indian J Gastroenterol
!v031!25
!v064!2006
!v065!20060000
!v118!45
!v514!^l239^f236
!v700!49
!v701!45
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000484
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sShneider^rND^nB
!v010!^sEmre^rND^nS
!v010!^sGroszmann^rND^nR
!v010!^sKarani^rND^nJ
!v010!^sMcKiernan^rND^nP
!v010!^sSarin^rND^nS
!v010!^sShashidhar^rND^nH
!v010!^sSquires^rND^nR
!v010!^sSuperina^rND^nR
!v010!^sde Ville de Goyet^rND^nJ
!v010!^sde Franchis^rND^nR
!v012!Expert pediatric opinion on the Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension^len
!v014!893-907
!v030!Pediatr Transplant
!v031!10
!v064!2006
!v065!20060000
!v118!46
!v514!^l907^f893
!v700!50
!v701!46
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000485
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sSogaard^rND^nKK
!v010!^sAstrup^rND^nLB
!v010!^sVilstrup^rND^nH
!v010!^sGronbaek^rND^nH
!v012!Portal vein thrombosis; risk factors, clinical presentation and treatment^len
!v014!34
!v030!BMC Gastroenterol
!v031!7
!v064!2007
!v065!20070000
!v118!47
!v514!^f34
!v700!51
!v701!47
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000486
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sUttenreuther-Fischer^rND^nMM
!v010!^sVetter^rND^nB
!v010!^sHellmann^rND^nC
!v010!^sOtting^rND^nU
!v010!^sZiemer^rND^nS
!v010!^sHausdorf^rND^nG
!v010!^sGaedicke^rND^nG
!v010!^sKulozik^rND^nAE
!v012!Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency^len
!v014!277-81
!v030!Eur J Pediatr
!v031!156
!v064!1997
!v065!19970000
!v118!48
!v514!^l281^f277
!v700!52
!v701!48
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000487
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sValla^rND^nDC
!v010!^sCondat^rND^nB
!v012!Portal vein thrombosis in adults: pathophysiology, pathogenesis and management^len
!v014!865-71
!v030!J Hepatol
!v031!32
!v064!2000
!v065!20000000
!v118!49
!v514!^l871^f865
!v700!53
!v701!49
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000488
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sWang^rND^nJT
!v010!^sZhao^rND^nHY
!v010!^sLiu^rND^nYL
!v012!Portal vein thrombosis^len
!v014!515-18
!v030!Hepatobiliary Pancreat Dis Int
!v031!4
!v064!2005
!v065!20050000
!v118!50
!v514!^l518^f515
!v700!54
!v701!50
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000489
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sWebb^rND^nLJ
!v010!^sSherlock^rND^nS
!v012!The aetiology, presentation and natural history of extra-hepatic portal venous obstruction^len
!v014!627-39
!v030!Q J Med
!v031!48
!v064!1979
!v065!19790000
!v118!51
!v514!^l639^f627
!v700!55
!v701!51
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000490
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sWebster^rND^nGJ
!v010!^sBurroughs^rND^nAK
!v010!^sRiordan^rND^nSM
!v012!Review article: portal vein thrombosis - new insights into aetiology and management^len
!v014!1-9
!v030!Aliment Pharmacol Ther
!v031!21
!v064!2005
!v065!20050000
!v118!52
!v514!^l9^f1
!v700!56
!v701!52
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000491
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sWeiss^rND^nB
!v010!^sShteyer^rND^nE
!v010!^sVivante^rND^nA
!v010!^sBerkowitz^rND^nD
!v010!^sReif^rND^nS
!v010!^sWeizman^rND^nZ
!v010!^sBujanover^rND^nY
!v010!^sShapiro^rND^nR
!v012!Etiology and long-term outcome of extrahepatic portal vein obstruction in children^len
!v014!4968-972
!v030!World J Gastroenterol
!v031!16
!v064!2010
!v065!20100000
!v118!53
!v514!^l4972^f4968
!v700!57
!v701!53
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000492
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sYachha^rND^nSK
!v010!^sAggarwal^rND^nR
!v010!^sSharma^rND^nBC
!v010!^sMisra^rND^nRN
!v010!^sAggarwal^rND^nA
!v010!^sNaik^rND^nSR
!v012!Functional protein C and anti-cardiolipin antibody in children with portal vein thrombosis^len
!v014!47-9
!v030!Indian J Gastroenterol
!v031!20
!v064!2001
!v065!20010000
!v118!54
!v514!^l49^f47
!v700!58
!v701!54
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000493
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sYamada^rND^nRM
!v010!^sAntunes^rND^nMM
!v010!^sCardoso^rND^nSR
!v010!^sServidoni^rND^nMF
!v010!^sHessel^rND^nG
!v014!49-53
!v030!Arq Gastroenterol
!v031!36
!v064!1999
!v065!19990000
!v118!55
!v514!^l53^f49
!v700!59
!v701!55
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000494
!v001!br1.1
!v002!0004-2803-ag-49-01-69.xml
!v004!v49n1
!v010!^sZargar^rND^nSA
!v010!^sJavid^rND^nG
!v010!^sKhan^rND^nBA
!v010!^sYattoo^rND^nGN
!v010!^sShah^rND^nAH
!v010!^sGulzar^rND^nGM
!v010!^sSingh^rND^nJ
!v010!^sRehman^rND^nBU
!v010!^sDin^rND^nZ
!v012!Endoscopic ligation compared with sclerotherapy for bleeding esophageal varices in children with extrahepatic portal venous obstruction^len
!v014!666-72
!v030!Hepatology
!v031!36
!v064!2002
!v065!20020000
!v118!56
!v514!^l672^f666
!v700!60
!v701!56
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-69.xml
!v705!S
!v706!c
!v708!56
!v865!20120300
!ID 000495
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v091!20120814
!v092!164324
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v703!97
!v705!S
!v706!o
!v708!1
!ID 000496
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sChatopadhyay^rauthor^nPronobesh
!v010!^sPandey^rauthor^nAnurag
!v010!^sChaurasia^rauthor^nAsshwani K.
!v010!^sUpadhyay^rauthor^nAddesh
!v010!^sKarmakar^rauthor^nSanjev
!v010!^sSingh^rauthor^nLokendra
!v012!^tHepatic hyperplasia and damages induces by zearalenone Fusarium mycotoxins in BALB/c mice
!v012!^tHiperplasia e danos hepaticos induzidos por micotoxinas do genero Fusarium-zearalenone em camundongos BAB/c^lpt
!v014!^l81^f77
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!EXPERIMENTAL_GASTROENTEROLOGY
!v064!Jan-Mar
!v065!20120300
!v070!Division of Pharmaceutical Technology, Defence Research Laboratory^iaff1^9Division of Pharmaceutical Technology, Defence Research Laboratory^5?
!v071!oa
!v072!19
!v083!^a<sec>					<title>CONTEXT:</title>					 Zearalenone is a mycoestrogen and considered a mycotoxin. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To establish whether zearalenone produced hepatotoxicity via oral administration. 				</sec>				<sec>					<title>METHODS:</title>					 Zearalenone was orally administered at a dose of 50 mg, 100 mg and 200 mg ZEN/body weight/daily, respectively, for 14 days to three groups of BALB/c mice. Diagnostic modalities used to evaluate hepatic damage and impaired hepatic function pre- and post zearalenone administration included hepatic marker enzyme activity, pentobarbital sleeping time, cytochrome P-450 activities and histopathologic evaluation of liver. 				</sec>				<sec>					<title>RESULTS:</title>					 Significant histopathologic changes viz. sinusoidal congestion, cytoplasmic vacuolization, hepatocellular necrosis and neutrophil infiltration were observed after evaluating of liver section from each group after accumulated zearalenone exposure. Further, zearalenone exposure increased activities of alanine transaminase, aspartate transaminase and lipid peroxides whereas activities of tissue glutathione and cytochrome P450 were decreased as compared to control mice. Zearalenone also increased the sleeping time and decreased sleeping latency after pentobarbital through intraperitoneal route as compared to control mice which indicates that the impairment of hepatic metabolizing enzymes by zearalenone. 				</sec>				<sec>					<title>CONCLUSION:</title>					 Zearalenone is a potential hepatotoxin by oral route.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 Zearalenone e um micoestrogeno e considerado como micotoxina.  				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar se o Zearalenone produz hepatotoxicidade por administracao via oral. 				</sec>				<sec>					<title>MeTODOS:</title>					 Zearalenone foi administrada por via oral em doses de 50 &#181;g, 100 &#181;g e 200 &#181;g/peso corporal/dia/14 dias, respectivamente, para tres grupos de camundongos BAB/C. Modalidades diagnosticas usadas para avaliar o dano hepatico e comprometimento da funcao hepatica pre- e pos-administracao de Zearalenone incluiram atividade enzimatica de marcadores hepaticos, tempo de sono por pentobarbital, atividade do citocromo P-450 e avaliacao histopatologica hepatica. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Alteracoes histopatologicas significantes como congestao sinusoidal, vacuolizacao citoplasmatica, necrose hepatocelular e infiltracao neutrofilica foram observadas apos avaliacao histologica de cada grupo apos exposicao acumulada de Zearalenone. Alem disto, a exposicao a Zearalenone incrementou a atividade das enzimas alanina transaminase e aspartato transaminase e peroxidos lipidicos, ao passo que as atividades teciduais de glutationa e citocromo P-450 diminuiram, quando comparadas com camundongos-controle. Zearalenone tambem aumentou o tempo de sono e diminuiu a latencia do sono apos a administracao de pentobarbital por via intra-abdominal, quando comparados com camundongos-controle, o que indica o comprometimento das enzimas do metabolismo hepatico por ela. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 Zearalenone e uma potente hepatotoxina quando administrada por via oral.				</sec>^lpt
!v085!^kZearalenone^len
!v085!^kHyperplasia^len
!v085!^kLiver, pathology^len
!v085!^kMice^len
!v085!^kHiperplasia^lpt
!v085!^kZearalenona^lpt
!v085!^kFigado, patologia^lpt
!v085!^kCamundongos^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m09^d01
!v112!2011
!v113!^y2011^m09^d20
!v114!2011
!v120!XML_3.0
!v121!77
!v237!10.1590/S0004-28032012000100013
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!h
!v708!1
!ID 000497
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sChatopadhyay^rauthor^nPronobesh
!v010!^sPandey^rauthor^nAnurag
!v010!^sChaurasia^rauthor^nAsshwani K.
!v010!^sUpadhyay^rauthor^nAddesh
!v010!^sKarmakar^rauthor^nSanjev
!v010!^sSingh^rauthor^nLokendra
!v012!^tHepatic hyperplasia and damages induces by zearalenone <italic>Fusarium</italic> mycotoxins in BALB/c mice
!v012!^tHiperplasia e danos hep&#225;ticos induzidos por micotoxinas do g&#234;nero <italic>Fusarium</italic>-zearalenone em camundongos BAB/c^lpt
!v014!^l81^f77
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!EXPERIMENTAL_GASTROENTEROLOGY
!v064!Jan-Mar
!v065!20120300
!v070!Division of Pharmaceutical Technology, Defence Research Laboratory^iaff1^9Division of Pharmaceutical Technology, Defence Research Laboratory^5?
!v071!oa
!v072!19
!v083!^a<sec>					<title>CONTEXT:</title>					<p> Zearalenone is a mycoestrogen and considered a mycotoxin. </p>				</sec>				<sec>					<title>OBJECTIVE:</title>					<p> To establish whether zearalenone produced hepatotoxicity via oral administration. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> Zearalenone was orally administered at a dose of 50 mg, 100 mg and 200 mg ZEN/body weight/daily, respectively, for 14 days to three groups of BALB/c mice. Diagnostic modalities used to evaluate hepatic damage and impaired hepatic function pre- and post zearalenone administration included hepatic marker enzyme activity, pentobarbital sleeping time, cytochrome P-<sub>450</sub> activities and histopathologic evaluation of liver. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> Significant histopathologic changes viz. sinusoidal congestion, cytoplasmic vacuolization, hepatocellular necrosis and neutrophil infiltration were observed after evaluating of liver section from each group after accumulated zearalenone exposure. Further, zearalenone exposure increased activities of alanine transaminase, aspartate transaminase and lipid peroxides whereas activities of tissue glutathione and cytochrome P450 were decreased as compared to control mice. Zearalenone also increased the sleeping time and decreased sleeping latency after pentobarbital through intraperitoneal route as compared to control mice which indicates that the impairment of hepatic metabolizing enzymes by zearalenone. </p>				</sec>				<sec>					<title>CONCLUSION:</title>					<p> Zearalenone is a potential hepatotoxin by oral route.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> Zearalenone &#233; um micoestr&#243;geno e considerado como micotoxina.  </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Avaliar se o Zearalenone produz hepatotoxicidade por administra&#231;&#227;o via oral. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Zearalenone foi administrada por via oral em doses de 50 &#181;g, 100 &#181;g e 200 &#181;g/peso corporal/dia/14 dias, respectivamente, para tr&#234;s grupos de camundongos BAB/C. Modalidades diagn&#243;sticas usadas para avaliar o dano hep&#225;tico e comprometimento da fun&#231;&#227;o hep&#225;tica pr&#233;- e p&#243;s-administra&#231;&#227;o de Zearalenone inclu&#237;ram atividade enzim&#225;tica de marcadores hep&#225;ticos, tempo de sono por pentobarbital, atividade do citocromo P-450 e avalia&#231;&#227;o histopatol&#243;gica hep&#225;tica. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Altera&#231;&#245;es histopatol&#243;gicas significantes como congest&#227;o sinusoidal, vacuoliza&#231;&#227;o citoplasm&#225;tica, necrose hepatocelular e infiltra&#231;&#227;o neutrof&#237;lica foram observadas ap&#243;s avalia&#231;&#227;o histol&#243;gica de cada grupo ap&#243;s exposi&#231;&#227;o acumulada de Zearalenone. Al&#233;m disto, a exposi&#231;&#227;o &#224; Zearalenone incrementou a atividade das enzimas alanina transaminase e aspartato transaminase e per&#243;xidos lip&#237;dicos, ao passo que as atividades teciduais de glutationa e citocromo P-450 diminuiram, quando comparadas com camundongos-controle. Zearalenone tamb&#233;m aumentou o tempo de sono e diminuiu a lat&#234;ncia do sono ap&#243;s a administra&#231;&#227;o de pentobarbital por via intra-abdominal, quando comparados com camundongos-controle, o que indica o comprometimento das enzimas do metabolismo hep&#225;tico por ela. </p>				</sec>				<sec>					<title>CONCLUS&#195;O:</title>					<p> Zearalenone &#233; uma potente hepatotoxina quando administrada por via oral.</p>				</sec>^lpt
!v085!^kZearalenone^len
!v085!^kHyperplasia^len
!v085!^kLiver, pathology^len
!v085!^kMice^len
!v085!^kHiperplasia^lpt
!v085!^kZearalenona^lpt
!v085!^kFígado, patologia^lpt
!v085!^kCamundongos^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m09^d01
!v112!2011
!v113!^y2011^m09^d20
!v114!2011
!v120!XML_3.0
!v121!77
!v237!10.1590/S0004-28032012000100013
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!f
!v708!1
!ID 000498
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sChatopadhyay^rauthor^nPronobesh
!v010!^sPandey^rauthor^nAnurag
!v010!^sChaurasia^rauthor^nAsshwani K.
!v010!^sUpadhyay^rauthor^nAddesh
!v010!^sKarmakar^rauthor^nSanjev
!v010!^sSingh^rauthor^nLokendra
!v012!^tHepatic hyperplasia and damages induces by zearalenone Fusarium mycotoxins in BALB/c mice
!v012!^tHiperplasia e danos hepaticos induzidos por micotoxinas do genero Fusarium-zearalenone em camundongos BAB/c^lpt
!v014!^l81^f77
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!EXPERIMENTAL_GASTROENTEROLOGY
!v064!Jan-Mar
!v065!20120300
!v070!Division of Pharmaceutical Technology, Defence Research Laboratory^iaff1^9Division of Pharmaceutical Technology, Defence Research Laboratory^5?
!v071!oa
!v072!19
!v083!^a<sec>					<title>CONTEXT:</title>					 Zearalenone is a mycoestrogen and considered a mycotoxin. 				</sec>				<sec>					<title>OBJECTIVE:</title>					 To establish whether zearalenone produced hepatotoxicity via oral administration. 				</sec>				<sec>					<title>METHODS:</title>					 Zearalenone was orally administered at a dose of 50 mg, 100 mg and 200 mg ZEN/body weight/daily, respectively, for 14 days to three groups of BALB/c mice. Diagnostic modalities used to evaluate hepatic damage and impaired hepatic function pre- and post zearalenone administration included hepatic marker enzyme activity, pentobarbital sleeping time, cytochrome P-450 activities and histopathologic evaluation of liver. 				</sec>				<sec>					<title>RESULTS:</title>					 Significant histopathologic changes viz. sinusoidal congestion, cytoplasmic vacuolization, hepatocellular necrosis and neutrophil infiltration were observed after evaluating of liver section from each group after accumulated zearalenone exposure. Further, zearalenone exposure increased activities of alanine transaminase, aspartate transaminase and lipid peroxides whereas activities of tissue glutathione and cytochrome P450 were decreased as compared to control mice. Zearalenone also increased the sleeping time and decreased sleeping latency after pentobarbital through intraperitoneal route as compared to control mice which indicates that the impairment of hepatic metabolizing enzymes by zearalenone. 				</sec>				<sec>					<title>CONCLUSION:</title>					 Zearalenone is a potential hepatotoxin by oral route.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 Zearalenone e um micoestrogeno e considerado como micotoxina.  				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar se o Zearalenone produz hepatotoxicidade por administracao via oral. 				</sec>				<sec>					<title>MeTODOS:</title>					 Zearalenone foi administrada por via oral em doses de 50 &#181;g, 100 &#181;g e 200 &#181;g/peso corporal/dia/14 dias, respectivamente, para tres grupos de camundongos BAB/C. Modalidades diagnosticas usadas para avaliar o dano hepatico e comprometimento da funcao hepatica pre- e pos-administracao de Zearalenone incluiram atividade enzimatica de marcadores hepaticos, tempo de sono por pentobarbital, atividade do citocromo P-450 e avaliacao histopatologica hepatica. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Alteracoes histopatologicas significantes como congestao sinusoidal, vacuolizacao citoplasmatica, necrose hepatocelular e infiltracao neutrofilica foram observadas apos avaliacao histologica de cada grupo apos exposicao acumulada de Zearalenone. Alem disto, a exposicao a Zearalenone incrementou a atividade das enzimas alanina transaminase e aspartato transaminase e peroxidos lipidicos, ao passo que as atividades teciduais de glutationa e citocromo P-450 diminuiram, quando comparadas com camundongos-controle. Zearalenone tambem aumentou o tempo de sono e diminuiu a latencia do sono apos a administracao de pentobarbital por via intra-abdominal, quando comparados com camundongos-controle, o que indica o comprometimento das enzimas do metabolismo hepatico por ela. 				</sec>				<sec>					<title>CONCLUSaO:</title>					 Zearalenone e uma potente hepatotoxina quando administrada por via oral.				</sec>^lpt
!v085!^kZearalenone^len
!v085!^kHyperplasia^len
!v085!^kLiver, pathology^len
!v085!^kMice^len
!v085!^kHiperplasia^lpt
!v085!^kZearalenona^lpt
!v085!^kFigado, patologia^lpt
!v085!^kCamundongos^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m09^d01
!v112!2011
!v113!^y2011^m09^d20
!v114!2011
!v120!XML_3.0
!v121!77
!v237!10.1590/S0004-28032012000100013
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!l
!v708!1
!ID 000499
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sAyed^rND^nY
!v010!^sAyed-Boussema^rND^nI
!v010!^sOuanes^rND^nZ
!v010!^sBacha^rND^nH
!v012!In vitro and in vivo induction of chromosome aberrations by alpha- and beta-zearalenols: comparison with zearalenone^len
!v030!Mutat Res
!v064!2011
!v065!20110000
!v071!journal
!v118!1
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000500
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sEllman^rND^nGL
!v012!Tissue sulfhydryl groups^len
!v014!70-7
!v030!Arch Biochem Biophys
!v031!82
!v064!1959
!v065!19590000
!v118!2
!v514!^l77^f70
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000501
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sFrizzell^rND^nC
!v010!^sNdossi^rND^nD
!v010!^sVerhaegen^rND^nS
!v010!^sDahl^rND^nE
!v010!^sEriksen^rND^nG
!v010!^sSorilie^rND^nM
!v010!^sRopstad^rND^nE
!v010!^sMuller^rND^nM
!v010!^sElliott^rND^nCt
!v010!^sConnolly^rND^nL
!v012!Endocrine disrupting effects of zearalenone, alpha- and beta-zearalenol at the level of nuclear receptor binding and steroidogenesis^len
!v014!210-17
!v030!Toxicol Lett
!v031!206
!v064!2011
!v065!20110000
!v118!3
!v514!^l217^f210
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000502
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sGuengerich^rND^nFP
!v012!Cytochrome P-450 3A4: regulation and role in drug metabolism^len
!v014!1-17
!v030!Annu Rev Pharmacol Toxicol
!v031!39
!v064!1999
!v065!19990000
!v118!4
!v514!^l17^f1
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000503
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sHidy^rND^nPH
!v010!^sBaldwin^rND^nRS
!v010!^sGreasham^rND^nRL
!v010!^sKeith^rND^nCL
!v010!^sMcMullen^rND^nJR
!v012!Zearalenone and some derivatives: production and biological activities^len
!v014!59-82
!v030!Adv Appl Microbiol
!v031!22
!v064!1977
!v065!19770000
!v118!5
!v514!^l82^f59
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000504
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sJaeschke^rND^nH
!v010!^sFarhood^rND^nA
!v012!Neutrophil and kupffer cell-induced oxidant stress and ischemic-reperfusion injury in rat liver^len
!v014!G355-GG62
!v030!Am J Physiol
!v031!260
!v064!1991
!v065!19910000
!v118!6
!v514!^lGG62^fG355
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000505
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sJordan^rND^nRA
!v010!^sSchenkman^rND^nJB
!v012!Relationship between malondialdehyde production and arachidonate consumption during NADPH supported microsomal lipid peroxidation^len
!v014!1393-400
!v030!Biochem Pharmacol
!v031!31
!v064!1982
!v065!19820000
!v118!7
!v514!^l1400^f1393
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000506
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sKatzenellenbogen^rND^nBS
!v010!^sKorach^rND^nKS
!v012!A new actor in the estrogen receptor drama-enter ER-beta^len
!v014!861-62
!v030!Endocrinology
!v031!138
!v064!1997
!v065!19970000
!v118!8
!v514!^l862^f861
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000507
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sKilakivi-Clarke^rND^nL
!v010!^sCho^rND^nE
!v010!^sOnojafe^rND^nI
!v010!^sRaygada^rND^nM
!v010!^sClarke^rND^nR
!v012!Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorgenesis in female rat offspring^len
!v014!1089-095
!v030!Oncol Rep
!v031!6
!v064!1999
!v065!19990000
!v118!9
!v514!^l1095^f1089
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000508
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sKuiper^rND^nGG
!v010!^sLemmen^rND^nJG
!v010!^sCarlsson^rND^nB
!v010!^sCorton^rND^nJC
!v010!^sSafe^rND^nSH
!v010!^svan der Saag^rND^nPT
!v010!^svan der Burg^rND^nB
!v010!^sGustafsson^rND^nJA
!v012!Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta^len
!v014!4252-263
!v030!Endocrinology
!v031!139
!v064!1998
!v065!19980000
!v118!10
!v514!^l4263^f4252
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000509
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sLa Vecchia^rND^nC
!v010!^sNegri^rND^nE
!v010!^sParazzini^rND^nF
!v012!Oral contraceptives and primary liver cancer^len
!v014!460-61
!v030!Br J Cancer
!v031!59
!v064!1989
!v065!19890000
!v118!11
!v514!^l461^f460
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000510
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sMant^rND^nJW
!v010!^sVessey^rND^nMP
!v012!Trends in mortality from primary liver cancer in England and Wales 1975-92: influence of oral contraceptives^len
!v014!800-03
!v030!Br J Cancer
!v031!72
!v064!1995
!v065!19950000
!v118!12
!v514!^l803^f800
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000511
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sMarin^rND^nDE
!v010!^sTaranu^rND^nI
!v010!^sBurlacu^rND^nR
!v010!^sTudor^rND^nDS
!v012!Effects of zearalenone and its derivatives on the innate immune response of swine^len
!v014!956-63
!v030!Toxicon
!v031!56
!v064!2010
!v065!20100000
!v118!13
!v514!^l963^f956
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000512
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sMarin^rND^nDE
!v010!^sTaranu^rND^nI
!v010!^sBurlacu^rND^nR
!v010!^sManda^rND^nG
!v010!^sMotiu^rND^nM
!v010!^sNeagoe^rND^nI
!v010!^sDragomir^rND^nC
!v010!^sStancu^rND^nM
!v010!^sCalin^rND^nL
!v012!Effects of zearalenone and its derivatives on porcine immune response^len
!v014!1981-988
!v030!Toxicol In Vitro
!v031!25
!v064!2011
!v065!20110000
!v118!14
!v514!^l1988^f1981
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000513
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sMarubayashi^rND^nS
!v010!^sDohi^rND^nK
!v010!^sOchi^rND^nK
!v010!^sKawaski^rND^nT
!v012!Role of free radicals in ischemic rat liver cell injury: prevention of damage by alpha-tocopherol administration^len
!v014!184-82
!v030!Surgery
!v031!99
!v064!1986
!v065!19860000
!v118!15
!v514!^l182^f184
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000514
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sOmura^rND^nT
!v010!^sSato^rND^nR
!v012!The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature^len
!v014!2370-378
!v030!J Biol Chem
!v031!239
!v064!1964
!v065!19640000
!v118!16
!v514!^l2378^f2370
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000515
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sSalah-Abbes^rND^nJ
!v010!^sAbbes^rND^nS
!v010!^sOuanes^rND^nZ
!v010!^sHouas^rND^nZ
!v010!^sAbdel-Wahhab^rND^nMA
!v010!^sBacha^rND^nH
!v010!^sOueslati^rND^nR
!v012!Tunisian radish extract (							Raphanus							sativus						) enhances the antioxidant status and protects against oxidative stress induced by zearalenone in Balb/c mice^len
!v014!6-14
!v030!J Appl Toxicol
!v031!28
!v064!2008
!v065!20080000
!v118!17
!v514!^l14^f6
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000516
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sSchenkman^rND^nJB
!v010!^sCinti^rND^nDL
!v012!Preparation of microsomes with calcium^len
!v014!83-9
!v030!Methods Enzymol
!v031!52
!v064!1978
!v065!19780000
!v118!18
!v514!^l89^f83
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000517
!v001!br1.1
!v002!0004-2803-ag-49-01-77.xml
!v004!v49n1
!v010!^sShimamatsu^rND^nK
!v010!^sWanless^rND^nIR
!v012!Role of ischemia causing apoptosis, athropy and nodular hyperplasia in human liver^len
!v014!343-50
!v030!Hepatology
!v031!26
!v064!1997
!v065!19970000
!v118!19
!v514!^l350^f343
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-77.xml
!v705!S
!v706!c
!v708!19
!v865!20120300
!ID 000518
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v091!20120814
!v092!164327
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v703!136
!v705!S
!v706!o
!v708!1
!ID 000519
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^1aff1^sFonseca^rauthor^nJorge
!v010!^sMartins-dos-Santos^rauthor^nJose
!v010!^sOliveira^rauthor^nPedro
!v010!^sLaranjeira^rauthor^nNuno
!v010!^sAguas^rauthor^nArtur
!v010!^sCastelo-Branco^rauthor^nNuno
!v012!^sa light and electron microscopy study of the rat gastric wall exposed to low frequency noise^tNoise-induced gastric lesions
!v012!^sum estudo por microscopia otica e eletronica da parede gastrica do rato exposta a ruido de baixa frequencia^tLesoes gastricas induzidas pelo ruido^lpt
!v014!^l88^f82
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!EXPERIMENTAL_GASTROENTEROLOGY
!v064!Jan-Mar
!v065!20120300
!v070!Instituto Superior de Ciencias da Saude Egas Moniz (CiiEM)^cAlmada^iaff1^l1^pPortugal^5?^9Instituto Superior de Ciencias da Saude Egas Moniz (CiiEM), Almada, Portugal
!v070!Instituto de Ciencias Biomedicas Abel Salazar - Universidade do Porto (UMIB)^cPorto^iaff2^l2^pPortugal^5?^9Instituto de Ciencias Biomedicas Abel Salazar - Universidade do Porto (UMIB), Porto, Portugal
!v070!Center for Human Performance^cAlverca^iaff3^l3^pPortugal^5?^9Center for Human Performance, Alverca, Portugal
!v071!oa
!v072!58
!v083!^a<sec>					<title>CONTEXT:</title>					 Only a few studies evaluated the digestive alterations caused by low frequency noise (LFN) and most focused only on mucosal alterations. 				</sec>				<sec>					<title>OBJECTIVES:</title>					 To investigate the morphological injury of LFN-exposed gastric wall, beyond the epithelial layer. 				</sec>				<sec>					<title>METHODS:</title>					 Wistar rats were exposed to low frequency noise (LFN), during increasing periods, 1 to 13 weeks. A control group was kept in silence. Gastric specimens were studied using: (i) light microscopy with hematoxylin-eosin and immunostaining for collagens; (ii) transmission electron microscopy; (iii) morphometry allowing statistical analysis. 				</sec>				<sec>					<title>RESULTS:</title>					 Submucosa of all LFN-exposed animals exhibit increased thickness with fibrous proliferation. Transmission electron microscopy showed massive collagen deposition. Immunostaining identified collagen IV as responsible for the increased thickness. Morphometry allowed the demonstration of a significant difference of thickness between control and exposed groups. Vascular alterations included: i) intima proliferation and thickening, rupture of the internal elastic lamina, thrombotic changes; ii) thickening of the media; iii) after 9 weeks of LFN-exposure, we found new formed vessel presenting tortuous and twisted. There is a significant difference of arterial wall thickness between control and exposed groups. 				</sec>				<sec>					<title>CONCLUSIONS:</title>					 Deeper layers of gastric wall undergo alterations, including fibrosis of the submucosa caused by collagen IV deposition, an early marker of neoangiogenesis. Vascular alterations included thickening and thrombotic phenomena, but also images of newly formed vessels. This study suggests that, at least in the stomach, LFN-induced fibrosis could be linked with neoangiogenesis.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 So um reduzido numero de estudos avaliou as alteracoes digestivas causadas pelo ruido de baixa frequencia (RBF) e, na sua maioria, focados nas alteracoes da mucosa. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar as lesoes morfologicas induzidas na parede gastrica pelo RBF, para alem da camada mucosa. 				</sec>				<sec>					<title>MeTODOS:</title>					 Ratos Wistar foram expostos a RBF, por periodos crescentes, desde 1 a 13 semanas. Um grupo controle foi mantido em silencio. Fragmentos da parede gastrica foram estudados com recurso a: (i) microscopia otica usando hematoxilina-eosina e imunomarcacao para colagenos; (ii) microscopia eletronica de transmissao; (iii) morfometria, permitindo a colheita de dados para analise estatistica. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Observaram-se espessamento e proliferacao de tecido fibroso na submucosa de todos os animais expostos aos RBF. A microscopia eletronica de transmissao mostrou marcada deposicao de colageno. A imunomarcacao identificou o colageno IV como responsavel pelo espessamento da submucosa. A morfometria permitiu demonstrar que a diferenca de espessura da submucosa entre o grupo controle e os grupos de animais expostos era estatisticamente significativo. As alteracoes vasculares incluiram: (i) proliferacao e espessamento da intima, com rotura da lamina elastica interna e fenomenos tromboticos; (ii) espessamento da media; (iii) apos 9 semanas de exposicao ao RBF, observaram-se vasos neoformados tortuosos e contorcidos. A espessura dos vasos dos animais expostos ao ruido e significativamente maior que a espessura no grupo controle. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 As camadas profundas da parede gastrica sofrem alteracoes que incluem fibrose causada pela deposicao de colageno IV, marcador precoce de neoangiogenese. As alteracoes vasculares incluem espessamento e fenomenos tromboticos e vasos neoformados. O presente estudo sugere que, pelo menos no estomago, a fibrose associada ao RBF pode estar ligada a neoangiogenese.				</sec>^lpt
!v085!^kGastric mucosa, physiopathology^len
!v085!^kNoise effects^len
!v085!^kMicroscopy, electron^len
!v085!^kRats^len
!v085!^kMucosa gastrica, fisiopatologia^lpt
!v085!^kEfeitos do ruido^lpt
!v085!^kMicroscopia eletronica^lpt
!v085!^kRatos^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m09^d25
!v112!2011
!v113!^y2011^m10^d10
!v114!2011
!v120!XML_3.0
!v121!82
!v237!10.1590/S0004-28032012000100014
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!h
!v708!1
!ID 000520
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^1aff1^sFonseca^rauthor^nJorge
!v010!^sMartins-dos-Santos^rauthor^nJosé
!v010!^sOliveira^rauthor^nPedro
!v010!^sLaranjeira^rauthor^nNuno
!v010!^sAguas^rauthor^nArtur
!v010!^sCastelo-Branco^rauthor^nNuno
!v012!^sa light and electron microscopy study of the rat gastric wall exposed to low frequency noise^tNoise-induced gastric lesions
!v012!^sum estudo por microscopia ótica e eletrônica da parede gástrica do rato exposta a ruído de baixa frequência^tLesões gástricas induzidas pelo ruído^lpt
!v014!^l88^f82
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!EXPERIMENTAL_GASTROENTEROLOGY
!v064!Jan-Mar
!v065!20120300
!v070!Instituto Superior de Ci&#234;ncias da Sa&#250;de Egas Moniz (CiiEM)^cAlmada^iaff1^l1^pPortugal^5?^9Instituto Superior de Ci&#234;ncias da Sa&#250;de Egas Moniz (CiiEM), Almada, Portugal
!v070!Instituto de Ci&#234;ncias Biom&#233;dicas Abel Salazar - Universidade do Porto (UMIB)^cPorto^iaff2^l2^pPortugal^5?^9Instituto de Ci&#234;ncias Biom&#233;dicas Abel Salazar - Universidade do Porto (UMIB), Porto, Portugal
!v070!Center for Human Performance^cAlverca^iaff3^l3^pPortugal^5?^9Center for Human Performance, Alverca, Portugal
!v071!oa
!v072!58
!v083!^a<sec>					<title>CONTEXT:</title>					<p> Only a few studies evaluated the digestive alterations caused by low frequency noise (LFN) and most focused only on mucosal alterations. </p>				</sec>				<sec>					<title>OBJECTIVES:</title>					<p> To investigate the morphological injury of LFN-exposed gastric wall, beyond the epithelial layer. </p>				</sec>				<sec>					<title>METHODS:</title>					<p> Wistar rats were exposed to low frequency noise (LFN), during increasing periods, 1 to 13 weeks. A control group was kept in silence. Gastric specimens were studied using: (i) light microscopy with hematoxylin-eosin and immunostaining for collagens; (ii) transmission electron microscopy; (iii) morphometry allowing statistical analysis. </p>				</sec>				<sec>					<title>RESULTS:</title>					<p> Submucosa of all LFN-exposed animals exhibit increased thickness with fibrous proliferation. Transmission electron microscopy showed massive collagen deposition. Immunostaining identified collagen IV as responsible for the increased thickness. Morphometry allowed the demonstration of a significant difference of thickness between control and exposed groups. Vascular alterations included: i) intima proliferation and thickening, rupture of the internal elastic lamina, thrombotic changes; ii) thickening of the media; iii) after 9 weeks of LFN-exposure, we found new formed vessel presenting tortuous and twisted. There is a significant difference of arterial wall thickness between control and exposed groups. </p>				</sec>				<sec>					<title>CONCLUSIONS:</title>					<p> Deeper layers of gastric wall undergo alterations, including fibrosis of the submucosa caused by collagen IV deposition, an early marker of neoangiogenesis. Vascular alterations included thickening and thrombotic phenomena, but also images of newly formed vessels. This study suggests that, at least in the stomach, LFN-induced fibrosis could be linked with neoangiogenesis.</p>				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					<p> S&#243; um reduzido n&#250;mero de estudos avaliou as altera&#231;&#245;es digestivas causadas pelo ru&#237;do de baixa frequ&#234;ncia (RBF) e, na sua maioria, focados nas altera&#231;&#245;es da mucosa. </p>				</sec>				<sec>					<title>OBJETIVO:</title>					<p> Avaliar as les&#245;es morfol&#243;gicas induzidas na parede g&#225;strica pelo RBF, para al&#233;m da camada mucosa. </p>				</sec>				<sec>					<title>M&#201;TODOS:</title>					<p> Ratos Wistar foram expostos a RBF, por per&#237;odos crescentes, desde 1 a 13 semanas. Um grupo controle foi mantido em sil&#234;ncio. Fragmentos da parede g&#225;strica foram estudados com recurso a: (i) microscopia &#243;tica usando hematoxilina-eosina e imunomarca&#231;&#227;o para col&#225;genos; (ii) microscopia eletr&#244;nica de transmiss&#227;o; (iii) morfometria, permitindo a colheita de dados para an&#225;lise estat&#237;stica. </p>				</sec>				<sec>					<title>RESULTADOS:</title>					<p> Observaram-se espessamento e prolifera&#231;&#227;o de tecido fibroso na submucosa de todos os animais expostos aos RBF. A microscopia eletr&#244;nica de transmiss&#227;o mostrou marcada deposi&#231;&#227;o de col&#225;geno. A imunomarca&#231;&#227;o identificou o col&#225;geno IV como respons&#225;vel pelo espessamento da submucosa. A morfometria permitiu demonstrar que a diferen&#231;a de espessura da submucosa entre o grupo controle e os grupos de animais expostos era estatisticamente significativo. As altera&#231;&#245;es vasculares inclu&#237;ram: (i) prolifera&#231;&#227;o e espessamento da &#237;ntima, com rotura da l&#226;mina el&#225;stica interna e fen&#244;menos tromb&#243;ticos; (ii) espessamento da m&#233;dia; (iii) ap&#243;s 9 semanas de exposi&#231;&#227;o ao RBF, observaram-se vasos neoformados tortuosos e contorcidos. A espessura dos vasos dos animais expostos ao ru&#237;do &#233; significativamente maior que a espessura no grupo controle. </p>				</sec>				<sec>					<title>CONCLUS&#213;ES:</title>					<p> As camadas profundas da parede g&#225;strica sofrem altera&#231;&#245;es que incluem fibrose causada pela deposi&#231;&#227;o de col&#225;geno IV, marcador precoce de neoangiog&#234;nese. As altera&#231;&#245;es vasculares incluem espessamento e fen&#244;menos tromb&#243;ticos e vasos neoformados. O presente estudo sugere que, pelo menos no est&#244;mago, a fibrose associada ao RBF pode estar ligada &#224; neoangiog&#234;nese.</p>				</sec>^lpt
!v085!^kGastric mucosa, physiopathology^len
!v085!^kNoise effects^len
!v085!^kMicroscopy, electron^len
!v085!^kRats^len
!v085!^kMucosa gástrica, fisiopatologia^lpt
!v085!^kEfeitos do ruído^lpt
!v085!^kMicroscopia eletrônica^lpt
!v085!^kRatos^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m09^d25
!v112!2011
!v113!^y2011^m10^d10
!v114!2011
!v120!XML_3.0
!v121!82
!v237!10.1590/S0004-28032012000100014
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!f
!v708!1
!ID 000521
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^1aff1^sFonseca^rauthor^nJorge
!v010!^sMartins-dos-Santos^rauthor^nJose
!v010!^sOliveira^rauthor^nPedro
!v010!^sLaranjeira^rauthor^nNuno
!v010!^sAguas^rauthor^nArtur
!v010!^sCastelo-Branco^rauthor^nNuno
!v012!^sa light and electron microscopy study of the rat gastric wall exposed to low frequency noise^tNoise-induced gastric lesions
!v012!^sum estudo por microscopia otica e eletronica da parede gastrica do rato exposta a ruido de baixa frequencia^tLesoes gastricas induzidas pelo ruido^lpt
!v014!^l88^f82
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!GRA
!v038!TAB
!v040!en
!v042!1
!v049!EXPERIMENTAL_GASTROENTEROLOGY
!v064!Jan-Mar
!v065!20120300
!v070!Instituto Superior de Ciencias da Saude Egas Moniz (CiiEM)^cAlmada^iaff1^l1^pPortugal^5?^9Instituto Superior de Ciencias da Saude Egas Moniz (CiiEM), Almada, Portugal
!v070!Instituto de Ciencias Biomedicas Abel Salazar - Universidade do Porto (UMIB)^cPorto^iaff2^l2^pPortugal^5?^9Instituto de Ciencias Biomedicas Abel Salazar - Universidade do Porto (UMIB), Porto, Portugal
!v070!Center for Human Performance^cAlverca^iaff3^l3^pPortugal^5?^9Center for Human Performance, Alverca, Portugal
!v071!oa
!v072!58
!v083!^a<sec>					<title>CONTEXT:</title>					 Only a few studies evaluated the digestive alterations caused by low frequency noise (LFN) and most focused only on mucosal alterations. 				</sec>				<sec>					<title>OBJECTIVES:</title>					 To investigate the morphological injury of LFN-exposed gastric wall, beyond the epithelial layer. 				</sec>				<sec>					<title>METHODS:</title>					 Wistar rats were exposed to low frequency noise (LFN), during increasing periods, 1 to 13 weeks. A control group was kept in silence. Gastric specimens were studied using: (i) light microscopy with hematoxylin-eosin and immunostaining for collagens; (ii) transmission electron microscopy; (iii) morphometry allowing statistical analysis. 				</sec>				<sec>					<title>RESULTS:</title>					 Submucosa of all LFN-exposed animals exhibit increased thickness with fibrous proliferation. Transmission electron microscopy showed massive collagen deposition. Immunostaining identified collagen IV as responsible for the increased thickness. Morphometry allowed the demonstration of a significant difference of thickness between control and exposed groups. Vascular alterations included: i) intima proliferation and thickening, rupture of the internal elastic lamina, thrombotic changes; ii) thickening of the media; iii) after 9 weeks of LFN-exposure, we found new formed vessel presenting tortuous and twisted. There is a significant difference of arterial wall thickness between control and exposed groups. 				</sec>				<sec>					<title>CONCLUSIONS:</title>					 Deeper layers of gastric wall undergo alterations, including fibrosis of the submucosa caused by collagen IV deposition, an early marker of neoangiogenesis. Vascular alterations included thickening and thrombotic phenomena, but also images of newly formed vessels. This study suggests that, at least in the stomach, LFN-induced fibrosis could be linked with neoangiogenesis.				</sec>^len
!v083!^a<sec>					<title>CONTEXTO:</title>					 So um reduzido numero de estudos avaliou as alteracoes digestivas causadas pelo ruido de baixa frequencia (RBF) e, na sua maioria, focados nas alteracoes da mucosa. 				</sec>				<sec>					<title>OBJETIVO:</title>					 Avaliar as lesoes morfologicas induzidas na parede gastrica pelo RBF, para alem da camada mucosa. 				</sec>				<sec>					<title>MeTODOS:</title>					 Ratos Wistar foram expostos a RBF, por periodos crescentes, desde 1 a 13 semanas. Um grupo controle foi mantido em silencio. Fragmentos da parede gastrica foram estudados com recurso a: (i) microscopia otica usando hematoxilina-eosina e imunomarcacao para colagenos; (ii) microscopia eletronica de transmissao; (iii) morfometria, permitindo a colheita de dados para analise estatistica. 				</sec>				<sec>					<title>RESULTADOS:</title>					 Observaram-se espessamento e proliferacao de tecido fibroso na submucosa de todos os animais expostos aos RBF. A microscopia eletronica de transmissao mostrou marcada deposicao de colageno. A imunomarcacao identificou o colageno IV como responsavel pelo espessamento da submucosa. A morfometria permitiu demonstrar que a diferenca de espessura da submucosa entre o grupo controle e os grupos de animais expostos era estatisticamente significativo. As alteracoes vasculares incluiram: (i) proliferacao e espessamento da intima, com rotura da lamina elastica interna e fenomenos tromboticos; (ii) espessamento da media; (iii) apos 9 semanas de exposicao ao RBF, observaram-se vasos neoformados tortuosos e contorcidos. A espessura dos vasos dos animais expostos ao ruido e significativamente maior que a espessura no grupo controle. 				</sec>				<sec>					<title>CONCLUSoES:</title>					 As camadas profundas da parede gastrica sofrem alteracoes que incluem fibrose causada pela deposicao de colageno IV, marcador precoce de neoangiogenese. As alteracoes vasculares incluem espessamento e fenomenos tromboticos e vasos neoformados. O presente estudo sugere que, pelo menos no estomago, a fibrose associada ao RBF pode estar ligada a neoangiogenese.				</sec>^lpt
!v085!^kGastric mucosa, physiopathology^len
!v085!^kNoise effects^len
!v085!^kMicroscopy, electron^len
!v085!^kRats^len
!v085!^kMucosa gastrica, fisiopatologia^lpt
!v085!^kEfeitos do ruido^lpt
!v085!^kMicroscopia eletronica^lpt
!v085!^kRatos^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m09^d25
!v112!2011
!v113!^y2011^m10^d10
!v114!2011
!v120!XML_3.0
!v121!82
!v237!10.1590/S0004-28032012000100014
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!l
!v708!1
!ID 000522
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sAnthony^rND^nA
!v010!^sHarclerode^rND^nJE
!v012!Noise stress in laboratory rodents: Effects of chronic noise exposure on sexual performance and reproductive function of guinea pigs^len
!v014!1437-440
!v030!J Acoust Soc Am
!v031!31
!v064!1959
!v065!19590000
!v071!journal
!v118!1
!v514!^l1440^f1437
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000523
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sAriizumi^rND^nM
!v010!^sNakamura^rND^nH
!v010!^sNakamura^rND^nH
!v010!^sOkazawa^rND^nT
!v010!^sOkada^rND^nA
!v012!^tAssessment of peripheral circulation under impulsive vibration or variation of temperature using the thermal diffusion method
!v014!21-2
!v118!2
!v514!^l22^f21
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000524
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sBerglung^rND^nB
!v010!^sLindvall^rND^nT
!v010!^sSchwela^rND^nD
!v018!Guidelines for Community Noise
!v062!World Organization , WHO
!v064!1999
!v065!19990000
!v066!Geneva
!v118!3
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000525
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sBovenzi^rND^nM
!v010!^sHolshof^rND^nCTJ
!v012!An updated review of epidemiologic studies on the relationship between exposure to whole body vibration and low back pain (1986-1997)^len
!v014!351-65
!v030!Int Arch Occup Environ Health
!v031!72
!v064!1999
!v065!19990000
!v118!4
!v514!^l365^f351
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000526
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sBovenzi^rND^nM
!v012!Health effects of mechanical vibration^len
!v014!58-64
!v030!G Ital Med Lav Ergon
!v031!27
!v064!2005
!v065!20050000
!v118!5
!v514!^l64^f58
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000527
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sBranco^rND^nNA
!v010!^sAlves-Pereira^rND^nM
!v012!Vibroacoustic disease^len
!v014!3-20
!v030!Noise Health
!v031!6
!v064!2004
!v065!20040000
!v118!6
!v514!^l20^f3
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000528
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sCastelo Branco^rND^nNA
!v012!A unique case of vibroacoustic disease: a tribute to an extraordinary patient^len
!v014!A27-A31
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!7
!v514!^lA31^fA27
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000529
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sCastelo Branco^rND^nNA
!v012!The clinical stages of vibroacoustic disease^len
!v014!A32-A39
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!8
!v514!^lA39^fA32
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000530
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sCastelo Branco^rND^nNA
!v010!^sAguas^rND^nAP
!v010!^sSousa Pereira^rND^nA
!v010!^sMonteiro^rND^nE
!v010!^sFragata^rND^nJI
!v010!^sTavares^rND^nF
!v010!^sGrande^rND^nNR
!v012!The human pericardium in vibroacoustic disease^len
!v014!A54-A62
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!9
!v514!^lA62^fA54
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000531
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sCastelo Branco^rND^nNA
!v010!^sAlves-Pereira^rND^nMM
!v010!^sMartins dos Santos^rND^nJ
!v010!^sMonteiro^rND^nE
!v010!^sMendez-Vilas^rND^nA
!v012!^tSEM and TEM study of rat respiratory epithelia exposed to low frequency noise
!v014!505-33
!v018!Science and technology education in microscopy: an overview
!v062!Formatex Microscopy Book Series
!v064!2003
!v065!20030000
!v066!Badajoz
!v118!10
!v514!^l533^f505
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000532
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sCastelo Branco^rND^nNA
!v010!^sAlves-Pereira^rND^nM
!v012!^tVibroacoustic disease - current concepts
!v014!1775-782
!v018!Proceedings
!v064!2004
!v065!20040000
!v118!11
!v514!^l1782^f1775
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000533
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sCherniack^rND^nM
!v010!^sClive^rND^nJ
!v010!^sSeider^rND^nA
!v012!Vibration exposure, smoking and vascular dysfunction^len
!v014!341-47
!v030!Occup Environ Med
!v031!57
!v064!2000
!v065!20000000
!v118!12
!v514!^l347^f341
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000534
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sCohen^rND^nA
!v012!The influence of a company hearing conservation program on extra-auditory problems in workers^len
!v014!146-62
!v030!J Safety Res
!v031!8
!v064!1976
!v065!19760000
!v118!13
!v514!^l162^f146
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000535
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sDa Fonseca^rND^nJ
!v010!^sdos Santos^rND^nJM
!v010!^sBranco^rND^nNC
!v010!^sAlves-Pereira^rND^nM
!v010!^sGrande^rND^nN
!v010!^sOliveira^rND^nP
!v010!^sMartins^rND^nAP
!v012!Noise-induced gastric lesions: a light and scanning electron microscopy study of the alterations of the rat gastric mucosa induced by low frequency noise^len
!v014!35-8
!v030!Cent Eur J Publ Health
!v031!14
!v064!2006
!v065!20060000
!v118!14
!v514!^l38^f35
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000536
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sDa Fonseca^rND^nJ
!v010!^sMartins dos Santos^rND^nJ
!v010!^sCastelo Branco^rND^nN
!v010!^sAlves-Pereira^rND^nM
!v010!^sGrande^rND^nN
!v010!^sOliveira^rND^nP
!v012!Noise-induced duodenal lesions^len
!v014!29-33
!v030!Eur J Anat
!v031!9
!v064!2006
!v065!20060000
!v118!15
!v514!^l33^f29
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000537
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sDe Sousa Pereira^rND^nA
!v010!^sAguas^rND^nAP
!v010!^sGrande^rND^nNR
!v010!^sMirones^rND^nJ
!v010!^sMonteiro^rND^nE
!v010!^sCastelo Branco^rND^nNA
!v012!The effect of chronic exposure to low frequency noise on rat tracheal epithelia^len
!v014!A86-A90
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!16
!v514!^lA90^fA86
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000538
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sdos Santos^rND^nJM
!v010!^sGrande^rND^nNR
!v010!^sCastelo Branco^rND^nNA
!v010!^sZagalo^rND^nC
!v010!^sOliveira^rND^nP
!v012!Vascular lesions and vibroacoustic disease^len
!v014!17-21
!v030!Eur J Anat
!v031!6
!v064!2002
!v065!20020000
!v118!17
!v514!^l21^f17
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000539
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sDupuis^rND^nH
!v010!^sRiedel^rND^nS
!v012!Experience on the reversibility of the vibration-induced white finger disease^len
!v014!19-21
!v030!Cent Eur J Publ Health
!v031!3
!v064!1995
!v065!19950000
!v118!18
!v514!^l21^f19
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000540
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sFonseca^rND^nJ
!v010!^sMirones^rND^nJ
!v010!^sMartins dos Santos^rND^nJ
!v010!^sOliveira^rND^nP
!v010!^sAlves-Pereira^rND^nM
!v010!^sCastelo Branco^rND^nNAA
!v012!^tGastrointestinal problems in vibroacoustic disease
!v018!Proceedings
!v118!19
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000541
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sGrande^rND^nNR
!v010!^sAguas^rND^nAP
!v010!^sSousa Pereira^rND^nA
!v010!^sMonteiro^rND^nE
!v010!^sCastelo Branco^rND^nNAA
!v012!Morphological changes in rat lung parenchyma exposed to low frequency noise^len
!v014!A70-A77
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!20
!v514!^lA77^fA70
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000542
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sHellman^rND^nR
!v010!^sZwicker^rND^nE
!v012!Why can a decrease in dB(A) produce an increase in loudness?^len
!v014!1700-705
!v030!J Acoust Soc Am
!v031!82
!v064!1987
!v065!19870000
!v118!21
!v514!^l1705^f1700
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000543
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sHirata^rND^nM
!v010!^sSakakibara^rND^nH
!v010!^sYamada^rND^nS
!v010!^sHashiguchi^rND^nT
!v010!^sToibana^rND^nN
!v010!^sKoshiyama^rND^nH
!v012!Nerve conduction velocities in the lower extremities among patients with vibration syndrome^len
!v014!78-80
!v030!Cent Eur J Publ Health
!v031!3
!v064!1995
!v065!19950000
!v118!22
!v514!^l80^f78
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000544
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sIngber^rND^nDE
!v012!Mechanical signalling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology^len
!v014!877-87
!v030!Circ Res
!v031!91
!v064!2002
!v065!20020000
!v118!23
!v514!^l887^f877
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000545
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sIngber^rND^nDE
!v012!Mechanobiology and diseases of mechanotransduction^len
!v014!564-77
!v030!Ann Med
!v031!35
!v064!2003
!v065!20030000
!v118!24
!v514!^l577^f564
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000546
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sIngber^rND^nDE
!v012!Tensegrity II. How structural networks influence cellular information processing networks^len
!v014!1397-408
!v030!J Cell Sci
!v031!116
!v064!2003
!v065!20030000
!v118!25
!v514!^l1408^f1397
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000547
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sIngber^rND^nDE
!v012!Mechanochemical basis of cell and tissue regulation^len
!v014!53-68
!v030!Mech Chem Biosyst
!v031!1
!v064!2004
!v065!20040000
!v118!26
!v514!^l68^f53
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000548
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sJohanning^rND^nE
!v012!Back disorders and health problems among subway train operators exposed to whole-body vibration^len
!v014!414-19
!v030!Scand J Work Environ Health
!v031!17
!v064!1991
!v065!19910000
!v118!27
!v514!^l419^f414
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000549
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sJohanning^rND^nE
!v010!^sWilder^rND^nDG
!v010!^sLandrigan^rND^nPJ
!v010!^sPope^rND^nMH
!v012!Whole-body vibration exposure in subway cars and review of adverse health effects^len
!v014!605-12
!v030!J Occup Med
!v031!33
!v064!1991
!v065!19910000
!v118!28
!v514!^l612^f605
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000550
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sKim^rND^nCY
!v010!^sRyu^rND^nJS
!v010!^sHong^rND^nSS
!v012!Effect of aircraft noise on gastric function^len
!v014!149-54
!v030!Yonsei Med J
!v031!9
!v064!1968
!v065!19680000
!v118!29
!v514!^l154^f149
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000551
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sKumar^rND^nA
!v010!^sVarghese^rND^nM
!v010!^sMohan^rND^nD
!v010!^sMahajan P Gulati^rND^nP
!v010!^sKale^rND^nS
!v012!Effect of whole-body vibration on the low back. A study of tractor-driving farmers in north India^len
!v014!2506-515
!v030!Spine
!v031!24
!v064!1999
!v065!19990000
!v118!30
!v514!^l2515^f2506
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000552
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sLeventhall^rND^nHG
!v012!Low frequency noise and annoyance^len
!v014!59-72
!v030!Noise Health
!v031!6
!v064!2004
!v065!20040000
!v118!31
!v514!^l72^f59
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000553
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sLundstrom^rND^nR
!v010!^sNilsson^rND^nT
!v010!^sBurstrom^rND^nL
!v010!^sHagberg^rND^nM
!v012!Vibrotactile perception densitivity and its relation to hand-arm vibration exposure^len
!v014!62-5
!v030!Cent Eur J Publ Health
!v031!3
!v064!1995
!v065!19950000
!v118!32
!v514!^l65^f62
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000554
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMarciniak^rND^nW
!v010!^sRodriguez^rND^nE
!v010!^sOlszowska^rND^nK
!v010!^sAtkov^rND^nO
!v010!^sBotvin^rND^nI
!v010!^sAraujo^rND^nA
!v010!^sPais^rND^nF
!v010!^sSoares Ribeiro^rND^nC
!v010!^sBordalo^rND^nA
!v010!^sLoureiro^rND^nJ
!v010!^sPrazeres de Sa^rND^nE
!v010!^sFerreira^rND^nD
!v010!^sCastelo Branco^rND^nMS
!v010!^sCastelo Branco^rND^nNA
!v012!Echocardiographic evaluation in 485 aeronautical workers exposed to different noise environenments^len
!v014!A46-A53
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!33
!v514!^lA53^fA46
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000555
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMartinho Pimenta^rND^nAJ
!v010!^sCastelo Branco^rND^nNA
!v012!Neurological aspects of vibroacoustic disease^len
!v014!A91-A99
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!34
!v514!^lA99^fA91
!v700!38
!v701!34
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000556
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMartins dos Santos^rND^nJ
!v010!^sGrande^rND^nNR
!v010!^sCastelo Branco^rND^nNAA
!v010!^sZagalo^rND^nC
!v010!^sOliveira^rND^nP
!v010!^sAlves-Pereira^rND^nMMS
!v012!Lymphatic lesions and vibroacoustic disease^len
!v014!17-20
!v030!Eur J Lymphology
!v031!12
!v064!2004
!v065!20040000
!v118!35
!v514!^l20^f17
!v700!39
!v701!35
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000557
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMatoba^rND^nT
!v010!^sIshitake^rND^nT
!v012!Cardiovascular reflexes during vibration stress^len
!v014!S61-S71
!v030!Kurume Med J
!v031!37
!v064!1990
!v065!19900000
!v118!36
!v514!^lS71^fS61
!v700!40
!v701!36
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000558
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMcGeoch^rND^nKL
!v010!^sLawson^rND^nIJ
!v010!^sBurke^rND^nF
!v010!^sProud^rND^nG
!v010!^sMiles^rND^nJ
!v012!Diagnostic criteria and staging of hand-arm vibration syndrome in the United Kingdom^len
!v014!527-34
!v030!Ind Health
!v031!43
!v064!2005
!v065!20050000
!v118!37
!v514!^l534^f527
!v700!41
!v701!37
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000559
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMendes^rND^nJ
!v010!^sMartins dos Santos^rND^nJ
!v010!^sOliveira^rND^nP
!v010!^sBranco^rND^nNA
!v012!Low-frequency noise effects on periodontium of the Wistar rat - a light microscopy study^len
!v014!27-30
!v030!Eur J Anat
!v031!11
!v064!2007
!v065!20070000
!v118!38
!v514!^l30^f27
!v700!42
!v701!38
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000560
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMiyashita^rND^nK
!v010!^sMorioka^rND^nI
!v010!^sTanabe^rND^nT
!v010!^sIwata^rND^nH
!v010!^sTakeda^rND^nS
!v012!Symptoms of construction workers exposed to whole-body vibration and local vibration^len
!v014!347-51
!v030!Int Arch Occup Environ Health
!v031!64
!v064!1992
!v065!19920000
!v118!39
!v514!^l351^f347
!v700!43
!v701!39
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000561
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMiyashita^rND^nK
!v010!^sMivamoto^rND^nK
!v010!^sKuruda^rND^nM
!v010!^sTakeda^rND^nS
!v010!^sIwata^rND^nH
!v012!Hand-arm vibration exposure and the development of vibration syndrome^len
!v014!43-8
!v030!Nagoya J Med Sci
!v031!57
!v064!1994
!v065!19940000
!v118!40
!v514!^l48^f43
!v700!44
!v701!40
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000562
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMoller^rND^nH
!v012!Physiological and psychological effects of infrasound in humans^len
!v014!1-17
!v030!J Low Freq Noise Vib
!v031!3
!v064!1984
!v065!19840000
!v118!41
!v514!^l17^f1
!v700!45
!v701!41
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000563
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sMoller^rND^nH
!v012!Annoyance of audible infrasound^len
!v014!s32
!v030!J Acoust Soc Am
!v031!78
!v064!1985
!v065!19850000
!v118!42
!v514!^fs32
!v700!46
!v701!42
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000564
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sNakamura^rND^nH
!v010!^sKatoh^rND^nA
!v010!^sNohara^rND^nS
!v010!^sNakamura^rND^nH
!v010!^sOkada^rND^nA
!v012!Experimental studies on the pathogenesis of the gastric mucosal lesions induced by whole-body vibration^len
!v014!220-29
!v030!Environ Res
!v031!58
!v064!1992
!v065!19920000
!v118!43
!v514!^l229^f220
!v700!47
!v701!43
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000565
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sOliveira^rND^nMJ
!v010!^sDe Sousa Pereira^rND^nA
!v010!^sAguas^rND^nAP
!v010!^sGrande^rND^nNR
!v010!^sMonteiro^rND^nE
!v010!^sSerrano^rND^nI
!v010!^sCastelo Branco^rND^nNA
!v012!Effects of low frequency noise upon the reaction of pleural milky spots to mycobacterial infection^len
!v014!A137-A154
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!44
!v514!^lA154^fA137
!v700!48
!v701!44
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000566
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sOliveira^rND^nMJ
!v010!^sPereira^rND^nAS
!v010!^sGuimaraes^rND^nL
!v010!^sFreitas^rND^nD
!v010!^sCarvalho^rND^nAP
!v010!^sGrande^rND^nNR
!v010!^saguas^rND^nAP
!v012!Chronic exposure of rats to cotton-mill-room noise changes the cell composition of the tracheal epithelium^len
!v014!1135-142
!v030!J Occup Environ Med
!v031!44
!v064!2002
!v065!20020000
!v118!45
!v514!^l1142^f1135
!v700!49
!v701!45
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000567
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sOliveira^rND^nMJ
!v010!^sPereira^rND^nAS
!v010!^sFerreira^rND^nPG
!v010!^sGrande^rND^nNR
!v010!^sAguas^rND^nAP
!v010!^sGuimaraes^rND^nL
!v010!^sFreitas^rND^nD
!v010!^sCarvalho^rND^nAP
!v012!Reduction of rat pleural microvilli caused by noise pollution^len
!v014!445-54
!v030!Exp Lung Res
!v031!29
!v064!2003
!v065!20030000
!v118!46
!v514!^l454^f445
!v700!50
!v701!46
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000568
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sOliveira^rND^nPM
!v010!^sPereira da Mata^rND^nAD
!v010!^sMartins dos Santos^rND^nJA
!v010!^sda Silva Marques^rND^nDN
!v010!^sBranco^rND^nNC
!v010!^sSilveira^rND^nJM
!v010!^sCorreia da Fonseca^rND^nJC
!v012!Low-frequency noise effects on the parotid gland of the Wistar rat^len
!v014!468-73
!v030!Oral Dis
!v031!13
!v064!2007
!v065!20070000
!v118!47
!v514!^l473^f468
!v700!51
!v701!47
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000569
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sPersson Waye^rND^nK
!v012!Effects of low frequency noise on sleep^len
!v014!87-91
!v030!Noise Health
!v031!6
!v064!2004
!v065!20040000
!v118!48
!v514!^l91^f87
!v700!52
!v701!48
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000570
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sPimenta^rND^nMG
!v010!^sMartinho Pimenta^rND^nAJ
!v010!^sCastelo Branco^rND^nMS
!v010!^sSilva Simoes^rND^nJM
!v010!^sCastelo Branco^rND^nNA
!v012!ERP P300 and brain magnetic resonance in patients with vibroacoustic disease^len
!v014!A107-A114
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!49
!v514!^lA114^fA107
!v700!53
!v701!49
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000571
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sReis Ferreira^rND^nJM
!v010!^sCouto^rND^nAR
!v010!^sJalles-Tavares^rND^nN
!v010!^sCastelo Branco^rND^nMS
!v010!^sCastelo Branco^rND^nNA
!v012!Air flow limitation in patients with vibroacoustic disease^len
!v014!A63-A69
!v030!Aviat Space Environ Med
!v031!70
!v064!1999
!v065!19990000
!v118!50
!v514!^lA69^fA63
!v700!54
!v701!50
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000572
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sSakakibara^rND^nH
!v010!^sHirata^rND^nM
!v010!^sHashiguchi^rND^nT
!v010!^sToibana^rND^nN
!v010!^sKoshiyama^rND^nH
!v010!^sZhu^rND^nSK
!v010!^sYamada^rND^nS
!v012!Digital nerve conduction velocity for evaluation of peripheral nerve impairments in vibration syndrome^len
!v014!52-3
!v030!Cent Eur J Publ Health
!v031!3
!v064!1995
!v065!19950000
!v118!51
!v514!^l53^f52
!v700!55
!v701!51
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000573
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sSakakibara^rND^nH
!v010!^sYamada^rND^nS
!v012!Vibration syndrome and autonomic nervous system^len
!v014!11-4
!v030!Cent Eur J Publ Health
!v031!3
!v064!1995
!v065!19950000
!v118!52
!v514!^l14^f11
!v700!56
!v701!52
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000574
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sSeidel^rND^nH
!v010!^sHeide^rND^nR
!v012!Long-term effects of whole-body vibration: a critical survey of the literature^len
!v014!1-26
!v030!Int Arch Occup Environ Med
!v031!58
!v064!1986
!v065!19860000
!v118!53
!v514!^l26^f1
!v700!57
!v701!53
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000575
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sStoyneva^rND^nZ
!v010!^sLyapina^rND^nM
!v010!^sTzevetkov^rND^nD
!v010!^sVodenicharov^rND^nE
!v012!Current pathophysiological views on vibration induced Raynaud's phenomenon^len
!v014!615-24
!v030!Cardiovasc Res
!v031!57
!v064!2003
!v065!20030000
!v118!54
!v514!^l624^f615
!v700!58
!v701!54
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000576
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sSukharevskaia^rND^nTM
!v010!^sNepomniashchikh^rND^nGI
!v010!^sBobrova^rND^nSV
!v010!^sBelov^rND^nIIu
!v010!^sAidagulova^rND^nSV
!v010!^sLapii^rND^nGA
!v012!Clinical endoscopic and pathomorphologic study of the stomach in vibration disease^len
!v014!16-9
!v030!Med Tr Prom Ekol
!v032!6
!v064!1999
!v065!19990000
!v118!55
!v514!^l19^f16
!v700!59
!v701!55
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000577
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sSutinen^rND^nP
!v010!^sKoskimies^rND^nK
!v010!^sAalto^rND^nH
!v010!^sStark^rND^nJ
!v010!^sPyykko^rND^nI
!v012!^tShoulder and elbow musculoskeletal disorder in forest workers exposed to hand-arm vibration
!v014!193-98
!v018!Proceedings
!v064!1998
!v065!19980000
!v118!56
!v514!^l198^f193
!v700!60
!v701!56
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000578
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sTakeuchi^rND^nT
!v010!^sFutatsuka^rND^nM
!v010!^sImanishi^rND^nH
!v010!^sYamada^rND^nS
!v012!Pathological changes observed in the finger biopsy of patients with vibration-induced white finger^len
!v014!280-83
!v030!Scand J Work Environ Health
!v031!12
!v064!1986
!v065!19860000
!v118!57
!v514!^l283^f280
!v700!61
!v701!57
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000579
!v001!br1.1
!v002!0004-2803-ag-49-01-82.xml
!v004!v49n1
!v010!^sTeles-Grilo^rND^nML
!v010!^sLeite-Almeida^rND^nH
!v010!^sMartins dos Santos^rND^nJ
!v010!^sOliveira^rND^nC
!v010!^sBoaventura^rND^nP
!v010!^sGrande^rND^nNR
!v012!Differential expression of collagens type I and type IV in lymphangiogenesis during the angiogenic process associated with bleomycin-induced pulmonary fibrosis in rat^len
!v014!130-35
!v030!Lymphology
!v031!38
!v064!2005
!v065!20050000
!v118!58
!v514!^l135^f130
!v700!62
!v701!58
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-82.xml
!v705!S
!v706!c
!v708!58
!v865!20120300
!ID 000580
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v091!20120814
!v092!164332
!v700!1
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v703!174
!v705!S
!v706!o
!v708!1
!ID 000581
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sSouza^rauthor^nMonica Rodrigues de Araujo
!v010!^sDiniz^rauthor^nMargareth de Fatima Formiga de Melo
!v010!^sMedeiros-Filho^rauthor^nJose Eymard Moraes de
!v010!^sAraujo^rauthor^nMaria Salete Trigueiro de
!v012!^tMetabolic syndrome and risk factors for non-alcoholic fatty liver disease
!v012!^tSindrome metabolica e fatores de risco para a doenca hepatica gordurosa nao-alcoolica^lpt
!v014!^l96^f89
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!ND
!v040!en
!v042!1
!v049!REVIEW
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal da Paraiba (UFPB)^cPB^iaff1^1^pBrasil^9Universidade Federal da Paraiba (UFPB), PB, Brasil
!v071!oa
!v072!96
!v083!^a<sec>               <title>CONTEXT:</title>                Non-alcoholic fatty liver disease (NAFLD), hepatic manifestation of metabolic syndrome, has been considered the most common liver disease nowadays, which is also the most frequent cause of elevated transaminases and cryptogenic cirrhosis. The greatest input of fatty acids into the liver and consequent increased beta-oxidation contribute to the formation of free radicals, release of inflammatory cytokines and varying degrees of hepatocytic aggression, whose histological expression may vary from steatosis (HS) to non-alcoholic steatohepatitis (NASH). The differentiation of these forms is required by the potential risk of progression to cirrhosis and development of hepatocellular carcinoma.             </sec>            <sec>               <title>OBJECTIVE:</title>                To review the literature about the major risk factors for NAFLD in the context of metabolic syndrome, focusing on underlying mechanisms and prevention.             </sec>            <sec>               <title>METHOD:</title>                PubMed, MEDLINE and SciELO data basis analysis was performed to identify studies describing the link between risk factors for metabolic syndrome and NAFLD. A combination of descriptors was used, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and risk factors. At the end, 96 clinical and experimental studies, cohorts, meta-analysis and systematic reviews of great impact and scientific relevance to the topic, were selected.             </sec>            <sec>               <title>RESULTS:</title>                The final analysis of all these data, pointed out the central obesity, type 2 diabetes, dyslipidemia and hypertension as the best risk factors related to NAFLD. However, other factors were highlighted, such as gender differences, ethnicity, genetic factors and the role of innate immunity system. How these additional factors may be involved in the installation, progression and disease prognosis is discussed.             </sec>            <sec>               <title>CONCLUSION:</title>                Risk factors for NAFLD in the context of metabolic syndrome expands the prospects to 1) recognize patients with metabolic syndrome at high risk for NAFLD, 2) elucidate pathways common to other co-morbidities, 3) determine risk factors associated with a worse prognosis, 4) develop therapeutic strategies with goal of reducing risk factors, 5) apply acquired knowledge in public health policies focusing on preventive strategies.            </sec>^len
!v083!^a<sec>               <title>CONTEXTO:</title>                A doenca hepatica gordurosa nao alcoolica (DHGNA) vem sendo considerada a manifestacao hepatica da sindrome metabolica e a hepatopatia mais frequente da atualidade, sendo tambem a causa mais frequente de aumento das transaminases e de cirrose criptogenica. O maior aporte de acidos graxos ao figado e consequente aumento da beta-oxidacao concorrem para formacao de radicais livres, liberacao de citocinas inflamatorias e graus variaveis de agressao hepatocitica, cuja expressao histologica pode variar da esteatose hepatica (EH) a esteatohepatite nao-alcoolica (EHNA), cuja diferenciacao se faz necessaria pelo risco potencial de progressao para cirrose e desenvolvimento do carcinoma hepatocelular.             </sec>            <sec>               <title>OBJETIVO:</title>                Revisar a literatura sobre os principais fatores de risco para a DHGNA no contexto da sindrome metabolica, com foco nos mecanismos subjacentes e nas estrategias de prevencao.             </sec>            <sec>               <title> MeTODO:</title>                Foi realizada pesquisa bibliografica no PubMed para identificar estudos que descrevessem a associacao entre os fatores de risco para sindrome metabolica e a DHGNA, utilizando-se a combinacao de descritores: "Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, metabolic syndrome and risk factors". Foram selecionados 96 estudos clinicos, experimentais, de cohort, metanalises e revisoes sistematicas de maior impacto e relevancia cientifica para o tema.             </sec>            <sec>               <title>RESULTADOS:</title>                A analise das informacoes consolidou a obesidade central, diabetes melitus tipo 2, dislipidemia e hipertensao como os fatores de risco mais bem relacionados a DHGNA. Entretanto, outros fatores foram destacados, como diferencas entre generos, etnia, fatores geneticos e o papel da imunidade inata, como estes fatores adicionais que podem estar implicados na instalacao, progressao e prognostico da doenca.             </sec>            <sec>               <title>CONCLUSaO:</title>                O conhecimento dos fatores de risco para a DHGNA no contexto da sindrome metabolica amplia os caminhos para: 1) reconhecer pacientes com risco elevado para a doenca; 2) elucidar vias comuns a outras comorbidades; 3) determinar fatores de risco relacionados a pior prognostico; 4) desenvolver estrategias terapeuticas com o objetivo de reduzir fatores de risco; 4) aplicar os conhecimentos adquiridos nas politicas publicas de saude com foco em estrategias preventivas.            </sec>^lpt
!v085!^kMetabolic syndrome X^len
!v085!^kFatty liver, non-alcoholic^len
!v085!^kRisk factors^len
!v085!^kSindrome X metabolica^lpt
!v085!^kFigado gorduroso nao-alcoolico^lpt
!v085!^kFatores de risco^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m05^d25
!v112!2011
!v113!^y2011^m09^d05
!v114!2011
!v120!XML_3.0
!v121!89
!v237!10.1590/S0004-28032012000100015
!v700!2
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!h
!v708!1
!ID 000582
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sSouza^rauthor^nMônica Rodrigues de Araújo
!v010!^sDiniz^rauthor^nMargareth de Fátima Formiga de Melo
!v010!^sMedeiros-Filho^rauthor^nJosé Eymard Moraes de
!v010!^sAraújo^rauthor^nMaria Salete Trigueiro de
!v012!^tMetabolic syndrome and risk factors for non-alcoholic fatty liver disease
!v012!^tSíndrome metabólica e fatores de risco para a doença hepática gordurosa não-alcoólica^lpt
!v014!^l96^f89
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!ND
!v040!en
!v042!1
!v049!REVIEW
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal da Paraíba (UFPB)^cPB^iaff1^1^pBrasil^9Universidade Federal da Paraíba (UFPB), PB, Brasil
!v071!oa
!v072!96
!v083!^a<sec>               <title>CONTEXT:</title>               <p> Non-alcoholic fatty liver disease (NAFLD), hepatic manifestation of metabolic syndrome, has been considered the most common liver disease nowadays, which is also the most frequent cause of elevated transaminases and cryptogenic cirrhosis. The greatest input of fatty acids into the liver and consequent increased beta-oxidation contribute to the formation of free radicals, release of inflammatory cytokines and varying degrees of hepatocytic aggression, whose histological expression may vary from steatosis (HS) to non-alcoholic steatohepatitis (NASH). The differentiation of these forms is required by the potential risk of progression to cirrhosis and development of hepatocellular carcinoma. </p>            </sec>            <sec>               <title>OBJECTIVE:</title>               <p> To review the literature about the major risk factors for NAFLD in the context of metabolic syndrome, focusing on underlying mechanisms and prevention. </p>            </sec>            <sec>               <title>METHOD:</title>               <p> PubMed, MEDLINE and SciELO data basis analysis was performed to identify studies describing the link between risk factors for metabolic syndrome and NAFLD. A combination of descriptors was used, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and risk factors. At the end, 96 clinical and experimental studies, cohorts, meta-analysis and systematic reviews of great impact and scientific relevance to the topic, were selected. </p>            </sec>            <sec>               <title>RESULTS:</title>               <p> The final analysis of all these data, pointed out the central obesity, type 2 diabetes, dyslipidemia and hypertension as the best risk factors related to NAFLD. However, other factors were highlighted, such as gender differences, ethnicity, genetic factors and the role of innate immunity system. How these additional factors may be involved in the installation, progression and disease prognosis is discussed. </p>            </sec>            <sec>               <title>CONCLUSION:</title>               <p> Risk factors for NAFLD in the context of metabolic syndrome expands the prospects to 1) recognize patients with metabolic syndrome at high risk for NAFLD, 2) elucidate pathways common to other co-morbidities, 3) determine risk factors associated with a worse prognosis, 4) develop therapeutic strategies with goal of reducing risk factors, 5) apply acquired knowledge in public health policies focusing on preventive strategies.</p>            </sec>^len
!v083!^a<sec>               <title>CONTEXTO:</title>               <p> A doen&#231;a hep&#225;tica gordurosa n&#227;o alco&#243;lica (DHGNA) vem sendo considerada a manifesta&#231;&#227;o hep&#225;tica da s&#237;ndrome metab&#243;lica e a hepatopatia mais frequente da atualidade, sendo tamb&#233;m a causa mais frequente de aumento das transaminases e de cirrose criptog&#234;nica. O maior aporte de &#225;cidos graxos ao f&#237;gado e consequente aumento da beta-oxida&#231;&#227;o concorrem para forma&#231;&#227;o de radicais livres, libera&#231;&#227;o de citocinas inflamat&#243;rias e graus vari&#225;veis de agress&#227;o hepatoc&#237;tica, cuja express&#227;o histol&#243;gica pode variar da esteatose hep&#225;tica (EH) &#224; esteatohepatite n&#227;o-alco&#243;lica (EHNA), cuja diferencia&#231;&#227;o se faz necess&#225;ria pelo risco potencial de progress&#227;o para cirrose e desenvolvimento do carcinoma hepatocelular. </p>            </sec>            <sec>               <title>OBJETIVO:</title>               <p> Revisar a literatura sobre os principais fatores de risco para a DHGNA no contexto da s&#237;ndrome metab&#243;lica, com foco nos mecanismos subjacentes e nas estrat&#233;gias de preven&#231;&#227;o. </p>            </sec>            <sec>               <title> M&#201;TODO:</title>               <p> Foi realizada pesquisa bibliogr&#225;fica no PubMed para identificar estudos que descrevessem a associa&#231;&#227;o entre os fatores de risco para s&#237;ndrome metab&#243;lica e a DHGNA, utilizando-se a combina&#231;&#227;o de descritores: "Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, metabolic syndrome and risk factors". Foram selecionados 96 estudos cl&#237;nicos, experimentais, de cohort, metan&#225;lises e revis&#245;es sistem&#225;ticas de maior impacto e relev&#226;ncia cient&#237;fica para o tema. </p>            </sec>            <sec>               <title>RESULTADOS:</title>               <p> A an&#225;lise das informa&#231;&#245;es consolidou a obesidade central, diabetes melitus tipo 2, dislipidemia e hipertens&#227;o como os fatores de risco mais bem relacionados &#224; DHGNA. Entretanto, outros fatores foram destacados, como diferen&#231;as entre g&#234;neros, etnia, fatores gen&#233;ticos e o papel da imunidade inata, como estes fatores adicionais que podem estar implicados na instala&#231;&#227;o, progress&#227;o e progn&#243;stico da doen&#231;a. </p>            </sec>            <sec>               <title>CONCLUS&#195;O:</title>               <p> O conhecimento dos fatores de risco para a DHGNA no contexto da s&#237;ndrome metab&#243;lica amplia os caminhos para: 1) reconhecer pacientes com risco elevado para a doen&#231;a; 2) elucidar vias comuns a outras comorbidades; 3) determinar fatores de risco relacionados a pior progn&#243;stico; 4) desenvolver estrat&#233;gias terap&#234;uticas com o objetivo de reduzir fatores de risco; 4) aplicar os conhecimentos adquiridos nas pol&#237;ticas p&#250;blicas de sa&#250;de com foco em estrat&#233;gias preventivas.</p>            </sec>^lpt
!v085!^kMetabolic syndrome X^len
!v085!^kFatty liver, non-alcoholic^len
!v085!^kRisk factors^len
!v085!^kSíndrome X metabólica^lpt
!v085!^kFígado gorduroso não-alcoólico^lpt
!v085!^kFatores de risco^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m05^d25
!v112!2011
!v113!^y2011^m09^d05
!v114!2011
!v120!XML_3.0
!v121!89
!v237!10.1590/S0004-28032012000100015
!v700!3
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!f
!v708!1
!ID 000583
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sSouza^rauthor^nMonica Rodrigues de Araujo
!v010!^sDiniz^rauthor^nMargareth de Fatima Formiga de Melo
!v010!^sMedeiros-Filho^rauthor^nJose Eymard Moraes de
!v010!^sAraujo^rauthor^nMaria Salete Trigueiro de
!v012!^tMetabolic syndrome and risk factors for non-alcoholic fatty liver disease
!v012!^tSindrome metabolica e fatores de risco para a doenca hepatica gordurosa nao-alcoolica^lpt
!v014!^l96^f89
!v030!Arq. Gastroenterol.
!v031!49
!v032!1
!v035!0004-2803
!v038!ND
!v040!en
!v042!1
!v049!REVIEW
!v064!Jan-Mar
!v065!20120300
!v070!Universidade Federal da Paraiba (UFPB)^cPB^iaff1^1^pBrasil^9Universidade Federal da Paraiba (UFPB), PB, Brasil
!v071!oa
!v072!96
!v083!^a<sec>               <title>CONTEXT:</title>                Non-alcoholic fatty liver disease (NAFLD), hepatic manifestation of metabolic syndrome, has been considered the most common liver disease nowadays, which is also the most frequent cause of elevated transaminases and cryptogenic cirrhosis. The greatest input of fatty acids into the liver and consequent increased beta-oxidation contribute to the formation of free radicals, release of inflammatory cytokines and varying degrees of hepatocytic aggression, whose histological expression may vary from steatosis (HS) to non-alcoholic steatohepatitis (NASH). The differentiation of these forms is required by the potential risk of progression to cirrhosis and development of hepatocellular carcinoma.             </sec>            <sec>               <title>OBJECTIVE:</title>                To review the literature about the major risk factors for NAFLD in the context of metabolic syndrome, focusing on underlying mechanisms and prevention.             </sec>            <sec>               <title>METHOD:</title>                PubMed, MEDLINE and SciELO data basis analysis was performed to identify studies describing the link between risk factors for metabolic syndrome and NAFLD. A combination of descriptors was used, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and risk factors. At the end, 96 clinical and experimental studies, cohorts, meta-analysis and systematic reviews of great impact and scientific relevance to the topic, were selected.             </sec>            <sec>               <title>RESULTS:</title>                The final analysis of all these data, pointed out the central obesity, type 2 diabetes, dyslipidemia and hypertension as the best risk factors related to NAFLD. However, other factors were highlighted, such as gender differences, ethnicity, genetic factors and the role of innate immunity system. How these additional factors may be involved in the installation, progression and disease prognosis is discussed.             </sec>            <sec>               <title>CONCLUSION:</title>                Risk factors for NAFLD in the context of metabolic syndrome expands the prospects to 1) recognize patients with metabolic syndrome at high risk for NAFLD, 2) elucidate pathways common to other co-morbidities, 3) determine risk factors associated with a worse prognosis, 4) develop therapeutic strategies with goal of reducing risk factors, 5) apply acquired knowledge in public health policies focusing on preventive strategies.            </sec>^len
!v083!^a<sec>               <title>CONTEXTO:</title>                A doenca hepatica gordurosa nao alcoolica (DHGNA) vem sendo considerada a manifestacao hepatica da sindrome metabolica e a hepatopatia mais frequente da atualidade, sendo tambem a causa mais frequente de aumento das transaminases e de cirrose criptogenica. O maior aporte de acidos graxos ao figado e consequente aumento da beta-oxidacao concorrem para formacao de radicais livres, liberacao de citocinas inflamatorias e graus variaveis de agressao hepatocitica, cuja expressao histologica pode variar da esteatose hepatica (EH) a esteatohepatite nao-alcoolica (EHNA), cuja diferenciacao se faz necessaria pelo risco potencial de progressao para cirrose e desenvolvimento do carcinoma hepatocelular.             </sec>            <sec>               <title>OBJETIVO:</title>                Revisar a literatura sobre os principais fatores de risco para a DHGNA no contexto da sindrome metabolica, com foco nos mecanismos subjacentes e nas estrategias de prevencao.             </sec>            <sec>               <title> MeTODO:</title>                Foi realizada pesquisa bibliografica no PubMed para identificar estudos que descrevessem a associacao entre os fatores de risco para sindrome metabolica e a DHGNA, utilizando-se a combinacao de descritores: "Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, metabolic syndrome and risk factors". Foram selecionados 96 estudos clinicos, experimentais, de cohort, metanalises e revisoes sistematicas de maior impacto e relevancia cientifica para o tema.             </sec>            <sec>               <title>RESULTADOS:</title>                A analise das informacoes consolidou a obesidade central, diabetes melitus tipo 2, dislipidemia e hipertensao como os fatores de risco mais bem relacionados a DHGNA. Entretanto, outros fatores foram destacados, como diferencas entre generos, etnia, fatores geneticos e o papel da imunidade inata, como estes fatores adicionais que podem estar implicados na instalacao, progressao e prognostico da doenca.             </sec>            <sec>               <title>CONCLUSaO:</title>                O conhecimento dos fatores de risco para a DHGNA no contexto da sindrome metabolica amplia os caminhos para: 1) reconhecer pacientes com risco elevado para a doenca; 2) elucidar vias comuns a outras comorbidades; 3) determinar fatores de risco relacionados a pior prognostico; 4) desenvolver estrategias terapeuticas com o objetivo de reduzir fatores de risco; 4) aplicar os conhecimentos adquiridos nas politicas publicas de saude com foco em estrategias preventivas.            </sec>^lpt
!v085!^kMetabolic syndrome X^len
!v085!^kFatty liver, non-alcoholic^len
!v085!^kRisk factors^len
!v085!^kSindrome X metabolica^lpt
!v085!^kFigado gorduroso nao-alcoolico^lpt
!v085!^kFatores de risco^lpt
!v100!Arquivos de Gastroenterologia
!v111!^y2011^m05^d25
!v112!2011
!v113!^y2011^m09^d05
!v114!2011
!v120!XML_3.0
!v121!89
!v237!10.1590/S0004-28032012000100015
!v700!4
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!l
!v708!1
!ID 000584
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sAdams^rND^nLA
!v010!^sLymp^rND^nJF
!v010!^sSt Sauver^rND^nJ
!v010!^sSanderson^rND^nSO
!v010!^sLindor^rND^nKD
!v010!^sFeldstein^rND^nA
!v010!^sAngulo^rND^nP
!v012!The natural history of nonalcoholic fatty liver disease: a population-based cohort study^len
!v014!113-21
!v030!Gastroenterology
!v031!129
!v064!2005
!v065!20050000
!v071!journal
!v118!1
!v514!^l121^f113
!v700!5
!v701!1
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000585
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sAngulo^rND^nP
!v012!GI epidemiology: nonalcoholic fatty liver disease^len
!v014!883-89
!v030!Aliment Pharmacol Ther
!v031!25
!v064!2007
!v065!20070000
!v118!2
!v514!^l889^f883
!v700!6
!v701!2
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000586
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sArun^rND^nJ
!v010!^sClements^rND^nRH
!v010!^sLazenby^rND^nAJ
!v010!^sLeeth^rND^nRR
!v010!^sAbrams^rND^nGA
!v012!The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women^len
!v014!1351-358
!v030!Obes Surg
!v031!16
!v064!2006
!v065!20060000
!v118!3
!v514!^l1358^f1351
!v700!7
!v701!3
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000587
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sBacon^rND^nBR
!v010!^sFarahvash^rND^nMJ
!v010!^sJanney^rND^nCG
!v010!^sNeuschwander-Tetri^rND^nBA
!v012!Nonalcoholic steatohepatitis: an expanded clinical entity^len
!v014!1103-109
!v030!Gastroenterology
!v031!107
!v064!1994
!v065!19940000
!v118!4
!v514!^l1109^f1103
!v700!8
!v701!4
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000588
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sBaranova^rND^nA
!v010!^sTran^rND^nTP
!v010!^sBirerdinc^rND^nA
!v010!^sYounossi^rND^nZM
!v012!Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease^len
!v014!801-14
!v030!Aliment Pharmacol Ther
!v031!33
!v064!2011
!v065!20110000
!v118!5
!v514!^l814^f801
!v700!9
!v701!5
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000589
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sBaskin^rND^nML
!v010!^sArd^rND^nJ
!v010!^sFranklin^rND^nF
!v010!^sAllison^rND^nDB
!v012!Prevalence of obesity in the United States^len
!v014!5-7
!v030!Obes Rev
!v031!6
!v064!2005
!v065!20050000
!v118!6
!v514!^l7^f5
!v700!10
!v701!6
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000590
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sBedogni^rND^nG
!v010!^sMiglioli^rND^nL
!v010!^sMasutti^rND^nF
!v010!^sTiribelli^rND^nC
!v010!^sMarchesini^rND^nG
!v010!^sBellentani^rND^nS
!v012!Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study^len
!v014!44-52
!v030!Hepatology
!v031!42
!v064!2005
!v065!20050000
!v118!7
!v514!^l52^f44
!v700!11
!v701!7
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000591
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sBloomgarden^rND^nZT
!v012!Definitions of the insulin resistance syndrome: the 1st World Congress on the Insulin Resistance Syndrome^len
!v014!824-30
!v030!Diabetes Care
!v031!27
!v064!2004
!v065!20040000
!v118!8
!v514!^l830^f824
!v700!12
!v701!8
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000592
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sBrowning^rND^nJD
!v010!^sSzczepaniak^rND^nLS
!v010!^sDobbins^rND^nR
!v010!^sNuremberg^rND^nP
!v010!^sHorton^rND^nJD
!v010!^sCohen^rND^nJC
!v010!^sGrundy^rND^nSM
!v010!^sHobbs^rND^nHH
!v012!Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity^len
!v014!1387-395
!v030!Hepatology
!v031!40
!v064!2004
!v065!20040000
!v118!9
!v514!^l1395^f1387
!v700!13
!v701!9
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000593
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sBrunt^rND^nEM
!v010!^sTiniakos^rND^nDG
!v012!Histopathology of nonalcoholic fatty liver disease^len
!v014!5286-296
!v030!World J Gastroenterol
!v031!16
!v064!2010
!v065!20100000
!v118!10
!v514!^l5296^f5286
!v700!14
!v701!10
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000594
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sCaldwell^rND^nSH
!v010!^sHarris^rND^nDM
!v010!^sPatrie^rND^nJT
!v010!^sHespenheide^rND^nEE
!v012!Is NASH underdiagnosed among African Americans?^len
!v014!1496-500
!v030!Am J Gastroenterol
!v031!96
!v064!2002
!v065!20020000
!v118!11
!v514!^l1500^f1496
!v700!15
!v701!11
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000595
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sCarr^rND^nMC
!v010!^sAyyobi^rND^nAF
!v010!^sMurdoch^rND^nSJ
!v010!^sDeeb^rND^nSS
!v010!^sBrunzell^rND^nJD
!v012!Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women^len
!v014!667-73
!v030!Arterioscler Thromb Vasc Biol
!v031!22
!v064!2002
!v065!20020000
!v118!12
!v514!^l673^f667
!v700!16
!v701!12
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000596
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sChalasani^rND^nN
!v010!^sGuo^rND^nX
!v010!^sLoomba^rND^nR
!v010!^sGoodarzi^rND^nMO
!v010!^sHaritunians^rND^nT
!v010!^sKwon^rND^nS
!v010!^sCui^rND^nJ
!v010!^sTaylor^rND^nKD
!v010!^sWilson^rND^nL
!v010!^sCummings^rND^nOW
!v010!^sChen^rND^nYD
!v010!^sRotter^rND^nJI
!v012!Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease^len
!v014!1567-576
!v030!Gastroenterology
!v031!139
!v064!2010
!v065!20100000
!v118!13
!v514!^l1576^f1567
!v700!17
!v701!13
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000597
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sChanson^rND^nP
!v010!^sSalenave^rND^nS
!v012!Metabolic syndrome in Cushing's syndrome^len
!v014!96-101
!v030!Neuroendocrinology
!v031!92
!v064!2010
!v065!20100000
!v118!14
!v514!^l101^f96
!v700!18
!v701!14
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000598
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sCheung^rND^nO
!v010!^sKapoor^rND^nA
!v010!^sPuri^rND^nP
!v010!^sSistrun^rND^nS
!v010!^sLuketic^rND^nVA
!v010!^sSargeant^rND^nCC
!v010!^sContos^rND^nMJ
!v010!^sShiffman^rND^nML
!v010!^sStravitz^rND^nRT
!v010!^sSterling^rND^nRK
!v010!^sSanyal^rND^nAJ
!v012!The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome^len
!v014!1091-100
!v030!Hepatology
!v031!46
!v064!2007
!v065!20070000
!v118!15
!v514!^l1100^f1091
!v700!19
!v701!15
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000599
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sChiang^rND^nCH
!v010!^sHuang^rND^nCC
!v010!^sChan^rND^nWL
!v010!^sChen^rND^nJW
!v010!^sLeu^rND^nHB
!v012!The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population^len
!v014!1399-404
!v030!Clin Biochem
!v031!43
!v064!2010
!v065!20100000
!v118!16
!v514!^l1404^f1399
!v700!20
!v701!16
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000600
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sChiang^rND^nDJ
!v010!^sPritchard^rND^nMT
!v010!^sNagy^rND^nLE
!v012!Obesity, diabetes mellitus, and liver fibrosis^len
!v014!G697-G702
!v030!Am J Physiol Gastrointest Liver Physiol
!v031!300
!v064!2011
!v065!20110000
!v118!17
!v514!^lG702^fG697
!v700!21
!v701!17
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000601
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sChitturi^rND^nS
!v010!^sWeltman^rND^nM
!v010!^sFarrell^rND^nGC
!v010!^sMcDonald^rND^nD
!v010!^sKench^rND^nJ
!v010!^sLiddle^rND^nC
!v010!^sSamarasinghe^rND^nD
!v010!^sLin^rND^nR
!v010!^sAbeygunasekera^rND^nS
!v010!^sGeorge^rND^nJ
!v012!HFE mutations, hepatic iron, and fibrosis:ethinic-specific association of NASH with C82Y but not with fibrotic severity^len
!v014!142-49
!v030!Hepatology
!v031!36
!v064!2002
!v065!20020000
!v118!18
!v514!^l149^f142
!v700!22
!v701!18
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000602
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sClark^rND^nJM
!v010!^sBrancati^rND^nFL
!v010!^sDiehl^rND^nAM
!v012!The prevalence and etiology of elevated aminotransferase levels in the United States^len
!v014!960-67
!v030!Am J Gastroenterol
!v031!98
!v064!2003
!v065!20030000
!v118!19
!v514!^l967^f960
!v700!23
!v701!19
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000603
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sClark^rND^nJM
!v010!^sDiehl^rND^nAM
!v012!Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis^len
!v014!3000-004
!v030!JAMA
!v031!289
!v064!2003
!v065!20030000
!v118!20
!v514!^l3004^f3000
!v700!24
!v701!20
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000604
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sClark^rND^nJM
!v012!The epidemiology of nonalcoholic fatty liver disease in adults^len
!v014!s5-10
!v030!J Clin Gastroenterol
!v031!40
!v032!3
!v064!2006
!v065!20060000
!v118!21
!v514!^l10^fs5
!v700!25
!v701!21
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000605
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sCorona^rND^nG
!v010!^sMonami^rND^nM
!v010!^sRastrelli^rND^nG
!v010!^sAversa^rND^nA
!v010!^sTishova^rND^nY
!v010!^sSaad^rND^nF
!v010!^sLenzi^rND^nA
!v010!^sForti^rND^nG
!v010!^sMannucci^rND^nE
!v010!^sMaggi^rND^nM
!v012!Testosterone and metabolic syndrome: a meta-analysis study^len
!v014!272-83
!v030!J Sex Med
!v031!8
!v064!2011
!v065!20110000
!v118!22
!v514!^l283^f272
!v700!26
!v701!22
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000606
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sCotrim^rND^nHP
!v010!^sParise^rND^nER
!v010!^sOliveira^rND^nCP
!v010!^sLeite^rND^nN
!v010!^sMartinelli^rND^nA
!v010!^sGalizzi^rND^nJ
!v010!^sC^rND^nSilva R de
!v010!^sMattos^rND^nA
!v010!^sPereira^rND^nL
!v010!^sAmorim^rND^nW
!v010!^sIvantes^rND^nC
!v010!^sSouza^rND^nF
!v010!^sCosta^rND^nM
!v010!^sMaia^rND^nL
!v010!^sL^rND
!v010!^sPessoa^rND^nM
!v010!^sOliveira^rND^nF
!v012!Nonalcoholic fatty liver disease in Brazil^len
!v014!33-7
!v030!Clinical and histological profile. Ann Hepatol
!v031!10
!v064!2011
!v065!20110000
!v118!23
!v514!^l37^f33
!v700!27
!v701!23
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000607
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sDamaso^rND^nAR
!v010!^sTock^rND^nL
!v010!^sTufik^rND^nS
!v010!^sPrado^rND^nWL
!v010!^sStella^rND^nSG
!v010!^sFisberg^rND^nM
!v010!^sCintra^rND^nIP
!v010!^sCaranti^rND^nDA
!v010!^sSiqueira^rND^nKO
!v010!^sNascimento^rND^nCM
!v010!^sOyama^rND^nLM
!v010!^sLederman^rND^nHM
!v010!^sCristofalo^rND^nD
!v010!^sAntunes^rND^nHK
!v010!^sComparoni^rND^nA
!v010!^sSantos^rND^nLC
!v010!^sMeloo^rND^nMT
!v012!Tratamento multidisciplinar reduz o tecido adiposo visceral, leptina, grelina e a prevalencia de esteatose hepatica nao alcoolica (NAFLD) em adolescentes obesos^lpt
!v014!263-67
!v030!Rev Bras Med Esporte
!v031!12
!v064!2006
!v065!20060000
!v118!24
!v514!^l267^f263
!v700!28
!v701!24
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000608
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sDay^rND^nCP
!v010!^sJames^rND^nOF
!v012!Steatohepatitis: a tale of two "hits"?^len
!v014!842
!v030!Gastroenterology
!v031!114
!v064!1998
!v065!19980000
!v118!25
!v514!^f842
!v700!29
!v701!25
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000609
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sDay^rND^nCP
!v012!The potential role of genes in nonalcoholic fatty liver disease^len
!v014!673-91
!v030!Clin Liver Dis
!v031!8
!v064!2004
!v065!20040000
!v118!26
!v514!^l691^f673
!v700!30
!v701!26
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000610
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sde Sousa^rND^nTF
!v010!^sNahas^rND^nMV
!v010!^sSilva^rND^nDA
!v010!^sDel Duca^rND^nGF
!v010!^sPeres^rND^nMA
!v012!Factors associated with central obesity in adults from Florianopolis, Santa Catarina: a population based-study^len
!v014!296-309
!v030!Rev Bras Epidemiol
!v031!14
!v064!2011
!v065!20110000
!v118!27
!v514!^l309^f296
!v700!31
!v701!27
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000611
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sDiehl^rND^nAM
!v010!^sGoodman^rND^nZ
!v010!^sIshak^rND^nKG
!v012!Alcohollike disease in nonalcoholics. A clinical and histological comparison with alcohol-induced liver injury^len
!v014!1056-062
!v030!Gastroenterology
!v031!94
!v064!1988
!v065!19880000
!v118!28
!v514!^l1062^f1056
!v700!32
!v701!28
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000612
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v012!Diretriz Brasileira de Diagnostico e Tratamento da Sindrome Metabolica I [Internet]^lpt
!v014!3-28
!v030!Arq Bras Cardiol
!v031!84
!v064!2005
!v065!20050000
!v118!29
!v514!^l28^f3
!v700!33
!v701!29
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000613
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sDixon^rND^nJB
!v010!^sBhathal^rND^nPS
!v010!^sO'Brien^rND^nPE
!v012!Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese^len
!v014!91-100
!v030!Gastroenterology
!v031!121
!v064!2001
!v065!20010000
!v118!30
!v514!^l100^f91
!v700!34
!v701!30
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000614
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sDonati^rND^nG
!v010!^sStagni^rND^nB
!v010!^sPiscaglia^rND^nF
!v010!^sVenturoli^rND^nN
!v010!^sMorselli-Labate^rND^nAM
!v010!^sRasciti^rND^nL
!v010!^sBolondi^rND^nL
!v012!Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance^len
!v014!1020-023
!v030!Gut
!v031!53
!v064!2004
!v065!20040000
!v118!31
!v514!^l1023^f1020
!v700!35
!v701!31
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000615
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sDowman^rND^nJK
!v010!^sTomlinson^rND^nJW
!v010!^sNewsome^rND^nPN
!v012!Pathogenesis of non-alcoholic fatty liver disease^len
!v014!71-83
!v030!QJM
!v031!103
!v064!2010
!v065!20100000
!v118!32
!v514!^l83^f71
!v700!36
!v701!32
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000616
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sDudley^rND^nKJ
!v010!^sSloboda^rND^nDM
!v010!^sConnor^rND^nKL
!v010!^sBeltrand^rND^nJ
!v010!^sVickers^rND^nMH
!v012!Offspring of mothers fed a high fat diet display hepatic cell cycle inhibition and associated changes in gene expression and DNA methylation^len
!v030!PLoS One
!v031!6
!v064!2011
!v065!20110000
!v118!33
!v700!37
!v701!33
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000617
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sEkstedt^rND^nM
!v010!^sFranzen^rND^nLE
!v010!^sMathiesen^rND^nUL
!v010!^sThorelius^rND^nL
!v010!^sHolmqvist^rND^nM
!v010!^sBodemar^rND^nG
!v010!^sKechagias^rND^nS
!v012!Long-term follow-up of patients with NAFLD and elevated liver enzymes^len
!v014!865-73
!v030!Hepatology
!v031!44
!v064!2006
!v065!20060000
!v118!34
!v514!^l873^f865
!v700!38
!v701!34
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000618
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sFehrenbach^rND^nH
!v010!^sWeiskirchen^rND^nR
!v010!^sKasper^rND^nM
!v010!^sGressner^rND^nAM
!v012!Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts^len
!v014!943-52
!v030!Hepatology
!v031!34
!v064!2001
!v065!20010000
!v118!35
!v514!^l952^f943
!v700!39
!v701!35
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000619
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sFerreira^rND^nVSG
!v010!^sPernambuco^rND^nRB
!v010!^sLopes^rND^nEP
!v010!^sMorais^rND^nCN
!v010!^sRodrigues^rND^nMC
!v010!^sArruda^rND^nMJ
!v010!^sSilva^rND^nLM
!v010!^sVilar^rND^nL
!v012!Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus^len
!v014!362-68
!v030!Arq Bras Endocrinol Metab
!v031!54
!v064!2010
!v065!20100000
!v118!36
!v514!^l368^f362
!v700!40
!v701!36
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000620
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sFord^rND^nES
!v010!^sGiles^rND^nWH
!v010!^sDietz^rND^nWH
!v012!Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey^len
!v014!356-59
!v030!JAMA
!v031!287
!v064!2002
!v065!20020000
!v118!37
!v514!^l359^f356
!v700!41
!v701!37
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000621
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sGalassi^rND^nA
!v010!^sReynolds^rND^nK
!v010!^sHe^rND^nJ
!v012!Metabolic syndrome and risk of cardiovascular disease: a meta-analysis^len
!v014!812-19
!v030!Am J Med
!v031!119
!v064!2006
!v065!20060000
!v118!38
!v514!^l819^f812
!v700!42
!v701!38
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000622
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sGeorge^rND^nDK
!v010!^sGoldwurm^rND^nS
!v010!^sMacDonald^rND^nGA
!v010!^sCowley^rND^nLL
!v010!^sWalker^rND^nNI
!v010!^sWard^rND^nPJ
!v010!^sJazwinska^rND^nEC
!v010!^sPowell^rND^nLW
!v012!Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis^len
!v014!311-18
!v030!Gastroenterology
!v031!114
!v064!1998
!v065!19980000
!v118!39
!v514!^l318^f311
!v700!43
!v701!39
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000623
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sGiday^rND^nSA
!v010!^sAshiny^rND^nZ
!v010!^sNaab^rND^nT
!v010!^sSmoot^rND^nD
!v010!^sBanks^rND^nA
!v012!Frequency of nonalcoholic fatty liver disease and degree of hepatic steatosis in African-American patients^len
!v014!1613-615
!v030!J Natl Med Assoc
!v031!98
!v064!2006
!v065!20060000
!v118!40
!v514!^l1615^f1613
!v700!44
!v701!40
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000624
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sGupte^rND^nP
!v010!^sAmarapurkar^rND^nD
!v010!^sAgal^rND^nS
!v010!^sBaijal^rND^nR
!v010!^sKulshrestha^rND^nP
!v010!^sPramanik^rND^nS
!v010!^sPatel^rND^nN
!v010!^sMadan^rND^nA
!v010!^sAmarapurkar^rND^nA
!v010!^sHafeezunnisa^rND
!v012!Non-alcoholic steatohepatitis in type 2 diabetes mellitus^len
!v014!854-58
!v030!J Gastroenterol Hepatol
!v031!19
!v064!2004
!v065!20040000
!v118!41
!v514!^l858^f854
!v700!45
!v701!41
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000625
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sHagymasi^rND^nK
!v010!^sReismann^rND^nP
!v010!^sRacz^rND^nK
!v010!^sTulassay^rND^nZ
!v014!2173-181
!v030!Orv Hetil
!v031!150
!v064!2009
!v065!20090000
!v118!42
!v514!^l2181^f2173
!v700!46
!v701!42
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000626
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sHashizume^rND^nH
!v010!^sSato^rND^nK
!v010!^sTakagi^rND^nH
!v010!^sHirokawa^rND^nT
!v010!^sKojima^rND^nA
!v010!^sSohara^rND^nN
!v010!^sKakizaki^rND^nS
!v010!^sMochida^rND^nY
!v010!^sShimura^rND^nT
!v010!^sSunose^rND^nY
!v010!^sOhwada^rND^nS
!v010!^sMori^rND^nM
!v012!Primary liver cancers with nonalcoholic steatohepatitis^len
!v014!827-24
!v030!Eur J Gastroenterol Hepatol
!v031!19
!v064!2007
!v065!20070000
!v118!43
!v514!^l824^f827
!v700!47
!v701!43
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000627
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sHassan^rND^nMM
!v010!^sKaseb^rND^nA
!v010!^sLi^rND^nD
!v010!^sPatt^rND^nYZ
!v010!^sVauthey^rND^nJN
!v010!^sThomas^rND^nMB
!v010!^sCurley^rND^nSA
!v010!^sSpitz^rND^nMR
!v010!^sSherman^rND^nSI
!v010!^sAbdalla^rND^nEK
!v010!^sDavila^rND^nM
!v010!^sLozano^rND^nRD
!v010!^sHassan^rND^nDM
!v010!^sChan^rND^nW
!v010!^sBrown^rND^nTD
!v010!^sAbbruzzese^rND^nJL
!v012!Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States^len
!v014!1563-570
!v030!Hepatology
!v031!49
!v064!2009
!v065!20090000
!v118!44
!v514!^l1570^f1563
!v700!48
!v701!44
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000628
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sHijona^rND^nE
!v010!^sHijona^rND^nL
!v010!^sArenas^rND^nJI
!v010!^sBujanda^rND^nL
!v012!Inflammatory mediators of hepatic steatosis^len
!v014!837419
!v030!Mediators Inflamm
!v031!2010
!v064!2010
!v065!20100000
!v118!45
!v514!^f837419
!v700!49
!v701!45
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000629
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sHsiao^rND^nPJ
!v010!^sKuo^rND^nKK
!v010!^sShin^rND^nSJ
!v010!^sYang^rND^nYH
!v010!^sLin^rND^nWY
!v010!^sYang^rND^nJF
!v010!^sChiu^rND^nCC
!v010!^sChuang^rND^nWL
!v010!^sTsai^rND^nTR
!v010!^sYu^rND^nML
!v012!Significant correlations between severe fatty liver and risk factors for metabolic syndrome^len
!v014!2118-123
!v030!J Gastroenterol Hepatol
!v031!22
!v064!2007
!v065!20070000
!v118!46
!v514!^l2123^f2118
!v700!50
!v701!46
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000630
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sHyogo^rND^nH
!v010!^sYamagishi^rND^nS
!v010!^sIwamoto^rND^nK
!v010!^sArihiro^rND^nK
!v010!^sTakeuchi^rND^nM
!v010!^sSato^rND^nT
!v010!^sOchi^rND^nH
!v010!^sNonaka^rND^nM
!v010!^sNabeshima^rND^nY
!v010!^sInoue^rND^nM
!v010!^sIshitobi^rND^nT
!v010!^sChayama^rND^nK
!v010!^sTazuma^rND^nS
!v012!Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis^len
!v014!1112-119
!v030!J Gastroenterol Hepatol
!v031!22
!v064!2007
!v065!20070000
!v118!47
!v514!^l1119^f1112
!v700!51
!v701!47
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000631
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sJimba^rND^nS
!v010!^sNakagami^rND^nT
!v010!^sTakahashi^rND^nM
!v010!^sWakamatsu^rND^nT
!v010!^sHirota^rND^nY
!v010!^sIwamoto^rND^nY
!v010!^sWasada^rND^nT
!v012!Prevalence of nonalcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults^len
!v014!1141-145
!v030!Diabet Med
!v031!22
!v064!2005
!v065!20050000
!v118!48
!v514!^l1145^f1141
!v700!52
!v701!48
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000632
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sKashireddy^rND^nPR
!v010!^sRao^rND^nMS
!v012!Sex differences in choline-deficient diet-induced steatohepatitis in mice^len
!v014!158-62
!v030!Exp Biol Med (Maywood)
!v031!229
!v064!2004
!v065!20040000
!v118!49
!v514!^l162^f158
!v700!53
!v701!49
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000633
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sKim^rND^nHJ
!v010!^sKim^rND^nHJ
!v010!^sLee^rND^nKE
!v010!^sKim^rND^nDJ
!v010!^sKim^rND^nSK
!v010!^sAhn^rND^nCW
!v010!^sLim^rND^nSK
!v010!^sKim^rND^nKR
!v010!^sLee^rND^nHC
!v010!^sHuh^rND^nKB
!v010!^sCha^rND^nBS
!v012!Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults^len
!v014!2169-175
!v030!Arch Intern Med
!v031!164
!v064!2004
!v065!20040000
!v118!50
!v514!^l2175^f2169
!v700!54
!v701!50
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000634
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sKobayashi^rND^nJ
!v010!^sMaruyama^rND^nT
!v010!^sWatanabe^rND^nH
!v010!^sKudoh^rND^nA
!v010!^sTateishi^rND^nS
!v010!^sSasaki^rND^nT
!v010!^sMurano^rND^nS
!v010!^sWatanabe^rND^nM
!v012!Gender differences in the effect of type 2 diabetes on serum lipids, pre-heparin plasma lipoprotein lipase mass and other metabolic parameters in Japanese population^len
!v014!39-45
!v030!Diabetes Res Clin Pract
!v031!62
!v064!2003
!v065!20030000
!v118!51
!v514!^l45^f39
!v700!55
!v701!51
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000635
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sKotronen^rND^nA
!v010!^sYki-Jarvinen^rND^nH
!v012!Fatty liver: a novel component of the metabolic syndrome^len
!v014!27-38
!v030!Arterioscler Thromb Vasc Biol
!v031!28
!v064!2008
!v065!20080000
!v118!52
!v514!^l38^f27
!v700!56
!v701!52
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000636
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sLaish^rND^nI
!v010!^sBraun^rND^nM
!v010!^sMor^rND^nE
!v010!^sSulkes^rND^nJ
!v010!^sHarif^rND^nY
!v010!^sBen Ari^rND^nZ
!v012!Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events^len
!v014!15-22
!v030!Liver Transpl
!v031!17
!v064!2011
!v065!20110000
!v118!53
!v514!^l22^f15
!v700!57
!v701!53
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000637
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sLavine^rND^nJE
!v010!^sSchwimmer^rND^nJB
!v012!Nonalcoholic fatty liver disease in the pediatric population^len
!v014!549-58
!v030!Clin Liver Dis
!v031!8
!v064!2004
!v065!20040000
!v118!54
!v514!^l558^f549
!v700!58
!v701!54
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000638
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sLi^rND^nW
!v010!^sMa^rND^nD
!v010!^sLiu^rND^nM
!v010!^sLiu^rND^nH
!v010!^sFeng^rND^nS
!v010!^sHao^rND^nZ
!v010!^sWu^rND^nB
!v010!^sZhang^rND^nS
!v012!Association between metabolic syndrome and risk of stroke: a meta-analysis of cohort studies^len
!v014!539-47
!v030!Cerebrovasc Dis
!v031!25
!v064!2008
!v065!20080000
!v118!55
!v514!^l547^f539
!v700!59
!v701!55
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000639
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sLiangpunsakul^rND^nS
!v010!^sChalasani^rND^nN
!v012!Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?^len
!v014!340-43
!v030!J Clin Gastroenterol
!v031!37
!v064!2003
!v065!20030000
!v118!56
!v514!^l343^f340
!v700!60
!v701!56
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000640
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sLoria^rND^nP
!v010!^sCarulli^rND^nL
!v010!^sBertolotti^rND^nM
!v010!^sLonardo^rND^nA
!v012!Endocrine and liver interaction: the role of endocrine pathways in NASH^len
!v014!236-47
!v030!Nat Rev Gastroenterol Hepatol
!v031!6
!v064!2009
!v065!20090000
!v118!57
!v514!^l247^f236
!v700!61
!v701!57
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000641
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sLudwig^rND^nJ
!v010!^sViggiano^rND^nTR
!v010!^sMcGill^rND^nDB
!v010!^sOh^rND^nBJ
!v012!Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease^len
!v014!434-38
!v030!Mayo Clin Proc
!v031!55
!v064!1980
!v065!19800000
!v118!58
!v514!^l438^f434
!v700!62
!v701!58
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000642
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sMarchesini^rND^nG
!v010!^sBrizi^rND^nM
!v010!^sBianchi^rND^nG
!v010!^sTomassetti^rND^nS
!v010!^sBugianesi^rND^nE
!v010!^sLenzi^rND^nM
!v010!^sMcCullough^rND^nAJ
!v010!^sNatale^rND^nS
!v010!^sForlani^rND^nG
!v010!^sMelchionda^rND^nN
!v012!Nonalcoholic fatty liver disease: a feature of the metabolic syndrome^len
!v014!1844-850
!v030!Diabetes
!v031!50
!v064!2001
!v065!20010000
!v118!59
!v514!^l1850^f1844
!v700!63
!v701!59
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000643
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sMarchesini^rND^nG
!v010!^sBugianesi^rND^nE
!v010!^sForlani^rND^nG
!v010!^sCerrelli^rND^nF
!v010!^sLenzi^rND^nM
!v010!^sManini^rND^nR
!v010!^sNatale^rND^nS
!v010!^sVanni^rND^nE
!v010!^sVillanova^rND^nN
!v010!^sMelchionda^rND^nN
!v010!^sRizzetto^rND^nM
!v012!Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome^len
!v014!917-23
!v030!Hepatology
!v031!37
!v064!2003
!v065!20030000
!v118!60
!v514!^l923^f917
!v700!64
!v701!60
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000644
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sMarchesini^rND^nG
!v010!^sMarzocchi^rND^nR
!v012!Metabolic syndrome and NASH^len
!v014!105-17
!v030!Clin Liver Dis
!v031!11
!v064!2007
!v065!20070000
!v118!61
!v514!^l117^f105
!v700!65
!v701!61
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000645
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sMarques-Vidal^rND^nP
!v010!^sMazoyer^rND^nE
!v010!^sBongard^rND^nV
!v010!^sGourdy^rND^nP
!v010!^sRuidavets^rND^nJB
!v010!^sDrouet^rND^nL
!v010!^sFerrieres^rND^nJ
!v012!Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers^len
!v014!1371-377
!v030!Diabetes Care
!v031!25
!v064!2002
!v065!20020000
!v118!62
!v514!^l1377^f1371
!v700!66
!v701!62
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000646
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sMcKimmie^rND^nRL
!v010!^sDaniel^rND^nKR
!v010!^sCarr^rND^nJJ
!v010!^sBowden^rND^nDW
!v010!^sFreedman^rND^nBI
!v010!^sRegsuter^rND^nTC
!v010!^sHsu^rND^nFC
!v010!^sLohman^rND^nKK
!v010!^sWeinberg^rND^nRB
!v010!^sWagenknecht^rND^nLE
!v012!Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study^len
!v014!3029-035
!v030!Am J Gastroenterol
!v031!103
!v064!2008
!v065!20080000
!v118!63
!v514!^l3035^f3029
!v700!67
!v701!63
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000647
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sMonnier^rND^nVM
!v012!Intervention against the Maillard reaction in vivo^len
!v014!1-15
!v030!Arch Biochem Biophys
!v031!419
!v064!2003
!v065!20030000
!v118!64
!v514!^l15^f1
!v700!68
!v701!64
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000648
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v012!Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report^len
!v014!3143-421
!v030!Circulation
!v031!106
!v064!2002
!v065!20020000
!v118!65
!v514!^l3421^f3143
!v700!69
!v701!65
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000649
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sNobili^rND^nV
!v010!^sAlisi^rND^nA
!v010!^sPanera^rND^nN
!v010!^sAgostoni^rND^nC
!v012!Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review^len
!v014!241-47
!v030!Pediatr Endocrinol Rev
!v031!6
!v064!2008
!v065!20080000
!v118!66
!v514!^l247^f241
!v700!70
!v701!66
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000650
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sPagadala^rND^nM
!v010!^sDasarathy^rND^nS
!v010!^sEghtesad^rND^nB
!v010!^sMcCullough^rND^nAJ
!v012!Posttransplant metabolic syndrome: an epidemic waiting to happen^len
!v014!1662-670
!v030!Liver Transpl
!v031!15
!v064!2009
!v065!20090000
!v118!67
!v514!^l1670^f1662
!v700!71
!v701!67
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000651
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sPagel^rND^nJF
!v012!Obstructive sleep apnea (OSA) in primary care: evidence-based practice^len
!v014!392-98
!v030!J Am Board Fam Med
!v031!20
!v064!2007
!v065!20070000
!v118!68
!v514!^l398^f392
!v700!72
!v701!68
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000652
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sPenninx^rND^nBW
!v010!^sNicklas^rND^nBJ
!v010!^sNewman^rND^nAB
!v010!^sHarris^rND^nTB
!v010!^sGoodpaster^rND^nBH
!v010!^sSatterfield^rND^nS
!v010!^sde Rekeneire^rND^nN
!v010!^sYaffe^rND^nK
!v010!^sPahor^rND^nM
!v010!^sKritchevsky^rND^nSB
!v012!Metabolic syndrome and physical decline in older persons: results from the health, aging and body composition study^len
!v014!96-102
!v030!J Gerontol A Biol Sci Med Sci
!v031!64
!v064!2009
!v065!20090000
!v118!69
!v514!^l102^f96
!v700!73
!v701!69
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000653
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sPovel^rND^nCM
!v010!^sBoer^rND^nJM
!v010!^sReiling^rND^nE
!v010!^sFeskens^rND^nEJ
!v012!Genetic variants and the metabolic syndrome: a systematic review^len
!v030!Obes Rev
!v064!2011
!v065!20110000
!v118!70
!v700!74
!v701!70
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000654
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sRashid^rND^nM
!v010!^sRoberts^rND^nEA
!v012!Nonalcoholic steatohepatitis in children^len
!v014!48-53
!v030!J Pediatr Gastroenterol Nutr
!v031!30
!v064!2000
!v065!20000000
!v118!71
!v514!^l53^f48
!v700!75
!v701!71
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000655
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sReaven^rND^nG
!v012!Syndrome X: 10 years after^len
!v014!S19-S20
!v030!Drugs
!v031!58
!v064!1999
!v065!19990000
!v118!72
!v514!^lS20^fS19
!v700!76
!v701!72
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000656
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sRivera^rND^nCA
!v012!Risk factors and mechanisms of non-alcoholic steatohepatitis^len
!v014!109-14
!v030!Pathophysiology
!v031!15
!v064!2008
!v065!20080000
!v118!73
!v514!^l114^f109
!v700!77
!v701!73
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000657
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sSavransky^rND^nV
!v010!^sNanayakkara^rND^nA
!v010!^sVivero^rND^nA
!v010!^sLi^rND^nJ
!v010!^sBevans^rND^nS
!v010!^sSmith^rND^nPL
!v010!^sTorbenson^rND^nMS
!v010!^sPolotsky^rND^nVY
!v012!Chronic intermittent hypoxia predisposes to liver injury^len
!v014!1007-013
!v030!Hepatology
!v031!45
!v064!2007
!v065!20070000
!v118!74
!v514!^l1013^f1007
!v700!78
!v701!74
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000658
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sSchwimmer^rND^nJB
!v010!^sMcGreal^rND^nN
!v010!^sDeutsch^rND^nR
!v010!^sFinegold^rND^nMJ
!v010!^sLavine^rND^nJE
!v012!Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents^len
!v030!Pediatrics
!v031!115
!v064!2005
!v065!20050000
!v118!75
!v700!79
!v701!75
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000659
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sSilveira^rND^nVM
!v010!^sHorta^rND^nBL
!v014!10-8
!v030!Rev Saude Publica
!v031!42
!v064!2008
!v065!20080000
!v118!76
!v514!^l18^f10
!v700!80
!v701!76
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000660
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sSingh^rND^nDK
!v010!^sSakhuja^rND^nP
!v010!^sMalhotra^rND^nV
!v010!^sGondal^rND^nR
!v010!^sSarin^rND^nSK
!v012!Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis^len
!v014!1967-976
!v030!Dig Dis Sci
!v031!53
!v064!2008
!v065!20080000
!v118!77
!v514!^l1976^f1967
!v700!81
!v701!77
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000661
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sSobhonslidsuk^rND^nA
!v010!^sJongjirasiri^rND^nS
!v010!^sThakkinstian^rND^nA
!v010!^sWisedopas^rND^nN
!v010!^sBunnag^rND^nP
!v010!^sPuavilai^rND^nG
!v012!Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis^len
!v014!3614-618
!v030!World J Gastroenterol
!v031!13
!v064!2007
!v065!20070000
!v118!78
!v514!^l3618^f3614
!v700!82
!v701!78
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000662
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sSolga^rND^nSF
!v010!^sClark^rND^nJM
!v010!^sAlkhuraishi^rND^nAR
!v010!^sTorbenson^rND^nM
!v010!^sTabesh^rND^nA
!v010!^sSchweitzer^rND^nM
!v010!^sDiehl^rND^nAM
!v010!^sMagnuson^rND^nTH
!v012!Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients^len
!v014!6-11
!v030!Surg Obes Relat Dis
!v031!1
!v064!2005
!v065!20050000
!v118!79
!v514!^l11^f6
!v700!83
!v701!79
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000663
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sTanne^rND^nF
!v010!^sGagnadoux^rND^nF
!v010!^sChazouilleres^rND^nO
!v010!^sFleury^rND^nB
!v010!^sWendum^rND^nD
!v010!^sLasnier^rND^nE
!v010!^sLebeau^rND^nB
!v010!^sPoupon^rND^nR
!v010!^sSerfaty^rND^nL
!v012!Chronic liver injury during obstructive sleep apnea^len
!v014!1290-296
!v030!Hepatology
!v031!41
!v064!2005
!v065!20050000
!v118!80
!v514!^l1296^f1290
!v700!84
!v701!80
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000664
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sTarantino^rND^nG
!v010!^sSaldalamacchia^rND^nG
!v010!^sConca^rND^nP
!v010!^sArena^rND^nA
!v012!Non-alcoholic fatty liver disease: further expression of the metabolic syndrome^len
!v014!293-93
!v030!J Gastroenterol Hepatol
!v031!22
!v064!2007
!v065!20070000
!v118!81
!v514!^l293^f293
!v700!85
!v701!81
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000665
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sTargher^rND^nG
!v010!^sBertolini^rND^nL
!v010!^sPadovani^rND^nR
!v010!^sRodella^rND^nS
!v010!^sZoppini^rND^nG
!v010!^sPichiri^rND^nI
!v010!^sSorgato^rND^nC
!v010!^sZenari^rND^nL
!v010!^sBonora^rND^nE
!v012!Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes^len
!v014!713-18
!v030!J Hepatol
!v031!53
!v064!2010
!v065!20100000
!v118!82
!v514!^l718^f713
!v700!86
!v701!82
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000666
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sTarquini^rND^nR
!v010!^sLazzeri^rND^nC
!v010!^sBoddi^rND^nM
!v010!^sMarra^rND^nF
!v010!^sAbbate^rND^nR
!v010!^sGensini^rND^nGF
!v012!Non-alcoholic fatty liver disease: a new challenge for cardiologists^len
!v014!660-69
!v030!G Ital Cardiol (Rome)
!v031!11
!v064!2010
!v065!20100000
!v118!83
!v514!^l669^f660
!v700!87
!v701!83
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000667
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sTikkanen^rND^nMJ
!v010!^sNikkila^rND^nEA
!v012!Regulation of hepatic lipase and serum lipoproteins by sex steroids^len
!v014!562-67
!v030!Am Heart J
!v031!113
!v064!1987
!v065!19870000
!v118!84
!v514!^l567^f562
!v700!88
!v701!84
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000668
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sVernon^rND^nG
!v010!^sBaranova^rND^nA
!v010!^sYounossi^rND^nZM
!v012!Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults^len
!v014!274-85
!v030!Aliment Pharmacol Ther
!v031!34
!v064!2011
!v065!20110000
!v118!85
!v514!^l285^f274
!v700!89
!v701!85
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000669
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sVillanova^rND^nN
!v010!^sMoscatiello^rND^nS
!v010!^sRamilli^rND^nS
!v010!^sBugianesi^rND^nE
!v010!^sMagalotti^rND^nD
!v010!^sVanni^rND^nE
!v010!^sZoli^rND^nM
!v010!^sMarchesini^rND^nG
!v012!Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease^len
!v014!473-80
!v030!Hepatology
!v031!42
!v064!2005
!v065!20050000
!v118!86
!v514!^l480^f473
!v700!90
!v701!86
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000670
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sVolzke^rND^nH
!v010!^sRobinson^rND^nDM
!v010!^sKleine^rND^nV
!v010!^sDeutscher^rND^nR
!v010!^sHoffmann^rND^nW
!v010!^sLudemann^rND^nJ
!v010!^sSchminke^rND^nU
!v010!^sKessler^rND^nC
!v010!^sJohn^rND^nU
!v012!Hepatic steatosis is associated with an increased risk of carotid atherosclerosis^len
!v014!1848-853
!v030!World J Gastroenterol
!v031!11
!v064!2005
!v065!20050000
!v118!87
!v514!^l1853^f1848
!v700!91
!v701!87
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000671
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sWeltman^rND^nMD
!v010!^sFarrell^rND^nGC
!v010!^sLiddle^rND^nC
!v012!Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation^len
!v014!1645-653
!v030!Gastroenterology
!v031!111
!v064!1996
!v065!19960000
!v118!88
!v514!^l1653^f1645
!v700!92
!v701!88
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000672
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sWeltman^rND^nMD
!v010!^sFarrell^rND^nGC
!v010!^sHall^rND^nP
!v010!^sIngelman-Sundberg^rND^nM
!v010!^sLiddle^rND^nC
!v012!Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis^len
!v014!128-33
!v030!Hepatology
!v031!27
!v064!1998
!v065!19980000
!v118!89
!v514!^l133^f128
!v700!93
!v701!89
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000673
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sWilliams^rND^nCM
!v012!Cardiovascular risk factors in women^len
!v014!383-91
!v030!Proc Nutr Soc
!v031!56
!v064!1997
!v065!19970000
!v118!90
!v514!^l391^f383
!v700!94
!v701!90
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000674
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sYatsuji^rND^nS
!v010!^sHashimoto^rND^nE
!v010!^sTobari^rND^nM
!v010!^sTokushige^rND^nK
!v010!^sShiratori^rND^nK
!v012!Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis^len
!v014!1034-043
!v030!Hepatol Res
!v031!37
!v064!2007
!v065!20070000
!v118!91
!v514!^l1043^f1034
!v700!95
!v701!91
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000675
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sYounossi^rND^nZM
!v010!^sGramlich^rND^nT
!v010!^sBacon^rND^nBR
!v010!^sMatteoni^rND^nCA
!v010!^sBoparai^rND^nN
!v010!^sO'Neill^rND^nR
!v010!^sMcCullough^rND^nAJ
!v012!Hepatic iron and nonalcoholic fatty liver disease^len
!v014!847-50
!v030!Hepatology
!v031!30
!v064!1999
!v065!19990000
!v118!92
!v514!^l850^f847
!v700!96
!v701!92
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000676
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sYounossi^rND^nZM
!v010!^sGramlich^rND^nT
!v010!^sMatteoni^rND^nCA
!v010!^sBoparai^rND^nN
!v010!^sMcCullough^rND^nAJ
!v012!Nonalcoholic fatty liver disease in patients with type 2 diabetes^len
!v014!262-65
!v030!Clin Gastroenterol Hepatol
!v031!2
!v064!2004
!v065!20040000
!v118!93
!v514!^l265^f262
!v700!97
!v701!93
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000677
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sZamora-Valdes^rND^nD
!v010!^sMendez-Sanchez^rND^nN
!v012!Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis^len
!v014!281-83
!v030!Ann Hepatol
!v031!6
!v064!2007
!v065!20070000
!v118!94
!v514!^l283^f281
!v700!98
!v701!94
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000678
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sZein^rND^nCO
!v010!^sUnalp^rND^nA
!v010!^sColvin^rND^nR
!v010!^sLiu^rND^nYC
!v010!^sMcCullough^rND^nAJ
!v012!Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease^len
!v014!753-59
!v030!J Hepatol
!v031!54
!v064!2011
!v065!20110000
!v118!95
!v514!^l759^f753
!v700!99
!v701!95
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
!ID 000679
!v001!br1.1
!v002!0004-2803-ag-49-01-89.xml
!v004!v49n1
!v010!^sZhu^rND^nX
!v010!^sCheng^rND^nSY
!v012!New insights into regulation of lipid metabolism by thyroid hormone^len
!v014!408-13
!v030!Curr Opin Endocrinol Diabetes Obes
!v031!17
!v064!2010
!v065!20100000
!v118!96
!v514!^l413^f408
!v700!100
!v701!96
!v702!z:/dados_pmc/serial/ag/v49n1/pmc/pmc_base/0004-2803-ag-49-01-89.xml
!v705!S
!v706!c
!v708!96
!v865!20120300
